data_2lnc_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lnc _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo . . . . . 0 CA--C 1.531 0.333 0 CA-C-O 120.54 0.142 . . . . 0.0 112.254 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 93' ' ' LEU . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.412 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.453 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.462 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.424 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.401 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.401 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.419 HG23 ' CD2' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.441 ' CD2' HG13 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.441 HG13 ' CD2' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.403 ' OE1' ' CE2' ' A' ' 67' ' ' PHE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.45 HG23 HD11 ' A' ' 54' ' ' ILE . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.424 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.421 ' HB3' ' CE3' ' A' ' 13' ' ' TRP . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.41 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.415 HD22 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.858 0.361 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.403 ' CB ' ' NE2' ' A' ' 164' ' ' HIS . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.519 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.437 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.412 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.412 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.417 ' CE1' HG11 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 62' ' ' PHE . 44.6 tt0 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.622 0.176 . . . . 0.0 112.355 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.422 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.437 ' CD1' ' CD2' ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.445 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.474 HG23 ' CE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.477 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.413 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.477 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.459 ' CD1' ' CB ' ' A' ' 149' ' ' PRO . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.403 ' CG1' ' CG1' ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.403 ' CG1' ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.412 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.406 ' O ' ' CD2' ' A' ' 37' ' ' HIS . 9.3 t60 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.412 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.413 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.456 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.406 ' HG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 54' ' ' ILE . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.419 ' CE2' HD12 ' A' ' 54' ' ' ILE . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.458 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.437 ' CD2' ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.404 HD11 HG21 ' A' ' 94' ' ' ILE . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.421 HD13 ' CE3' ' A' ' 13' ' ' TRP . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.877 0.37 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.423 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.41 ' HB2' ' NE2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.446 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.446 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.459 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.458 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.405 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.404 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.423 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_exo . . . . . 0 CA--C 1.527 0.139 0 CA-C-O 120.781 0.242 . . . . 0.0 112.409 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.441 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.411 ' HB ' ' HG3' ' A' ' 149' ' ' PRO . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.408 ' CE2' ' HD2' ' A' ' 40' ' ' PRO . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.418 ' CG ' HD11 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.408 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.452 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.462 HG23 HD11 ' A' ' 54' ' ' ILE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.415 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.408 ' CE1' HD13 ' A' ' 54' ' ' ILE . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.418 HD11 ' CG ' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.45 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.873 0.368 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.411 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.452 HG23 HD12 ' A' ' 142' ' ' ILE . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.446 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.406 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.411 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.45 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.428 ' CE1' HG11 ' A' ' 174' ' ' VAL . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.428 HG11 ' CE1' ' A' ' 164' ' ' HIS . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.415 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.757 0.232 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.432 ' CZ3' HD21 ' A' ' 93' ' ' LEU . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.452 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.445 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.422 ' CE1' ' HB3' ' A' ' 137' ' ' MET . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.42 HD13 ' CZ ' ' A' ' 67' ' ' PHE . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.7 m170 -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' CD1' ' A' ' 65' ' ' PHE . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.414 ' CD1' HG23 ' A' ' 63' ' ' THR . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.42 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.454 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.432 HD21 ' CZ3' ' A' ' 13' ' ' TRP . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.903 0.383 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' MET . . . . . 0.422 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.423 ' HG ' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.401 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.657 ' O ' ' N ' ' A' ' 144' ' ' GLY . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.424 ' HD2' ' CG2' ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.409 ' CB ' ' HB ' ' A' ' 142' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.427 ' CG ' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.456 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.423 ' CD2' ' HG ' ' A' ' 139' ' ' LEU . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.403 ' O ' ' CD2' ' A' ' 62' ' ' PHE . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 39.7 mt-30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 C--O 1.231 0.151 0 CA-C-O 120.858 0.274 . . . . 0.0 112.253 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.411 ' CZ2' HD13 ' A' ' 101' ' ' LEU . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.443 ' HB2' ' CE2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.443 ' CE2' ' HB2' ' A' ' 18' ' ' LYS . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.462 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.411 ' CG ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.48 HG22 HD12 ' A' ' 33' ' ' ILE . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.417 ' CG2' ' ND1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.429 ' CD2' HG23 ' A' ' 38' ' ' VAL . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.429 HG23 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.454 HD12 HG23 ' A' ' 54' ' ' ILE . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.469 HG22 HD11 ' A' ' 56' ' ' ILE . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.411 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.421 ' CE2' HD11 ' A' ' 54' ' ' ILE . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.407 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . 0.407 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.411 HD13 ' CG ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.445 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.411 HD13 ' CZ2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 . . . . . 0 CA--C 1.527 0.086 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.451 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.549 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.549 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.445 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.451 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.411 ' HA ' ' CD1' ' A' ' 62' ' ' PHE . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 7.3 mm-40 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo . . . . . 0 CA--C 1.527 0.159 0 CA-C-O 120.703 0.21 . . . . 0.0 112.419 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.408 HG21 ' CD ' ' A' ' 149' ' ' PRO . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.44 ' CE3' ' HB2' ' A' ' 18' ' ' LYS . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.46 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.422 ' CD2' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.1 t60 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.425 HD12 ' CE1' ' A' ' 67' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.436 HD11 HG21 ' A' ' 56' ' ' ILE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.421 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.425 ' CE1' HD12 ' A' ' 54' ' ' ILE . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.466 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . 0.466 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.461 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.434 HG21 HD12 ' A' ' 94' ' ' ILE . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.825 0.345 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.478 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.442 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.414 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.414 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.478 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.7 t-80 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.1 m120 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 CA--C 1.527 0.171 0 CA-C-O 120.731 0.221 . . . . 0.0 112.345 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.419 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.419 ' CE3' ' HA ' ' A' ' 10' ' ' PRO . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.464 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.451 ' CG2' ' CD2' ' A' ' 37' ' ' HIS . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.451 ' CD2' ' CG2' ' A' ' 35' ' ' THR . 0.5 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.423 HG21 ' CD2' ' A' ' 37' ' ' HIS . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.41 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.462 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.423 ' CE1' HD12 ' A' ' 54' ' ' ILE . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NE ' ' CE2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.455 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.419 HD12 ' CD2' ' A' ' 13' ' ' TRP . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 37.8 m80 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.885 0.374 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.424 HD23 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.437 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.455 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.418 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.406 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.424 ' CE1' HD23 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.416 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.446 ' CG ' ' CE1' ' A' ' 62' ' ' PHE . 1.2 mm100 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.769 0.237 . . . . 0.0 112.351 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.451 ' CE3' ' CD2' ' A' ' 101' ' ' LEU . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.45 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.416 HG22 HD13 ' A' ' 33' ' ' ILE . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.445 HD13 HG23 ' A' ' 54' ' ' ILE . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.411 ' CZ ' HD12 ' A' ' 54' ' ' ILE . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' CD2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.451 ' CD2' ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 34.8 m170 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.439 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.458 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.527 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.527 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.417 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.413 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.418 ' CD2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.405 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.416 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CD1' ' HG3' ' A' ' 153' ' ' LYS . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.405 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.416 HG12 ' CE2' ' A' ' 25' ' ' PHE . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.458 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . 0.401 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.765 0.235 . . . . 0.0 112.315 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.414 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.451 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.415 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.405 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.405 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.432 HG21 ' CE1' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.432 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.3 p-80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.415 HG21 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.414 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.435 HD11 ' CE1' ' A' ' 67' ' ' PHE . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.42 ' CD2' HG22 ' A' ' 54' ' ' ILE . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.435 ' CE1' HD11 ' A' ' 54' ' ' ILE . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.415 ' HG3' ' CD2' ' A' ' 26' ' ' TRP . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.772 0.32 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.443 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.439 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.467 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.467 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.43 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.443 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 21.9 t-80 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo . . . . . 0 CA--C 1.527 0.156 0 CA-C-O 120.737 0.224 . . . . 0.0 112.295 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.423 ' CE3' HD23 ' A' ' 93' ' ' LEU . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.417 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.415 HG21 ' CE1' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.418 ' CD2' HG13 ' A' ' 38' ' ' VAL . 6.5 p-80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.418 HG13 ' CD2' ' A' ' 37' ' ' HIS . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.449 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.414 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.417 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.46 ' CG1' ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.423 HD23 ' CE3' ' A' ' 13' ' ' TRP . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.822 0.344 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.43 ' HB3' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.42 ' OG1' ' N ' ' A' ' 145' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.497 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.42 ' N ' ' OG1' ' A' ' 141' ' ' THR . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.414 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.417 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CE2' ' HB2' ' A' ' 153' ' ' LYS . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.417 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.46 ' CE1' ' CG1' ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.414 ' HG3' ' CD2' ' A' ' 62' ' ' PHE . 30.3 mt-30 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.781 0.242 . . . . 0.0 112.406 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.439 ' CE2' ' CD2' ' A' ' 101' ' ' LEU . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.43 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.429 ' HB2' ' CZ2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.429 ' CZ2' ' HB2' ' A' ' 18' ' ' LYS . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.43 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.424 ' CD2' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.42 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.42 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.419 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.484 HD13 HG23 ' A' ' 54' ' ' ILE . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.417 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . 0.419 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . 0.419 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.424 HD13 ' CD2' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.455 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD2' ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.792 0.329 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.472 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.472 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.402 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.408 ' HB1' ' CE1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 163' ' ' VAL . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.455 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 149' ' ' PRO . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.42 ' CE1' HG13 ' A' ' 92' ' ' VAL . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.417 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo . . . . . 0 C--O 1.232 0.198 0 CA-C-O 120.711 0.213 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.438 ' CZ3' ' CD2' ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.426 HG22 ' CE3' ' A' ' 23' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.464 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.3 t60 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.462 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.432 HD11 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.415 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.401 ' CD2' ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.453 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.438 ' CD2' ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.447 HD13 HG21 ' A' ' 94' ' ' ILE . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.418 HD21 ' CE3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.4 ' CG2' ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . 0.4 ' NE2' ' CG2' ' A' ' 111' ' ' ILE . 2.0 t-160 . . . . . 0 C--O 1.233 0.191 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.448 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.443 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.46 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.46 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.415 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.425 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.453 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.448 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 23.8 t-80 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.405 ' CG2' ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo . . . . . 0 CA--C 1.528 0.195 0 CA-C-O 120.58 0.158 . . . . 0.0 112.265 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.425 ' CZ3' ' HB3' ' A' ' 93' ' ' LEU . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.466 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.407 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.428 ' CG ' ' CD1' ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.0 t60 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.428 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.428 ' CD1' ' CG ' ' A' ' 26' ' ' TRP . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.453 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.425 ' HB3' ' CZ3' ' A' ' 13' ' ' TRP . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.411 HD11 HG21 ' A' ' 94' ' ' ILE . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.415 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.762 0.315 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.479 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.418 ' CG2' ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.5 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.407 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.453 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.407 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.426 ' CD1' ' N ' ' A' ' 158' ' ' TRP . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.407 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.479 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.414 ' HB ' ' CE1' ' A' ' 164' ' ' HIS . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo . . . . . 0 CA--C 1.529 0.269 0 N-CA-C 112.513 0.159 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.44 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.462 HG23 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.412 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.404 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.475 ' CD1' ' HA ' ' A' ' 145' ' ' ASP . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.458 ' CD1' ' CB ' ' A' ' 149' ' ' PRO . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.413 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 HG23 ' A' ' 33' ' ' ILE . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.425 ' CD2' ' CG1' ' A' ' 38' ' ' VAL . 4.6 p-80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.425 ' CG1' ' CD2' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.456 ' CE1' ' CD1' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.456 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.421 ' CD1' HG22 ' A' ' 54' ' ' ILE . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.413 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.452 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.421 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.9 m170 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.882 0.373 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.436 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.446 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.407 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.445 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.445 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.475 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.458 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.452 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.416 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.405 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.446 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . 0.402 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.419 ' HA ' ' CD1' ' A' ' 62' ' ' PHE . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo . . . . . 0 CA--C 1.53 0.278 0 CA-C-O 120.504 0.126 . . . . 0.0 112.324 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.42 ' CD1' HD21 ' A' ' 93' ' ' LEU . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.449 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.449 ' CD2' ' HB2' ' A' ' 18' ' ' LYS . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.463 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.1 t60 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CE1' ' CD1' ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.41 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.417 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . 0.408 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.418 ' CD2' HG23 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.42 HD21 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.414 HD12 ' CZ3' ' A' ' 13' ' ' TRP . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 29.2 m80 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.76 0.315 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.441 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.485 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.485 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.416 HG21 ' CD2' ' A' ' 25' ' ' PHE . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.418 HG12 ' CE1' ' A' ' 164' ' ' HIS . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.417 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo . . . . . 0 CA--C 1.528 0.193 0 CA-C-O 120.699 0.208 . . . . 0.0 112.512 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.414 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.441 ' CD2' ' CD1' ' A' ' 101' ' ' LEU . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 ' HD3' ' A' ' 149' ' ' PRO . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.41 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' SER . . . . . 0.402 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.9 t60 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.45 ' CD1' ' CE2' ' A' ' 67' ' ' PHE . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.407 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.416 HG22 ' CD1' ' A' ' 65' ' ' PHE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.416 ' CD1' HG22 ' A' ' 63' ' ' THR . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.42 ' HE1' ' CE2' ' A' ' 67' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.425 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.415 HD22 ' CD1' ' A' ' 13' ' ' TRP . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.441 ' CD1' ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.752 0.311 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.5 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.437 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.428 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.458 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.427 ' HD3' HG21 ' A' ' 16' ' ' VAL . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.425 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.406 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.5 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 36.4 t-80 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 164' ' ' HIS . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.407 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.589 0.162 . . . . 0.0 112.281 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.441 ' CE3' ' CD2' ' A' ' 101' ' ' LEU . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CZ ' ' A' ' 25' ' ' PHE . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.433 HG21 ' HD3' ' A' ' 149' ' ' PRO . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.419 HG23 ' CE1' ' A' ' 47' ' ' PHE . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CZ ' ' CB ' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.1 t60 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.419 ' CE1' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.534 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.534 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.419 HD12 ' CE1' ' A' ' 46' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . 0.416 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.416 ' CZ ' HG12 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.417 ' CE2' HD11 ' A' ' 54' ' ' ILE . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.421 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.421 HD22 ' CD1' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.426 HG21 HD12 ' A' ' 94' ' ' ILE . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.441 ' CD2' ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.74 0.305 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.528 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.464 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' THR . . . . . 0.401 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.442 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.433 ' HD3' HG21 ' A' ' 16' ' ' VAL . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.421 ' CE2' HG22 ' A' ' 92' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.452 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.404 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.528 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 18.5 t-80 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.414 ' HG2' ' CE2' ' A' ' 158' ' ' TRP . 50.9 Cg_exo . . . . . 0 CA--C 1.528 0.189 0 CA-C-O 120.755 0.231 . . . . 0.0 112.338 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.439 ' CZ3' ' CD2' ' A' ' 93' ' ' LEU . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . 0.415 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.45 ' CD1' ' CE2' ' A' ' 67' ' ' PHE . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.439 ' CD2' ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 94' ' ' ILE . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.811 0.338 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.435 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.401 ' CD2' ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.486 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.486 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.418 ' O ' ' HA2' ' A' ' 22' ' ' GLY . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.414 ' CE2' ' HG2' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.42 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.435 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . 0.401 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.777 0.24 . . . . 0.0 112.331 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.417 ' CD2' HD11 ' A' ' 101' ' ' LEU . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.456 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.421 HG22 ' CD ' ' A' ' 149' ' ' PRO . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.456 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.405 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 18' ' ' LYS . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.456 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.418 ' CG ' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.411 HG23 ' CE1' ' A' ' 65' ' ' PHE . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.421 HG22 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.408 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.423 ' CD2' HG11 ' A' ' 38' ' ' VAL . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.423 HG11 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.408 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.456 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.415 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . 0.421 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . 0.411 ' CE1' HG23 ' A' ' 34' ' ' THR . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.408 ' CE2' HD12 ' A' ' 54' ' ' ILE . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.418 HD13 ' CG ' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.454 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . 0.407 HD12 ' CE1' ' A' ' 25' ' ' PHE . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.417 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.455 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.445 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.463 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . 0.439 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.424 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.408 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.424 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . 0.41 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 19.6 t-80 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.414 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . 0.421 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 CA--C 1.53 0.275 0 CA-C-O 120.682 0.201 . . . . 0.0 112.269 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.421 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 10' ' ' PRO . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.461 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.441 HG23 ' CE3' ' A' ' 23' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.414 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.471 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PHE . . . . . 0.461 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TRP . . . . . 0.419 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . 0.414 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.513 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.513 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.456 ' CD1' ' CD1' ' A' ' 46' ' ' PHE . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.448 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' MET . . . . . 0.439 ' CE ' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.46 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' A' ' 13' ' ' TRP . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.768 0.318 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.461 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' ILE . . . . . 0.569 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.569 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' PRO . . . . . 0.453 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' TYR . . . . . 0.46 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' HIS . . . . . 0.424 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ARG . . . . . 0.424 ' HG3' ' CD2' ' A' ' 152' ' ' HIS . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 mtm . . . . . 0 N--CA 1.486 1.349 0 CA-C-O 120.849 0.357 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.4 m80 60.45 80.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -132.78 -46.73 0.87 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -68.55 136.93 53.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.893 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 61.12 112.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 8.0 m170 -143.26 169.19 18.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.925 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -60.29 146.22 44.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -97.14 149.77 36.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.43 124.23 12.59 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.421 ' CE3' ' HB3' ' A' ' 93' ' ' LEU . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.412 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.453 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.462 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.424 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.401 ' CB ' ' CD ' ' A' ' 29' ' ' PRO . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.401 ' CD ' ' CB ' ' A' ' 28' ' ' SER . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.419 HG23 ' CD2' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.441 ' CD2' HG13 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.441 HG13 ' CD2' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.403 ' OE1' ' CE2' ' A' ' 67' ' ' PHE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.45 HG23 HD11 ' A' ' 54' ' ' ILE . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.424 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.421 ' HB3' ' CE3' ' A' ' 13' ' ' TRP . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.41 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.415 HD22 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.48 168.63 21.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 88.8 p -100.93 105.12 16.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.5 mtp -80.28 168.13 19.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.962 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 ttm105 -124.82 109.71 13.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.6 mt -122.07 121.61 64.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.081 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.0 mp0 60.64 31.97 20.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.31 30.99 59.77 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.477 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.9 123.73 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.786 0.327 . . . . 0.0 110.907 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.5 mt -77.62 120.4 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.1 p -128.43 147.73 32.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.038 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -95.79 122.51 38.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.403 ' CB ' ' NE2' ' A' ' 164' ' ' HIS . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.519 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.519 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.437 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.412 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.412 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.408 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.417 ' CE1' HG11 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 62' ' ' PHE . 44.6 tt0 -92.08 158.85 15.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -99.24 129.1 45.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.093 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 180.0 -140.82 4.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.22 166.25 3.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.819 0.342 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 96.46 -27.5 17.1 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.85 -30.31 21.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.824 0.345 . . . . 0.0 110.919 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.63 -31.57 13.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.56 153.71 34.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.074 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.6 -32.79 15.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.235 -0.888 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -131.95 -177.73 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.8 p80 -91.31 127.91 36.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -132.72 141.63 48.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.94 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -97.99 -37.4 9.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.88 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.2 p80 -176.49 150.99 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -105.28 -68.06 0.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.864 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.65 165.64 21.97 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.11 124.42 12.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.551 2.168 . . . . 0.0 112.355 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.422 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.437 ' CD1' ' CD2' ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.445 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.474 HG23 ' CE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.477 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.413 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.477 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.459 ' CD1' ' CB ' ' A' ' 149' ' ' PRO . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.403 ' CG1' ' CG1' ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.403 ' CG1' ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.412 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.406 ' O ' ' CD2' ' A' ' 37' ' ' HIS . 9.3 t60 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.412 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.413 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.456 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.406 ' HG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.449 HD13 HG23 ' A' ' 54' ' ' ILE . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.415 ' CD2' ' HB1' ' A' ' 180' ' ' ALA . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.419 ' CE2' HD12 ' A' ' 54' ' ' ILE . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.458 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.437 ' CD2' ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.404 HD11 HG21 ' A' ' 94' ' ' ILE . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.421 HD13 ' CE3' ' A' ' 13' ' ' TRP . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -136.33 133.83 37.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.6 p -71.17 107.96 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.4 mmm -93.36 147.02 23.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -106.33 123.78 48.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.965 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.21 124.4 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.162 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 60.29 31.45 20.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.874 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.13 28.51 64.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.521 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -131.8 140.32 49.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.6 mt -94.0 123.97 37.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.1 m -129.81 141.0 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.07 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -98.64 125.59 43.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.423 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.41 ' HB2' ' NE2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.446 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.446 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.441 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.459 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.458 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.405 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.404 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.423 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.6 tp-100 -60.05 91.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . 0.415 ' HB1' ' CD2' ' A' ' 62' ' ' PHE . . . -175.58 116.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.102 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -149.79 179.53 26.48 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.443 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -75.16 126.59 31.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.67 43.97 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -83.35 -49.27 9.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.733 0.302 . . . . 0.0 110.889 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.32 31.52 2.13 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.975 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.95 77.85 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.6 mp 60.3 79.97 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.859 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.949 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 120.856 0.36 . . . . 0.0 111.221 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.8 p-80 -134.16 -47.2 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 m80 60.43 -176.84 0.11 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -170.44 129.86 0.87 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -130.29 131.48 45.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -109.62 131.09 55.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -132.08 28.56 4.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.415 ' HB2' ' CZ2' ' A' ' 13' ' ' TRP . . . -144.76 90.02 6.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.022 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_exo -51.94 149.13 21.24 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.459 2.106 . . . . 0.0 112.409 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.415 ' CZ2' ' HB2' ' A' ' 8' ' ' ALA . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.441 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.411 ' HB ' ' HG3' ' A' ' 149' ' ' PRO . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.408 ' CE2' ' HD2' ' A' ' 40' ' ' PRO . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.418 ' CG ' HD11 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.408 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.452 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.462 HG23 HD11 ' A' ' 54' ' ' ILE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.415 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.408 ' CE1' HD13 ' A' ' 54' ' ' ILE . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.418 HD11 ' CG ' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.45 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.07 152.94 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.6 t -102.29 103.22 13.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -85.02 157.57 20.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -109.54 109.55 20.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 25.2 mm -116.23 106.24 19.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 60.29 35.63 20.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.37 28.31 55.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.522 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.4 ttt-85 -130.09 119.05 22.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.809 0.338 . . . . 0.0 110.96 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.3 mt -71.32 104.8 3.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.796 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 19.5 m -106.35 145.56 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -98.94 119.25 37.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.411 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.452 HG23 HD12 ' A' ' 142' ' ' ILE . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.446 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.406 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.411 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.45 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.428 ' CE1' HG11 ' A' ' 174' ' ' VAL . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.428 HG11 ' CE1' ' A' ' 164' ' ' HIS . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.415 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER -61.81 130.78 47.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -95.59 123.67 39.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.027 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -142.34 130.92 4.46 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.525 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.49 122.61 40.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.739 0.304 . . . . 0.0 110.875 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.41 46.24 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.553 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -105.3 -40.02 5.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.793 0.33 . . . . 0.0 110.885 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 4.4 m -98.08 -32.15 11.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -99.97 175.63 5.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.102 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 1.2 tp 60.5 35.43 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.289 -0.863 . . . . 0.0 110.882 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 mmm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.764 0.316 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -67.61 91.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.1 m-70 -107.46 164.76 11.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m-70 -143.21 134.63 26.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.3 p80 -103.11 134.73 46.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -176.7 118.97 0.12 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 68.39 -68.87 0.16 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.005 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.428 ' HB2' ' CH2' ' A' ' 13' ' ' TRP . . . -123.7 77.07 56.4 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.013 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -56.87 161.16 10.83 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.615 2.21 . . . . 0.0 112.476 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.432 ' CZ3' HD21 ' A' ' 93' ' ' LEU . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.452 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.445 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.422 ' CE1' ' HB3' ' A' ' 137' ' ' MET . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.42 HD13 ' CZ ' ' A' ' 67' ' ' PHE . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.7 m170 -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CE1' ' HA ' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.414 HG23 ' CD1' ' A' ' 65' ' ' PHE . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.414 ' CD1' HG23 ' A' ' 63' ' ' THR . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.42 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.454 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.432 HD21 ' CZ3' ' A' ' 13' ' ' TRP . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.61 148.98 31.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.7 108.48 20.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.66 137.92 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.956 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 -114.2 118.59 34.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.5 112.39 27.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.28 35.67 20.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.56 28.61 57.1 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 52.2 mtt-85 -127.44 120.48 28.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.7 mt -82.29 125.26 30.77 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 5.7 m -134.76 97.55 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -66.53 125.65 26.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.878 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' MET . . . . . 0.422 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.423 ' HG ' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.401 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.657 ' O ' ' N ' ' A' ' 144' ' ' GLY . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.424 ' HD2' ' CG2' ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.409 ' CB ' ' HB ' ' A' ' 142' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.427 ' CG ' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.456 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.423 ' CD2' ' HG ' ' A' ' 139' ' ' LEU . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.403 ' O ' ' CD2' ' A' ' 62' ' ' PHE . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 39.7 mt-30 -63.4 146.11 54.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.41 133.54 11.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.124 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 103.74 28.7 5.86 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -90.82 129.54 36.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.72 34.81 5.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.49 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -132.17 -67.15 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 9.7 m -132.51 -64.86 0.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.44 -178.38 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.152 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -99.0 -31.36 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.928 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.937 179.974 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.6 mtt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.806 0.336 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -87.53 138.87 31.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.916 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -105.67 127.15 52.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.797 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.1 100.79 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.73 -179.1 5.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.897 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -71.64 -177.43 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.936 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -176.58 111.24 0.09 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.418 ' HB1' ' CZ3' ' A' ' 158' ' ' TRP . . . -74.37 152.85 87.96 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.102 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -54.09 154.75 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.609 2.206 . . . . 0.0 112.253 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.411 ' CZ2' HD13 ' A' ' 101' ' ' LEU . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.443 ' HB2' ' CE2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.443 ' CE2' ' HB2' ' A' ' 18' ' ' LYS . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.462 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.411 ' CG ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.48 HG22 HD12 ' A' ' 33' ' ' ILE . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.417 ' CG2' ' ND1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.429 ' CD2' HG23 ' A' ' 38' ' ' VAL . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.429 HG23 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.454 HD12 HG23 ' A' ' 54' ' ' ILE . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.469 HG22 HD11 ' A' ' 56' ' ' ILE . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.411 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.421 ' CE2' HD11 ' A' ' 54' ' ' ILE . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.407 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . 0.407 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.411 HD13 ' CG ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.445 ' CG2' ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.411 HD13 ' CZ2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.57 163.86 35.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -98.09 110.68 23.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.888 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.52 145.67 25.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.3 ttt180 -108.11 136.61 47.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.1 mt -140.05 110.7 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.091 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 60.34 35.45 20.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.919 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.13 31.05 39.87 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.469 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.7 mmt180 -131.09 109.02 10.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.1 mt -79.78 113.29 17.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.06 127.36 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 -90.15 115.8 27.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.847 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.451 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.549 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.549 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.434 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.445 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.451 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.411 ' HA ' ' CD1' ' A' ' 62' ' ' PHE . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 7.3 mm-40 -134.02 142.12 47.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -111.25 84.26 1.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.028 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 105.86 -177.39 22.59 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.492 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -131.76 166.96 20.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -149.04 28.5 1.26 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -109.89 -67.49 0.98 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.838 0.352 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.12 -56.99 2.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -81.14 117.4 21.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 8.4 tt -177.53 -39.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.955 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.5 mtt . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.818 0.342 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -106.82 116.66 32.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.877 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -163.86 31.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.968 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -113.83 137.95 50.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -140.16 -68.2 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.984 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.1 t-160 -160.58 145.13 14.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.904 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -169.98 -176.43 2.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.405 ' HB1' ' CZ2' ' A' ' 13' ' ' TRP . . . -57.0 108.99 1.41 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.052 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -56.3 148.69 59.67 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.438 2.092 . . . . 0.0 112.419 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.405 ' CZ2' ' HB1' ' A' ' 8' ' ' ALA . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.408 HG21 ' CD ' ' A' ' 149' ' ' PRO . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.44 ' CE3' ' HB2' ' A' ' 18' ' ' LYS . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.46 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.422 ' CD2' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.1 t60 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.425 HD12 ' CE1' ' A' ' 67' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.436 HD11 HG21 ' A' ' 56' ' ' ILE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.421 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.425 ' CE1' HD12 ' A' ' 54' ' ' ILE . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.466 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . 0.466 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.461 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.434 HG21 HD12 ' A' ' 94' ' ' ILE . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.44 151.77 49.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -97.06 111.02 23.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -91.43 157.91 16.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.899 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -127.52 121.86 31.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.924 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.35 113.51 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? 60.4 31.68 20.42 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.67 28.8 45.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.5 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.2 mmp_? -128.97 108.11 10.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.933 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 12.0 mt -72.82 130.62 40.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.63 129.23 6.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.109 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -69.61 136.37 51.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.832 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.478 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.442 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.414 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.414 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.478 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.7 t-80 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.1 m120 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -66.49 143.93 56.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -109.99 -171.24 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.019 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -175.22 66.44 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.526 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -97.25 167.76 10.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.908 0.385 . . . . 0.0 110.852 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 174.76 -95.57 0.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.97 -43.18 10.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.857 0.361 . . . . 0.0 110.974 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.1 m -68.11 74.32 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.84 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -103.08 -177.88 3.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.108 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.3 tp 60.43 80.1 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.861 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.872 179.917 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.802 0.334 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 50.6 p-80 -81.35 98.71 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 m80 60.34 81.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.959 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 48.7 p-80 -98.81 31.53 2.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.89 31.67 6.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.829 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 1.5 t-160 -141.46 129.68 22.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.932 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.403 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 2.5 m170 -171.71 140.91 1.37 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -66.37 147.17 99.02 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.95 154.43 17.41 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.499 2.133 . . . . 0.0 112.345 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.419 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.419 ' CE3' ' HA ' ' A' ' 10' ' ' PRO . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.41 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.464 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.451 ' CG2' ' CD2' ' A' ' 37' ' ' HIS . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.451 ' CD2' ' CG2' ' A' ' 35' ' ' THR . 0.5 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.423 HG21 ' CD2' ' A' ' 37' ' ' HIS . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.41 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.462 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.423 ' CE1' HD12 ' A' ' 54' ' ' ILE . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' NE ' ' CE2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.455 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.419 HD12 ' CD2' ' A' ' 13' ' ' TRP . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.5 151.04 47.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.1 p -87.37 114.21 23.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.06 145.12 26.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.855 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -111.94 132.86 54.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.8 mp -137.87 115.72 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 60.58 31.32 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.83 30.92 41.59 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.456 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 109.91 10.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.896 0.379 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 52.0 mt -73.1 135.9 44.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 9.9 p -147.68 154.46 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.108 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -102.27 130.41 48.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.424 HD23 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.423 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.437 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.455 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.418 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.406 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.424 ' CE1' HD23 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.416 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.446 ' CG ' ' CE1' ' A' ' 62' ' ' PHE . 1.2 mm100 -59.7 134.38 56.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -107.55 157.07 18.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.145 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 88.86 -134.37 12.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -89.76 172.52 8.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.841 0.353 . . . . 0.0 110.902 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 165.19 -73.31 0.17 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -104.68 -31.71 9.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -72.53 -31.62 65.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.977 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -59.95 104.37 0.29 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.11 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.44 102.9 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.864 -179.98 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.3 mtp . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.763 0.315 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -143.62 125.52 15.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -106.65 128.03 53.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -97.48 -31.64 12.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -84.15 -177.62 6.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.857 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.4 m80 -127.23 -174.82 3.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -106.98 -39.52 5.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.892 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.419 ' HB2' ' CZ2' ' A' ' 13' ' ' TRP . . . -114.7 87.82 15.24 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.06 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.23 152.23 19.96 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.696 2.264 . . . . 0.0 112.351 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.451 ' CE3' ' CD2' ' A' ' 101' ' ' LEU . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.45 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.416 HG22 HD13 ' A' ' 33' ' ' ILE . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.445 HD13 HG23 ' A' ' 54' ' ' ILE . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.411 ' CZ ' HD12 ' A' ' 54' ' ' ILE . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.418 HG22 ' CD2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.451 ' CD2' ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.56 127.42 13.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.4 m -87.69 96.67 10.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mtt -93.45 163.62 13.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 57.7 ttp180 -106.73 121.11 43.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -118.1 106.37 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.118 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.9 mm100 60.31 31.24 20.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 97.1 -25.61 26.22 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.551 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 -91.28 125.03 35.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.7 mt -80.4 142.24 34.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.933 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.75 153.96 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.1 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -82.38 114.21 20.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.439 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.458 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.527 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.527 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.417 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.413 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.418 ' CD2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.405 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.416 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CD1' ' HG3' ' A' ' 153' ' ' LYS . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.405 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.416 HG12 ' CE2' ' A' ' 25' ' ' PHE . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.458 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . 0.401 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -154.86 137.7 15.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -109.0 -171.19 1.8 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.058 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -138.51 133.31 6.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.554 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -139.82 121.23 15.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.868 0.366 . . . . 0.0 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 75.58 28.23 61.76 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -104.23 -62.71 1.28 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.859 0.361 . . . . 0.0 110.884 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.67 -42.14 8.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.949 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.03 129.27 40.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.091 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -132.47 -67.09 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.966 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.76 -179.953 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.862 0.363 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.5 m170 60.42 35.48 20.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.3 m80 -168.91 119.99 0.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 7.5 t-160 -74.16 132.15 41.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.935 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -152.56 79.81 1.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.874 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -74.24 -179.6 3.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -172.48 35.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.39 149.65 76.14 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.082 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.95 148.59 37.77 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.508 2.139 . . . . 0.0 112.315 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.434 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.414 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.434 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.451 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.415 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.405 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.405 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.432 HG21 ' CE1' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.432 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.3 p-80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.415 HG21 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.414 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.435 HD11 ' CE1' ' A' ' 67' ' ' PHE . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.42 ' CD2' HG22 ' A' ' 54' ' ' ILE . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.435 ' CE1' HD11 ' A' ' 54' ' ' ILE . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.415 ' HG3' ' CD2' ' A' ' 26' ' ' TRP . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -144.68 129.14 17.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.06 108.1 12.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.881 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.4 mtp -91.85 163.46 14.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -127.46 120.54 28.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.963 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.78 115.78 32.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.17 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 60.15 35.65 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.01 30.92 60.48 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.457 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 -130.76 107.94 9.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.7 mt -74.69 120.65 20.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.11 169.8 20.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.071 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -106.87 127.99 53.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.933 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.443 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.439 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.467 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.467 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.43 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.443 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 21.9 t-80 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 59.97 102.8 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -142.19 152.51 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 59.77 168.86 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.47 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -107.62 48.07 0.86 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.938 0.399 . . . . 0.0 110.848 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -99.33 -27.52 8.09 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.623 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -86.47 -30.63 21.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.775 0.322 . . . . 0.0 110.873 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -93.31 47.58 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -136.97 102.87 4.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -33.01 71.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.895 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 ptt? . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.831 0.348 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -137.49 150.86 47.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 24.7 m-70 -72.82 154.0 40.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.951 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -133.53 97.09 3.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 63.7 m80 -106.92 85.63 2.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t60 -96.46 137.1 36.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 m170 -171.25 146.75 2.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.4 ' HB3' ' CH2' ' A' ' 158' ' ' TRP . . . -79.75 149.77 71.49 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.013 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.52 171.78 10.15 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.548 2.166 . . . . 0.0 112.295 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.423 ' CE3' HD23 ' A' ' 93' ' ' LEU . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.417 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.415 HG21 ' CE1' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.418 ' CD2' HG13 ' A' ' 38' ' ' VAL . 6.5 p-80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.418 HG13 ' CD2' ' A' ' 37' ' ' HIS . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.449 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.414 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.417 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.46 ' CG1' ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.423 HD23 ' CE3' ' A' ' 13' ' ' TRP . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -131.38 141.38 49.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.3 m -91.0 115.71 28.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.882 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.3 mtt -104.9 162.78 13.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.865 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -127.43 121.46 30.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -140.13 128.56 25.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.191 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 71.7 mm-40 60.25 35.86 20.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.942 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.38 28.43 73.57 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.455 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -134.46 107.85 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.346 . . . . 0.0 110.934 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -64.51 119.1 9.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.846 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 31.3 m -115.42 175.56 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.093 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -127.38 119.43 26.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.43 ' HB3' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.42 ' OG1' ' N ' ' A' ' 145' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.497 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.497 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.42 ' N ' ' OG1' ' A' ' 141' ' ' THR . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.414 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CE1' ' CG2' ' A' ' 92' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.417 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CE2' ' HB2' ' A' ' 153' ' ' LYS . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.417 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.46 ' CE1' ' CG1' ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.414 ' HG3' ' CD2' ' A' ' 62' ' ' PHE . 30.3 mt-30 -96.62 178.01 5.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . 59.9 -171.12 0.13 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.128 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.09 28.16 3.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.496 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -61.46 -178.08 0.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 166.77 -87.48 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -87.32 -31.43 20.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -98.7 31.48 2.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -85.02 133.85 34.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.9 mp -90.29 -32.83 16.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 mtt . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.784 0.326 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 60.85 156.7 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 60.46 100.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -108.28 136.22 48.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.925 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.7 m170 -164.51 -177.81 5.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . 0.401 ' CD2' ' O ' ' A' ' 103' ' ' PRO . 18.7 m170 60.47 64.46 1.2 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.828 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 27.9 t-80 -177.29 106.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -93.08 149.1 36.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.146 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.0 159.93 3.5 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.614 2.21 . . . . 0.0 112.406 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.439 ' CE2' ' CD2' ' A' ' 101' ' ' LEU . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.43 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.429 ' HB2' ' CZ2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.429 ' CZ2' ' HB2' ' A' ' 18' ' ' LYS . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.43 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.424 ' CD2' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.42 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.419 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.3 t60 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.42 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.419 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.484 HD13 HG23 ' A' ' 54' ' ' ILE . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.417 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . 0.419 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . 0.419 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.424 HD13 ' CD2' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.455 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD2' ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.401 ' O ' ' CD2' ' A' ' 6' ' ' HIS . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.97 173.16 11.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.8 p -97.42 96.22 8.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.8 mmm -80.47 150.09 29.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -99.34 117.27 33.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.969 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.42 119.5 52.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 60.3 31.3 20.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.969 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.73 27.76 56.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.512 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -136.47 134.64 37.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.916 0.389 . . . . 0.0 110.887 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 82.5 mt -88.12 118.42 27.68 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.45 136.32 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 -91.23 121.34 32.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.472 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.472 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.402 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.408 ' HB1' ' CE1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 163' ' ' VAL . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.455 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.415 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 149' ' ' PRO . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.42 ' CE1' HG13 ' A' ' 92' ' ' VAL . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.417 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.407 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER -176.91 -170.1 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -149.96 121.49 7.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.092 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -83.76 109.37 3.17 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -110.16 -174.44 2.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.919 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 106.71 -30.94 8.74 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.534 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -104.15 -33.52 8.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.978 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 29.6 m -106.33 35.6 2.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.89 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -146.72 97.94 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.105 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.1 pp -134.18 125.99 29.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.892 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.7 mtt . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.898 0.38 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . 0.4 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 11.8 m-70 -82.77 -179.25 7.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.4 ' CG ' ' O ' ' A' ' 2' ' ' HIS . 50.8 m-70 -163.79 -177.92 5.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.77 157.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.004 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -133.54 -176.5 4.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -98.72 31.21 2.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.949 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 7.2 m80 60.15 103.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.416 ' HB3' ' CZ2' ' A' ' 13' ' ' TRP . . . -144.76 69.81 14.97 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.004 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.85 155.4 10.97 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.568 2.179 . . . . 0.0 112.445 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.438 ' CZ3' ' CD2' ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.426 HG22 ' CE3' ' A' ' 23' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.416 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.464 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.3 t60 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.462 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.416 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.432 HD11 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.415 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.401 ' CD2' ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.453 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.438 ' CD2' ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.447 HD13 HG21 ' A' ' 94' ' ' ILE . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.418 HD21 ' CE3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.4 ' CG2' ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -142.53 160.77 39.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.9 t -88.22 105.8 17.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.3 mtp -93.17 140.65 29.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.947 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.2 ttt85 -94.73 116.78 29.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -140.16 138.84 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.2 mm100 59.98 29.32 18.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.945 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.04 8.69 87.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.939 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.45 146.97 46.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.809 0.338 . . . . 0.0 110.953 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 24.6 mt -81.93 147.16 29.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 15.3 m -142.06 142.75 27.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.4 ' NE2' ' CG2' ' A' ' 111' ' ' ILE . 2.0 t-160 -84.02 111.42 19.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.448 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.443 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.46 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.46 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.421 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.415 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.425 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.453 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.448 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 23.8 t-80 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 8.4 m-80 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.405 ' CG2' ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 59.89 79.76 0.22 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -100.99 172.76 6.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.105 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -169.76 140.48 6.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -76.12 178.49 6.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.791 0.329 . . . . 0.0 110.957 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -161.95 34.21 0.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.511 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -89.42 -46.72 8.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 2.0 m -130.91 35.92 3.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 62.01 151.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 14.7 mt -153.75 131.04 11.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.965 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.946 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.83 0.348 . . . . 0.0 111.207 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -80.6 115.38 20.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -101.14 -174.53 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.8 m-70 -98.49 -74.55 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -78.31 153.17 31.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -176.64 -40.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -84.09 -178.63 7.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.865 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -61.19 164.63 7.98 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -61.97 129.17 26.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.614 2.209 . . . . 0.0 112.265 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.425 ' CZ3' ' HB3' ' A' ' 93' ' ' LEU . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.466 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.407 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.428 ' CG ' ' CD1' ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 10.0 t60 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.428 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.428 ' CD1' ' CG ' ' A' ' 26' ' ' TRP . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.453 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.425 ' HB3' ' CZ3' ' A' ' 13' ' ' TRP . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.411 HD11 HG21 ' A' ' 94' ' ' ILE . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.415 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -130.95 174.42 10.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -102.64 112.28 24.97 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.2 mtt -101.31 179.41 4.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.868 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.9 ttp180 -127.46 127.79 44.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.92 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 26.6 mm -128.96 114.12 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.2 35.66 20.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.936 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.5 28.3 57.79 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.9 mtt85 -132.77 125.4 30.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -76.08 117.54 17.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.39 145.41 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.032 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -88.31 137.85 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.953 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.479 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.418 ' CG2' ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.5 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.5 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.407 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.453 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.407 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.426 ' CD1' ' N ' ' A' ' 158' ' ' TRP . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.407 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.479 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.414 ' HB ' ' CE1' ' A' ' 164' ' ' HIS . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -177.06 -174.97 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.13 -175.85 5.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -132.71 27.92 3.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.452 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -113.23 78.99 1.18 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.895 0.379 . . . . 0.0 110.825 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 142.78 51.64 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.4 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -89.07 -32.38 17.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.751 0.31 . . . . 0.0 110.869 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 62.9 m -107.42 -31.54 8.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -79.99 -169.89 2.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.063 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.54 -32.83 9.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.958 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 21.5 tp10 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.884 179.989 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.5 ttp . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -103.06 149.5 24.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -100.38 126.33 46.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.83 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -92.54 124.1 36.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 -89.92 -53.41 4.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.8 t-80 -176.57 152.41 1.03 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -129.91 131.75 46.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -97.73 171.39 5.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.083 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_exo -48.42 104.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.673 2.248 . . . . 0.0 112.513 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . . . . . . . . . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.44 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.462 HG23 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.412 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.404 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.475 ' CD1' ' HA ' ' A' ' 145' ' ' ASP . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.458 ' CD1' ' CB ' ' A' ' 149' ' ' PRO . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.413 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 HG23 ' A' ' 33' ' ' ILE . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.425 ' CD2' ' CG1' ' A' ' 38' ' ' VAL . 4.6 p-80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.425 ' CG1' ' CD2' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.456 ' CE1' ' CD1' ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.456 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.421 ' CD1' HG22 ' A' ' 54' ' ' ILE . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.413 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.452 ' CG2' ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.421 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.49 137.96 23.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.78 85.28 7.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -75.95 163.35 27.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.1 ttm180 -95.75 120.13 35.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 30.2 mm -127.21 110.88 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 60.63 30.68 19.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.037 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.67 23.86 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.584 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 8.7 mtp180 -89.33 172.7 8.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 21.8 mt -109.65 126.05 53.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.825 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.17 133.55 62.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.13 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.9 m170 -89.21 111.47 22.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.436 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.446 ' N ' ' CE1' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.407 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.445 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.445 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.475 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.458 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.452 ' CE2' ' CG2' ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.416 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.405 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.446 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . 0.402 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.419 ' HA ' ' CD1' ' A' ' 62' ' ' PHE . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -60.2 147.49 39.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -171.36 106.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.129 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 69.52 129.69 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.06 175.28 0.3 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.807 0.337 . . . . 0.0 111.037 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.56 -44.95 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.467 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -91.51 -31.95 15.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.84 0.352 . . . . 0.0 110.918 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 15.3 t 44.83 36.56 1.91 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.361 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -91.36 130.11 37.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.007 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 51.2 mt -90.44 119.21 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.864 179.935 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 46.7 ttm . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.891 0.376 . . . . 0.0 111.255 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 12.4 m80 -131.73 -52.27 0.99 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -142.8 86.88 1.96 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 8.0 m80 61.64 153.46 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.912 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -58.94 -28.74 66.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.014 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.5 m-70 -128.07 163.37 24.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.928 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -134.53 149.87 50.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -137.0 165.25 36.34 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -64.78 124.71 13.57 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.582 2.188 . . . . 0.0 112.324 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.42 ' CD1' HD21 ' A' ' 93' ' ' LEU . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.449 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.449 ' CD2' ' HB2' ' A' ' 18' ' ' LYS . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.463 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.1 t60 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CE1' ' CD1' ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.451 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.41 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.417 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . 0.408 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.418 ' CD2' HG23 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.42 HD21 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.414 HD12 ' CZ3' ' A' ' 13' ' ' TRP . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -141.42 167.15 22.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.417 ' HB3' ' CE1' ' A' ' 122' ' ' HIS . 72.6 p -102.44 90.59 3.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mmm -68.47 147.14 52.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.971 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.1 ttm-85 -95.53 134.37 38.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.0 mt -138.12 103.19 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.142 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 60.69 31.29 20.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.951 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 88.33 27.84 24.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.573 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 80.2 mtt85 -136.4 127.01 27.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.3 mt -88.17 118.86 28.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -115.15 125.55 72.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.054 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . 0.417 ' CE1' ' HB3' ' A' ' 113' ' ' SER . 29.2 m80 -87.17 112.38 21.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.441 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.485 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.485 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.416 HG21 ' CD2' ' A' ' 25' ' ' PHE . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.441 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.418 HG12 ' CE1' ' A' ' 164' ' ' HIS . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.417 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 59.09 -168.63 0.14 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . 60.84 106.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.11 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 135.15 44.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -163.7 135.17 4.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.781 0.324 . . . . 0.0 110.993 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -177.08 49.59 0.1 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.435 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -159.4 -45.61 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.838 0.352 . . . . 0.0 110.922 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -68.36 -40.77 81.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -83.7 125.78 32.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.101 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -106.46 31.6 5.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.92 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.304 -0.855 . . . . 0.0 110.895 179.946 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 mmt . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.852 0.358 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -147.58 -48.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -137.1 35.36 2.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -127.8 34.66 4.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.924 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 t60 -96.76 -31.17 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.966 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.6 m80 -94.77 137.2 34.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -105.71 -29.69 9.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.912 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.403 ' O ' ' CZ2' ' A' ' 13' ' ' TRP . . . -107.47 99.43 28.41 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.067 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -50.59 151.26 10.7 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.47 2.113 . . . . 0.0 112.512 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.414 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.441 ' CD2' ' CD1' ' A' ' 101' ' ' LEU . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 ' HD3' ' A' ' 149' ' ' PRO . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.41 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . 0.402 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.9 t60 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.45 ' CD1' ' CE2' ' A' ' 67' ' ' PHE . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.407 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.416 HG22 ' CD1' ' A' ' 65' ' ' PHE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.416 ' CD1' HG22 ' A' ' 63' ' ' THR . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.42 ' HE1' ' CE2' ' A' ' 67' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.425 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.415 HD22 ' CD1' ' A' ' 13' ' ' TRP . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.441 ' CD1' ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.95 135.19 34.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.7 t -80.13 103.96 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -87.66 146.53 25.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.915 179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.2 ttm180 -99.45 122.13 42.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -137.87 121.57 21.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.137 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 60.44 31.34 20.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 75.9 29.71 58.69 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.483 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.5 mtt180 -136.42 136.05 39.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.798 0.332 . . . . 0.0 110.837 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 23.8 mt -88.85 111.63 22.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 6.3 m -108.54 126.85 65.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -93.31 119.75 32.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.923 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.5 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.437 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.428 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.458 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.44 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.427 ' HD3' HG21 ' A' ' 16' ' ' VAL . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.425 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.406 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.5 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 36.4 t-80 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 164' ' ' HIS . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.407 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -60.85 147.93 41.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -145.69 -172.11 3.83 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.35 -137.62 9.68 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.486 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -78.97 153.34 30.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.786 0.327 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -157.8 -99.13 0.15 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -103.21 -57.01 2.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.794 0.33 . . . . 0.0 110.913 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 4.9 t -141.53 -48.33 0.39 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.889 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -84.17 105.27 14.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.084 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.2 pp -106.38 -32.97 7.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.017 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.289 -0.862 . . . . 0.0 110.894 179.946 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.9 ptt? . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.774 0.321 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.55 89.44 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.008 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -134.09 106.89 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.95 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -83.99 -59.01 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -166.87 162.99 16.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -96.72 41.93 1.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.836 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.2 t60 61.09 90.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -67.16 157.5 84.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.07 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_exo -51.97 125.05 16.09 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.586 2.191 . . . . 0.0 112.281 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.441 ' CE3' ' CD2' ' A' ' 101' ' ' LEU . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CZ ' ' A' ' 25' ' ' PHE . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.433 HG21 ' HD3' ' A' ' 149' ' ' PRO . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.419 HG23 ' CE1' ' A' ' 47' ' ' PHE . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CZ ' ' CB ' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.1 t60 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.419 ' CE1' HG23 ' A' ' 17' ' ' THR . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.534 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.534 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.419 HD12 ' CE1' ' A' ' 46' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . 0.416 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.416 ' CZ ' HG12 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.417 ' CE2' HD11 ' A' ' 54' ' ' ILE . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.421 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.421 HD22 ' CD1' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.426 HG21 HD12 ' A' ' 94' ' ' ILE . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.441 ' CD2' ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 148.14 30.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -87.03 103.38 15.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.91 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -87.41 159.33 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.78 126.86 36.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.46 HG22 HD11 ' A' ' 116' ' ' ILE . 30.9 mt -128.88 108.47 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.129 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 60.68 31.19 20.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.911 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 96.15 -25.66 24.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -99.31 130.33 45.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.858 0.361 . . . . 0.0 110.851 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 12.3 mt -79.33 139.92 37.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.908 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.33 145.39 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.075 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -86.58 127.18 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.528 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.464 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' THR . . . . . 0.401 ' HB ' ' CB ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.442 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.433 ' HD3' HG21 ' A' ' 16' ' ' VAL . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.421 ' CE2' HG22 ' A' ' 92' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.452 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.404 ' O ' ' CE1' ' A' ' 152' ' ' HIS . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.528 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 18.5 t-80 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 60.32 108.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -142.52 131.18 22.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 161.14 -28.47 0.3 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.593 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -131.42 129.41 41.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 111.001 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.45 -66.53 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 31.1 tt0 -106.34 -70.05 0.8 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.897 0.38 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.0 t -111.37 -38.7 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.54 88.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.078 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 11.1 mt -69.05 -31.86 70.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.835 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.813 -179.867 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.851 0.357 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 4.4 m80 -106.39 -176.61 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -109.46 37.65 2.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.953 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -60.09 -57.22 13.75 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER 60.73 -170.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -80.8 -176.62 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -66.83 -68.09 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.94 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -98.37 149.29 35.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.008 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.414 ' HG2' ' CE2' ' A' ' 158' ' ' TRP . 50.9 Cg_exo -53.84 151.94 24.57 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.62 2.213 . . . . 0.0 112.338 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.439 ' CZ3' ' CD2' ' A' ' 93' ' ' LEU . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.418 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.415 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . 0.415 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.6 t60 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.45 ' CD1' ' CE2' ' A' ' 67' ' ' PHE . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.451 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.439 ' CD2' ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.436 HG22 HD12 ' A' ' 94' ' ' ILE . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.93 177.49 7.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -102.8 107.0 17.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.2 mtt -84.69 148.71 26.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.96 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.6 ttt180 -96.91 127.94 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.825 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -135.45 108.76 9.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.19 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 60.38 33.62 20.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.59 28.43 43.29 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.7 mmm180 -135.3 131.62 36.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.814 0.34 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.1 mt -87.21 121.88 30.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.884 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -127.6 135.8 62.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -76.7 126.85 31.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.435 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.401 ' CD2' ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.486 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.486 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.418 ' O ' ' HA2' ' A' ' 22' ' ' GLY . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.451 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.414 ' CE2' ' HG2' ' A' ' 9' ' ' PRO . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.42 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.435 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . 0.401 ' CB ' ' CD2' ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 58.91 31.29 21.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -60.44 87.35 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.063 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.66 173.6 43.84 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.58 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -59.17 122.16 13.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.888 0.375 . . . . 0.0 111.005 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -136.52 -69.52 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.526 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -94.39 -36.33 11.97 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.865 0.364 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.59 31.06 3.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.34 -53.21 60.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.17 -31.81 71.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.992 179.946 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.774 0.321 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 27.8 m80 68.6 -68.12 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.895 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 55.7 m-70 -124.85 -175.47 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.923 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -99.58 -67.95 0.83 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.855 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.1 m170 -73.74 -176.55 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.929 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -122.21 -176.47 3.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -175.38 140.9 0.51 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -85.61 144.55 40.19 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.033 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -54.82 154.77 19.95 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.553 2.169 . . . . 0.0 112.331 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.417 ' CD2' HD11 ' A' ' 101' ' ' LEU . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.456 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.421 HG22 ' CD ' ' A' ' 149' ' ' PRO . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.456 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.405 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 18' ' ' LYS . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.456 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.418 ' CG ' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.411 HG23 ' CE1' ' A' ' 65' ' ' PHE . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.421 HG22 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.408 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.423 ' CD2' HG11 ' A' ' 38' ' ' VAL . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.423 HG11 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.408 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.456 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.415 ' CD1' ' CE1' ' A' ' 46' ' ' PHE . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . 0.421 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . 0.411 ' CE1' HG23 ' A' ' 34' ' ' THR . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.408 ' CE2' HD12 ' A' ' 54' ' ' ILE . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.418 HD13 ' CG ' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.454 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . 0.407 HD12 ' CE1' ' A' ' 25' ' ' PHE . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.417 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 169.91 18.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 84.1 p -86.72 102.24 14.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.6 mtp -86.17 150.01 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.4 ttt85 -106.46 109.54 21.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.18 110.73 33.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.056 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 60.4 31.35 20.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.62 28.51 42.89 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.463 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -130.57 107.9 9.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.86 0.362 . . . . 0.0 110.837 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.8 mt -65.45 122.49 17.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.44 144.76 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.103 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -93.51 117.28 29.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.455 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.445 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.463 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.424 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . 0.439 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.454 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.424 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.408 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.424 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . 0.41 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 19.6 t-80 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.414 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . 0.421 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 -176.96 93.92 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -154.17 116.79 4.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.102 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -158.05 -172.82 25.68 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.54 -172.58 4.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.812 0.339 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -164.72 -65.93 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.514 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -64.73 -54.53 30.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.837 0.351 . . . . 0.0 110.957 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 89.1 m 55.83 54.93 7.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.964 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.11 31.15 21.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.176 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.9 106.64 11.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.902 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.178 -0.915 . . . . 0.0 110.937 179.917 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.871 0.367 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -98.84 31.65 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -149.1 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -91.17 129.65 37.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.2 t-80 -100.36 -31.51 11.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m170 -59.99 127.86 33.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -126.98 157.52 39.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.401 ' O ' ' CZ2' ' A' ' 13' ' ' TRP . . . -63.41 158.34 58.43 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.12 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.66 144.74 97.45 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.684 2.256 . . . . 0.0 112.269 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.421 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 10' ' ' PRO . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.461 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.441 HG23 ' CE3' ' A' ' 23' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.414 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.471 ' CZ3' ' HB2' ' A' ' 18' ' ' LYS . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PHE . . . . . 0.461 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TRP . . . . . 0.419 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . 0.414 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.513 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.513 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.456 ' CD1' ' CD1' ' A' ' 46' ' ' PHE . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.448 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' MET . . . . . 0.439 ' CE ' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.46 ' CG2' ' CZ ' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' A' ' 13' ' ' TRP . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -146.21 159.1 43.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.3 m -84.93 109.79 18.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.63 154.43 17.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.907 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.4 ttt180 -98.01 128.84 44.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 32.8 mt -140.19 119.35 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.71 31.39 20.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.4 28.0 60.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.568 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.7 mtp85 -136.44 141.18 43.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.4 mt -88.38 118.9 28.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -129.46 138.58 53.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.197 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -76.0 141.63 42.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.461 ' HB2' ' CD2' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' ILE . . . . . 0.569 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.569 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ASP . . . . . 0.425 ' HA ' ' CD1' ' A' ' 23' ' ' TRP . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' PRO . . . . . 0.453 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' TYR . . . . . 0.46 ' CZ ' ' CG2' ' A' ' 92' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' HIS . . . . . 0.424 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ARG . . . . . 0.424 ' HG3' ' CD2' ' A' ' 152' ' ' HIS . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' VAL . . . . . . . . . . . . . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 18.7 m120 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -110.61 165.84 11.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -174.9 145.22 0.83 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 101.79 35.3 4.07 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.442 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -90.91 131.35 36.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.843 0.354 . . . . 0.0 110.92 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.42 8.31 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.526 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.1 -64.26 1.18 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.847 0.356 . . . . 0.0 110.966 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 63.1 m -106.12 -47.07 3.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.58 165.89 7.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.101 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.3 tp -172.51 121.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.926 179.982 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.474 ' CG ' HD13 ' A' ' 12' ' ' LEU . 36.2 Cg_endo . . . . . 0 CA--C 1.531 0.333 0 CA-C-O 120.54 0.142 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.026 HD21 HG11 ' A' ' 151' ' ' VAL . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.803 ' O ' HG12 ' A' ' 16' ' ' VAL . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.803 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.484 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.426 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.582 ' HE3' HG22 ' A' ' 16' ' ' VAL . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.726 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.451 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.866 HG21 HG23 ' A' ' 33' ' ' ILE . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB2' ' HB ' ' A' ' 31' ' ' VAL . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.408 ' HB2' ' HB3' ' A' ' 70' ' ' LYS . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.514 HG12 ' HB ' ' A' ' 27' ' ' VAL . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.866 HG23 HG21 ' A' ' 27' ' ' VAL . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.596 HG22 ' H ' ' A' ' 36' ' ' THR . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.596 ' H ' HG22 ' A' ' 35' ' ' THR . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.467 ' CE1' HG13 ' A' ' 38' ' ' VAL . 0.1 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' CE1' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 35' ' ' THR . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.484 HG21 ' HE1' ' A' ' 19' ' ' PHE . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HD11 ' A' ' 54' ' ' ILE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.4 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.525 HD11 ' O ' ' A' ' 49' ' ' GLU . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.92 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 ' CG2' ' A' ' 63' ' ' THR . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.655 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.92 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.451 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.457 ' O ' HG12 ' A' ' 160' ' ' VAL . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.598 HD22 HG13 ' A' ' 160' ' ' VAL . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.528 ' N ' HD13 ' A' ' 80' ' ' LEU . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.429 ' HA ' HG13 ' A' ' 178' ' ' VAL . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.792 ' SG ' HG21 ' A' ' 88' ' ' THR . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.792 HG21 ' SG ' ' A' ' 84' ' ' CYS . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.473 HG21 ' CE1' ' A' ' 164' ' ' HIS . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.606 HD11 ' CD2' ' A' ' 12' ' ' LEU . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.542 HG23 ' CG ' ' A' ' 145' ' ' ASP . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.426 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.646 HD23 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 102' ' ' LEU . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.474 ' CD1' HD11 ' A' ' 94' ' ' ILE . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.661 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.465 ' O ' HG23 ' A' ' 111' ' ' ILE . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.858 0.361 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.488 ' O ' HG13 ' A' ' 106' ' ' VAL . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.569 HD12 ' HB2' ' A' ' 134' ' ' ALA . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.419 ' N ' HD23 ' A' ' 128' ' ' LEU . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.569 ' HB2' HD12 ' A' ' 128' ' ' LEU . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.51 ' C ' ' HB3' ' A' ' 167' ' ' ALA . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.559 ' HB3' HG22 ' A' ' 141' ' ' THR . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.854 HD23 ' CG2' ' A' ' 174' ' ' VAL . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.559 HG22 ' HB3' ' A' ' 138' ' ' ASP . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.531 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.531 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.542 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.409 ' HB3' ' HB2' ' A' ' 25' ' ' PHE . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.711 ' O ' HG23 ' A' ' 160' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.026 HG11 HD21 ' A' ' 12' ' ' LEU . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.46 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.46 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.452 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' HG21 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.51 ' HB3' ' C ' ' A' ' 136' ' ' GLY . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.854 ' CG2' HD23 ' A' ' 139' ' ' LEU . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.452 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.47 HG12 ' N ' ' A' ' 179' ' ' GLN . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 178' ' ' VAL . 26.1 tt0 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.484 ' CG ' HD13 ' A' ' 12' ' ' LEU . 37.3 Cg_endo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.622 0.176 . . . . 0.0 112.355 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.484 HD13 ' CG ' ' A' ' 9' ' ' PRO . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.881 ' CD1' HD22 ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.822 ' NH1' HD13 ' A' ' 75' ' ' LEU . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.739 HG22 ' HE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.512 ' O ' HG12 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.739 ' HE3' HG22 ' A' ' 16' ' ' VAL . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CZ ' HG11 ' A' ' 160' ' ' VAL . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.768 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 HD11 ' A' ' 80' ' ' LEU . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.674 HG22 ' H ' ' A' ' 37' ' ' HIS . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.674 ' H ' HG22 ' A' ' 35' ' ' THR . 26.0 t-80 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.429 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.484 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.561 HD22 HD11 ' A' ' 56' ' ' ILE . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 55' ' ' ALA . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.851 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.561 HD11 HD22 ' A' ' 51' ' ' LEU . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.401 ' HG2' HG21 ' A' ' 36' ' ' THR . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.424 ' O ' ' HB1' ' A' ' 177' ' ' ALA . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.851 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.768 ' CG ' HG23 ' A' ' 30' ' ' THR . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.597 ' CG ' HD12 ' A' ' 75' ' ' LEU . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.822 HD13 ' NH1' ' A' ' 15' ' ' ARG . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 159' ' ' VAL . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.71 HD11 HD13 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.558 ' HG2' HG11 ' A' ' 159' ' ' VAL . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.682 ' O ' HG22 ' A' ' 151' ' ' VAL . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.881 HD22 ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.671 HG23 ' CG ' ' A' ' 145' ' ' ASP . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.982 HD22 HG21 ' A' ' 130' ' ' THR . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.595 HG22 HD21 ' A' ' 139' ' ' LEU . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' MET . . . . . 0.443 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.567 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.877 0.37 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.569 ' O ' HG23 ' A' ' 173' ' ' THR . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.442 ' O ' HG13 ' A' ' 106' ' ' VAL . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.599 ' CD2' HD13 ' A' ' 139' ' ' LEU . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.743 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.982 HG21 HD22 ' A' ' 104' ' ' LEU . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.403 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' MET . . . . . 0.406 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.672 ' HB2' HG23 ' A' ' 141' ' ' THR . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.599 HD13 ' CD2' ' A' ' 128' ' ' LEU . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.672 HG23 ' HB2' ' A' ' 138' ' ' ASP . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.479 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.671 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.414 ' HB3' HG11 ' A' ' 38' ' ' VAL . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.412 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.564 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.793 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 160' ' ' VAL . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.565 ' HD3' HG21 ' A' ' 159' ' ' VAL . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HD2' ' A' ' 153' ' ' LYS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.565 HG21 ' HD3' ' A' ' 154' ' ' ARG . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 151' ' ' VAL . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.406 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.569 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.518 HG11 HD23 ' A' ' 139' ' ' LEU . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 61' ' ' GLU . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.644 HG23 ' CD2' ' A' ' 80' ' ' LEU . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.432 ' N ' HG13 ' A' ' 178' ' ' VAL . 9.3 tp60 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.459 ' HD2' HD13 ' A' ' 12' ' ' LEU . 57.4 Cg_exo . . . . . 0 CA--C 1.527 0.139 0 CA-C-O 120.781 0.242 . . . . 0.0 112.409 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.703 HG23 ' O ' ' A' ' 74' ' ' ASP . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.091 HD21 HG11 ' A' ' 151' ' ' VAL . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.878 ' O ' HG12 ' A' ' 16' ' ' VAL . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HG2' HD22 ' A' ' 75' ' ' LEU . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.878 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 43' ' ' VAL . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.538 ' O ' HG11 ' A' ' 38' ' ' VAL . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.489 ' HE3' HG22 ' A' ' 16' ' ' VAL . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.481 ' HB3' HD13 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.732 HG13 HG12 ' A' ' 33' ' ' ILE . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.48 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.732 HG12 HG13 ' A' ' 27' ' ' VAL . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.585 HG22 ' H ' ' A' ' 37' ' ' HIS . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.817 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.585 ' H ' HG22 ' A' ' 35' ' ' THR . 38.1 t-80 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.538 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.817 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.42 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 41' ' ' THR . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.494 HG21 ' CE1' ' A' ' 19' ' ' PHE . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.498 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.426 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.498 HD12 ' HE1' ' A' ' 46' ' ' PHE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.925 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.605 ' OG1' HG23 ' A' ' 36' ' ' THR . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.925 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.483 ' C ' HG23 ' A' ' 30' ' ' THR . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.703 ' O ' HG23 ' A' ' 11' ' ' THR . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.481 HD13 ' HB3' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.505 HD12 HG13 ' A' ' 160' ' ' VAL . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.768 HG22 ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.515 HD22 ' HE1' ' A' ' 13' ' ' TRP . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 104' ' ' LEU . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.76 HD23 ' O ' ' A' ' 94' ' ' ILE . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.044 HD11 HD11 ' A' ' 94' ' ' ILE . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.737 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.59 ' HG3' HD12 ' A' ' 129' ' ' LEU . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.873 0.368 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.771 ' O ' HG23 ' A' ' 173' ' ' THR . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.676 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.59 HD12 ' HG3' ' A' ' 107' ' ' ARG . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.533 ' HA ' HD11 ' A' ' 128' ' ' LEU . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.732 ' HB2' HG23 ' A' ' 141' ' ' THR . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.692 HD23 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.732 HG23 ' HB2' ' A' ' 138' ' ' ASP . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.464 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.464 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.61 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.614 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.614 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.768 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.091 HG11 HD21 ' A' ' 12' ' ' LEU . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.4 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.736 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.736 HG23 ' HB2' ' A' ' 154' ' ' ARG . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.474 ' O ' HD11 ' A' ' 80' ' ' LEU . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.444 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.826 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.826 HG12 ' HB2' ' A' ' 167' ' ' ALA . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.419 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.757 0.232 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 12' ' ' LEU . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.757 ' O ' HG12 ' A' ' 16' ' ' VAL . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.681 ' NH1' HD22 ' A' ' 75' ' ' LEU . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.757 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.536 ' HE1' HG21 ' A' ' 43' ' ' VAL . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.618 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.514 ' HE3' HG22 ' A' ' 16' ' ' VAL . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.797 HG21 HG23 ' A' ' 33' ' ' ILE . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.402 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.453 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.448 HG22 ' HD2' ' A' ' 66' ' ' ARG . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.801 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 38' ' ' VAL . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.401 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.618 ' H ' HG22 ' A' ' 35' ' ' THR . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.683 HG22 ' HB ' ' A' ' 35' ' ' THR . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' HE1' ' A' ' 19' ' ' PHE . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.586 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.586 HD12 ' HA ' ' A' ' 51' ' ' LEU . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.7 m170 -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HB3' HG23 ' A' ' 35' ' ' THR . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.444 ' CZ ' ' HG2' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.898 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.401 ' CD2' ' OE1' ' A' ' 49' ' ' GLU . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 30' ' ' THR . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.414 ' HE1' ' HD2' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.681 HD22 ' NH1' ' A' ' 15' ' ' ARG . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' MET . . . . . 0.459 ' HE3' ' N ' ' A' ' 160' ' ' VAL . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 81' ' ' GLU . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.467 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.636 ' N ' HG11 ' A' ' 178' ' ' VAL . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.775 ' O ' HG22 ' A' ' 151' ' ' VAL . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.595 HG21 ' NE2' ' A' ' 164' ' ' HIS . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.486 ' N ' HG12 ' A' ' 92' ' ' VAL . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.883 HG21 HG13 ' A' ' 142' ' ' ILE . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.752 ' CD2' HD11 ' A' ' 142' ' ' ILE . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.4 HD12 HD11 ' A' ' 94' ' ' ILE . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.565 HG22 HD23 ' A' ' 128' ' ' LEU . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.903 0.383 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.429 ' C ' HG22 ' A' ' 174' ' ' VAL . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.621 HD21 HG11 ' A' ' 174' ' ' VAL . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.584 HD12 ' C ' ' A' ' 128' ' ' LEU . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 132' ' ' ALA . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.552 ' HB2' ' OD1' ' A' ' 172' ' ' ASN . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' MET . . . . . 0.427 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.432 ' HG ' ' CG ' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.404 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.883 HG13 HG21 ' A' ' 94' ' ' ILE . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.586 ' OD1' HG23 ' A' ' 94' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.438 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.881 ' O ' HG23 ' A' ' 160' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 91' ' ' SER . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.493 ' HD3' HG21 ' A' ' 159' ' ' VAL . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.481 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.769 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.595 ' NE2' HG21 ' A' ' 92' ' ' VAL . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.821 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.552 ' OD1' ' HB2' ' A' ' 132' ' ' ALA . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.821 HG12 ' HB2' ' A' ' 167' ' ' ALA . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.421 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.769 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.636 HG11 ' N ' ' A' ' 83' ' ' GLY . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.444 ' HG2' ' CZ ' ' A' ' 62' ' ' PHE . 22.1 mt-30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.784 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo . . . . . 0 C--O 1.231 0.151 0 CA-C-O 120.858 0.274 . . . . 0.0 112.253 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.942 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.791 ' O ' HG12 ' A' ' 16' ' ' VAL . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.791 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB2' ' CH2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.4 ' CB ' HG12 ' A' ' 38' ' ' VAL . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.42 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.66 ' HE3' HG22 ' A' ' 16' ' ' VAL . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.664 ' CE2' HG11 ' A' ' 160' ' ' VAL . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.552 ' CB ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.782 HG21 HG23 ' A' ' 33' ' ' ILE . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.533 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.782 HG23 HG21 ' A' ' 27' ' ' VAL . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.738 HG21 ' CE1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.845 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.738 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.642 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.845 HG12 ' O ' ' A' ' 36' ' ' THR . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.937 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.857 HD11 HG23 ' A' ' 63' ' ' THR . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.52 ' N ' HD13 ' A' ' 56' ' ' ILE . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 56' ' ' ILE . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.937 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.533 ' HB3' HG23 ' A' ' 30' ' ' THR . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PRO . . . . . 0.415 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.552 HD13 ' CB ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' MET . . . . . 0.519 ' CE ' HG13 ' A' ' 160' ' ' VAL . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.655 ' HA ' HG21 ' A' ' 178' ' ' VAL . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.626 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HG21 ' A' ' 151' ' ' VAL . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.765 HD11 ' CG ' ' A' ' 104' ' ' LEU . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.589 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.765 ' CG ' HD11 ' A' ' 94' ' ' ILE . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.779 HG22 HD23 ' A' ' 128' ' ' LEU . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.775 HG23 ' OE1' ' A' ' 124' ' ' GLN . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 . . . . . 0 CA--C 1.527 0.086 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLN . . . . . 0.775 ' OE1' HG23 ' A' ' 111' ' ' ILE . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 173' ' ' THR . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 106' ' ' VAL . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 128' ' ' LEU . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.421 HG21 HD22 ' A' ' 133' ' ' ASN . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.488 ' O ' HD13 ' A' ' 139' ' ' LEU . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.517 ' HB2' HD22 ' A' ' 139' ' ' LEU . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.855 HD23 ' HB2' ' A' ' 167' ' ' ALA . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.702 ' HA ' HD13 ' A' ' 94' ' ' ILE . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.554 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.554 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.769 ' CG ' ' HB2' ' A' ' 148' ' ' ALA . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.42 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.769 ' HB2' ' CG ' ' A' ' 145' ' ' ASP . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 93' ' ' LEU . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.942 HG11 HD21 ' A' ' 12' ' ' LEU . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.408 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.474 ' CB ' HG23 ' A' ' 159' ' ' VAL . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.474 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.862 HG12 HG12 ' A' ' 151' ' ' VAL . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.502 ' O ' HG11 ' A' ' 178' ' ' VAL . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.457 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.421 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.855 ' HB2' HD23 ' A' ' 139' ' ' LEU . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.487 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.487 ' H ' HG22 ' A' ' 168' ' ' THR . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 126' ' ' GLY . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.568 ' CG2' HG11 ' A' ' 106' ' ' VAL . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 165' ' ' ALA . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.655 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.438 ' N ' HG23 ' A' ' 178' ' ' VAL . 7.3 mm-40 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HD2' HD13 ' A' ' 12' ' ' LEU . 46.7 Cg_exo . . . . . 0 CA--C 1.527 0.159 0 CA-C-O 120.703 0.21 . . . . 0.0 112.419 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 74' ' ' ASP . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.644 HD13 ' HD2' ' A' ' 9' ' ' PRO . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.79 ' O ' HG12 ' A' ' 16' ' ' VAL . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 13' ' ' TRP . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.467 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.5 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.826 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.518 ' CD2' HD11 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.844 HG13 HD11 ' A' ' 80' ' ' LEU . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.628 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.826 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.771 ' HB ' HG22 ' A' ' 38' ' ' VAL . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.767 ' H ' HG22 ' A' ' 35' ' ' THR . 40.1 t-80 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.771 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.467 HG21 ' HE1' ' A' ' 19' ' ' PHE . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.654 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.674 HG21 ' CD2' ' A' ' 65' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.794 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.563 HG23 ' HE1' ' A' ' 65' ' ' PHE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.674 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.794 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.628 ' C ' HG23 ' A' ' 30' ' ' THR . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.57 ' N ' HG23 ' A' ' 30' ' ' THR . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.479 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.56 ' O ' HG23 ' A' ' 11' ' ' THR . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.662 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 27' ' ' VAL . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.539 ' HA2' HD11 ' A' ' 111' ' ' ILE . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.662 HG22 HD22 ' A' ' 129' ' ' LEU . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.486 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.712 HG22 ' CE1' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.45 ' N ' HG12 ' A' ' 92' ' ' VAL . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.636 HD11 ' CD1' ' A' ' 104' ' ' LEU . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.4 HD12 ' HA ' ' A' ' 102' ' ' LEU . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.636 ' CD1' HD11 ' A' ' 94' ' ' ILE . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.539 HD11 ' HA2' ' A' ' 83' ' ' GLY . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.825 0.345 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.618 HD23 HD11 ' A' ' 139' ' ' LEU . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.662 HD22 HG22 ' A' ' 89' ' ' VAL . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HA ' HD13 ' A' ' 128' ' ' LEU . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.423 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.826 HD22 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.641 HG21 ' HB3' ' A' ' 145' ' ' ASP . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.579 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.579 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.639 ' O ' HG11 ' A' ' 38' ' ' VAL . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.613 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.74 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 91' ' ' SER . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.407 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.415 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.455 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.431 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.3 t60 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.644 ' CB ' HG12 ' A' ' 174' ' ' VAL . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.826 HG11 HD22 ' A' ' 139' ' ' LEU . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.486 ' N ' HG22 ' A' ' 178' ' ' VAL . 4.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.763 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo . . . . . 0 CA--C 1.527 0.171 0 CA-C-O 120.731 0.221 . . . . 0.0 112.345 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.446 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.771 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.768 ' O ' HG12 ' A' ' 16' ' ' VAL . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.768 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.555 ' O ' HG12 ' A' ' 38' ' ' VAL . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.485 ' HE3' HG22 ' A' ' 16' ' ' VAL . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.621 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.557 ' CG2' HG12 ' A' ' 31' ' ' VAL . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.41 ' HB2' ' CG ' ' A' ' 70' ' ' LYS . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.557 HG12 ' CG2' ' A' ' 27' ' ' VAL . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.621 HD11 ' HB3' ' A' ' 25' ' ' PHE . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' HG22 ' A' ' 38' ' ' VAL . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.785 ' O ' HG12 ' A' ' 39' ' ' VAL . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CE1' HG21 ' A' ' 35' ' ' THR . 0.0 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 21' ' ' SER . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.785 HG12 ' O ' ' A' ' 36' ' ' THR . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.4 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.611 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.611 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.466 HG13 HG23 ' A' ' 63' ' ' THR . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.466 HG23 HG13 ' A' ' 56' ' ' ILE . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.41 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.535 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 72' ' ' ARG . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.795 HD21 HG23 ' A' ' 178' ' ' VAL . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.473 ' HA ' HG21 ' A' ' 178' ' ' VAL . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.787 ' O ' HG22 ' A' ' 151' ' ' VAL . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 93' ' ' LEU . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.537 HD22 ' HD1' ' A' ' 13' ' ' TRP . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.775 HG23 ' CG ' ' A' ' 145' ' ' ASP . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.613 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.894 HD22 HG21 ' A' ' 130' ' ' THR . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.558 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.765 HG23 ' NE2' ' A' ' 124' ' ' GLN . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 37.8 m80 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.885 0.374 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLN . . . . . 0.765 ' NE2' HG23 ' A' ' 111' ' ' ILE . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' O ' HG23 ' A' ' 173' ' ' THR . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.477 ' O ' HG13 ' A' ' 106' ' ' VAL . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.556 HD11 HG13 ' A' ' 174' ' ' VAL . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.894 HG21 HD22 ' A' ' 104' ' ' LEU . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 131' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 132' ' ' ALA . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.432 ' HB1' ' OD1' ' A' ' 172' ' ' ASN . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.416 ' HB3' ' HA3' ' A' ' 140' ' ' GLY . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.795 ' OD1' HD23 ' A' ' 139' ' ' LEU . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.96 HD22 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 133' ' ' ASN . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.657 HG21 ' HB3' ' A' ' 145' ' ' ASP . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.775 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.861 ' O ' HG23 ' A' ' 160' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 91' ' ' SER . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.422 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.494 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.584 HG13 ' O ' ' A' ' 79' ' ' VAL . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.96 ' CE1' HD22 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 177' ' ' ALA . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.432 ' OD1' ' HB1' ' A' ' 132' ' ' ALA . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 126' ' ' GLY . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.558 ' CG2' HG11 ' A' ' 106' ' ' VAL . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 165' ' ' ALA . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.795 HG23 HD21 ' A' ' 80' ' ' LEU . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.479 ' N ' HG22 ' A' ' 178' ' ' VAL . 1.2 mm100 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.687 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.8 Cg_exo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.769 0.237 . . . . 0.0 112.351 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.687 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.879 ' O ' HG12 ' A' ' 16' ' ' VAL . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.879 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.77 ' CE2' HG11 ' A' ' 160' ' ' VAL . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.435 ' HB3' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.544 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.413 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.49 HG12 ' CG2' ' A' ' 27' ' ' VAL . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.544 HD13 ' CG1' ' A' ' 27' ' ' VAL . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.4 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.754 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.754 ' H ' HG22 ' A' ' 35' ' ' THR . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.718 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.88 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 56' ' ' ILE . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 62' ' ' PHE . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.505 ' HB3' ' HB3' ' A' ' 59' ' ' ALA . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.4 ' HB ' HG23 ' A' ' 34' ' ' THR . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.88 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.575 ' HB3' HG23 ' A' ' 30' ' ' THR . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.435 HD13 ' HB3' ' A' ' 26' ' ' TRP . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.713 HD21 HG12 ' A' ' 178' ' ' VAL . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.415 ' HA ' HG21 ' A' ' 178' ' ' VAL . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.747 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.55 HD21 HG21 ' A' ' 151' ' ' VAL . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.577 HD12 ' HG ' ' A' ' 104' ' ' LEU . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.555 HD22 ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.427 ' O ' HD12 ' A' ' 94' ' ' ILE . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.577 ' HG ' HD12 ' A' ' 94' ' ' ILE . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.615 HG22 HD23 ' A' ' 128' ' ' LEU . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.564 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 34.8 m170 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 1.049 HD13 HD12 ' A' ' 139' ' ' LEU . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.406 HD12 ' N ' ' A' ' 129' ' ' LEU . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 1.049 HD12 HD13 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.691 HG21 ' HB3' ' A' ' 145' ' ' ASP . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.537 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.537 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.691 ' HB3' HG21 ' A' ' 141' ' ' THR . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.566 ' O ' HG11 ' A' ' 38' ' ' VAL . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.58 ' HB2' ' OD1' ' A' ' 145' ' ' ASP . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.446 ' HG2' HD12 ' A' ' 93' ' ' LEU . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CE2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 160' ' ' VAL . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.413 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.515 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.539 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 154' ' ' ARG . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 151' ' ' VAL . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.916 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.431 ' O ' HD12 ' A' ' 128' ' ' LEU . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 128' ' ' LEU . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.713 HG12 HD21 ' A' ' 80' ' ' LEU . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.434 ' N ' HG23 ' A' ' 178' ' ' VAL . 3.0 mm-40 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.7 Cg_exo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.765 0.235 . . . . 0.0 112.315 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.578 ' CD2' HD11 ' A' ' 93' ' ' LEU . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.778 ' O ' HG12 ' A' ' 16' ' ' VAL . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB3' HG12 ' A' ' 38' ' ' VAL . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.604 ' HE3' HG22 ' A' ' 16' ' ' VAL . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' HB3' HD11 ' A' ' 33' ' ' ILE . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.436 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.707 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.594 HG23 ' HD3' ' A' ' 70' ' ' LYS . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.707 HG23 HG21 ' A' ' 27' ' ' VAL . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.765 HG21 ' CD2' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.778 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.765 ' CD2' HG21 ' A' ' 35' ' ' THR . 4.7 p80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 36' ' ' THR . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.636 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.636 HD12 ' HA ' ' A' ' 51' ' ' LEU . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.926 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.704 ' HG3' HG21 ' A' ' 36' ' ' THR . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.505 ' CD1' ' HB1' ' A' ' 177' ' ' ALA . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.522 ' C ' HG22 ' A' ' 30' ' ' THR . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HD3' HG23 ' A' ' 30' ' ' THR . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.571 HD12 ' HG3' ' A' ' 72' ' ' ARG . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.683 ' O ' HG22 ' A' ' 160' ' ' VAL . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.854 HD12 HG23 ' A' ' 160' ' ' VAL . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.404 ' HA3' HD13 ' A' ' 111' ' ' ILE . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.578 HD11 ' CD2' ' A' ' 12' ' ' LEU . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.998 HD11 HD11 ' A' ' 104' ' ' LEU . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.783 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 94' ' ' ILE . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.478 HG12 ' N ' ' A' ' 107' ' ' ARG . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.478 ' N ' HG12 ' A' ' 106' ' ' VAL . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.404 HD13 ' HA3' ' A' ' 83' ' ' GLY . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.772 0.32 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.901 HD23 HD13 ' A' ' 139' ' ' LEU . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.418 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.901 HD13 HD23 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.42 HG21 ' O ' ' A' ' 145' ' ' ASP . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.535 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.706 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.465 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 160' ' ' VAL . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.447 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.447 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.422 HG12 ' N ' ' A' ' 160' ' ' VAL . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 151' ' ' VAL . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.691 ' O ' HG12 ' A' ' 178' ' ' VAL . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 147' ' ' GLY . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.501 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.6 t60 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.621 ' HB2' ' CG1' ' A' ' 174' ' ' VAL . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.466 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.466 ' H ' HG22 ' A' ' 168' ' ' THR . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.661 HG21 ' CD2' ' A' ' 139' ' ' LEU . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.505 ' HB1' ' CD1' ' A' ' 62' ' ' PHE . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 161' ' ' CYS . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.417 ' HD2' HD13 ' A' ' 12' ' ' LEU . 37.5 Cg_endo . . . . . 0 CA--C 1.527 0.156 0 CA-C-O 120.737 0.224 . . . . 0.0 112.295 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.502 ' CD2' HD21 ' A' ' 93' ' ' LEU . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.818 ' O ' HG12 ' A' ' 16' ' ' VAL . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.401 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HE3' HG22 ' A' ' 16' ' ' VAL . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.432 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.513 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' O ' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' A' ' 27' ' ' VAL . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.554 ' CG2' HG11 ' A' ' 27' ' ' VAL . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.618 HG21 ' NE2' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.889 ' O ' HG12 ' A' ' 39' ' ' VAL . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.618 ' NE2' HG21 ' A' ' 35' ' ' THR . 14.9 p80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.545 HG22 ' HB ' ' A' ' 35' ' ' THR . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.889 HG12 ' O ' ' A' ' 36' ' ' THR . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.418 ' HA ' HD12 ' A' ' 54' ' ' ILE . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.418 HG22 ' HD1' ' A' ' 65' ' ' PHE . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HD1' HG22 ' A' ' 63' ' ' THR . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.783 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.432 ' O ' HG22 ' A' ' 30' ' ' THR . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.432 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 159' ' ' VAL . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.439 ' HG2' HG11 ' A' ' 159' ' ' VAL . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HA ' HG21 ' A' ' 178' ' ' VAL . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.416 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.846 HG11 ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.799 HD11 HG13 ' A' ' 151' ' ' VAL . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.507 HD12 HD11 ' A' ' 104' ' ' LEU . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.41 HD22 ' CE3' ' A' ' 13' ' ' TRP . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.522 HD23 HD21 ' A' ' 104' ' ' LEU . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.522 HD21 HD23 ' A' ' 102' ' ' LEU . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.585 ' HB3' ' OG1' ' A' ' 130' ' ' THR . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.72 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.568 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.822 0.344 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.55 ' O ' HG13 ' A' ' 106' ' ' VAL . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 132' ' ' ALA . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.585 ' OG1' ' HB3' ' A' ' 105' ' ' ALA . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.519 ' HA ' HD22 ' A' ' 128' ' ' LEU . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.442 ' O ' HD21 ' A' ' 128' ' ' LEU . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.466 ' CG ' HG22 ' A' ' 141' ' ' THR . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.866 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.466 HG22 ' CG ' ' A' ' 138' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' ILE . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.506 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.505 ' OD1' HG23 ' A' ' 94' ' ' ILE . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.44 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.638 ' O ' HD12 ' A' ' 93' ' ' LEU . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.799 HG13 HD11 ' A' ' 93' ' ' LEU . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.426 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CE2' ' HB2' ' A' ' 153' ' ' LYS . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.548 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.846 ' CE1' HG11 ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.511 ' HA ' HD13 ' A' ' 128' ' ' LEU . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.866 HG21 HD23 ' A' ' 139' ' ' LEU . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.493 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.519 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.49 ' N ' HG22 ' A' ' 178' ' ' VAL . 30.3 mt-30 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.643 ' HD2' HD13 ' A' ' 12' ' ' LEU . 54.2 Cg_exo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.781 0.242 . . . . 0.0 112.406 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.643 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.471 ' CE2' HD22 ' A' ' 101' ' ' LEU . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.761 HG12 ' HE3' ' A' ' 23' ' ' TRP . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.431 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.761 ' HE3' HG12 ' A' ' 16' ' ' VAL . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.507 ' HB3' HD11 ' A' ' 33' ' ' ILE . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.616 ' HB3' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG13 HG12 ' A' ' 33' ' ' ILE . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' CA ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.501 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.84 HD13 ' CD1' ' A' ' 80' ' ' LEU . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.786 HG22 ' H ' ' A' ' 37' ' ' HIS . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.44 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.786 ' H ' HG22 ' A' ' 35' ' ' THR . 27.6 t-80 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.44 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 41' ' ' THR . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.501 ' O ' HD11 ' A' ' 54' ' ' ILE . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.501 HD11 ' O ' ' A' ' 49' ' ' GLU . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.419 ' C ' HG23 ' A' ' 30' ' ' THR . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.473 ' CA ' HG23 ' A' ' 30' ' ' THR . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.432 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PRO . . . . . 0.432 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.616 HD13 ' HB3' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' MET . . . . . 0.439 ' HE3' ' HE2' ' A' ' 25' ' ' PHE . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.84 ' CD1' HD13 ' A' ' 33' ' ' ILE . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.765 HG22 ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.577 HD11 ' CG1' ' A' ' 151' ' ' VAL . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.493 HD11 HD12 ' A' ' 104' ' ' LEU . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.469 ' HG3' HD11 ' A' ' 101' ' ' LEU . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.471 HD22 ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 139' ' ' LEU . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 127' ' ' MET . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.446 ' CZ ' HD13 ' A' ' 129' ' ' LEU . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.564 ' O ' HG23 ' A' ' 111' ' ' ILE . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.792 0.329 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.563 ' O ' HG13 ' A' ' 106' ' ' VAL . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.983 HD21 HD11 ' A' ' 139' ' ' LEU . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.446 HD13 ' CZ ' ' A' ' 107' ' ' ARG . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.528 ' O ' HD11 ' A' ' 128' ' ' LEU . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' MET . . . . . 0.402 ' HA ' ' HA ' ' A' ' 166' ' ' ALA . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.983 HD11 HD21 ' A' ' 128' ' ' LEU . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.568 HG21 ' H ' ' A' ' 146' ' ' CYS . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.475 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.427 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.568 ' H ' HG21 ' A' ' 141' ' ' THR . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.432 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.807 ' HB3' ' ND1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.563 ' HG2' HD12 ' A' ' 93' ' ' LEU . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.765 ' CE2' HG22 ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.577 ' CG1' HD11 ' A' ' 93' ' ' LEU . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.425 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.407 ' HE3' ' N ' ' A' ' 157' ' ' ASP . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ASP . . . . . 0.407 ' N ' ' HE3' ' A' ' 153' ' ' LYS . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CD2' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.425 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.632 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.807 ' ND1' ' HB3' ' A' ' 148' ' ' ALA . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' MET . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.616 HG21 HD23 ' A' ' 139' ' ' LEU . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.632 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.711 HG23 HD21 ' A' ' 80' ' ' LEU . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.444 ' N ' HG22 ' A' ' 178' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.78 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.7 Cg_exo . . . . . 0 C--O 1.232 0.198 0 CA-C-O 120.711 0.213 . . . . 0.0 112.445 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.78 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.867 ' CZ3' HD22 ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.745 ' NE ' HD21 ' A' ' 75' ' ' LEU . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.755 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.696 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.439 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.731 ' HE3' HG22 ' A' ' 16' ' ' VAL . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 33' ' ' ILE . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.544 HG11 ' CG2' ' A' ' 33' ' ' ILE . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.407 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.669 HD11 ' HB3' ' A' ' 25' ' ' PHE . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.546 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.595 ' HB ' HG22 ' A' ' 38' ' ' VAL . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 35' ' ' THR . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.595 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 35' ' ' THR . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.545 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.696 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 50' ' ' PRO . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 49' ' ' GLU . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.578 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.545 HD12 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.872 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 ' HB ' HG23 ' A' ' 34' ' ' THR . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.872 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HB3' HG23 ' A' ' 30' ' ' THR . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.709 ' HG2' HD12 ' A' ' 75' ' ' LEU . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.745 HD21 ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 159' ' ' VAL . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 89' ' ' VAL . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.793 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.514 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.867 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.804 HG23 ' CG ' ' A' ' 145' ' ' ASP . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.582 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.667 HD13 HD12 ' A' ' 139' ' ' LEU . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 174' ' ' VAL . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' MET . . . . . 0.409 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.573 HG22 ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.573 ' NE2' HG22 ' A' ' 111' ' ' ILE . 2.0 t-160 . . . . . 0 C--O 1.233 0.191 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLN . . . . . 0.663 ' C ' HG13 ' A' ' 175' ' ' VAL . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.645 ' HA ' HG22 ' A' ' 175' ' ' VAL . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.586 HD21 HG22 ' A' ' 174' ' ' VAL . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.446 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.873 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.537 HG21 ' HB3' ' A' ' 145' ' ' ASP . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.549 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.455 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.804 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.434 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.606 ' CD ' HG23 ' A' ' 16' ' ' VAL . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.514 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 160' ' ' VAL . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 151' ' ' VAL . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.461 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.8 t60 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.514 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.534 ' O ' HG23 ' A' ' 173' ' ' THR . 9.6 m120 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.585 ' N ' HD23 ' A' ' 128' ' ' LEU . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.873 HG21 ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.76 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HG2' HD13 ' A' ' 12' ' ' LEU . 24.8 Cg_endo . . . . . 0 CA--C 1.528 0.195 0 CA-C-O 120.58 0.158 . . . . 0.0 112.265 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.683 HG23 HD23 ' A' ' 75' ' ' LEU . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.506 HD13 ' HG2' ' A' ' 9' ' ' PRO . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.69 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.489 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.491 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.455 ' CB ' HD13 ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 31' ' ' VAL . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.505 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.662 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.539 HG12 ' CG2' ' A' ' 27' ' ' VAL . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 ' HB3' ' A' ' 25' ' ' PHE . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.421 HG23 ' HB ' ' A' ' 63' ' ' THR . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.742 HG22 ' H ' ' A' ' 37' ' ' HIS . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.723 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.742 ' H ' HG22 ' A' ' 35' ' ' THR . 38.2 t-80 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.715 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 36' ' ' THR . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.489 HG21 ' HE1' ' A' ' 19' ' ' PHE . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' O ' HD11 ' A' ' 54' ' ' ILE . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.806 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.421 ' HB ' HG23 ' A' ' 34' ' ' THR . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.806 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 30' ' ' THR . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.662 ' C ' HG23 ' A' ' 30' ' ' THR . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.405 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.683 HD23 HG23 ' A' ' 11' ' ' THR . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 107' ' ' ARG . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 93' ' ' LEU . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.601 HD11 HG22 ' A' ' 151' ' ' VAL . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 1.117 HD11 HD11 ' A' ' 104' ' ' LEU . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.734 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.117 HD11 HD11 ' A' ' 94' ' ' ILE . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.528 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.595 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.71 ' HB2' HD12 ' A' ' 129' ' ' LEU . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.579 ' O ' HG23 ' A' ' 111' ' ' ILE . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.762 0.315 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.459 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.71 HD12 ' HB2' ' A' ' 107' ' ' ARG . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.858 HG21 ' HA ' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB3' HG22 ' A' ' 141' ' ' THR . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.769 HD12 HD22 ' A' ' 104' ' ' LEU . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.549 HG22 ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.496 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.496 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.601 HG22 HD11 ' A' ' 93' ' ' LEU . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.498 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.703 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.403 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.703 HG12 ' HB2' ' A' ' 167' ' ' ALA . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 178' ' ' VAL . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.468 ' HA ' ' HD2' ' A' ' 10' ' ' PRO . 81.4 Cg_exo . . . . . 0 CA--C 1.529 0.269 0 N-CA-C 112.513 0.159 . . . . 0.0 112.513 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.866 HD11 ' HE3' ' A' ' 78' ' ' MET . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.717 ' O ' HG12 ' A' ' 16' ' ' VAL . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.402 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.851 ' CE3' HG22 ' A' ' 16' ' ' VAL . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.516 ' HB3' HD11 ' A' ' 33' ' ' ILE . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.426 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.705 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.705 HG23 HG21 ' A' ' 27' ' ' VAL . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.752 ' O ' HG23 ' A' ' 39' ' ' VAL . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.71 ' CE1' HG13 ' A' ' 38' ' ' VAL . 8.4 p80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.71 HG13 ' CE1' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 35' ' ' THR . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.457 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.406 HD21 ' HZ ' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CE2' ' A' ' 67' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.93 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 63' ' ' THR . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.428 ' OE1' ' HB1' ' A' ' 165' ' ' ALA . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.431 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 HG23 ' HG2' ' A' ' 58' ' ' GLN . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.93 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.533 ' CE2' HD11 ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.452 ' O ' HG22 ' A' ' 30' ' ' THR . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.437 ' HG2' HG23 ' A' ' 30' ' ' THR . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.426 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.471 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.471 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' MET . . . . . 0.866 ' HE3' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.592 ' HB ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.76 ' HG2' HG11 ' A' ' 159' ' ' VAL . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.477 ' HA2' ' NE2' ' A' ' 124' ' ' GLN . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.598 ' O ' HG22 ' A' ' 151' ' ' VAL . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.592 HG22 ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD11 HG11 ' A' ' 151' ' ' VAL . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.849 HD13 ' HA ' ' A' ' 141' ' ' THR . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.425 HD23 HD21 ' A' ' 104' ' ' LEU . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 140' ' ' GLY . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.69 HG11 HG21 ' A' ' 174' ' ' VAL . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' MET . . . . . 0.455 ' HE3' ' HB3' ' A' ' 124' ' ' GLN . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.766 HD11 ' HB3' ' A' ' 122' ' ' HIS . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 122' ' ' HIS . . . . . 0.766 ' HB3' HD11 ' A' ' 111' ' ' ILE . 3.9 m170 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.882 0.373 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLN . . . . . 0.477 ' NE2' ' HA2' ' A' ' 83' ' ' GLY . 0.0 OUTLIER -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.781 ' O ' HG23 ' A' ' 173' ' ' THR . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.844 HD11 HD12 ' A' ' 139' ' ' LEU . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.935 HD23 ' HB3' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.433 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.849 ' HA ' HD13 ' A' ' 94' ' ' ILE . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.443 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.842 ' O ' HG21 ' A' ' 141' ' ' THR . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.497 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.469 ' HD3' HG23 ' A' ' 16' ' ' VAL . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CE2' HG22 ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 160' ' ' VAL . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.411 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.76 HG11 ' HG2' ' A' ' 81' ' ' GLU . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 151' ' ' VAL . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.766 ' O ' HG11 ' A' ' 178' ' ' VAL . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.458 ' HA3' HG13 ' A' ' 178' ' ' VAL . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.428 ' HB1' ' OE1' ' A' ' 61' ' ' GLU . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.935 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 126' ' ' GLY . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.69 HG21 HG11 ' A' ' 106' ' ' VAL . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.692 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.766 HG11 ' O ' ' A' ' 161' ' ' CYS . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.517 ' HG2' HD13 ' A' ' 12' ' ' LEU . 34.7 Cg_endo . . . . . 0 CA--C 1.53 0.278 0 CA-C-O 120.504 0.126 . . . . 0.0 112.324 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.667 HD21 HG11 ' A' ' 151' ' ' VAL . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.859 ' O ' HG12 ' A' ' 16' ' ' VAL . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.859 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.553 ' HE1' HG21 ' A' ' 43' ' ' VAL . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.577 ' HE3' HG22 ' A' ' 16' ' ' VAL . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.655 ' HB3' HD11 ' A' ' 33' ' ' ILE . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.644 ' HB3' HD11 ' A' ' 75' ' ' LEU . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.503 HG21 HG12 ' A' ' 31' ' ' VAL . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.47 ' C ' HD13 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.743 HG23 ' O ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.503 HG12 HG21 ' A' ' 27' ' ' VAL . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.655 HD11 ' HB3' ' A' ' 25' ' ' PHE . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.592 ' HB ' HG22 ' A' ' 38' ' ' VAL . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 16.0 t-80 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HB ' ' A' ' 35' ' ' THR . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 35' ' ' THR . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.553 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.912 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.417 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.65 ' OE2' ' HB1' ' A' ' 165' ' ' ALA . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.422 ' CE2' ' HG2' ' A' ' 64' ' ' GLN . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.422 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.434 ' CE2' HG21 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.912 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LYS . . . . . 0.743 ' O ' HG23 ' A' ' 30' ' ' THR . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.644 HD11 ' HB3' ' A' ' 26' ' ' TRP . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.638 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 160' ' ' VAL . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLU . . . . . 0.507 ' HA ' HG11 ' A' ' 178' ' ' VAL . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.651 HG22 ' HG2' ' A' ' 107' ' ' ARG . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.529 HG22 ' CE1' ' A' ' 150' ' ' TYR . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.853 HD22 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 1.065 HD11 HD11 ' A' ' 104' ' ' LEU . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 94' ' ' ILE . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.749 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.065 HD11 HD11 ' A' ' 94' ' ' ILE . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.445 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.651 ' HG2' HG22 ' A' ' 89' ' ' VAL . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 123' ' ' GLY . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 29.2 m80 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.76 0.315 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.568 ' O ' HD12 ' A' ' 111' ' ' ILE . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.429 ' OG ' HG22 ' A' ' 175' ' ' VAL . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 134' ' ' ALA . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.615 HD22 ' HG3' ' A' ' 107' ' ' ARG . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.637 ' HB1' ' ND2' ' A' ' 172' ' ' ASN . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 167' ' ' ALA . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.675 HD12 HD13 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.65 HG21 ' HB3' ' A' ' 145' ' ' ASP . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.478 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.65 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.435 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.675 ' O ' HG23 ' A' ' 160' ' ' VAL . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.667 HG11 HD21 ' A' ' 12' ' ' LEU . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.401 ' NE2' ' HB ' ' A' ' 159' ' ' VAL . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.444 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.444 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.638 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 150' ' ' TYR . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 147' ' ' GLY . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.65 ' HB1' ' OE2' ' A' ' 61' ' ' GLU . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 136' ' ' GLY . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.497 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.497 ' H ' HG22 ' A' ' 168' ' ' THR . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.637 ' ND2' ' HB1' ' A' ' 132' ' ' ALA . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.6 HG21 ' CD2' ' A' ' 139' ' ' LEU . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.429 HG22 ' OG ' ' A' ' 125' ' ' SER . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.507 HG11 ' HA ' ' A' ' 82' ' ' GLU . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.48 ' N ' HG13 ' A' ' 178' ' ' VAL . 1.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HD2' HD13 ' A' ' 12' ' ' LEU . 78.5 Cg_exo . . . . . 0 CA--C 1.528 0.193 0 CA-C-O 120.699 0.208 . . . . 0.0 112.512 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.435 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.492 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.887 ' O ' HG12 ' A' ' 16' ' ' VAL . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.887 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.537 HG21 ' CD2' ' A' ' 47' ' ' PHE . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' HE1' HG21 ' A' ' 43' ' ' VAL . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.48 ' O ' HG11 ' A' ' 38' ' ' VAL . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.42 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 80' ' ' LEU . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.469 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.54 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.515 ' C ' HD12 ' A' ' 33' ' ' ILE . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.698 HG22 ' H ' ' A' ' 37' ' ' HIS . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.847 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.698 ' H ' HG22 ' A' ' 35' ' ' THR . 22.9 t-80 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.48 HG11 ' O ' ' A' ' 21' ' ' SER . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.847 HG12 ' O ' ' A' ' 36' ' ' THR . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.473 HG21 ' HE1' ' A' ' 19' ' ' PHE . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LYS . . . . . 0.54 ' O ' HD23 ' A' ' 51' ' ' LEU . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CD2' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.416 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.416 ' CB ' ' HB2' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.846 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.586 HG23 ' CG2' ' A' ' 63' ' ' THR . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.62 ' CG ' HG23 ' A' ' 35' ' ' THR . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.586 ' CG2' HG23 ' A' ' 56' ' ' ILE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.846 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.464 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.469 ' CG ' HG23 ' A' ' 30' ' ' THR . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.514 ' HE2' ' HB3' ' A' ' 47' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.447 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.646 ' O ' HG13 ' A' ' 159' ' ' VAL . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.572 HD21 HG12 ' A' ' 27' ' ' VAL . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.572 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.614 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.728 HD12 ' HG2' ' A' ' 149' ' ' PRO . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.421 HD11 HD12 ' A' ' 104' ' ' LEU . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.655 HH22 HD22 ' A' ' 102' ' ' LEU . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.505 HD13 ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.655 HD22 HH22 ' A' ' 96' ' ' ARG . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.573 HD21 HD23 ' A' ' 102' ' ' LEU . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.513 HG22 ' HG ' ' A' ' 139' ' ' LEU . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.423 ' HB2' HD13 ' A' ' 129' ' ' LEU . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.477 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.752 0.311 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.484 ' OG ' HG22 ' A' ' 173' ' ' THR . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.512 ' O ' HG23 ' A' ' 173' ' ' THR . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.591 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.433 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' MET . . . . . 0.478 ' HA ' ' HB1' ' A' ' 166' ' ' ALA . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.509 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.703 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 138' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.459 ' O ' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.493 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.728 ' HG2' HD12 ' A' ' 93' ' ' LEU . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.614 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 160' ' ' VAL . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 79' ' ' VAL . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 151' ' ' VAL . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 147' ' ' GLY . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.654 ' CE1' HG11 ' A' ' 174' ' ' VAL . 4.7 t60 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.603 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.478 ' HB1' ' HA ' ' A' ' 137' ' ' MET . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.743 ' HB2' HG22 ' A' ' 174' ' ' VAL . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.512 HG23 ' O ' ' A' ' 126' ' ' GLY . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.743 HG22 ' HB2' ' A' ' 167' ' ' ALA . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.603 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.481 ' N ' HG13 ' A' ' 178' ' ' VAL . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' HB2' ' A' ' 12' ' ' LEU . 58.2 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.589 0.162 . . . . 0.0 112.281 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.56 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.849 ' O ' HG12 ' A' ' 16' ' ' VAL . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' NE ' HD21 ' A' ' 75' ' ' LEU . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.849 HG12 ' O ' ' A' ' 13' ' ' TRP . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' HE1' HG21 ' A' ' 43' ' ' VAL . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE2' ' HB2' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.707 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.738 HG22 ' HA ' ' A' ' 70' ' ' LYS . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.626 HG22 ' HD2' ' A' ' 66' ' ' ARG . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.707 HD13 ' CG1' ' A' ' 27' ' ' VAL . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.777 ' H ' HG22 ' A' ' 35' ' ' THR . 33.3 t-80 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.767 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.465 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.613 ' HA ' HD12 ' A' ' 54' ' ' ILE . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.555 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.621 HG21 ' CD2' ' A' ' 65' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.791 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.686 HG23 ' CE1' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 62' ' ' PHE . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.428 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.686 ' CE1' HG23 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.738 ' HA ' HG22 ' A' ' 30' ' ' THR . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG2' HD12 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.722 HD12 ' HG2' ' A' ' 72' ' ' ARG . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 159' ' ' VAL . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.649 HD23 HG13 ' A' ' 160' ' ' VAL . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.412 ' HB2' ' HE3' ' A' ' 108' ' ' MET . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.748 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.716 ' HB ' HD12 ' A' ' 104' ' ' LEU . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.573 HD22 ' CD2' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.756 HD11 HD11 ' A' ' 104' ' ' LEU . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.684 HD23 ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.675 ' HB3' HD12 ' A' ' 94' ' ' ILE . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.837 HD13 ' HB3' ' A' ' 139' ' ' LEU . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.475 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.475 ' N ' HG12 ' A' ' 106' ' ' VAL . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' MET . . . . . 0.412 ' HE3' ' HB2' ' A' ' 84' ' ' CYS . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.497 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.74 0.305 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.506 HD21 ' HA ' ' A' ' 172' ' ' ASN . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.406 HD11 ' CZ ' ' A' ' 107' ' ' ARG . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.492 ' ND2' ' CD2' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' MET . . . . . 0.799 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.837 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.485 HG21 ' O ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.647 ' O ' HG11 ' A' ' 38' ' ' VAL . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.531 ' HG2' HD12 ' A' ' 93' ' ' LEU . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.85 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 91' ' ' SER . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.505 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 79' ' ' VAL . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 150' ' ' TYR . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 147' ' ' GLY . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.545 ' HE1' HG11 ' A' ' 174' ' ' VAL . 2.4 t60 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.799 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.506 ' HA ' HD21 ' A' ' 128' ' ' LEU . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.827 HG21 HD23 ' A' ' 139' ' ' LEU . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 177' ' ' ALA . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.774 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.9 Cg_exo . . . . . 0 CA--C 1.528 0.189 0 CA-C-O 120.755 0.231 . . . . 0.0 112.338 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.774 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.684 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 13' ' ' TRP . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.588 ' O ' HG11 ' A' ' 38' ' ' VAL . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.545 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.527 HG22 ' HG2' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' CG2' ' A' ' 27' ' ' VAL . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' PHE . . . . . 0.459 ' HA ' HG22 ' A' ' 27' ' ' VAL . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.658 ' O ' HD12 ' A' ' 33' ' ' ILE . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.57 HG22 ' H ' ' A' ' 37' ' ' HIS . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.822 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.57 ' H ' HG22 ' A' ' 35' ' ' THR . 23.0 t-80 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.588 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.822 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.562 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.562 HD12 ' HA ' ' A' ' 51' ' ' LEU . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.822 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.462 HD12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CZ ' HD12 ' A' ' 56' ' ' ILE . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.822 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.527 ' HG2' HG22 ' A' ' 30' ' ' THR . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.754 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.638 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.762 HD13 ' HA ' ' A' ' 141' ' ' THR . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.579 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.482 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.514 ' CD1' HD11 ' A' ' 94' ' ' ILE . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.553 HG11 HG22 ' A' ' 174' ' ' VAL . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.554 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.811 0.338 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.53 ' HG2' HG23 ' A' ' 173' ' ' THR . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 139' ' ' LEU . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.668 HD23 ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.762 ' HA ' HD13 ' A' ' 94' ' ' ILE . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.495 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.601 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.754 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 93' ' ' LEU . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.593 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.466 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 147' ' ' GLY . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.668 ' CB ' HD23 ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' GLY . . . . . 0.497 ' O ' HD21 ' A' ' 139' ' ' LEU . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 173' ' ' THR . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.53 HG23 ' HG2' ' A' ' 127' ' ' MET . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.553 HG22 HG11 ' A' ' 106' ' ' VAL . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 166' ' ' ALA . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.804 ' HD2' HD13 ' A' ' 12' ' ' LEU . 53.0 Cg_exo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.777 0.24 . . . . 0.0 112.331 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 74' ' ' ASP . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.804 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.611 ' O ' HG12 ' A' ' 16' ' ' VAL . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.629 HG22 ' HE3' ' A' ' 23' ' ' TRP . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.401 ' HA3' ' HD3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.629 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' HD12 ' A' ' 93' ' ' LEU . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.586 ' HB3' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 31' ' ' VAL . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.537 HG12 HG21 ' A' ' 27' ' ' VAL . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.726 HG21 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.486 ' H ' HG22 ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.726 ' CE1' HG21 ' A' ' 35' ' ' THR . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.43 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.461 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.466 ' O ' HD11 ' A' ' 54' ' ' ILE . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.601 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.601 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.941 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 63' ' ' THR . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.535 ' CG2' HG23 ' A' ' 56' ' ' ILE . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.941 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HG21 ' A' ' 11' ' ' THR . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.586 HD13 ' HB3' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.917 HD12 HG13 ' A' ' 160' ' ' VAL . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.806 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.667 ' CB ' HD12 ' A' ' 104' ' ' LEU . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.649 HD11 HD23 ' A' ' 12' ' ' LEU . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.769 HD12 ' HB3' ' A' ' 102' ' ' LEU . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.436 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.511 ' NH2' HD13 ' A' ' 142' ' ' ILE . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.769 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.813 HD13 ' HB3' ' A' ' 139' ' ' LEU . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 127' ' ' MET . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.713 HD12 ' OE1' ' A' ' 124' ' ' GLN . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLN . . . . . 0.713 ' OE1' HD12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.43 ' OG ' HG21 ' A' ' 173' ' ' THR . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.817 ' O ' HG22 ' A' ' 174' ' ' VAL . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' MET . . . . . 0.463 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.686 ' CD2' ' HB2' ' A' ' 134' ' ' ALA . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' ALA . . . . . 0.686 ' HB2' ' CD2' ' A' ' 128' ' ' LEU . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.813 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.638 HG21 ' O ' ' A' ' 145' ' ' ASP . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.511 HD13 ' NH2' ' A' ' 96' ' ' ARG . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.638 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.645 ' O ' HG23 ' A' ' 160' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.806 HG22 ' O ' ' A' ' 91' ' ' SER . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.425 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.433 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.499 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.465 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 79' ' ' VAL . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.917 HG13 HD12 ' A' ' 80' ' ' LEU . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 147' ' ' GLY . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.475 ' CE1' ' HB2' ' A' ' 139' ' ' LEU . 2.4 t60 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.903 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ASN . . . . . 0.447 ' O ' HD12 ' A' ' 128' ' ' LEU . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.43 HG21 ' OG ' ' A' ' 125' ' ' SER . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.903 HG12 ' HB2' ' A' ' 167' ' ' ALA . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 179' ' ' GLN . . . . . 0.442 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 CA--C 1.53 0.275 0 CA-C-O 120.682 0.201 . . . . 0.0 112.269 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.569 ' O ' HD23 ' A' ' 12' ' ' LEU . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' TRP . . . . . 0.738 ' O ' HG12 ' A' ' 16' ' ' VAL . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.736 ' NH2' HD22 ' A' ' 75' ' ' LEU . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.722 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PHE . . . . . 0.491 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TRP . . . . . 0.434 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 33' ' ' ILE . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 70' ' ' LYS . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.52 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.742 HG12 HG13 ' A' ' 27' ' ' VAL . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 37' ' ' HIS . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.788 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.648 ' H ' HG22 ' A' ' 35' ' ' THR . 23.0 t-80 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.4 HG22 ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 36' ' ' THR . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.529 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.901 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLU . . . . . 0.404 ' HG2' HG23 ' A' ' 35' ' ' THR . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ARG . . . . . 0.901 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.628 ' CE2' ' HE3' ' A' ' 71' ' ' MET . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HA ' HG22 ' A' ' 30' ' ' THR . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' MET . . . . . 0.628 ' HE3' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.411 ' HG2' HD12 ' A' ' 75' ' ' LEU . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.736 HD22 ' NH2' ' A' ' 15' ' ' ARG . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.683 HD13 ' N ' ' A' ' 81' ' ' GLU . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.683 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.698 HG22 ' CE1' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.431 HD22 ' CD1' ' A' ' 13' ' ' TRP . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.738 HD13 HG22 ' A' ' 141' ' ' THR . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.523 HD12 HD11 ' A' ' 94' ' ' ILE . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.768 0.318 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.765 HD22 ' O ' ' A' ' 133' ' ' ASN . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.471 HG21 HD22 ' A' ' 133' ' ' ASN . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.765 ' O ' HD22 ' A' ' 128' ' ' LEU . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.532 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' THR . . . . . 0.738 HG22 HD13 ' A' ' 94' ' ' ILE . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ASP . . . . . 0.647 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ALA . . . . . 0.605 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' PRO . . . . . 0.572 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.408 HG11 HD21 ' A' ' 12' ' ' LEU . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' HIS . . . . . 0.443 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' LYS . . . . . 0.429 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ARG . . . . . 0.469 ' HB2' HG23 ' A' ' 159' ' ' VAL . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' CYS . . . . . 0.68 ' O ' HG22 ' A' ' 178' ' ' VAL . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ALA . . . . . 0.419 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.482 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.532 HG21 HD23 ' A' ' 139' ' ' LEU . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 176' ' ' CYS . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' CYS . . . . . 0.451 ' N ' HG12 ' A' ' 175' ' ' VAL . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.68 HG22 ' O ' ' A' ' 161' ' ' CYS . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 mtm . . . . . 0 N--CA 1.486 1.349 0 CA-C-O 120.849 0.357 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.4 m80 60.45 80.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -132.78 -46.73 0.87 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -68.55 136.93 53.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.893 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 61.12 112.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -143.26 169.19 18.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.925 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -60.29 146.22 44.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -97.14 149.77 36.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.474 ' CG ' HD13 ' A' ' 12' ' ' LEU . 36.2 Cg_endo -65.43 124.23 12.59 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.026 HD21 HG11 ' A' ' 151' ' ' VAL . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.803 ' O ' HG12 ' A' ' 16' ' ' VAL . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.803 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.484 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.426 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.582 ' HE3' HG22 ' A' ' 16' ' ' VAL . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.726 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.451 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.866 HG21 HG23 ' A' ' 33' ' ' ILE . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB2' ' HB ' ' A' ' 31' ' ' VAL . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.408 ' HB2' ' HB3' ' A' ' 70' ' ' LYS . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.514 HG12 ' HB ' ' A' ' 27' ' ' VAL . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.866 HG23 HG21 ' A' ' 27' ' ' VAL . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.596 HG22 ' H ' ' A' ' 36' ' ' THR . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.596 ' H ' HG22 ' A' ' 35' ' ' THR . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.467 ' CE1' HG13 ' A' ' 38' ' ' VAL . 0.1 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.467 HG13 ' CE1' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 35' ' ' THR . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.484 HG21 ' HE1' ' A' ' 19' ' ' PHE . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HD11 ' A' ' 54' ' ' ILE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.4 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.525 HD11 ' O ' ' A' ' 49' ' ' GLU . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.92 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 ' CG2' ' A' ' 63' ' ' THR . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.446 ' HA3' HG21 ' A' ' 121' ' ' VAL . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.655 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.92 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.451 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.457 ' O ' HG12 ' A' ' 160' ' ' VAL . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.598 HD22 HG13 ' A' ' 160' ' ' VAL . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.528 ' N ' HD13 ' A' ' 80' ' ' LEU . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.429 ' HA ' HG13 ' A' ' 178' ' ' VAL . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.792 ' SG ' HG21 ' A' ' 88' ' ' THR . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.792 HG21 ' SG ' ' A' ' 84' ' ' CYS . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.473 HG21 ' CE1' ' A' ' 164' ' ' HIS . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.606 HD11 ' CD2' ' A' ' 12' ' ' LEU . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.542 HG23 ' CG ' ' A' ' 145' ' ' ASP . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.426 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.646 HD23 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 102' ' ' LEU . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.474 ' CD1' HD11 ' A' ' 94' ' ' ILE . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.661 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.465 ' O ' HG23 ' A' ' 111' ' ' ILE . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.48 168.63 21.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 88.8 p -100.93 105.12 16.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.5 mtp -80.28 168.13 19.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.962 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 ttm105 -124.82 109.71 13.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.614 HG22 ' OE1' ' A' ' 117' ' ' GLN . 4.6 mt -122.07 121.61 64.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.081 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.614 ' OE1' HG22 ' A' ' 116' ' ' ILE . 9.0 mp0 60.64 31.97 20.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.31 30.99 59.77 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.477 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.9 123.73 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.786 0.327 . . . . 0.0 110.907 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.5 mt -77.62 120.4 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.59 HG11 HD12 ' A' ' 116' ' ' ILE . 11.1 p -128.43 147.73 32.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.038 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -95.79 122.51 38.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.488 ' O ' HG13 ' A' ' 106' ' ' VAL . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.569 HD12 ' HB2' ' A' ' 134' ' ' ALA . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.419 ' N ' HD23 ' A' ' 128' ' ' LEU . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.569 ' HB2' HD12 ' A' ' 128' ' ' LEU . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.51 ' C ' ' HB3' ' A' ' 167' ' ' ALA . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.559 ' HB3' HG22 ' A' ' 141' ' ' THR . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.854 HD23 ' CG2' ' A' ' 174' ' ' VAL . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.559 HG22 ' HB3' ' A' ' 138' ' ' ASP . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.531 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.531 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.542 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.409 ' HB3' ' HB2' ' A' ' 25' ' ' PHE . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.711 ' O ' HG23 ' A' ' 160' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.026 HG11 HD21 ' A' ' 12' ' ' LEU . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.46 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.46 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.452 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' HG21 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.51 ' HB3' ' C ' ' A' ' 136' ' ' GLY . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.854 ' CG2' HD23 ' A' ' 139' ' ' LEU . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.452 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.47 HG12 ' N ' ' A' ' 179' ' ' GLN . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 178' ' ' VAL . 26.1 tt0 -92.08 158.85 15.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -99.24 129.1 45.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.093 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 180.0 -140.82 4.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.22 166.25 3.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.819 0.342 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 96.46 -27.5 17.1 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.85 -30.31 21.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.824 0.345 . . . . 0.0 110.919 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.63 -31.57 13.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.56 153.71 34.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.074 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.6 -32.79 15.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.235 -0.888 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -131.95 -177.73 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.8 p80 -91.31 127.91 36.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -132.72 141.63 48.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.94 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -97.99 -37.4 9.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.88 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.2 p80 -176.49 150.99 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -105.28 -68.06 0.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.864 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -144.65 165.64 21.97 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 37.3 Cg_endo -66.11 124.42 12.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.551 2.168 . . . . 0.0 112.355 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.484 HD13 ' CG ' ' A' ' 9' ' ' PRO . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.881 ' CD1' HD22 ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.822 ' NH1' HD13 ' A' ' 75' ' ' LEU . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.739 HG22 ' HE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.512 ' O ' HG12 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.739 ' HE3' HG22 ' A' ' 16' ' ' VAL . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CZ ' HG11 ' A' ' 160' ' ' VAL . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.768 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 HD11 ' A' ' 80' ' ' LEU . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.674 HG22 ' H ' ' A' ' 37' ' ' HIS . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.674 ' H ' HG22 ' A' ' 35' ' ' THR . 26.0 t-80 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.429 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.484 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.561 HD22 HD11 ' A' ' 56' ' ' ILE . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 55' ' ' ALA . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.851 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.561 HD11 HD22 ' A' ' 51' ' ' LEU . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.401 ' HG2' HG21 ' A' ' 36' ' ' THR . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.424 ' O ' ' HB1' ' A' ' 177' ' ' ALA . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.496 ' CG ' ' HB3' ' A' ' 180' ' ' ALA . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.851 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.768 ' CG ' HG23 ' A' ' 30' ' ' THR . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.597 ' CG ' HD12 ' A' ' 75' ' ' LEU . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.822 HD13 ' NH1' ' A' ' 15' ' ' ARG . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 159' ' ' VAL . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.71 HD11 HD13 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.558 ' HG2' HG11 ' A' ' 159' ' ' VAL . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.682 ' O ' HG22 ' A' ' 151' ' ' VAL . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.881 HD22 ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.671 HG23 ' CG ' ' A' ' 145' ' ' ASP . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.982 HD22 HG21 ' A' ' 130' ' ' THR . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.595 HG22 HD21 ' A' ' 139' ' ' LEU . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' MET . . . . . 0.443 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.567 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -136.33 133.83 37.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.6 p -71.17 107.96 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.4 mmm -93.36 147.02 23.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -106.33 123.78 48.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.965 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.433 HD13 HG21 ' A' ' 121' ' ' VAL . 3.9 mp -139.21 124.4 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 60.29 31.45 20.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.874 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.13 28.51 64.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.521 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -131.8 140.32 49.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.6 mt -94.0 123.97 37.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.433 HG21 HD13 ' A' ' 116' ' ' ILE . 6.1 m -129.81 141.0 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.07 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -98.64 125.59 43.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.569 ' O ' HG23 ' A' ' 173' ' ' THR . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.442 ' O ' HG13 ' A' ' 106' ' ' VAL . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.599 ' CD2' HD13 ' A' ' 139' ' ' LEU . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.743 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.982 HG21 HD22 ' A' ' 104' ' ' LEU . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.403 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' MET . . . . . 0.406 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.672 ' HB2' HG23 ' A' ' 141' ' ' THR . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.599 HD13 ' CD2' ' A' ' 128' ' ' LEU . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.672 HG23 ' HB2' ' A' ' 138' ' ' ASP . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.479 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.671 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.414 ' HB3' HG11 ' A' ' 38' ' ' VAL . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.412 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.564 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.793 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 160' ' ' VAL . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.565 ' HD3' HG21 ' A' ' 159' ' ' VAL . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HD2' ' A' ' 153' ' ' LYS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.565 HG21 ' HD3' ' A' ' 154' ' ' ARG . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 151' ' ' VAL . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.406 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.569 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.518 HG11 HD23 ' A' ' 139' ' ' LEU . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 61' ' ' GLU . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.644 HG23 ' CD2' ' A' ' 80' ' ' LEU . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.432 ' N ' HG13 ' A' ' 178' ' ' VAL . 9.3 tp60 -60.05 91.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.496 ' HB3' ' CG ' ' A' ' 62' ' ' PHE . . . -175.58 116.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.102 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -149.79 179.53 26.48 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.443 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -75.16 126.59 31.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.67 43.97 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -83.35 -49.27 9.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.733 0.302 . . . . 0.0 110.889 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.32 31.52 2.13 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.975 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.95 77.85 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.6 mp 60.3 79.97 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.859 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.949 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 120.856 0.36 . . . . 0.0 111.221 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.8 p-80 -134.16 -47.2 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 m80 60.43 -176.84 0.11 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -170.44 129.86 0.87 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -130.29 131.48 45.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -109.62 131.09 55.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 13.9 p-80 -132.08 28.56 4.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.76 90.02 6.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.022 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.459 ' HD2' HD13 ' A' ' 12' ' ' LEU . 57.4 Cg_exo -51.94 149.13 21.24 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.459 2.106 . . . . 0.0 112.409 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.703 HG23 ' O ' ' A' ' 74' ' ' ASP . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.091 HD21 HG11 ' A' ' 151' ' ' VAL . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.878 ' O ' HG12 ' A' ' 16' ' ' VAL . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HG2' HD22 ' A' ' 75' ' ' LEU . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.878 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 43' ' ' VAL . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.538 ' O ' HG11 ' A' ' 38' ' ' VAL . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.489 ' HE3' HG22 ' A' ' 16' ' ' VAL . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.481 ' HB3' HD13 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.732 HG13 HG12 ' A' ' 33' ' ' ILE . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.48 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.732 HG12 HG13 ' A' ' 27' ' ' VAL . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.585 HG22 ' H ' ' A' ' 37' ' ' HIS . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.817 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.585 ' H ' HG22 ' A' ' 35' ' ' THR . 38.1 t-80 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.538 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.817 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.42 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 41' ' ' THR . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.494 HG21 ' CE1' ' A' ' 19' ' ' PHE . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.498 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.426 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.498 HD12 ' HE1' ' A' ' 46' ' ' PHE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.925 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.605 ' OG1' HG23 ' A' ' 36' ' ' THR . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.925 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.483 ' C ' HG23 ' A' ' 30' ' ' THR . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.703 ' O ' HG23 ' A' ' 11' ' ' THR . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.481 HD13 ' HB3' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.505 HD12 HG13 ' A' ' 160' ' ' VAL . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.768 HG22 ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.515 HD22 ' HE1' ' A' ' 13' ' ' TRP . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 104' ' ' LEU . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.76 HD23 ' O ' ' A' ' 94' ' ' ILE . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.044 HD11 HD11 ' A' ' 94' ' ' ILE . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.737 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.59 ' HG3' HD12 ' A' ' 129' ' ' LEU . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.07 152.94 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.6 t -102.29 103.22 13.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -85.02 157.57 20.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -109.54 109.55 20.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 25.2 mm -116.23 106.24 19.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 60.29 35.63 20.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.37 28.31 55.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.522 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.4 ttt-85 -130.09 119.05 22.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.809 0.338 . . . . 0.0 110.96 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.3 mt -71.32 104.8 3.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.796 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 19.5 m -106.35 145.56 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -98.94 119.25 37.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.771 ' O ' HG23 ' A' ' 173' ' ' THR . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.676 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.59 HD12 ' HG3' ' A' ' 107' ' ' ARG . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.533 ' HA ' HD11 ' A' ' 128' ' ' LEU . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.732 ' HB2' HG23 ' A' ' 141' ' ' THR . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.692 HD23 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.732 HG23 ' HB2' ' A' ' 138' ' ' ASP . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.464 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.464 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.61 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.614 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.614 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.768 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.091 HG11 HD21 ' A' ' 12' ' ' LEU . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.4 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.736 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.736 HG23 ' HB2' ' A' ' 154' ' ' ARG . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.474 ' O ' HD11 ' A' ' 80' ' ' LEU . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.444 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.826 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.826 HG12 ' HB2' ' A' ' 167' ' ' ALA . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.419 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER -61.81 130.78 47.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -95.59 123.67 39.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.027 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -142.34 130.92 4.46 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.525 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.49 122.61 40.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.739 0.304 . . . . 0.0 110.875 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.41 46.24 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.553 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -105.3 -40.02 5.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.793 0.33 . . . . 0.0 110.885 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 4.4 m -98.08 -32.15 11.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -99.97 175.63 5.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.102 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 1.2 tp 60.5 35.43 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.289 -0.863 . . . . 0.0 110.882 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 mmm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.764 0.316 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -67.61 91.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.1 m-70 -107.46 164.76 11.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m-70 -143.21 134.63 26.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.3 p80 -103.11 134.73 46.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -176.7 118.97 0.12 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 68.39 -68.87 0.16 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.005 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.76 ' HB1' ' CZ2' ' A' ' 13' ' ' TRP . . . -123.7 77.07 56.4 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.013 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -56.87 161.16 10.83 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.615 2.21 . . . . 0.0 112.476 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 12' ' ' LEU . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.76 ' CZ2' ' HB1' ' A' ' 8' ' ' ALA . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.681 ' NH1' HD22 ' A' ' 75' ' ' LEU . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.757 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.536 ' HE1' HG21 ' A' ' 43' ' ' VAL . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.618 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.514 ' HE3' HG22 ' A' ' 16' ' ' VAL . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.797 HG21 HG23 ' A' ' 33' ' ' ILE . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.402 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.453 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.448 HG22 ' HD2' ' A' ' 66' ' ' ARG . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.801 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 38' ' ' VAL . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.401 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.618 ' H ' HG22 ' A' ' 35' ' ' THR . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.683 HG22 ' HB ' ' A' ' 35' ' ' THR . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' HE1' ' A' ' 19' ' ' PHE . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.586 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.586 HD12 ' HA ' ' A' ' 51' ' ' LEU . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HB3' HG23 ' A' ' 35' ' ' THR . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.444 ' CZ ' ' HG2' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.898 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.401 ' CD2' ' OE1' ' A' ' 49' ' ' GLU . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 30' ' ' THR . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.414 ' HE1' ' HD2' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.681 HD22 ' NH1' ' A' ' 15' ' ' ARG . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' MET . . . . . 0.459 ' HE3' ' N ' ' A' ' 160' ' ' VAL . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 81' ' ' GLU . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.467 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.636 ' N ' HG11 ' A' ' 178' ' ' VAL . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.775 ' O ' HG22 ' A' ' 151' ' ' VAL . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.595 HG21 ' NE2' ' A' ' 164' ' ' HIS . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.486 ' N ' HG12 ' A' ' 92' ' ' VAL . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.883 HG21 HG13 ' A' ' 142' ' ' ILE . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.752 ' CD2' HD11 ' A' ' 142' ' ' ILE . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.4 HD12 HD11 ' A' ' 94' ' ' ILE . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.565 HG22 HD23 ' A' ' 128' ' ' LEU . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.61 148.98 31.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.7 108.48 20.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.66 137.92 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.956 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 -114.2 118.59 34.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.5 112.39 27.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.28 35.67 20.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.56 28.61 57.1 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 52.2 mtt-85 -127.44 120.48 28.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.7 mt -82.29 125.26 30.77 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.438 ' O ' HG23 ' A' ' 121' ' ' VAL . 5.7 m -134.76 97.55 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -66.53 125.65 26.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.878 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.429 ' C ' HG22 ' A' ' 174' ' ' VAL . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.621 HD21 HG11 ' A' ' 174' ' ' VAL . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.584 HD12 ' C ' ' A' ' 128' ' ' LEU . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 132' ' ' ALA . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.552 ' HB2' ' OD1' ' A' ' 172' ' ' ASN . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' MET . . . . . 0.427 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.432 ' HG ' ' CG ' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.404 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.883 HG13 HG21 ' A' ' 94' ' ' ILE . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.586 ' OD1' HG23 ' A' ' 94' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.438 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.881 ' O ' HG23 ' A' ' 160' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 91' ' ' SER . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.493 ' HD3' HG21 ' A' ' 159' ' ' VAL . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.481 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.769 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.595 ' NE2' HG21 ' A' ' 92' ' ' VAL . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.821 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.552 ' OD1' ' HB2' ' A' ' 132' ' ' ALA . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.821 HG12 ' HB2' ' A' ' 167' ' ' ALA . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.421 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.769 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.636 HG11 ' N ' ' A' ' 83' ' ' GLY . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.444 ' HG2' ' CZ ' ' A' ' 62' ' ' PHE . 22.1 mt-30 -63.4 146.11 54.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.41 133.54 11.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.124 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 103.74 28.7 5.86 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -90.82 129.54 36.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.72 34.81 5.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.49 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -132.17 -67.15 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 9.7 m -132.51 -64.86 0.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.44 -178.38 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.152 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.618 HD13 ' O ' ' A' ' 187' ' ' LEU . 0.5 OUTLIER -99.0 -31.36 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.928 -179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.937 179.974 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.6 mtt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.806 0.336 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -87.53 138.87 31.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.916 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -105.67 127.15 52.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.797 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.1 100.79 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.73 -179.1 5.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.897 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -71.64 -177.43 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.936 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -176.58 111.24 0.09 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.609 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -74.37 152.85 87.96 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.102 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.784 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo -54.09 154.75 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.609 2.206 . . . . 0.0 112.253 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.942 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.791 ' O ' HG12 ' A' ' 16' ' ' VAL . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.791 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB2' ' CH2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.4 ' CB ' HG12 ' A' ' 38' ' ' VAL . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.42 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.66 ' HE3' HG22 ' A' ' 16' ' ' VAL . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.664 ' CE2' HG11 ' A' ' 160' ' ' VAL . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.552 ' CB ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.782 HG21 HG23 ' A' ' 33' ' ' ILE . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.533 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.782 HG23 HG21 ' A' ' 27' ' ' VAL . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.738 HG21 ' CE1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.845 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.738 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.642 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.845 HG12 ' O ' ' A' ' 36' ' ' THR . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.937 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.857 HD11 HG23 ' A' ' 63' ' ' THR . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.52 ' N ' HD13 ' A' ' 56' ' ' ILE . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 56' ' ' ILE . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.937 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.533 ' HB3' HG23 ' A' ' 30' ' ' THR . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PRO . . . . . 0.415 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.552 HD13 ' CB ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' MET . . . . . 0.519 ' CE ' HG13 ' A' ' 160' ' ' VAL . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.655 ' HA ' HG21 ' A' ' 178' ' ' VAL . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.626 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HG21 ' A' ' 151' ' ' VAL . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.765 HD11 ' CG ' ' A' ' 104' ' ' LEU . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.589 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.765 ' CG ' HD11 ' A' ' 94' ' ' ILE . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.779 HG22 HD23 ' A' ' 128' ' ' LEU . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.775 HG23 ' OE1' ' A' ' 124' ' ' GLN . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.57 163.86 35.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -98.09 110.68 23.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.888 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.52 145.67 25.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.3 ttt180 -108.11 136.61 47.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.1 mt -140.05 110.7 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.091 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 60.34 35.45 20.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.919 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.13 31.05 39.87 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.469 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.7 mmt180 -131.09 109.02 10.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.1 mt -79.78 113.29 17.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.06 127.36 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 -90.15 115.8 27.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.847 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLN . . . . . 0.775 ' OE1' HG23 ' A' ' 111' ' ' ILE . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 173' ' ' THR . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 106' ' ' VAL . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 128' ' ' LEU . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.421 HG21 HD22 ' A' ' 133' ' ' ASN . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.488 ' O ' HD13 ' A' ' 139' ' ' LEU . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.517 ' HB2' HD22 ' A' ' 139' ' ' LEU . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.855 HD23 ' HB2' ' A' ' 167' ' ' ALA . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.702 ' HA ' HD13 ' A' ' 94' ' ' ILE . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.554 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.554 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.769 ' CG ' ' HB2' ' A' ' 148' ' ' ALA . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.42 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.769 ' HB2' ' CG ' ' A' ' 145' ' ' ASP . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 93' ' ' LEU . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.942 HG11 HD21 ' A' ' 12' ' ' LEU . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.408 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.474 ' CB ' HG23 ' A' ' 159' ' ' VAL . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.576 ' CZ3' ' HB2' ' A' ' 8' ' ' ALA . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.474 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.862 HG12 HG12 ' A' ' 151' ' ' VAL . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.502 ' O ' HG11 ' A' ' 178' ' ' VAL . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.457 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.421 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.855 ' HB2' HD23 ' A' ' 139' ' ' LEU . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.487 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.487 ' H ' HG22 ' A' ' 168' ' ' THR . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 126' ' ' GLY . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.568 ' CG2' HG11 ' A' ' 106' ' ' VAL . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 165' ' ' ALA . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.655 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.438 ' N ' HG23 ' A' ' 178' ' ' VAL . 7.3 mm-40 -134.02 142.12 47.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -111.25 84.26 1.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.028 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 105.86 -177.39 22.59 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.492 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -131.76 166.96 20.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -149.04 28.5 1.26 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -109.89 -67.49 0.98 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.838 0.352 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.12 -56.99 2.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -81.14 117.4 21.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 8.4 tt -177.53 -39.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.955 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.5 mtt . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.818 0.342 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -106.82 116.66 32.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.877 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -163.86 31.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.968 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -113.83 137.95 50.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -140.16 -68.2 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.984 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.1 t-160 -160.58 145.13 14.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.904 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -169.98 -176.43 2.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.544 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -57.0 108.99 1.41 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.052 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HD2' HD13 ' A' ' 12' ' ' LEU . 46.7 Cg_exo -56.3 148.69 59.67 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.438 2.092 . . . . 0.0 112.419 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 74' ' ' ASP . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.644 HD13 ' HD2' ' A' ' 9' ' ' PRO . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.79 ' O ' HG12 ' A' ' 16' ' ' VAL . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 13' ' ' TRP . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.467 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.5 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.826 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.518 ' CD2' HD11 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.844 HG13 HD11 ' A' ' 80' ' ' LEU . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.628 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.826 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.771 ' HB ' HG22 ' A' ' 38' ' ' VAL . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.767 ' H ' HG22 ' A' ' 35' ' ' THR . 40.1 t-80 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.771 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.467 HG21 ' HE1' ' A' ' 19' ' ' PHE . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.654 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.674 HG21 ' CD2' ' A' ' 65' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.794 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.563 HG23 ' HE1' ' A' ' 65' ' ' PHE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.674 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.794 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.628 ' C ' HG23 ' A' ' 30' ' ' THR . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.57 ' N ' HG23 ' A' ' 30' ' ' THR . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.479 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.56 ' O ' HG23 ' A' ' 11' ' ' THR . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.662 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 27' ' ' VAL . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.539 ' HA2' HD11 ' A' ' 111' ' ' ILE . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.662 HG22 HD22 ' A' ' 129' ' ' LEU . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.486 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.712 HG22 ' CE1' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.45 ' N ' HG12 ' A' ' 92' ' ' VAL . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.636 HD11 ' CD1' ' A' ' 104' ' ' LEU . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.4 HD12 ' HA ' ' A' ' 102' ' ' LEU . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.636 ' CD1' HD11 ' A' ' 94' ' ' ILE . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.539 HD11 ' HA2' ' A' ' 83' ' ' GLY . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.44 151.77 49.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -97.06 111.02 23.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -91.43 157.91 16.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.899 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -127.52 121.86 31.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.924 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.35 113.51 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? 60.4 31.68 20.42 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.67 28.8 45.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.5 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.2 mmp_? -128.97 108.11 10.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.933 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 12.0 mt -72.82 130.62 40.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.63 129.23 6.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.109 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -69.61 136.37 51.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.832 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.618 HD23 HD11 ' A' ' 139' ' ' LEU . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.662 HD22 HG22 ' A' ' 89' ' ' VAL . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HA ' HD13 ' A' ' 128' ' ' LEU . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.423 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.826 HD22 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.641 HG21 ' HB3' ' A' ' 145' ' ' ASP . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.579 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.579 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.639 ' O ' HG11 ' A' ' 38' ' ' VAL . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.613 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.74 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 91' ' ' SER . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.407 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.415 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.455 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.431 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.3 t60 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.644 ' CB ' HG12 ' A' ' 174' ' ' VAL . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.826 HG11 HD22 ' A' ' 139' ' ' LEU . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.486 ' N ' HG22 ' A' ' 178' ' ' VAL . 4.2 tt0 -66.49 143.93 56.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -109.99 -171.24 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.019 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -175.22 66.44 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.526 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -97.25 167.76 10.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.908 0.385 . . . . 0.0 110.852 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 174.76 -95.57 0.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.97 -43.18 10.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.857 0.361 . . . . 0.0 110.974 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.1 m -68.11 74.32 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.84 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -103.08 -177.88 3.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.108 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.3 tp 60.43 80.1 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.861 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.872 179.917 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.802 0.334 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 50.6 p-80 -81.35 98.71 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 m80 60.34 81.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.959 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 48.7 p-80 -98.81 31.53 2.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.89 31.67 6.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.829 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 1.5 t-160 -141.46 129.68 22.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.932 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.403 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 2.5 m170 -171.71 140.91 1.37 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.424 ' HB3' ' NE1' ' A' ' 13' ' ' TRP . . . -66.37 147.17 99.02 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.056 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.763 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo -53.95 154.43 17.41 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.499 2.133 . . . . 0.0 112.345 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.446 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.771 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.768 ' O ' HG12 ' A' ' 16' ' ' VAL . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.768 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.555 ' O ' HG12 ' A' ' 38' ' ' VAL . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.485 ' HE3' HG22 ' A' ' 16' ' ' VAL . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.621 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.557 ' CG2' HG12 ' A' ' 31' ' ' VAL . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.41 ' HB2' ' CG ' ' A' ' 70' ' ' LYS . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.557 HG12 ' CG2' ' A' ' 27' ' ' VAL . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.621 HD11 ' HB3' ' A' ' 25' ' ' PHE . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' HG22 ' A' ' 38' ' ' VAL . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.785 ' O ' HG12 ' A' ' 39' ' ' VAL . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CE1' HG21 ' A' ' 35' ' ' THR . 0.0 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 21' ' ' SER . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.785 HG12 ' O ' ' A' ' 36' ' ' THR . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.4 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.611 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.611 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.466 HG13 HG23 ' A' ' 63' ' ' THR . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.466 HG23 HG13 ' A' ' 56' ' ' ILE . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.41 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.535 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 72' ' ' ARG . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.795 HD21 HG23 ' A' ' 178' ' ' VAL . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.473 ' HA ' HG21 ' A' ' 178' ' ' VAL . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.787 ' O ' HG22 ' A' ' 151' ' ' VAL . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 93' ' ' LEU . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.537 HD22 ' HD1' ' A' ' 13' ' ' TRP . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.775 HG23 ' CG ' ' A' ' 145' ' ' ASP . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.613 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.894 HD22 HG21 ' A' ' 130' ' ' THR . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.558 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.765 HG23 ' NE2' ' A' ' 124' ' ' GLN . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.5 151.04 47.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.1 p -87.37 114.21 23.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.06 145.12 26.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.855 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -111.94 132.86 54.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.8 mp -137.87 115.72 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 60.58 31.32 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.83 30.92 41.59 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.456 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 109.91 10.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.896 0.379 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 52.0 mt -73.1 135.9 44.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.418 HG22 ' N ' ' A' ' 122' ' ' HIS . 9.9 p -147.68 154.46 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.418 ' N ' HG22 ' A' ' 121' ' ' VAL . 37.8 m80 -102.27 130.41 48.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLN . . . . . 0.765 ' NE2' HG23 ' A' ' 111' ' ' ILE . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' O ' HG23 ' A' ' 173' ' ' THR . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.477 ' O ' HG13 ' A' ' 106' ' ' VAL . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.556 HD11 HG13 ' A' ' 174' ' ' VAL . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.894 HG21 HD22 ' A' ' 104' ' ' LEU . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 132' ' ' ALA . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.432 ' HB1' ' OD1' ' A' ' 172' ' ' ASN . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.416 ' HB3' ' HA3' ' A' ' 140' ' ' GLY . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.795 ' OD1' HD23 ' A' ' 139' ' ' LEU . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.96 HD22 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 133' ' ' ASN . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.657 HG21 ' HB3' ' A' ' 145' ' ' ASP . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.775 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.861 ' O ' HG23 ' A' ' 160' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 91' ' ' SER . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.422 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.494 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.584 HG13 ' O ' ' A' ' 79' ' ' VAL . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.96 ' CE1' HD22 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 177' ' ' ALA . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.432 ' OD1' ' HB1' ' A' ' 132' ' ' ALA . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 126' ' ' GLY . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.558 ' CG2' HG11 ' A' ' 106' ' ' VAL . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 165' ' ' ALA . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.795 HG23 HD21 ' A' ' 80' ' ' LEU . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.479 ' N ' HG22 ' A' ' 178' ' ' VAL . 1.2 mm100 -59.7 134.38 56.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -107.55 157.07 18.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.145 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 88.86 -134.37 12.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -89.76 172.52 8.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.841 0.353 . . . . 0.0 110.902 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 165.19 -73.31 0.17 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -104.68 -31.71 9.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -72.53 -31.62 65.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.977 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -59.95 104.37 0.29 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.11 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.44 102.9 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.864 -179.98 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.3 mtp . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.763 0.315 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -143.62 125.52 15.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -106.65 128.03 53.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -97.48 -31.64 12.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -84.15 -177.62 6.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.857 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.4 m80 -127.23 -174.82 3.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -106.98 -39.52 5.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.892 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.7 87.82 15.24 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.687 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.8 Cg_exo -53.23 152.23 19.96 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.696 2.264 . . . . 0.0 112.351 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.687 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.879 ' O ' HG12 ' A' ' 16' ' ' VAL . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.879 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.77 ' CE2' HG11 ' A' ' 160' ' ' VAL . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.435 ' HB3' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.544 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.413 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.49 HG12 ' CG2' ' A' ' 27' ' ' VAL . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.544 HD13 ' CG1' ' A' ' 27' ' ' VAL . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.4 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.754 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.754 ' H ' HG22 ' A' ' 35' ' ' THR . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.718 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.88 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 56' ' ' ILE . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 62' ' ' PHE . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.505 ' HB3' ' HB3' ' A' ' 59' ' ' ALA . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.4 ' HB ' HG23 ' A' ' 34' ' ' THR . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.88 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.575 ' HB3' HG23 ' A' ' 30' ' ' THR . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.435 HD13 ' HB3' ' A' ' 26' ' ' TRP . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.713 HD21 HG12 ' A' ' 178' ' ' VAL . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.415 ' HA ' HG21 ' A' ' 178' ' ' VAL . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.747 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.55 HD21 HG21 ' A' ' 151' ' ' VAL . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.577 HD12 ' HG ' ' A' ' 104' ' ' LEU . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.555 HD22 ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.427 ' O ' HD12 ' A' ' 94' ' ' ILE . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.577 ' HG ' HD12 ' A' ' 94' ' ' ILE . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.615 HG22 HD23 ' A' ' 128' ' ' LEU . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.564 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.56 127.42 13.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.4 m -87.69 96.67 10.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mtt -93.45 163.62 13.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 57.7 ttp180 -106.73 121.11 43.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.416 HD13 ' CG2' ' A' ' 121' ' ' VAL . 3.9 mp -118.1 106.37 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.118 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.9 mm100 60.31 31.24 20.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 97.1 -25.61 26.22 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.551 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 -91.28 125.03 35.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.7 mt -80.4 142.24 34.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.933 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.439 HG13 ' HB2' ' A' ' 180' ' ' ALA . 21.5 t -147.75 153.96 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.1 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.0 m-70 -82.38 114.21 20.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 1.049 HD13 HD12 ' A' ' 139' ' ' LEU . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.406 HD12 ' N ' ' A' ' 129' ' ' LEU . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 1.049 HD12 HD13 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.691 HG21 ' HB3' ' A' ' 145' ' ' ASP . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.537 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.537 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.691 ' HB3' HG21 ' A' ' 141' ' ' THR . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.566 ' O ' HG11 ' A' ' 38' ' ' VAL . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.58 ' HB2' ' OD1' ' A' ' 145' ' ' ASP . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.446 ' HG2' HD12 ' A' ' 93' ' ' LEU . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CE2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 160' ' ' VAL . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.413 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.515 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.539 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 154' ' ' ARG . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 151' ' ' VAL . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.916 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.431 ' O ' HD12 ' A' ' 128' ' ' LEU . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 128' ' ' LEU . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.713 HG12 HD21 ' A' ' 80' ' ' LEU . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.434 ' N ' HG23 ' A' ' 178' ' ' VAL . 3.0 mm-40 -154.86 137.7 15.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.439 ' HB2' HG13 ' A' ' 121' ' ' VAL . . . -109.0 -171.19 1.8 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.058 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -138.51 133.31 6.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.554 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -139.82 121.23 15.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.868 0.366 . . . . 0.0 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 75.58 28.23 61.76 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -104.23 -62.71 1.28 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.859 0.361 . . . . 0.0 110.884 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.67 -42.14 8.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.949 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.03 129.27 40.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.091 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -132.47 -67.09 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.966 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.76 -179.953 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.862 0.363 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.5 m170 60.42 35.48 20.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.3 m80 -168.91 119.99 0.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 7.5 t-160 -74.16 132.15 41.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.935 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -152.56 79.81 1.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.874 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -74.24 -179.6 3.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -172.48 35.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.575 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -60.39 149.65 76.14 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.082 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.7 Cg_exo -53.95 148.59 37.77 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.508 2.139 . . . . 0.0 112.315 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.578 ' CD2' HD11 ' A' ' 93' ' ' LEU . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.778 ' O ' HG12 ' A' ' 16' ' ' VAL . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB3' HG12 ' A' ' 38' ' ' VAL . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.604 ' HE3' HG22 ' A' ' 16' ' ' VAL . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' HB3' HD11 ' A' ' 33' ' ' ILE . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.436 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.707 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.594 HG23 ' HD3' ' A' ' 70' ' ' LYS . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.707 HG23 HG21 ' A' ' 27' ' ' VAL . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.765 HG21 ' CD2' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.778 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.765 ' CD2' HG21 ' A' ' 35' ' ' THR . 4.7 p80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 36' ' ' THR . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.636 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.636 HD12 ' HA ' ' A' ' 51' ' ' LEU . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.926 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.704 ' HG3' HG21 ' A' ' 36' ' ' THR . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.883 ' CD2' ' HB2' ' A' ' 180' ' ' ALA . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.522 ' C ' HG22 ' A' ' 30' ' ' THR . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HD3' HG23 ' A' ' 30' ' ' THR . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.571 HD12 ' HG3' ' A' ' 72' ' ' ARG . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.683 ' O ' HG22 ' A' ' 160' ' ' VAL . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.854 HD12 HG23 ' A' ' 160' ' ' VAL . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.404 ' HA3' HD13 ' A' ' 111' ' ' ILE . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.578 HD11 ' CD2' ' A' ' 12' ' ' LEU . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.998 HD11 HD11 ' A' ' 104' ' ' LEU . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.783 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 94' ' ' ILE . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.478 HG12 ' N ' ' A' ' 107' ' ' ARG . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.478 ' N ' HG12 ' A' ' 106' ' ' VAL . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.404 HD13 ' HA3' ' A' ' 83' ' ' GLY . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -144.68 129.14 17.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.06 108.1 12.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.881 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.4 mtp -91.85 163.46 14.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -127.46 120.54 28.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.963 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.78 115.78 32.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.17 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 60.15 35.65 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.01 30.92 60.48 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.457 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 -130.76 107.94 9.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.7 mt -74.69 120.65 20.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.11 169.8 20.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.071 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -106.87 127.99 53.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.933 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.901 HD23 HD13 ' A' ' 139' ' ' LEU . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.418 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.901 HD13 HD23 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.42 HG21 ' O ' ' A' ' 145' ' ' ASP . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.535 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.706 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.465 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 160' ' ' VAL . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.447 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.447 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.422 HG12 ' N ' ' A' ' 160' ' ' VAL . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 151' ' ' VAL . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.691 ' O ' HG12 ' A' ' 178' ' ' VAL . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 147' ' ' GLY . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.501 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.6 t60 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.621 ' HB2' ' CG1' ' A' ' 174' ' ' VAL . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.466 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.466 ' H ' HG22 ' A' ' 168' ' ' THR . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.661 HG21 ' CD2' ' A' ' 139' ' ' LEU . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.505 ' HB1' ' CD1' ' A' ' 62' ' ' PHE . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 161' ' ' CYS . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 59.97 102.8 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.883 ' HB2' ' CD2' ' A' ' 62' ' ' PHE . . . -142.19 152.51 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 59.77 168.86 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.47 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -107.62 48.07 0.86 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.938 0.399 . . . . 0.0 110.848 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -99.33 -27.52 8.09 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.623 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -86.47 -30.63 21.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.775 0.322 . . . . 0.0 110.873 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -93.31 47.58 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -136.97 102.87 4.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -33.01 71.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.895 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 ptt? . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.831 0.348 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -137.49 150.86 47.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.9 m80 -72.82 154.0 40.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.951 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -133.53 97.09 3.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 63.7 m80 -106.92 85.63 2.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t60 -96.46 137.1 36.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 m170 -171.25 146.75 2.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.753 ' HB1' HD13 ' A' ' 12' ' ' LEU . . . -79.75 149.77 71.49 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.013 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.417 ' HD2' HD13 ' A' ' 12' ' ' LEU . 37.5 Cg_endo -66.52 171.78 10.15 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.548 2.166 . . . . 0.0 112.295 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.753 HD13 ' HB1' ' A' ' 8' ' ' ALA . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.818 ' O ' HG12 ' A' ' 16' ' ' VAL . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.401 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HE3' HG22 ' A' ' 16' ' ' VAL . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.432 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.513 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' O ' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' A' ' 27' ' ' VAL . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.554 ' CG2' HG11 ' A' ' 27' ' ' VAL . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.618 HG21 ' NE2' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.889 ' O ' HG12 ' A' ' 39' ' ' VAL . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.618 ' NE2' HG21 ' A' ' 35' ' ' THR . 14.9 p80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.545 HG22 ' HB ' ' A' ' 35' ' ' THR . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.889 HG12 ' O ' ' A' ' 36' ' ' THR . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.418 ' HA ' HD12 ' A' ' 54' ' ' ILE . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.528 ' HA3' HG11 ' A' ' 121' ' ' VAL . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.418 HG22 ' HD1' ' A' ' 65' ' ' PHE . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HD1' HG22 ' A' ' 63' ' ' THR . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.783 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.432 ' O ' HG22 ' A' ' 30' ' ' THR . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.432 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 159' ' ' VAL . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.439 ' HG2' HG11 ' A' ' 159' ' ' VAL . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HA ' HG21 ' A' ' 178' ' ' VAL . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.416 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.846 HG11 ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.799 HD11 HG13 ' A' ' 151' ' ' VAL . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.507 HD12 HD11 ' A' ' 104' ' ' LEU . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.41 HD22 ' CE3' ' A' ' 13' ' ' TRP . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.522 HD23 HD21 ' A' ' 104' ' ' LEU . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.522 HD21 HD23 ' A' ' 102' ' ' LEU . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.585 ' HB3' ' OG1' ' A' ' 130' ' ' THR . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.72 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.568 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -131.38 141.38 49.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.665 ' HB3' HD11 ' A' ' 120' ' ' LEU . 1.3 m -91.0 115.71 28.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.882 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.659 ' O ' HD13 ' A' ' 120' ' ' LEU . 2.3 mtt -104.9 162.78 13.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.865 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -127.43 121.46 30.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -140.13 128.56 25.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.191 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 71.7 mm-40 60.25 35.86 20.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.942 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.38 28.43 73.57 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.455 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -134.46 107.85 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.346 . . . . 0.0 110.934 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.665 HD11 ' HB3' ' A' ' 113' ' ' SER . 0.1 OUTLIER -64.51 119.1 9.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.846 -179.969 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.528 HG11 ' HA3' ' A' ' 60' ' ' GLY . 31.3 m -115.42 175.56 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.093 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -127.38 119.43 26.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.55 ' O ' HG13 ' A' ' 106' ' ' VAL . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 132' ' ' ALA . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.585 ' OG1' ' HB3' ' A' ' 105' ' ' ALA . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.519 ' HA ' HD22 ' A' ' 128' ' ' LEU . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.442 ' O ' HD21 ' A' ' 128' ' ' LEU . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.466 ' CG ' HG22 ' A' ' 141' ' ' THR . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.866 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.466 HG22 ' CG ' ' A' ' 138' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 142' ' ' ILE . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.506 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.505 ' OD1' HG23 ' A' ' 94' ' ' ILE . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.44 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.638 ' O ' HD12 ' A' ' 93' ' ' LEU . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.799 HG13 HD11 ' A' ' 93' ' ' LEU . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.426 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.472 ' CH2' ' HB2' ' A' ' 8' ' ' ALA . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.548 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.846 ' CE1' HG11 ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.511 ' HA ' HD13 ' A' ' 128' ' ' LEU . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.866 HG21 HD23 ' A' ' 139' ' ' LEU . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.493 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.519 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.49 ' N ' HG22 ' A' ' 178' ' ' VAL . 30.3 mt-30 -96.62 178.01 5.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 82' ' ' GLU . . . 59.9 -171.12 0.13 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.128 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.09 28.16 3.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.496 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLU . . . . . 0.4 ' HB2' ' HB2' ' A' ' 186' ' ' ALA . 4.0 pt-20 -61.46 -178.08 0.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 166.77 -87.48 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -87.32 -31.43 20.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -98.7 31.48 2.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 182' ' ' GLU . . . -85.02 133.85 34.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.9 mp -90.29 -32.83 16.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 mtt . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.784 0.326 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 60.85 156.7 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.3 t60 60.46 100.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -108.28 136.22 48.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.925 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -164.51 -177.81 5.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.9 m-70 60.47 64.46 1.2 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.828 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 27.9 t-80 -177.29 106.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -93.08 149.1 36.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.146 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.643 ' HD2' HD13 ' A' ' 12' ' ' LEU . 54.2 Cg_exo -52.0 159.93 3.5 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.614 2.21 . . . . 0.0 112.406 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.643 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.713 ' HE1' ' HB3' ' A' ' 8' ' ' ALA . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.761 HG12 ' HE3' ' A' ' 23' ' ' TRP . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.431 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.761 ' HE3' HG12 ' A' ' 16' ' ' VAL . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.507 ' HB3' HD11 ' A' ' 33' ' ' ILE . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.616 ' HB3' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG13 HG12 ' A' ' 33' ' ' ILE . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' CA ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.501 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.84 HD13 ' CD1' ' A' ' 80' ' ' LEU . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.786 HG22 ' H ' ' A' ' 37' ' ' HIS . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.44 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.786 ' H ' HG22 ' A' ' 35' ' ' THR . 27.6 t-80 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.44 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 41' ' ' THR . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.501 ' O ' HD11 ' A' ' 54' ' ' ILE . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.501 HD11 ' O ' ' A' ' 49' ' ' GLU . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.419 ' C ' HG23 ' A' ' 30' ' ' THR . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.473 ' CA ' HG23 ' A' ' 30' ' ' THR . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.432 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PRO . . . . . 0.432 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.616 HD13 ' HB3' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' MET . . . . . 0.439 ' HE3' ' HE2' ' A' ' 25' ' ' PHE . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.84 ' CD1' HD13 ' A' ' 33' ' ' ILE . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.765 HG22 ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.577 HD11 ' CG1' ' A' ' 151' ' ' VAL . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.493 HD11 HD12 ' A' ' 104' ' ' LEU . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.469 ' HG3' HD11 ' A' ' 101' ' ' LEU . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.471 HD22 ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 139' ' ' LEU . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 127' ' ' MET . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.446 ' CZ ' HD13 ' A' ' 129' ' ' LEU . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.564 ' O ' HG23 ' A' ' 111' ' ' ILE . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.97 173.16 11.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.8 p -97.42 96.22 8.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.8 mmm -80.47 150.09 29.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -99.34 117.27 33.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.969 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.42 119.5 52.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 60.3 31.3 20.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.969 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.73 27.76 56.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.512 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -136.47 134.64 37.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.916 0.389 . . . . 0.0 110.887 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 82.5 mt -88.12 118.42 27.68 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.45 136.32 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 -91.23 121.34 32.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.563 ' O ' HG13 ' A' ' 106' ' ' VAL . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.983 HD21 HD11 ' A' ' 139' ' ' LEU . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.446 HD13 ' CZ ' ' A' ' 107' ' ' ARG . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.528 ' O ' HD11 ' A' ' 128' ' ' LEU . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' MET . . . . . 0.402 ' HA ' ' HA ' ' A' ' 166' ' ' ALA . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.983 HD11 HD21 ' A' ' 128' ' ' LEU . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.568 HG21 ' H ' ' A' ' 146' ' ' CYS . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.475 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.568 ' H ' HG21 ' A' ' 141' ' ' THR . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.432 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.807 ' HB3' ' ND1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.563 ' HG2' HD12 ' A' ' 93' ' ' LEU . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.765 ' CE2' HG22 ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.577 ' CG1' HD11 ' A' ' 93' ' ' LEU . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.425 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.407 ' HE3' ' N ' ' A' ' 157' ' ' ASP . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ASP . . . . . 0.407 ' N ' ' HE3' ' A' ' 153' ' ' LYS . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CD2' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.425 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.632 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.807 ' ND1' ' HB3' ' A' ' 148' ' ' ALA . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' MET . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.616 HG21 HD23 ' A' ' 139' ' ' LEU . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.632 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.711 HG23 HD21 ' A' ' 80' ' ' LEU . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.444 ' N ' HG22 ' A' ' 178' ' ' VAL . 0.0 OUTLIER -176.91 -170.1 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -149.96 121.49 7.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.092 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -83.76 109.37 3.17 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -110.16 -174.44 2.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.919 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 106.71 -30.94 8.74 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.534 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -104.15 -33.52 8.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.978 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 185' ' ' THR . . . . . 0.571 HG22 ' O ' ' A' ' 185' ' ' THR . 29.6 m -106.33 35.6 2.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.89 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -146.72 97.94 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.105 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.676 ' O ' HD12 ' A' ' 187' ' ' LEU . 4.1 pp -134.18 125.99 29.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.892 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.7 mtt . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.898 0.38 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' HIS . . . . . 0.4 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 3.8 m80 -82.77 -179.25 7.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.4 ' CG ' ' O ' ' A' ' 2' ' ' HIS . 21.5 m80 -163.79 -177.92 5.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.77 157.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.004 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -133.54 -176.5 4.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -98.72 31.21 2.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.949 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 7.2 m80 60.15 103.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.527 ' HB1' ' HE1' ' A' ' 13' ' ' TRP . . . -144.76 69.81 14.97 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.004 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.78 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.7 Cg_exo -52.85 155.4 10.97 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.568 2.179 . . . . 0.0 112.445 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.78 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.867 ' CZ3' HD22 ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.745 ' NE ' HD21 ' A' ' 75' ' ' LEU . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.755 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.696 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.439 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.731 ' HE3' HG22 ' A' ' 16' ' ' VAL . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 33' ' ' ILE . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.544 HG11 ' CG2' ' A' ' 33' ' ' ILE . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.407 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.669 HD11 ' HB3' ' A' ' 25' ' ' PHE . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.546 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.595 ' HB ' HG22 ' A' ' 38' ' ' VAL . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 35' ' ' THR . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.595 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 35' ' ' THR . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.545 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.696 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 50' ' ' PRO . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 49' ' ' GLU . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.578 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.545 HD12 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.872 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 ' HB ' HG23 ' A' ' 34' ' ' THR . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.872 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HB3' HG23 ' A' ' 30' ' ' THR . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.709 ' HG2' HD12 ' A' ' 75' ' ' LEU . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.745 HD21 ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 159' ' ' VAL . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 89' ' ' VAL . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.793 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.514 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.867 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.804 HG23 ' CG ' ' A' ' 145' ' ' ASP . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.582 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.667 HD13 HD12 ' A' ' 139' ' ' LEU . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 174' ' ' VAL . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' MET . . . . . 0.409 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.573 HG22 ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -142.53 160.77 39.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.9 t -88.22 105.8 17.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.3 mtp -93.17 140.65 29.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.947 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.2 ttt85 -94.73 116.78 29.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -140.16 138.84 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.2 mm100 59.98 29.32 18.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.945 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.04 8.69 87.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.939 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.45 146.97 46.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.809 0.338 . . . . 0.0 110.953 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 24.6 mt -81.93 147.16 29.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 15.3 m -142.06 142.75 27.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.573 ' NE2' HG22 ' A' ' 111' ' ' ILE . 2.0 t-160 -84.02 111.42 19.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLN . . . . . 0.663 ' C ' HG13 ' A' ' 175' ' ' VAL . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.645 ' HA ' HG22 ' A' ' 175' ' ' VAL . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.586 HD21 HG22 ' A' ' 174' ' ' VAL . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.446 ' C ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.873 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.537 HG21 ' HB3' ' A' ' 145' ' ' ASP . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.549 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.455 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.804 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.434 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.606 ' CD ' HG23 ' A' ' 16' ' ' VAL . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.514 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 160' ' ' VAL . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 151' ' ' VAL . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.461 ' CE1' ' N ' ' A' ' 139' ' ' LEU . 2.8 t60 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.514 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.534 ' O ' HG23 ' A' ' 173' ' ' THR . 9.6 m120 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.585 ' N ' HD23 ' A' ' 128' ' ' LEU . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.873 HG21 ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.76 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 59.89 79.76 0.22 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -100.99 172.76 6.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.105 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -169.76 140.48 6.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' GLU . . . . . 0.483 ' HB2' HD12 ' A' ' 187' ' ' LEU . 1.1 mt-10 -76.12 178.49 6.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.791 0.329 . . . . 0.0 110.957 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -161.95 34.21 0.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.511 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -89.42 -46.72 8.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 2.0 m -130.91 35.92 3.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 62.01 151.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.483 HD12 ' HB2' ' A' ' 182' ' ' GLU . 14.7 mt -153.75 131.04 11.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.965 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.946 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.83 0.348 . . . . 0.0 111.207 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -80.6 115.38 20.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -101.14 -174.53 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.8 m-70 -98.49 -74.55 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -78.31 153.17 31.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -176.64 -40.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -84.09 -178.63 7.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.865 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.689 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -61.19 164.63 7.98 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.689 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 24.8 Cg_endo -61.97 129.17 26.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.614 2.209 . . . . 0.0 112.265 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.683 HG23 HD23 ' A' ' 75' ' ' LEU . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.506 HD13 ' HG2' ' A' ' 9' ' ' PRO . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.69 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.489 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.491 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.455 ' CB ' HD13 ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 31' ' ' VAL . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.505 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.662 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.539 HG12 ' CG2' ' A' ' 27' ' ' VAL . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 ' HB3' ' A' ' 25' ' ' PHE . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.421 HG23 ' HB ' ' A' ' 63' ' ' THR . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.742 HG22 ' H ' ' A' ' 37' ' ' HIS . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.723 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.742 ' H ' HG22 ' A' ' 35' ' ' THR . 38.2 t-80 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.715 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 36' ' ' THR . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.489 HG21 ' HE1' ' A' ' 19' ' ' PHE . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' O ' HD11 ' A' ' 54' ' ' ILE . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.806 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.421 ' HB ' HG23 ' A' ' 34' ' ' THR . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.806 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 30' ' ' THR . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.662 ' C ' HG23 ' A' ' 30' ' ' THR . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.405 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.683 HD23 HG23 ' A' ' 11' ' ' THR . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 107' ' ' ARG . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 93' ' ' LEU . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.601 HD11 HG22 ' A' ' 151' ' ' VAL . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 1.117 HD11 HD11 ' A' ' 104' ' ' LEU . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.734 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.117 HD11 HD11 ' A' ' 94' ' ' ILE . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.528 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.595 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.71 ' HB2' HD12 ' A' ' 129' ' ' LEU . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.579 ' O ' HG23 ' A' ' 111' ' ' ILE . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -130.95 174.42 10.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.487 ' HB2' HD11 ' A' ' 120' ' ' LEU . 0.9 OUTLIER -102.64 112.28 24.97 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.477 ' O ' HD13 ' A' ' 120' ' ' LEU . 1.2 mtt -101.31 179.41 4.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.501 ' O ' HD13 ' A' ' 116' ' ' ILE . 17.9 ttp180 -127.46 127.79 44.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.92 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 115' ' ' ARG . 26.6 mm -128.96 114.12 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.2 35.66 20.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.936 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.5 28.3 57.79 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.9 mtt85 -132.77 125.4 30.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.487 HD11 ' HB2' ' A' ' 113' ' ' SER . 0.1 OUTLIER -76.08 117.54 17.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.39 145.41 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.032 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -88.31 137.85 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.953 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.459 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.71 HD12 ' HB2' ' A' ' 107' ' ' ARG . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.858 HG21 ' HA ' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB3' HG22 ' A' ' 141' ' ' THR . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.769 HD12 HD22 ' A' ' 104' ' ' LEU . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.549 HG22 ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.496 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.496 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.601 HG22 HD11 ' A' ' 93' ' ' LEU . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.498 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.703 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.403 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.703 HG12 ' HB2' ' A' ' 167' ' ' ALA . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 178' ' ' VAL . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -177.06 -174.97 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.13 -175.85 5.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -132.71 27.92 3.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.452 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -113.23 78.99 1.18 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.895 0.379 . . . . 0.0 110.825 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 142.78 51.64 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.4 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -89.07 -32.38 17.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.751 0.31 . . . . 0.0 110.869 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 62.9 m -107.42 -31.54 8.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -79.99 -169.89 2.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.063 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.54 -32.83 9.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.958 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 21.5 tp10 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.884 179.989 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.5 ttp . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -103.06 149.5 24.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -100.38 126.33 46.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.83 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -92.54 124.1 36.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 -89.92 -53.41 4.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.8 t-80 -176.57 152.41 1.03 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -129.91 131.75 46.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -97.73 171.39 5.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.083 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 81.4 Cg_exo -48.42 104.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.673 2.248 . . . . 0.0 112.513 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.866 HD11 ' HE3' ' A' ' 78' ' ' MET . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.717 ' O ' HG12 ' A' ' 16' ' ' VAL . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.402 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.851 ' CE3' HG22 ' A' ' 16' ' ' VAL . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.516 ' HB3' HD11 ' A' ' 33' ' ' ILE . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.426 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.705 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.705 HG23 HG21 ' A' ' 27' ' ' VAL . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.752 ' O ' HG23 ' A' ' 39' ' ' VAL . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.71 ' CE1' HG13 ' A' ' 38' ' ' VAL . 8.4 p80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.71 HG13 ' CE1' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 35' ' ' THR . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.457 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.406 HD21 ' HZ ' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CE2' ' A' ' 67' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.93 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 63' ' ' THR . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.844 ' HB3' ' HB1' ' A' ' 180' ' ' ALA . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.428 ' OE1' ' HB1' ' A' ' 165' ' ' ALA . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.431 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 HG23 ' HG2' ' A' ' 58' ' ' GLN . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.93 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.533 ' CE2' HD11 ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.452 ' O ' HG22 ' A' ' 30' ' ' THR . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.437 ' HG2' HG23 ' A' ' 30' ' ' THR . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.426 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.471 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.471 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' MET . . . . . 0.866 ' HE3' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.592 ' HB ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.76 ' HG2' HG11 ' A' ' 159' ' ' VAL . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.477 ' HA2' ' NE2' ' A' ' 124' ' ' GLN . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.598 ' O ' HG22 ' A' ' 151' ' ' VAL . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.592 HG22 ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD11 HG11 ' A' ' 151' ' ' VAL . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.849 HD13 ' HA ' ' A' ' 141' ' ' THR . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.425 HD23 HD21 ' A' ' 104' ' ' LEU . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 140' ' ' GLY . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.69 HG11 HG21 ' A' ' 174' ' ' VAL . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' MET . . . . . 0.455 ' HE3' ' HB3' ' A' ' 124' ' ' GLN . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.766 HD11 ' HB3' ' A' ' 122' ' ' HIS . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.49 137.96 23.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.78 85.28 7.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -75.95 163.35 27.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.584 ' O ' HD13 ' A' ' 116' ' ' ILE . 6.1 ttm180 -95.75 120.13 35.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 115' ' ' ARG . 30.2 mm -127.21 110.88 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 60.63 30.68 19.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.037 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.67 23.86 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.584 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 8.7 mtp180 -89.33 172.7 8.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 120' ' ' LEU . 21.8 mt -109.65 126.05 53.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.17 133.55 62.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.13 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.766 ' HB3' HD11 ' A' ' 111' ' ' ILE . 3.9 m170 -89.21 111.47 22.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLN . . . . . 0.477 ' NE2' ' HA2' ' A' ' 83' ' ' GLY . 0.0 OUTLIER -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.781 ' O ' HG23 ' A' ' 173' ' ' THR . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.844 HD11 HD12 ' A' ' 139' ' ' LEU . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.935 HD23 ' HB3' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.433 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.849 ' HA ' HD13 ' A' ' 94' ' ' ILE . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.443 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.842 ' O ' HG21 ' A' ' 141' ' ' THR . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.497 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.469 ' HD3' HG23 ' A' ' 16' ' ' VAL . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CE2' HG22 ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 160' ' ' VAL . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.411 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.76 HG11 ' HG2' ' A' ' 81' ' ' GLU . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 151' ' ' VAL . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.766 ' O ' HG11 ' A' ' 178' ' ' VAL . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.458 ' HA3' HG13 ' A' ' 178' ' ' VAL . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.428 ' HB1' ' OE1' ' A' ' 61' ' ' GLU . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.935 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 126' ' ' GLY . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.69 HG21 HG11 ' A' ' 106' ' ' VAL . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.692 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.766 HG11 ' O ' ' A' ' 161' ' ' CYS . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -60.2 147.49 39.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.844 ' HB1' ' HB3' ' A' ' 59' ' ' ALA . . . -171.36 106.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.129 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 69.52 129.69 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.06 175.28 0.3 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.807 0.337 . . . . 0.0 111.037 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.56 -44.95 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.467 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' GLU . . . . . 0.464 ' O ' HG22 ' A' ' 185' ' ' THR . 9.3 mt-10 -91.51 -31.95 15.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.84 0.352 . . . . 0.0 110.918 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 184' ' ' GLU . 15.3 t 44.83 36.56 1.91 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.361 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -91.36 130.11 37.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.007 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 51.2 mt -90.44 119.21 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.864 179.935 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 46.7 ttm . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.891 0.376 . . . . 0.0 111.255 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 12.4 m80 -131.73 -52.27 0.99 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -142.8 86.88 1.96 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 8.0 m80 61.64 153.46 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.912 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -58.94 -28.74 66.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.014 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.5 m-70 -128.07 163.37 24.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.928 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -134.53 149.87 50.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.733 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -137.0 165.25 36.34 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 34.7 Cg_endo -64.78 124.71 13.57 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.582 2.188 . . . . 0.0 112.324 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.667 HD21 HG11 ' A' ' 151' ' ' VAL . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.859 ' O ' HG12 ' A' ' 16' ' ' VAL . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.859 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.553 ' HE1' HG21 ' A' ' 43' ' ' VAL . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.577 ' HE3' HG22 ' A' ' 16' ' ' VAL . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.655 ' HB3' HD11 ' A' ' 33' ' ' ILE . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.644 ' HB3' HD11 ' A' ' 75' ' ' LEU . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.503 HG21 HG12 ' A' ' 31' ' ' VAL . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.47 ' C ' HD13 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.743 HG23 ' O ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.503 HG12 HG21 ' A' ' 27' ' ' VAL . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.655 HD11 ' HB3' ' A' ' 25' ' ' PHE . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.592 ' HB ' HG22 ' A' ' 38' ' ' VAL . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 16.0 t-80 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HB ' ' A' ' 35' ' ' THR . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 35' ' ' THR . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.553 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.912 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.417 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.65 ' OE2' ' HB1' ' A' ' 165' ' ' ALA . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.422 ' CE2' ' HG2' ' A' ' 64' ' ' GLN . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.422 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.434 ' CE2' HG21 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.912 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . 0.743 ' O ' HG23 ' A' ' 30' ' ' THR . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.644 HD11 ' HB3' ' A' ' 26' ' ' TRP . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.638 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 160' ' ' VAL . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.507 ' HA ' HG11 ' A' ' 178' ' ' VAL . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.651 HG22 ' HG2' ' A' ' 107' ' ' ARG . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.529 HG22 ' CE1' ' A' ' 150' ' ' TYR . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.853 HD22 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 1.065 HD11 HD11 ' A' ' 104' ' ' LEU . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 94' ' ' ILE . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.749 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.065 HD11 HD11 ' A' ' 94' ' ' ILE . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.445 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.651 ' HG2' HG22 ' A' ' 89' ' ' VAL . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 123' ' ' GLY . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -141.42 167.15 22.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' HIS . 72.6 p -102.44 90.59 3.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mmm -68.47 147.14 52.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.971 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.1 ttm-85 -95.53 134.37 38.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.0 mt -138.12 103.19 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.142 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 60.69 31.29 20.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.951 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 88.33 27.84 24.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.573 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 80.2 mtt85 -136.4 127.01 27.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.3 mt -88.17 118.86 28.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 121' ' ' VAL . 11.0 p -115.15 125.55 72.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.054 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' HIS . . . . . 0.435 ' CE1' ' HB3' ' A' ' 113' ' ' SER . 29.2 m80 -87.17 112.38 21.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.568 ' O ' HD12 ' A' ' 111' ' ' ILE . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.429 ' OG ' HG22 ' A' ' 175' ' ' VAL . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 134' ' ' ALA . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.615 HD22 ' HG3' ' A' ' 107' ' ' ARG . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.637 ' HB1' ' ND2' ' A' ' 172' ' ' ASN . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 167' ' ' ALA . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.675 HD12 HD13 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.65 HG21 ' HB3' ' A' ' 145' ' ' ASP . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.478 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.65 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.435 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.675 ' O ' HG23 ' A' ' 160' ' ' VAL . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.667 HG11 HD21 ' A' ' 12' ' ' LEU . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.401 ' NE2' ' HB ' ' A' ' 159' ' ' VAL . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.444 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.444 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.638 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 150' ' ' TYR . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 147' ' ' GLY . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.65 ' HB1' ' OE2' ' A' ' 61' ' ' GLU . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 136' ' ' GLY . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.497 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.497 ' H ' HG22 ' A' ' 168' ' ' THR . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.637 ' ND2' ' HB1' ' A' ' 132' ' ' ALA . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.6 HG21 ' CD2' ' A' ' 139' ' ' LEU . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.429 HG22 ' OG ' ' A' ' 125' ' ' SER . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.507 HG11 ' HA ' ' A' ' 82' ' ' GLU . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.48 ' N ' HG13 ' A' ' 178' ' ' VAL . 1.0 OUTLIER 59.09 -168.63 0.14 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . 60.84 106.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.11 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 135.15 44.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -163.7 135.17 4.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.781 0.324 . . . . 0.0 110.993 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -177.08 49.59 0.1 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.435 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -159.4 -45.61 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.838 0.352 . . . . 0.0 110.922 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -68.36 -40.77 81.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -83.7 125.78 32.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.101 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.418 HD13 ' HA ' ' A' ' 187' ' ' LEU . 4.4 mm? -106.46 31.6 5.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.304 -0.855 . . . . 0.0 110.895 179.946 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 mmt . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.852 0.358 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -147.58 -48.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -137.1 35.36 2.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -127.8 34.66 4.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.924 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 t60 -96.76 -31.17 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.966 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.6 m80 -94.77 137.2 34.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -105.71 -29.69 9.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.912 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.604 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -107.47 99.43 28.41 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.067 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HD2' HD13 ' A' ' 12' ' ' LEU . 78.5 Cg_exo -50.59 151.26 10.7 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.47 2.113 . . . . 0.0 112.512 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.435 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.492 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.887 ' O ' HG12 ' A' ' 16' ' ' VAL . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.887 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.537 HG21 ' CD2' ' A' ' 47' ' ' PHE . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' HE1' HG21 ' A' ' 43' ' ' VAL . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.48 ' O ' HG11 ' A' ' 38' ' ' VAL . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.42 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 80' ' ' LEU . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.469 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.54 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.515 ' C ' HD12 ' A' ' 33' ' ' ILE . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.698 HG22 ' H ' ' A' ' 37' ' ' HIS . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.847 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.698 ' H ' HG22 ' A' ' 35' ' ' THR . 22.9 t-80 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.48 HG11 ' O ' ' A' ' 21' ' ' SER . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.847 HG12 ' O ' ' A' ' 36' ' ' THR . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.473 HG21 ' HE1' ' A' ' 19' ' ' PHE . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LYS . . . . . 0.54 ' O ' HD23 ' A' ' 51' ' ' LEU . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CD2' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.416 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.416 ' CB ' ' HB2' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.846 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.586 HG23 ' CG2' ' A' ' 63' ' ' THR . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.62 ' CG ' HG23 ' A' ' 35' ' ' THR . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.586 ' CG2' HG23 ' A' ' 56' ' ' ILE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.846 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.464 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.469 ' CG ' HG23 ' A' ' 30' ' ' THR . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.514 ' HE2' ' HB3' ' A' ' 47' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.447 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.646 ' O ' HG13 ' A' ' 159' ' ' VAL . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.572 HD21 HG12 ' A' ' 27' ' ' VAL . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.572 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.614 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.728 HD12 ' HG2' ' A' ' 149' ' ' PRO . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.421 HD11 HD12 ' A' ' 104' ' ' LEU . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.655 HH22 HD22 ' A' ' 102' ' ' LEU . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.505 HD13 ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.655 HD22 HH22 ' A' ' 96' ' ' ARG . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.573 HD21 HD23 ' A' ' 102' ' ' LEU . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.513 HG22 ' HG ' ' A' ' 139' ' ' LEU . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.423 ' HB2' HD13 ' A' ' 129' ' ' LEU . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.477 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.95 135.19 34.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.7 t -80.13 103.96 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' MET . . . . . 0.408 ' O ' HG22 ' A' ' 121' ' ' VAL . 0.9 OUTLIER -87.66 146.53 25.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.915 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.2 ttm180 -99.45 122.13 42.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -137.87 121.57 21.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.137 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 60.44 31.34 20.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 75.9 29.71 58.69 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.483 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.5 mtt180 -136.42 136.05 39.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.798 0.332 . . . . 0.0 110.837 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 23.8 mt -88.85 111.63 22.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.408 HG22 ' O ' ' A' ' 114' ' ' MET . 6.3 m -108.54 126.85 65.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -93.31 119.75 32.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.923 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.484 ' OG ' HG22 ' A' ' 173' ' ' THR . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.512 ' O ' HG23 ' A' ' 173' ' ' THR . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.591 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.433 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' MET . . . . . 0.478 ' HA ' ' HB1' ' A' ' 166' ' ' ALA . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.509 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.703 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 138' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.459 ' O ' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.493 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.728 ' HG2' HD12 ' A' ' 93' ' ' LEU . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.614 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 160' ' ' VAL . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 79' ' ' VAL . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 151' ' ' VAL . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 147' ' ' GLY . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.654 ' CE1' HG11 ' A' ' 174' ' ' VAL . 4.7 t60 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.603 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.478 ' HB1' ' HA ' ' A' ' 137' ' ' MET . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.743 ' HB2' HG22 ' A' ' 174' ' ' VAL . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.512 HG23 ' O ' ' A' ' 126' ' ' GLY . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.743 HG22 ' HB2' ' A' ' 167' ' ' ALA . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.603 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.481 ' N ' HG13 ' A' ' 178' ' ' VAL . 0.4 OUTLIER -60.85 147.93 41.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -145.69 -172.11 3.83 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.35 -137.62 9.68 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.486 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -78.97 153.34 30.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.786 0.327 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -157.8 -99.13 0.15 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -103.21 -57.01 2.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.794 0.33 . . . . 0.0 110.913 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' THR . . . . . 0.405 HG23 ' N ' ' A' ' 186' ' ' ALA . 4.9 t -141.53 -48.33 0.39 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.889 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 186' ' ' ALA . . . . . 0.405 ' N ' HG23 ' A' ' 185' ' ' THR . . . -84.17 105.27 14.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.084 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 187' ' ' LEU . . . . . 0.603 HD12 ' HG3' ' A' ' 188' ' ' GLU . 4.2 pp -106.38 -32.97 7.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.017 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.603 ' HG3' HD12 ' A' ' 187' ' ' LEU . 5.4 mt-10 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.289 -0.862 . . . . 0.0 110.894 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.9 ptt? . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.774 0.321 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.55 89.44 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.008 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -134.09 106.89 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.95 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -83.99 -59.01 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -166.87 162.99 16.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -96.72 41.93 1.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.836 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.2 t60 61.09 90.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -67.16 157.5 84.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.07 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' HB2' ' A' ' 12' ' ' LEU . 58.2 Cg_exo -51.97 125.05 16.09 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.586 2.191 . . . . 0.0 112.281 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.56 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.849 ' O ' HG12 ' A' ' 16' ' ' VAL . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' NE ' HD21 ' A' ' 75' ' ' LEU . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.849 HG12 ' O ' ' A' ' 13' ' ' TRP . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' HE1' HG21 ' A' ' 43' ' ' VAL . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE2' ' HB2' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.707 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.738 HG22 ' HA ' ' A' ' 70' ' ' LYS . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.626 HG22 ' HD2' ' A' ' 66' ' ' ARG . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.707 HD13 ' CG1' ' A' ' 27' ' ' VAL . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.777 ' H ' HG22 ' A' ' 35' ' ' THR . 33.3 t-80 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.767 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.465 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.613 ' HA ' HD12 ' A' ' 54' ' ' ILE . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.555 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.621 HG21 ' CD2' ' A' ' 65' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.791 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.686 HG23 ' CE1' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 62' ' ' PHE . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.428 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.686 ' CE1' HG23 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.738 ' HA ' HG22 ' A' ' 30' ' ' THR . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG2' HD12 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.722 HD12 ' HG2' ' A' ' 72' ' ' ARG . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 159' ' ' VAL . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.649 HD23 HG13 ' A' ' 160' ' ' VAL . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.412 ' HB2' ' HE3' ' A' ' 108' ' ' MET . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.748 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.716 ' HB ' HD12 ' A' ' 104' ' ' LEU . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.573 HD22 ' CD2' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.756 HD11 HD11 ' A' ' 104' ' ' LEU . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.684 HD23 ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.675 ' HB3' HD12 ' A' ' 94' ' ' ILE . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.837 HD13 ' HB3' ' A' ' 139' ' ' LEU . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.475 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.475 ' N ' HG12 ' A' ' 106' ' ' VAL . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' MET . . . . . 0.412 ' HE3' ' HB2' ' A' ' 84' ' ' CYS . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.497 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 148.14 30.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -87.03 103.38 15.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.91 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -87.41 159.33 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.434 ' HA ' HD23 ' A' ' 120' ' ' LEU . 0.1 OUTLIER -90.78 126.86 36.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 30.9 mt -128.88 108.47 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.129 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 60.68 31.19 20.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.911 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 96.15 -25.66 24.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -99.31 130.33 45.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.858 0.361 . . . . 0.0 110.851 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.462 HD12 ' HB2' ' A' ' 184' ' ' GLU . 12.3 mt -79.33 139.92 37.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.908 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.33 145.39 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.075 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 3.7 m80 -86.58 127.18 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.506 HD21 ' HA ' ' A' ' 172' ' ' ASN . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.406 HD11 ' CZ ' ' A' ' 107' ' ' ARG . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.492 ' ND2' ' CD2' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' MET . . . . . 0.799 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.837 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.485 HG21 ' O ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.647 ' O ' HG11 ' A' ' 38' ' ' VAL . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.531 ' HG2' HD12 ' A' ' 93' ' ' LEU . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.85 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 91' ' ' SER . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.505 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 79' ' ' VAL . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 150' ' ' TYR . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 147' ' ' GLY . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.545 ' HE1' HG11 ' A' ' 174' ' ' VAL . 2.4 t60 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.799 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.506 ' HA ' HD21 ' A' ' 128' ' ' LEU . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.827 HG21 HD23 ' A' ' 139' ' ' LEU . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 177' ' ' ALA . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 6.1 tt0 60.32 108.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -142.52 131.18 22.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 161.14 -28.47 0.3 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.593 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -131.42 129.41 41.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 111.001 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.45 -66.53 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' GLU . . . . . 0.462 ' HB2' HD12 ' A' ' 120' ' ' LEU . 31.1 tt0 -106.34 -70.05 0.8 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.897 0.38 . . . . 0.0 110.927 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.0 t -111.37 -38.7 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.54 88.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.078 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 11.1 mt -69.05 -31.86 70.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.835 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.813 -179.867 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.851 0.357 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 4.4 m80 -106.39 -176.61 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -109.46 37.65 2.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.953 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -60.09 -57.22 13.75 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER 60.73 -170.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -80.8 -176.62 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -66.83 -68.09 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.94 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -98.37 149.29 35.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.008 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.774 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.9 Cg_exo -53.84 151.94 24.57 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.62 2.213 . . . . 0.0 112.338 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.774 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.684 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 13' ' ' TRP . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.588 ' O ' HG11 ' A' ' 38' ' ' VAL . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.545 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.527 HG22 ' HG2' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' CG2' ' A' ' 27' ' ' VAL . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' PHE . . . . . 0.459 ' HA ' HG22 ' A' ' 27' ' ' VAL . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.658 ' O ' HD12 ' A' ' 33' ' ' ILE . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.57 HG22 ' H ' ' A' ' 37' ' ' HIS . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.822 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.57 ' H ' HG22 ' A' ' 35' ' ' THR . 23.0 t-80 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.588 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.822 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.562 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.562 HD12 ' HA ' ' A' ' 51' ' ' LEU . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.822 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.462 HD12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CZ ' HD12 ' A' ' 56' ' ' ILE . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.822 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.527 ' HG2' HG22 ' A' ' 30' ' ' THR . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.754 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.638 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.762 HD13 ' HA ' ' A' ' 141' ' ' THR . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.579 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.482 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.514 ' CD1' HD11 ' A' ' 94' ' ' ILE . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.553 HG11 HG22 ' A' ' 174' ' ' VAL . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.554 ' O ' HG23 ' A' ' 111' ' ' ILE . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.93 177.49 7.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -102.8 107.0 17.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.2 mtt -84.69 148.71 26.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.96 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.6 ttt180 -96.91 127.94 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.825 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -135.45 108.76 9.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.19 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 60.38 33.62 20.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.59 28.43 43.29 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.7 mmm180 -135.3 131.62 36.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.814 0.34 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.1 mt -87.21 121.88 30.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.884 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -127.6 135.8 62.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -76.7 126.85 31.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.53 ' HG2' HG23 ' A' ' 173' ' ' THR . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 139' ' ' LEU . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.668 HD23 ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.762 ' HA ' HD13 ' A' ' 94' ' ' ILE . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.495 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.601 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.754 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 93' ' ' LEU . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.593 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.466 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 147' ' ' GLY . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.668 ' CB ' HD23 ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' GLY . . . . . 0.497 ' O ' HD21 ' A' ' 139' ' ' LEU . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 173' ' ' THR . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.53 HG23 ' HG2' ' A' ' 127' ' ' MET . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.553 HG22 HG11 ' A' ' 106' ' ' VAL . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 166' ' ' ALA . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 58.91 31.29 21.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -60.44 87.35 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.063 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.66 173.6 43.84 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.58 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -59.17 122.16 13.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.888 0.375 . . . . 0.0 111.005 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -136.52 -69.52 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.526 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -94.39 -36.33 11.97 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.865 0.364 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.59 31.06 3.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.34 -53.21 60.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.17 -31.81 71.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.992 179.946 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.774 0.321 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 27.8 m80 68.6 -68.12 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.895 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 55.7 m-70 -124.85 -175.47 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.923 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -99.58 -67.95 0.83 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.855 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.1 m170 -73.74 -176.55 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.929 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -122.21 -176.47 3.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.8 t-80 -175.38 140.9 0.51 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.456 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -85.61 144.55 40.19 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.033 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.804 ' HD2' HD13 ' A' ' 12' ' ' LEU . 53.0 Cg_exo -54.82 154.77 19.95 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.553 2.169 . . . . 0.0 112.331 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 74' ' ' ASP . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.804 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.611 ' O ' HG12 ' A' ' 16' ' ' VAL . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.629 HG22 ' HE3' ' A' ' 23' ' ' TRP . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.401 ' HA3' ' HD3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.629 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' HD12 ' A' ' 93' ' ' LEU . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.586 ' HB3' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 31' ' ' VAL . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.537 HG12 HG21 ' A' ' 27' ' ' VAL . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.726 HG21 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.486 ' H ' HG22 ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.726 ' CE1' HG21 ' A' ' 35' ' ' THR . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.43 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.461 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.466 ' O ' HD11 ' A' ' 54' ' ' ILE . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.601 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.601 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.941 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 63' ' ' THR . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.535 ' CG2' HG23 ' A' ' 56' ' ' ILE . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.941 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HG21 ' A' ' 11' ' ' THR . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.586 HD13 ' HB3' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.917 HD12 HG13 ' A' ' 160' ' ' VAL . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 180' ' ' ALA . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.806 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.667 ' CB ' HD12 ' A' ' 104' ' ' LEU . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.649 HD11 HD23 ' A' ' 12' ' ' LEU . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.769 HD12 ' HB3' ' A' ' 102' ' ' LEU . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.436 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.511 ' NH2' HD13 ' A' ' 142' ' ' ILE . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.769 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.813 HD13 ' HB3' ' A' ' 139' ' ' LEU . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 127' ' ' MET . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.713 HD12 ' OE1' ' A' ' 124' ' ' GLN . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 169.91 18.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 84.1 p -86.72 102.24 14.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.6 mtp -86.17 150.01 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.4 ttt85 -106.46 109.54 21.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.18 110.73 33.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.056 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 60.4 31.35 20.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.62 28.51 42.89 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.463 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.429 ' O ' HG23 ' A' ' 121' ' ' VAL . 2.7 mmp_? -130.57 107.9 9.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.86 0.362 . . . . 0.0 110.837 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.8 mt -65.45 122.49 17.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 119' ' ' ARG . 21.5 t -135.44 144.76 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.103 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -93.51 117.28 29.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLN . . . . . 0.713 ' OE1' HD12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.43 ' OG ' HG21 ' A' ' 173' ' ' THR . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.817 ' O ' HG22 ' A' ' 174' ' ' VAL . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' MET . . . . . 0.463 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.686 ' CD2' ' HB2' ' A' ' 134' ' ' ALA . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.686 ' HB2' ' CD2' ' A' ' 128' ' ' LEU . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.813 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.638 HG21 ' O ' ' A' ' 145' ' ' ASP . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.511 HD13 ' NH2' ' A' ' 96' ' ' ARG . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.638 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.645 ' O ' HG23 ' A' ' 160' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.806 HG22 ' O ' ' A' ' 91' ' ' SER . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.425 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.433 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.499 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.465 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 79' ' ' VAL . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.917 HG13 HD12 ' A' ' 80' ' ' LEU . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 147' ' ' GLY . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.475 ' CE1' ' HB2' ' A' ' 139' ' ' LEU . 2.4 t60 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.903 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ASN . . . . . 0.447 ' O ' HD12 ' A' ' 128' ' ' LEU . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.43 HG21 ' OG ' ' A' ' 125' ' ' SER . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.903 HG12 ' HB2' ' A' ' 167' ' ' ALA . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' GLN . . . . . 0.442 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 -176.96 93.92 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' ALA . . . . . 0.406 ' HB3' ' HB3' ' A' ' 82' ' ' GLU . . . -154.17 116.79 4.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.102 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -158.05 -172.82 25.68 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.54 -172.58 4.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.812 0.339 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -164.72 -65.93 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.514 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -64.73 -54.53 30.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.837 0.351 . . . . 0.0 110.957 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 185' ' ' THR . 89.1 m 55.83 54.93 7.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.964 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.11 31.15 21.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.176 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.9 106.64 11.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.902 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.178 -0.915 . . . . 0.0 110.937 179.917 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.871 0.367 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -98.84 31.65 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -149.1 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -91.17 129.65 37.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.2 t-80 -100.36 -31.51 11.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m170 -59.99 127.86 33.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -126.98 157.52 39.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.512 ' HB3' ' NE1' ' A' ' 13' ' ' TRP . . . -63.41 158.34 58.43 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.12 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 18.6 Cg_endo -58.66 144.74 97.45 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.684 2.256 . . . . 0.0 112.269 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.569 ' O ' HD23 ' A' ' 12' ' ' LEU . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' TRP . . . . . 0.738 ' O ' HG12 ' A' ' 16' ' ' VAL . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.736 ' NH2' HD22 ' A' ' 75' ' ' LEU . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.722 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PHE . . . . . 0.491 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TRP . . . . . 0.434 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 33' ' ' ILE . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 70' ' ' LYS . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.52 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.742 HG12 HG13 ' A' ' 27' ' ' VAL . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 37' ' ' HIS . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.788 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.648 ' H ' HG22 ' A' ' 35' ' ' THR . 23.0 t-80 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.4 HG22 ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 36' ' ' THR . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.529 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.901 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.404 ' HG2' HG23 ' A' ' 35' ' ' THR . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ARG . . . . . 0.901 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.628 ' CE2' ' HE3' ' A' ' 71' ' ' MET . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HA ' HG22 ' A' ' 30' ' ' THR . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' MET . . . . . 0.628 ' HE3' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.411 ' HG2' HD12 ' A' ' 75' ' ' LEU . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.736 HD22 ' NH2' ' A' ' 15' ' ' ARG . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.683 HD13 ' N ' ' A' ' 81' ' ' GLU . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.683 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.698 HG22 ' CE1' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.431 HD22 ' CD1' ' A' ' 13' ' ' TRP . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.738 HD13 HG22 ' A' ' 141' ' ' THR . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.523 HD12 HD11 ' A' ' 94' ' ' ILE . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -146.21 159.1 43.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.3 m -84.93 109.79 18.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.63 154.43 17.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.907 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.4 ttt180 -98.01 128.84 44.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 32.8 mt -140.19 119.35 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.71 31.39 20.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.4 28.0 60.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.568 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.7 mtp85 -136.44 141.18 43.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.4 mt -88.38 118.9 28.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -129.46 138.58 53.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.197 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -76.0 141.63 42.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.765 HD22 ' O ' ' A' ' 133' ' ' ASN . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.471 HG21 HD22 ' A' ' 133' ' ' ASN . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.765 ' O ' HD22 ' A' ' 128' ' ' LEU . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.532 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' THR . . . . . 0.738 HG22 HD13 ' A' ' 94' ' ' ILE . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ASP . . . . . 0.647 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ALA . . . . . 0.605 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' PRO . . . . . 0.572 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.408 HG11 HD21 ' A' ' 12' ' ' LEU . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' HIS . . . . . 0.443 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' LYS . . . . . 0.429 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ARG . . . . . 0.469 ' HB2' HG23 ' A' ' 159' ' ' VAL . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' CYS . . . . . 0.68 ' O ' HG22 ' A' ' 178' ' ' VAL . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ALA . . . . . 0.419 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.482 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 55.7 m-80 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.532 HG21 HD23 ' A' ' 139' ' ' LEU . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 176' ' ' CYS . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' CYS . . . . . 0.451 ' N ' HG12 ' A' ' 175' ' ' VAL . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.68 HG22 ' O ' ' A' ' 161' ' ' CYS . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -110.61 165.84 11.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -174.9 145.22 0.83 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 101.79 35.3 4.07 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.442 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -90.91 131.35 36.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.843 0.354 . . . . 0.0 110.92 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.42 8.31 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.526 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.1 -64.26 1.18 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.847 0.356 . . . . 0.0 110.966 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 63.1 m -106.12 -47.07 3.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.58 165.89 7.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.101 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.3 tp -172.51 121.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.926 179.982 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.474 ' CG ' HD13 ' A' ' 12' ' ' LEU . 36.2 Cg_endo . . . . . 0 CA--C 1.531 0.333 0 CA-C-O 120.54 0.142 . . . . 0.0 112.254 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.026 HD21 HG11 ' A' ' 151' ' ' VAL . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.803 ' O ' HG12 ' A' ' 16' ' ' VAL . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.803 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.484 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.426 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.582 ' HE3' HG22 ' A' ' 16' ' ' VAL . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.726 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.451 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.866 HG21 HG23 ' A' ' 33' ' ' ILE . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB2' ' HB ' ' A' ' 31' ' ' VAL . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.408 ' HB2' ' HB3' ' A' ' 70' ' ' LYS . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.514 HG12 ' HB ' ' A' ' 27' ' ' VAL . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.866 HG23 HG21 ' A' ' 27' ' ' VAL . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.596 HG22 ' H ' ' A' ' 36' ' ' THR . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.596 ' H ' HG22 ' A' ' 35' ' ' THR . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.621 ' CD2' HG13 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.621 HG13 ' CD2' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 35' ' ' THR . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.484 HG21 ' HE1' ' A' ' 19' ' ' PHE . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HD11 ' A' ' 54' ' ' ILE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.4 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.525 HD11 ' O ' ' A' ' 49' ' ' GLU . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.92 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 ' CG2' ' A' ' 63' ' ' THR . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.655 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.92 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.451 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.457 ' O ' HG12 ' A' ' 160' ' ' VAL . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.598 HD22 HG13 ' A' ' 160' ' ' VAL . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.528 ' N ' HD13 ' A' ' 80' ' ' LEU . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.429 ' HA ' HG13 ' A' ' 178' ' ' VAL . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.792 ' SG ' HG21 ' A' ' 88' ' ' THR . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.792 HG21 ' SG ' ' A' ' 84' ' ' CYS . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.473 HG21 ' CE1' ' A' ' 164' ' ' HIS . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.606 HD11 ' CD2' ' A' ' 12' ' ' LEU . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.542 HG23 ' CG ' ' A' ' 145' ' ' ASP . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.426 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.646 HD23 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 102' ' ' LEU . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.474 ' CD1' HD11 ' A' ' 94' ' ' ILE . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.661 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.465 HG23 ' O ' ' A' ' 111' ' ' ILE . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.858 0.361 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.488 ' O ' HG13 ' A' ' 106' ' ' VAL . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.569 HD12 ' HB2' ' A' ' 134' ' ' ALA . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.419 ' N ' HD23 ' A' ' 128' ' ' LEU . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.569 ' HB2' HD12 ' A' ' 128' ' ' LEU . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.51 ' C ' ' HB3' ' A' ' 167' ' ' ALA . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.559 ' HB3' HG22 ' A' ' 141' ' ' THR . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.854 HD23 ' CG2' ' A' ' 174' ' ' VAL . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.559 HG22 ' HB3' ' A' ' 138' ' ' ASP . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.531 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.531 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.542 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.409 ' HB3' ' HB2' ' A' ' 25' ' ' PHE . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.711 ' O ' HG23 ' A' ' 160' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.026 HG11 HD21 ' A' ' 12' ' ' LEU . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.46 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.46 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.452 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' HG21 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.51 ' HB3' ' C ' ' A' ' 136' ' ' GLY . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.854 ' CG2' HD23 ' A' ' 139' ' ' LEU . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.452 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.47 HG12 ' N ' ' A' ' 179' ' ' GLN . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 178' ' ' VAL . 44.6 tt0 . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.484 ' CG ' HD13 ' A' ' 12' ' ' LEU . 37.3 Cg_endo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.622 0.176 . . . . 0.0 112.355 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.484 HD13 ' CG ' ' A' ' 9' ' ' PRO . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.881 ' CD1' HD22 ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.822 ' NH1' HD13 ' A' ' 75' ' ' LEU . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.739 HG22 ' HE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.512 ' O ' HG12 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.739 ' HE3' HG22 ' A' ' 16' ' ' VAL . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CZ ' HG11 ' A' ' 160' ' ' VAL . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.768 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 HD11 ' A' ' 80' ' ' LEU . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.674 HG22 ' H ' ' A' ' 37' ' ' HIS . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.674 ' H ' HG22 ' A' ' 35' ' ' THR . 9.3 t60 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.429 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.484 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.561 HD22 HD11 ' A' ' 56' ' ' ILE . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 55' ' ' ALA . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.851 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.561 HD11 HD22 ' A' ' 51' ' ' LEU . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.401 ' HG2' HG21 ' A' ' 36' ' ' THR . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.424 ' O ' ' HB1' ' A' ' 177' ' ' ALA . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.851 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.768 ' CG ' HG23 ' A' ' 30' ' ' THR . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.597 ' CG ' HD12 ' A' ' 75' ' ' LEU . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.822 HD13 ' NH1' ' A' ' 15' ' ' ARG . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 159' ' ' VAL . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.71 HD11 HD13 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.558 ' HG2' HG11 ' A' ' 159' ' ' VAL . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.682 ' O ' HG22 ' A' ' 151' ' ' VAL . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.881 HD22 ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.671 HG23 ' CG ' ' A' ' 145' ' ' ASP . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.982 HD22 HG21 ' A' ' 130' ' ' THR . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.595 HG22 HD21 ' A' ' 139' ' ' LEU . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . 0.443 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 . . . . . 0 N--CA 1.458 -0.059 0 CA-C-O 120.877 0.37 . . . . 0.0 110.881 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.569 ' O ' HG23 ' A' ' 173' ' ' THR . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.442 ' O ' HG13 ' A' ' 106' ' ' VAL . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.599 ' CD2' HD13 ' A' ' 139' ' ' LEU . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.743 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.982 HG21 HD22 ' A' ' 104' ' ' LEU . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.403 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . 0.406 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.672 ' HB2' HG23 ' A' ' 141' ' ' THR . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.599 HD13 ' CD2' ' A' ' 128' ' ' LEU . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.672 HG23 ' HB2' ' A' ' 138' ' ' ASP . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.479 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.671 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.414 ' HB3' HG11 ' A' ' 38' ' ' VAL . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.412 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.564 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.793 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 160' ' ' VAL . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.565 ' HD3' HG21 ' A' ' 159' ' ' VAL . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HD2' ' A' ' 153' ' ' LYS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.565 HG21 ' HD3' ' A' ' 154' ' ' ARG . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 151' ' ' VAL . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.406 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.569 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.518 HG11 HD23 ' A' ' 139' ' ' LEU . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 61' ' ' GLU . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.644 HG23 ' CD2' ' A' ' 80' ' ' LEU . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.432 ' N ' HG13 ' A' ' 178' ' ' VAL . 1.6 tp-100 . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.459 ' HD2' HD13 ' A' ' 12' ' ' LEU . 57.4 Cg_exo . . . . . 0 CA--C 1.527 0.139 0 CA-C-O 120.781 0.242 . . . . 0.0 112.409 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.703 HG23 ' O ' ' A' ' 74' ' ' ASP . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.091 HD21 HG11 ' A' ' 151' ' ' VAL . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.878 ' O ' HG12 ' A' ' 16' ' ' VAL . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HG2' HD22 ' A' ' 75' ' ' LEU . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.878 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 43' ' ' VAL . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.538 ' O ' HG11 ' A' ' 38' ' ' VAL . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.489 ' HE3' HG22 ' A' ' 16' ' ' VAL . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' HB2' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.481 ' HB3' HD13 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.732 HG13 HG12 ' A' ' 33' ' ' ILE . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.48 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.732 HG12 HG13 ' A' ' 27' ' ' VAL . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.585 HG22 ' H ' ' A' ' 37' ' ' HIS . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.817 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.585 ' H ' HG22 ' A' ' 35' ' ' THR . 10.3 t60 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.538 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.817 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.42 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 41' ' ' THR . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.494 HG21 ' CE1' ' A' ' 19' ' ' PHE . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.498 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.426 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.498 HD12 ' HE1' ' A' ' 46' ' ' PHE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.925 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.605 ' OG1' HG23 ' A' ' 36' ' ' THR . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.925 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.483 ' C ' HG23 ' A' ' 30' ' ' THR . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.703 ' O ' HG23 ' A' ' 11' ' ' THR . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.481 HD13 ' HB3' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.505 HD12 HG13 ' A' ' 160' ' ' VAL . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.768 HG22 ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.515 HD22 ' HE1' ' A' ' 13' ' ' TRP . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 104' ' ' LEU . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.76 HD23 ' O ' ' A' ' 94' ' ' ILE . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.044 HD11 HD11 ' A' ' 94' ' ' ILE . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.737 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.59 ' HG3' HD12 ' A' ' 129' ' ' LEU . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.873 0.368 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.771 ' O ' HG23 ' A' ' 173' ' ' THR . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.676 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.59 HD12 ' HG3' ' A' ' 107' ' ' ARG . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.533 ' HA ' HD11 ' A' ' 128' ' ' LEU . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.732 ' HB2' HG23 ' A' ' 141' ' ' THR . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.692 HD23 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.732 HG23 ' HB2' ' A' ' 138' ' ' ASP . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.464 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.464 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.61 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.614 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.614 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.768 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.091 HG11 HD21 ' A' ' 12' ' ' LEU . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.4 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.736 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.736 HG23 ' HB2' ' A' ' 154' ' ' ARG . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.474 ' O ' HD11 ' A' ' 80' ' ' LEU . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.444 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.826 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.826 HG12 ' HB2' ' A' ' 167' ' ' ALA . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.419 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.757 0.232 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 12' ' ' LEU . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.757 ' O ' HG12 ' A' ' 16' ' ' VAL . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.681 ' NH1' HD22 ' A' ' 75' ' ' LEU . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.757 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.536 ' HE1' HG21 ' A' ' 43' ' ' VAL . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.618 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.514 ' HE3' HG22 ' A' ' 16' ' ' VAL . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.797 HG21 HG23 ' A' ' 33' ' ' ILE . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.402 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.453 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.448 HG22 ' HD2' ' A' ' 66' ' ' ARG . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.801 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 38' ' ' VAL . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.401 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.618 ' H ' HG22 ' A' ' 35' ' ' THR . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.683 HG22 ' HB ' ' A' ' 35' ' ' THR . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' HE1' ' A' ' 19' ' ' PHE . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.586 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.586 HD12 ' HA ' ' A' ' 51' ' ' LEU . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.7 m170 -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HB3' HG23 ' A' ' 35' ' ' THR . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.444 ' CZ ' ' HG2' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.898 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.401 ' CD2' ' OE1' ' A' ' 49' ' ' GLU . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 30' ' ' THR . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.414 ' HE1' ' HD2' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.681 HD22 ' NH1' ' A' ' 15' ' ' ARG . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . 0.459 ' HE3' ' N ' ' A' ' 160' ' ' VAL . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 81' ' ' GLU . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.467 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.636 ' N ' HG11 ' A' ' 178' ' ' VAL . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.775 ' O ' HG22 ' A' ' 151' ' ' VAL . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.595 HG21 ' NE2' ' A' ' 164' ' ' HIS . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.486 ' N ' HG12 ' A' ' 92' ' ' VAL . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.883 HG21 HG13 ' A' ' 142' ' ' ILE . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.752 ' CD2' HD11 ' A' ' 142' ' ' ILE . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.4 HD12 HD11 ' A' ' 94' ' ' ILE . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.565 HG22 HD23 ' A' ' 128' ' ' LEU . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.903 0.383 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.429 ' C ' HG22 ' A' ' 174' ' ' VAL . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.621 HD21 HG11 ' A' ' 174' ' ' VAL . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.584 HD12 ' C ' ' A' ' 128' ' ' LEU . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 132' ' ' ALA . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.552 ' HB2' ' OD1' ' A' ' 172' ' ' ASN . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . 0.427 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.432 ' HG ' ' CG ' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.404 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.883 HG13 HG21 ' A' ' 94' ' ' ILE . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.586 ' OD1' HG23 ' A' ' 94' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.438 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.881 ' O ' HG23 ' A' ' 160' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 91' ' ' SER . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.493 ' HD3' HG21 ' A' ' 159' ' ' VAL . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.481 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.769 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.595 ' NE2' HG21 ' A' ' 92' ' ' VAL . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.821 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.552 ' OD1' ' HB2' ' A' ' 132' ' ' ALA . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.821 HG12 ' HB2' ' A' ' 167' ' ' ALA . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.421 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.769 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.636 HG11 ' N ' ' A' ' 83' ' ' GLY . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.444 ' HG2' ' CZ ' ' A' ' 62' ' ' PHE . 39.7 mt-30 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.784 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo . . . . . 0 C--O 1.231 0.151 0 CA-C-O 120.858 0.274 . . . . 0.0 112.253 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.942 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.791 ' O ' HG12 ' A' ' 16' ' ' VAL . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.791 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB2' ' CH2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.4 ' CB ' HG12 ' A' ' 38' ' ' VAL . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.42 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.66 ' HE3' HG22 ' A' ' 16' ' ' VAL . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.664 ' CE2' HG11 ' A' ' 160' ' ' VAL . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.552 ' CB ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.782 HG21 HG23 ' A' ' 33' ' ' ILE . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.533 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.782 HG23 HG21 ' A' ' 27' ' ' VAL . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.738 HG21 ' CE1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.845 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.738 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.642 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.845 HG12 ' O ' ' A' ' 36' ' ' THR . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.937 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.857 HD11 HG23 ' A' ' 63' ' ' THR . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.52 ' N ' HD13 ' A' ' 56' ' ' ILE . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 56' ' ' ILE . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.937 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.533 ' HB3' HG23 ' A' ' 30' ' ' THR . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . 0.415 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.552 HD13 ' CB ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . 0.519 ' CE ' HG13 ' A' ' 160' ' ' VAL . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.655 ' HA ' HG21 ' A' ' 178' ' ' VAL . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.626 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HG21 ' A' ' 151' ' ' VAL . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.765 HD11 ' CG ' ' A' ' 104' ' ' LEU . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.589 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.765 ' CG ' HD11 ' A' ' 94' ' ' ILE . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.779 HG22 HD23 ' A' ' 128' ' ' LEU . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.775 HG23 ' OE1' ' A' ' 124' ' ' GLN . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 . . . . . 0 CA--C 1.527 0.086 0 CA-C-O 120.81 0.338 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . 0.775 ' OE1' HG23 ' A' ' 111' ' ' ILE . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 173' ' ' THR . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 106' ' ' VAL . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 128' ' ' LEU . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.421 HG21 HD22 ' A' ' 133' ' ' ASN . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.488 ' O ' HD13 ' A' ' 139' ' ' LEU . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.517 ' HB2' HD22 ' A' ' 139' ' ' LEU . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.855 HD23 ' HB2' ' A' ' 167' ' ' ALA . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.702 ' HA ' HD13 ' A' ' 94' ' ' ILE . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.554 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.554 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.769 ' CG ' ' HB2' ' A' ' 148' ' ' ALA . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.42 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.769 ' HB2' ' CG ' ' A' ' 145' ' ' ASP . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 93' ' ' LEU . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.942 HG11 HD21 ' A' ' 12' ' ' LEU . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.408 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.474 ' CB ' HG23 ' A' ' 159' ' ' VAL . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.474 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.862 HG12 HG12 ' A' ' 151' ' ' VAL . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.502 ' O ' HG11 ' A' ' 178' ' ' VAL . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.457 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.421 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.855 ' HB2' HD23 ' A' ' 139' ' ' LEU . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.487 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.487 ' H ' HG22 ' A' ' 168' ' ' THR . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 126' ' ' GLY . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.568 ' CG2' HG11 ' A' ' 106' ' ' VAL . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 165' ' ' ALA . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.655 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.438 ' N ' HG23 ' A' ' 178' ' ' VAL . 7.3 mm-40 . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HD2' HD13 ' A' ' 12' ' ' LEU . 46.7 Cg_exo . . . . . 0 CA--C 1.527 0.159 0 CA-C-O 120.703 0.21 . . . . 0.0 112.419 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 74' ' ' ASP . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.644 HD13 ' HD2' ' A' ' 9' ' ' PRO . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.79 ' O ' HG12 ' A' ' 16' ' ' VAL . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 13' ' ' TRP . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.467 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.5 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.826 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.518 ' CD2' HD11 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.844 HG13 HD11 ' A' ' 80' ' ' LEU . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.628 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.826 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.771 ' HB ' HG22 ' A' ' 38' ' ' VAL . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.767 ' H ' HG22 ' A' ' 35' ' ' THR . 10.1 t60 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.771 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.467 HG21 ' HE1' ' A' ' 19' ' ' PHE . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.654 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.674 HG21 ' CD2' ' A' ' 65' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.794 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.563 HG23 ' HE1' ' A' ' 65' ' ' PHE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.674 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.794 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.628 ' C ' HG23 ' A' ' 30' ' ' THR . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.57 ' N ' HG23 ' A' ' 30' ' ' THR . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.479 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.56 ' O ' HG23 ' A' ' 11' ' ' THR . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.662 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 27' ' ' VAL . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.539 ' HA2' HD11 ' A' ' 111' ' ' ILE . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.662 HG22 HD22 ' A' ' 129' ' ' LEU . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.486 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.712 HG22 ' CE1' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.45 ' N ' HG12 ' A' ' 92' ' ' VAL . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.636 HD11 ' CD1' ' A' ' 104' ' ' LEU . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.4 HD12 ' HA ' ' A' ' 102' ' ' LEU . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.636 ' CD1' HD11 ' A' ' 94' ' ' ILE . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.539 HD11 ' HA2' ' A' ' 83' ' ' GLY . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.825 0.345 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.618 HD23 HD11 ' A' ' 139' ' ' LEU . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.662 HD22 HG22 ' A' ' 89' ' ' VAL . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HA ' HD13 ' A' ' 128' ' ' LEU . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.826 HD22 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.641 HG21 ' HB3' ' A' ' 145' ' ' ASP . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.579 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.579 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.639 ' O ' HG11 ' A' ' 38' ' ' VAL . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.613 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.74 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 91' ' ' SER . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.407 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.415 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.455 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.7 t-80 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.644 ' CB ' HG12 ' A' ' 174' ' ' VAL . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.1 m120 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.826 HG11 HD22 ' A' ' 139' ' ' LEU . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.486 ' N ' HG22 ' A' ' 178' ' ' VAL . 4.2 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.763 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo . . . . . 0 CA--C 1.527 0.171 0 CA-C-O 120.731 0.221 . . . . 0.0 112.345 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.446 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.771 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.768 ' O ' HG12 ' A' ' 16' ' ' VAL . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.768 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.555 ' O ' HG12 ' A' ' 38' ' ' VAL . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.485 ' HE3' HG22 ' A' ' 16' ' ' VAL . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.621 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.557 ' CG2' HG12 ' A' ' 31' ' ' VAL . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.41 ' HB2' ' CG ' ' A' ' 70' ' ' LYS . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.557 HG12 ' CG2' ' A' ' 27' ' ' VAL . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.621 HD11 ' HB3' ' A' ' 25' ' ' PHE . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' HG22 ' A' ' 38' ' ' VAL . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.785 ' O ' HG12 ' A' ' 39' ' ' VAL . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.559 ' HD2' HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' HD2' ' A' ' 37' ' ' HIS . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.785 HG12 ' O ' ' A' ' 36' ' ' THR . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.4 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.611 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.611 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.466 HG13 HG23 ' A' ' 63' ' ' THR . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.466 HG23 HG13 ' A' ' 56' ' ' ILE . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.414 ' NE2' HG13 ' A' ' 31' ' ' VAL . 0.4 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.41 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.535 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 72' ' ' ARG . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.795 HD21 HG23 ' A' ' 178' ' ' VAL . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.473 ' HA ' HG21 ' A' ' 178' ' ' VAL . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.787 ' O ' HG22 ' A' ' 151' ' ' VAL . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 93' ' ' LEU . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.537 HD22 ' HD1' ' A' ' 13' ' ' TRP . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.775 HG23 ' CG ' ' A' ' 145' ' ' ASP . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.613 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.894 HD22 HG21 ' A' ' 130' ' ' THR . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.558 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.765 HG23 ' NE2' ' A' ' 124' ' ' GLN . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 37.8 m80 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.885 0.374 . . . . 0.0 110.871 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . 0.765 ' NE2' HG23 ' A' ' 111' ' ' ILE . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' O ' HG23 ' A' ' 173' ' ' THR . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.477 ' O ' HG13 ' A' ' 106' ' ' VAL . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.556 HD11 HG13 ' A' ' 174' ' ' VAL . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.894 HG21 HD22 ' A' ' 104' ' ' LEU . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 132' ' ' ALA . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.432 ' HB1' ' OD1' ' A' ' 172' ' ' ASN . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.416 ' HB3' ' HA3' ' A' ' 140' ' ' GLY . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.795 ' OD1' HD23 ' A' ' 139' ' ' LEU . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.96 HD22 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 133' ' ' ASN . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.657 HG21 ' HB3' ' A' ' 145' ' ' ASP . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.775 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.861 ' O ' HG23 ' A' ' 160' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 91' ' ' SER . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.422 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.494 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.584 HG13 ' O ' ' A' ' 79' ' ' VAL . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.96 ' CE1' HD22 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 177' ' ' ALA . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.432 ' OD1' ' HB1' ' A' ' 132' ' ' ALA . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 126' ' ' GLY . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.558 ' CG2' HG11 ' A' ' 106' ' ' VAL . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 165' ' ' ALA . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.795 HG23 HD21 ' A' ' 80' ' ' LEU . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.479 ' N ' HG22 ' A' ' 178' ' ' VAL . 1.2 mm100 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.687 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.8 Cg_exo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.769 0.237 . . . . 0.0 112.351 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.687 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.879 ' O ' HG12 ' A' ' 16' ' ' VAL . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.879 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.77 ' CE2' HG11 ' A' ' 160' ' ' VAL . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.435 ' HB3' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.544 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.413 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.49 HG12 ' CG2' ' A' ' 27' ' ' VAL . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.544 HD13 ' CG1' ' A' ' 27' ' ' VAL . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.4 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.754 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.754 ' H ' HG22 ' A' ' 35' ' ' THR . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.718 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.88 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 56' ' ' ILE . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 62' ' ' PHE . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.505 ' HB3' ' HB3' ' A' ' 59' ' ' ALA . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.4 ' HB ' HG23 ' A' ' 34' ' ' THR . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.88 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.575 ' HB3' HG23 ' A' ' 30' ' ' THR . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.435 HD13 ' HB3' ' A' ' 26' ' ' TRP . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.713 HD21 HG12 ' A' ' 178' ' ' VAL . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.415 ' HA ' HG21 ' A' ' 178' ' ' VAL . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.747 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.55 HD21 HG21 ' A' ' 151' ' ' VAL . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.577 HD12 ' HG ' ' A' ' 104' ' ' LEU . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.555 HD22 ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.427 ' O ' HD12 ' A' ' 94' ' ' ILE . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.577 ' HG ' HD12 ' A' ' 94' ' ' ILE . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.615 HG22 HD23 ' A' ' 128' ' ' LEU . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.564 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 34.8 m170 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.836 0.351 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 1.049 HD13 HD12 ' A' ' 139' ' ' LEU . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.406 HD12 ' N ' ' A' ' 129' ' ' LEU . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 1.049 HD12 HD13 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.691 HG21 ' HB3' ' A' ' 145' ' ' ASP . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.537 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.537 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.691 ' HB3' HG21 ' A' ' 141' ' ' THR . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.566 ' O ' HG11 ' A' ' 38' ' ' VAL . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.58 ' HB2' ' OD1' ' A' ' 145' ' ' ASP . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.446 ' HG2' HD12 ' A' ' 93' ' ' LEU . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CE2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 160' ' ' VAL . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.413 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.515 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.539 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 154' ' ' ARG . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 151' ' ' VAL . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.916 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.431 ' O ' HD12 ' A' ' 128' ' ' LEU . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 128' ' ' LEU . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.713 HG12 HD21 ' A' ' 80' ' ' LEU . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.434 ' N ' HG23 ' A' ' 178' ' ' VAL . 3.0 mm-40 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.7 Cg_exo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.765 0.235 . . . . 0.0 112.315 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.578 ' CD2' HD11 ' A' ' 93' ' ' LEU . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.778 ' O ' HG12 ' A' ' 16' ' ' VAL . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB3' HG12 ' A' ' 38' ' ' VAL . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.604 ' HE3' HG22 ' A' ' 16' ' ' VAL . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.55 ' HB3' HD11 ' A' ' 33' ' ' ILE . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.436 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.707 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.594 HG23 ' HD3' ' A' ' 70' ' ' LYS . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.707 HG23 HG21 ' A' ' 27' ' ' VAL . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.827 HG21 ' CE1' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.778 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.827 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.3 p-80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 36' ' ' THR . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.636 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.636 HD12 ' HA ' ' A' ' 51' ' ' LEU . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.926 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.704 ' HG3' HG21 ' A' ' 36' ' ' THR . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.505 ' CD1' ' HB1' ' A' ' 177' ' ' ALA . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.522 ' C ' HG22 ' A' ' 30' ' ' THR . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HD3' HG23 ' A' ' 30' ' ' THR . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.571 HD12 ' HG3' ' A' ' 72' ' ' ARG . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.683 ' O ' HG22 ' A' ' 160' ' ' VAL . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.854 HD12 HG23 ' A' ' 160' ' ' VAL . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.404 ' HA3' HD13 ' A' ' 111' ' ' ILE . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.578 HD11 ' CD2' ' A' ' 12' ' ' LEU . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.998 HD11 HD11 ' A' ' 104' ' ' LEU . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.783 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 94' ' ' ILE . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.478 HG12 ' N ' ' A' ' 107' ' ' ARG . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.478 ' N ' HG12 ' A' ' 106' ' ' VAL . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.404 HD13 ' HA3' ' A' ' 83' ' ' GLY . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.772 0.32 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.901 HD23 HD13 ' A' ' 139' ' ' LEU . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.901 HD13 HD23 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.42 HG21 ' O ' ' A' ' 145' ' ' ASP . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.535 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.706 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.465 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 160' ' ' VAL . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.447 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.447 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.422 HG12 ' N ' ' A' ' 160' ' ' VAL . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 151' ' ' VAL . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.691 ' O ' HG12 ' A' ' 178' ' ' VAL . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 147' ' ' GLY . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 21.9 t-80 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.621 ' HB2' ' CG1' ' A' ' 174' ' ' VAL . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.466 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.466 ' H ' HG22 ' A' ' 168' ' ' THR . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.661 HG21 ' CD2' ' A' ' 139' ' ' LEU . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.505 ' HB1' ' CD1' ' A' ' 62' ' ' PHE . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 161' ' ' CYS . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.417 ' HD2' HD13 ' A' ' 12' ' ' LEU . 37.5 Cg_endo . . . . . 0 CA--C 1.527 0.156 0 CA-C-O 120.737 0.224 . . . . 0.0 112.295 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.502 ' CD2' HD21 ' A' ' 93' ' ' LEU . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.818 ' O ' HG12 ' A' ' 16' ' ' VAL . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.401 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HE3' HG22 ' A' ' 16' ' ' VAL . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.432 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.513 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' O ' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' A' ' 27' ' ' VAL . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.554 ' CG2' HG11 ' A' ' 27' ' ' VAL . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.814 HG21 ' CE1' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.889 ' O ' HG12 ' A' ' 39' ' ' VAL . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.814 ' CE1' HG21 ' A' ' 35' ' ' THR . 6.5 p-80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.545 HG22 ' HB ' ' A' ' 35' ' ' THR . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.889 HG12 ' O ' ' A' ' 36' ' ' THR . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.418 ' HA ' HD12 ' A' ' 54' ' ' ILE . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.518 ' NE2' HG21 ' A' ' 36' ' ' THR . 21.8 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.418 HG22 ' HD1' ' A' ' 65' ' ' PHE . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HD1' HG22 ' A' ' 63' ' ' THR . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.783 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.432 ' O ' HG22 ' A' ' 30' ' ' THR . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.432 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 159' ' ' VAL . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.439 ' HG2' HG11 ' A' ' 159' ' ' VAL . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HA ' HG21 ' A' ' 178' ' ' VAL . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.416 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.846 HG11 ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.799 HD11 HG13 ' A' ' 151' ' ' VAL . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.507 HD12 HD11 ' A' ' 104' ' ' LEU . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.41 HD22 ' CE3' ' A' ' 13' ' ' TRP . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.522 HD23 HD21 ' A' ' 104' ' ' LEU . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.522 HD21 HD23 ' A' ' 102' ' ' LEU . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.585 ' HB3' ' OG1' ' A' ' 130' ' ' THR . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.72 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.568 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.822 0.344 . . . . 0.0 110.886 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.55 ' O ' HG13 ' A' ' 106' ' ' VAL . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 132' ' ' ALA . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.585 ' OG1' ' HB3' ' A' ' 105' ' ' ALA . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.519 ' HA ' HD22 ' A' ' 128' ' ' LEU . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.442 ' O ' HD21 ' A' ' 128' ' ' LEU . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.466 ' CG ' HG22 ' A' ' 141' ' ' THR . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.866 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.466 HG22 ' CG ' ' A' ' 138' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 142' ' ' ILE . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.506 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.505 ' OD1' HG23 ' A' ' 94' ' ' ILE . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.44 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.638 ' O ' HD12 ' A' ' 93' ' ' LEU . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.799 HG13 HD11 ' A' ' 93' ' ' LEU . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.426 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.42 ' CE2' ' HB2' ' A' ' 153' ' ' LYS . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.548 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.846 ' CE1' HG11 ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.511 ' HA ' HD13 ' A' ' 128' ' ' LEU . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.866 HG21 HD23 ' A' ' 139' ' ' LEU . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.493 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.519 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.49 ' N ' HG22 ' A' ' 178' ' ' VAL . 30.3 mt-30 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.643 ' HD2' HD13 ' A' ' 12' ' ' LEU . 54.2 Cg_exo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.781 0.242 . . . . 0.0 112.406 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.643 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.471 ' CE2' HD22 ' A' ' 101' ' ' LEU . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.761 HG12 ' HE3' ' A' ' 23' ' ' TRP . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.431 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.761 ' HE3' HG12 ' A' ' 16' ' ' VAL . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.507 ' HB3' HD11 ' A' ' 33' ' ' ILE . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.616 ' HB3' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.505 HG13 HG12 ' A' ' 33' ' ' ILE . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' CA ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.501 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.84 HD13 ' CD1' ' A' ' 80' ' ' LEU . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.786 HG22 ' H ' ' A' ' 37' ' ' HIS . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.44 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.786 ' H ' HG22 ' A' ' 35' ' ' THR . 10.3 t60 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.44 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 41' ' ' THR . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.501 ' O ' HD11 ' A' ' 54' ' ' ILE . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.501 HD11 ' O ' ' A' ' 49' ' ' GLU . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.419 ' C ' HG23 ' A' ' 30' ' ' THR . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.473 ' CA ' HG23 ' A' ' 30' ' ' THR . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.432 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . 0.432 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.616 HD13 ' HB3' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . 0.439 ' HE3' ' HE2' ' A' ' 25' ' ' PHE . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.84 ' CD1' HD13 ' A' ' 33' ' ' ILE . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.765 HG22 ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.577 HD11 ' CG1' ' A' ' 151' ' ' VAL . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.493 HD11 HD12 ' A' ' 104' ' ' LEU . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.469 ' HG3' HD11 ' A' ' 101' ' ' LEU . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.471 HD22 ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 139' ' ' LEU . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 127' ' ' MET . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.446 ' CZ ' HD13 ' A' ' 129' ' ' LEU . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.564 HG23 ' O ' ' A' ' 111' ' ' ILE . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.792 0.329 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.563 ' O ' HG13 ' A' ' 106' ' ' VAL . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.983 HD21 HD11 ' A' ' 139' ' ' LEU . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.446 HD13 ' CZ ' ' A' ' 107' ' ' ARG . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.528 ' O ' HD11 ' A' ' 128' ' ' LEU . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . 0.402 ' HA ' ' HA ' ' A' ' 166' ' ' ALA . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.983 HD11 HD21 ' A' ' 128' ' ' LEU . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.568 HG21 ' H ' ' A' ' 146' ' ' CYS . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.475 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.427 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.568 ' H ' HG21 ' A' ' 141' ' ' THR . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.432 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.807 ' HB3' ' ND1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.563 ' HG2' HD12 ' A' ' 93' ' ' LEU . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.765 ' CE2' HG22 ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.577 ' CG1' HD11 ' A' ' 93' ' ' LEU . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.425 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.407 ' HE3' ' N ' ' A' ' 157' ' ' ASP . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . 0.407 ' N ' ' HE3' ' A' ' 153' ' ' LYS . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CD2' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.425 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.632 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.807 ' ND1' ' HB3' ' A' ' 148' ' ' ALA . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' MET . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.616 HG21 HD23 ' A' ' 139' ' ' LEU . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.632 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.711 HG23 HD21 ' A' ' 80' ' ' LEU . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.444 ' N ' HG22 ' A' ' 178' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.78 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.7 Cg_exo . . . . . 0 C--O 1.232 0.198 0 CA-C-O 120.711 0.213 . . . . 0.0 112.445 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.78 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.867 ' CZ3' HD22 ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.745 ' NE ' HD21 ' A' ' 75' ' ' LEU . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.755 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.696 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.439 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.731 ' HE3' HG22 ' A' ' 16' ' ' VAL . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 33' ' ' ILE . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.544 HG11 ' CG2' ' A' ' 33' ' ' ILE . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.407 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.669 HD11 ' HB3' ' A' ' 25' ' ' PHE . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.546 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.595 ' HB ' HG22 ' A' ' 38' ' ' VAL . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 35' ' ' THR . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.3 t60 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.595 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 35' ' ' THR . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.545 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.696 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 50' ' ' PRO . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 49' ' ' GLU . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.578 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.545 HD12 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.872 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 ' HB ' HG23 ' A' ' 34' ' ' THR . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.872 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HB3' HG23 ' A' ' 30' ' ' THR . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.709 ' HG2' HD12 ' A' ' 75' ' ' LEU . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.745 HD21 ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 159' ' ' VAL . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 89' ' ' VAL . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.793 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.514 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.867 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.804 HG23 ' CG ' ' A' ' 145' ' ' ASP . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.582 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.667 HD13 HD12 ' A' ' 139' ' ' LEU . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 174' ' ' VAL . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . 0.409 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.573 HG22 ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.573 ' NE2' HG22 ' A' ' 111' ' ' ILE . 2.0 t-160 . . . . . 0 C--O 1.233 0.191 0 CA-C-O 120.903 0.382 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . 0.663 ' C ' HG13 ' A' ' 175' ' ' VAL . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.645 ' HA ' HG22 ' A' ' 175' ' ' VAL . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.586 HD21 HG22 ' A' ' 174' ' ' VAL . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.474 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.873 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.537 HG21 ' HB3' ' A' ' 145' ' ' ASP . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.549 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.455 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.804 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.434 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.606 ' CD ' HG23 ' A' ' 16' ' ' VAL . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.514 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 160' ' ' VAL . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 151' ' ' VAL . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.474 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 23.8 t-80 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.514 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.534 ' O ' HG23 ' A' ' 173' ' ' THR . 8.4 m-80 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.585 ' N ' HD23 ' A' ' 128' ' ' LEU . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.873 HG21 ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.76 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HG2' HD13 ' A' ' 12' ' ' LEU . 24.8 Cg_endo . . . . . 0 CA--C 1.528 0.195 0 CA-C-O 120.58 0.158 . . . . 0.0 112.265 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.683 HG23 HD23 ' A' ' 75' ' ' LEU . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.506 HD13 ' HG2' ' A' ' 9' ' ' PRO . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.69 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.489 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.491 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.455 ' CB ' HD13 ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 31' ' ' VAL . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.505 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.662 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.539 HG12 ' CG2' ' A' ' 27' ' ' VAL . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 ' HB3' ' A' ' 25' ' ' PHE . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.421 HG23 ' HB ' ' A' ' 63' ' ' THR . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.742 HG22 ' H ' ' A' ' 37' ' ' HIS . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.723 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.742 ' H ' HG22 ' A' ' 35' ' ' THR . 10.0 t60 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.715 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 36' ' ' THR . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.489 HG21 ' HE1' ' A' ' 19' ' ' PHE . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' O ' HD11 ' A' ' 54' ' ' ILE . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.806 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.421 ' HB ' HG23 ' A' ' 34' ' ' THR . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.806 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 30' ' ' THR . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.662 ' C ' HG23 ' A' ' 30' ' ' THR . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.405 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.683 HD23 HG23 ' A' ' 11' ' ' THR . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 107' ' ' ARG . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 93' ' ' LEU . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.601 HD11 HG22 ' A' ' 151' ' ' VAL . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 1.117 HD11 HD11 ' A' ' 104' ' ' LEU . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.734 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.117 HD11 HD11 ' A' ' 94' ' ' ILE . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.528 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.595 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.71 ' HB2' HD12 ' A' ' 129' ' ' LEU . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 111' ' ' ILE . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.762 0.315 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.459 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.71 HD12 ' HB2' ' A' ' 107' ' ' ARG . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.858 HG21 ' HA ' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB3' HG22 ' A' ' 141' ' ' THR . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.769 HD12 HD22 ' A' ' 104' ' ' LEU . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.549 HG22 ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.496 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.496 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.601 HG22 HD11 ' A' ' 93' ' ' LEU . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.498 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.703 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.403 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.703 HG12 ' HB2' ' A' ' 167' ' ' ALA . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 178' ' ' VAL . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.468 ' HA ' ' HD2' ' A' ' 10' ' ' PRO . 81.4 Cg_exo . . . . . 0 CA--C 1.529 0.269 0 N-CA-C 112.513 0.159 . . . . 0.0 112.513 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.866 HD11 ' HE3' ' A' ' 78' ' ' MET . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.717 ' O ' HG12 ' A' ' 16' ' ' VAL . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.402 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.851 ' CE3' HG22 ' A' ' 16' ' ' VAL . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.516 ' HB3' HD11 ' A' ' 33' ' ' ILE . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.426 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.705 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.705 HG23 HG21 ' A' ' 27' ' ' VAL . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.752 ' O ' HG23 ' A' ' 39' ' ' VAL . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.653 ' CE1' HG21 ' A' ' 35' ' ' THR . 4.6 p-80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.608 HG13 ' CD2' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 35' ' ' THR . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.457 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.406 HD21 ' HZ ' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CE2' ' A' ' 67' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.93 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 63' ' ' THR . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.428 ' OE1' ' HB1' ' A' ' 165' ' ' ALA . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.431 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 HG23 ' HG2' ' A' ' 58' ' ' GLN . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.93 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.533 ' CE2' HD11 ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.452 ' O ' HG22 ' A' ' 30' ' ' THR . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.437 ' HG2' HG23 ' A' ' 30' ' ' THR . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.426 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.471 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.471 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . 0.866 ' HE3' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.592 ' HB ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.76 ' HG2' HG11 ' A' ' 159' ' ' VAL . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.598 ' O ' HG22 ' A' ' 151' ' ' VAL . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.592 HG22 ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.495 HD11 HG11 ' A' ' 151' ' ' VAL . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.849 HD13 ' HA ' ' A' ' 141' ' ' THR . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.425 HD23 HD21 ' A' ' 104' ' ' LEU . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 140' ' ' GLY . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.69 HG11 HG21 ' A' ' 174' ' ' VAL . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . 0.455 ' HE3' ' HB3' ' A' ' 124' ' ' GLN . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.766 HD11 ' HB3' ' A' ' 122' ' ' HIS . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . 0.766 ' HB3' HD11 ' A' ' 111' ' ' ILE . 3.9 m170 . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.882 0.373 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . 0.594 ' NE2' HD12 ' A' ' 111' ' ' ILE . 1.2 mp0 -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.781 ' O ' HG23 ' A' ' 173' ' ' THR . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.844 HD11 HD12 ' A' ' 139' ' ' LEU . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.935 HD23 ' HB3' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.433 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.849 ' HA ' HD13 ' A' ' 94' ' ' ILE . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.443 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.842 ' O ' HG21 ' A' ' 141' ' ' THR . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.497 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.469 ' HD3' HG23 ' A' ' 16' ' ' VAL . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CE2' HG22 ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 160' ' ' VAL . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.411 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.76 HG11 ' HG2' ' A' ' 81' ' ' GLU . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 151' ' ' VAL . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.766 ' O ' HG11 ' A' ' 178' ' ' VAL . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.458 ' HA3' HG13 ' A' ' 178' ' ' VAL . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.428 ' HB1' ' OE1' ' A' ' 61' ' ' GLU . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.935 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 126' ' ' GLY . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.69 HG21 HG11 ' A' ' 106' ' ' VAL . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.692 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.766 HG11 ' O ' ' A' ' 161' ' ' CYS . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.517 ' HG2' HD13 ' A' ' 12' ' ' LEU . 34.7 Cg_endo . . . . . 0 CA--C 1.53 0.278 0 CA-C-O 120.504 0.126 . . . . 0.0 112.324 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.667 HD21 HG11 ' A' ' 151' ' ' VAL . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.859 ' O ' HG12 ' A' ' 16' ' ' VAL . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.859 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.553 ' HE1' HG21 ' A' ' 43' ' ' VAL . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.577 ' HE3' HG22 ' A' ' 16' ' ' VAL . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.655 ' HB3' HD11 ' A' ' 33' ' ' ILE . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.644 ' HB3' HD11 ' A' ' 75' ' ' LEU . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.503 HG21 HG12 ' A' ' 31' ' ' VAL . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.47 ' C ' HD13 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.743 HG23 ' O ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.503 HG12 HG21 ' A' ' 27' ' ' VAL . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.655 HD11 ' HB3' ' A' ' 25' ' ' PHE . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.592 ' HB ' HG22 ' A' ' 38' ' ' VAL . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.1 t60 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HB ' ' A' ' 35' ' ' THR . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 35' ' ' THR . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.553 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.912 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.417 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.536 ' HB1' HE22 ' A' ' 179' ' ' GLN . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.65 ' OE2' ' HB1' ' A' ' 165' ' ' ALA . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.422 ' CE2' ' HG2' ' A' ' 64' ' ' GLN . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.422 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.434 ' CE2' HG21 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.912 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . 0.743 ' O ' HG23 ' A' ' 30' ' ' THR . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.644 HD11 ' HB3' ' A' ' 26' ' ' TRP . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.638 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 160' ' ' VAL . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . 0.507 ' HA ' HG11 ' A' ' 178' ' ' VAL . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.651 HG22 ' HG2' ' A' ' 107' ' ' ARG . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.529 HG22 ' CE1' ' A' ' 150' ' ' TYR . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.853 HD22 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 1.065 HD11 HD11 ' A' ' 104' ' ' LEU . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 94' ' ' ILE . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.749 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.065 HD11 HD11 ' A' ' 94' ' ' ILE . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.445 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.651 ' HG2' HG22 ' A' ' 89' ' ' VAL . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 123' ' ' GLY . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 29.2 m80 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.76 0.315 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.568 ' O ' HD12 ' A' ' 111' ' ' ILE . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.429 ' OG ' HG22 ' A' ' 175' ' ' VAL . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 134' ' ' ALA . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.615 HD22 ' HG3' ' A' ' 107' ' ' ARG . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.637 ' HB1' ' ND2' ' A' ' 172' ' ' ASN . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.474 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 167' ' ' ALA . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.675 HD12 HD13 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.65 HG21 ' HB3' ' A' ' 145' ' ' ASP . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.478 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.65 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.435 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.675 ' O ' HG23 ' A' ' 160' ' ' VAL . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.667 HG11 HD21 ' A' ' 12' ' ' LEU . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.401 ' NE2' ' HB ' ' A' ' 159' ' ' VAL . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.444 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.444 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.638 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 150' ' ' TYR . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 147' ' ' GLY . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.65 ' HB1' ' OE2' ' A' ' 61' ' ' GLU . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 136' ' ' GLY . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.497 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.497 ' H ' HG22 ' A' ' 168' ' ' THR . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.637 ' ND2' ' HB1' ' A' ' 132' ' ' ALA . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.6 HG21 ' CD2' ' A' ' 139' ' ' LEU . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.429 HG22 ' OG ' ' A' ' 125' ' ' SER . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.507 HG11 ' HA ' ' A' ' 82' ' ' GLU . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.536 HE22 ' HB1' ' A' ' 59' ' ' ALA . 1.1 tt0 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HD2' HD13 ' A' ' 12' ' ' LEU . 78.5 Cg_exo . . . . . 0 CA--C 1.528 0.193 0 CA-C-O 120.699 0.208 . . . . 0.0 112.512 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.435 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.492 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.887 ' O ' HG12 ' A' ' 16' ' ' VAL . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.887 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.537 HG21 ' CD2' ' A' ' 47' ' ' PHE . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' HE1' HG21 ' A' ' 43' ' ' VAL . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.48 ' O ' HG11 ' A' ' 38' ' ' VAL . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.42 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 80' ' ' LEU . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.469 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.54 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.515 ' C ' HD12 ' A' ' 33' ' ' ILE . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.698 HG22 ' H ' ' A' ' 37' ' ' HIS . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.847 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.698 ' H ' HG22 ' A' ' 35' ' ' THR . 9.9 t60 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.48 HG11 ' O ' ' A' ' 21' ' ' SER . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.847 HG12 ' O ' ' A' ' 36' ' ' THR . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.473 HG21 ' HE1' ' A' ' 19' ' ' PHE . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . 0.54 ' O ' HD23 ' A' ' 51' ' ' LEU . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CD2' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.416 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.416 ' CB ' ' HB2' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.846 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.586 HG23 ' CG2' ' A' ' 63' ' ' THR . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.464 ' NE2' HG22 ' A' ' 56' ' ' ILE . 0.0 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.62 ' CG ' HG23 ' A' ' 35' ' ' THR . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.586 ' CG2' HG23 ' A' ' 56' ' ' ILE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.846 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.464 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.469 ' CG ' HG23 ' A' ' 30' ' ' THR . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.514 ' HE2' ' HB3' ' A' ' 47' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.447 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.646 ' O ' HG13 ' A' ' 159' ' ' VAL . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.572 HD21 HG12 ' A' ' 27' ' ' VAL . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.572 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.614 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.728 HD22 ' CD1' ' A' ' 13' ' ' TRP . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.421 HD11 HD12 ' A' ' 104' ' ' LEU . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.655 HH22 HD22 ' A' ' 102' ' ' LEU . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.505 HD13 ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.655 HD22 HH22 ' A' ' 96' ' ' ARG . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.573 HD21 HD23 ' A' ' 102' ' ' LEU . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.513 HG22 ' HG ' ' A' ' 139' ' ' LEU . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.423 ' HB2' HD13 ' A' ' 129' ' ' LEU . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.477 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.752 0.311 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.484 ' OG ' HG22 ' A' ' 173' ' ' THR . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.512 ' O ' HG23 ' A' ' 173' ' ' THR . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.591 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.433 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . 0.478 ' HA ' ' HB1' ' A' ' 166' ' ' ALA . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.523 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.703 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 138' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.459 ' O ' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.493 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.728 ' HG2' HD12 ' A' ' 93' ' ' LEU . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.614 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 160' ' ' VAL . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 79' ' ' VAL . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 151' ' ' VAL . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 147' ' ' GLY . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.523 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 36.4 t-80 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.603 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.478 ' HB1' ' HA ' ' A' ' 137' ' ' MET . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.743 ' HB2' HG22 ' A' ' 174' ' ' VAL . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.512 HG23 ' O ' ' A' ' 126' ' ' GLY . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.743 HG22 ' HB2' ' A' ' 167' ' ' ALA . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.603 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.481 ' N ' HG13 ' A' ' 178' ' ' VAL . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' HB2' ' A' ' 12' ' ' LEU . 58.2 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 CA-C-O 120.589 0.162 . . . . 0.0 112.281 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 12' ' ' LEU . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.849 ' O ' HG12 ' A' ' 16' ' ' VAL . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.453 ' NE ' HD21 ' A' ' 75' ' ' LEU . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.849 HG12 ' O ' ' A' ' 13' ' ' TRP . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' HE1' HG21 ' A' ' 43' ' ' VAL . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE2' ' HB2' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.707 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.738 HG22 ' HA ' ' A' ' 70' ' ' LYS . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.626 HG22 ' HD2' ' A' ' 66' ' ' ARG . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.707 HD13 ' CG1' ' A' ' 27' ' ' VAL . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.777 ' H ' HG22 ' A' ' 35' ' ' THR . 8.1 t60 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.767 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.465 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.613 ' HA ' HD12 ' A' ' 54' ' ' ILE . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.555 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.621 HG21 ' CD2' ' A' ' 65' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.791 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.686 HG23 ' CE1' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 62' ' ' PHE . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.428 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.686 ' CE1' HG23 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.738 ' HA ' HG22 ' A' ' 30' ' ' THR . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG2' HD12 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.722 HD12 ' HG2' ' A' ' 72' ' ' ARG . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 159' ' ' VAL . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.649 HD23 HG13 ' A' ' 160' ' ' VAL . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.412 ' HB2' ' HE3' ' A' ' 108' ' ' MET . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.748 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.716 ' HB ' HD12 ' A' ' 104' ' ' LEU . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.573 HD22 ' CD2' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.756 HD11 HD11 ' A' ' 104' ' ' LEU . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.684 HD23 ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.675 ' HB3' HD12 ' A' ' 94' ' ' ILE . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.837 HD13 ' HB3' ' A' ' 139' ' ' LEU . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.475 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.475 ' N ' HG12 ' A' ' 106' ' ' VAL . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . 0.412 ' HE3' ' HB2' ' A' ' 84' ' ' CYS . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.74 0.305 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.506 HD21 ' HA ' ' A' ' 172' ' ' ASN . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.406 HD11 ' CZ ' ' A' ' 107' ' ' ARG . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.746 HG21 HD22 ' A' ' 133' ' ' ASN . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.746 HD22 HG21 ' A' ' 130' ' ' THR . 1.7 m-20 -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . 0.799 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.55 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.837 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.485 HG21 ' O ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.647 ' O ' HG11 ' A' ' 38' ' ' VAL . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.531 ' HG2' HD12 ' A' ' 93' ' ' LEU . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.85 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 91' ' ' SER . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.505 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.555 HG23 ' HB3' ' A' ' 154' ' ' ARG . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 150' ' ' TYR . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 147' ' ' GLY . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.55 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 18.5 t-80 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.799 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.506 ' HA ' HD21 ' A' ' 128' ' ' LEU . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.827 HG21 HD23 ' A' ' 139' ' ' LEU . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 177' ' ' ALA . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.774 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.9 Cg_exo . . . . . 0 CA--C 1.528 0.189 0 CA-C-O 120.755 0.231 . . . . 0.0 112.338 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.774 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.684 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 13' ' ' TRP . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.588 ' O ' HG11 ' A' ' 38' ' ' VAL . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.545 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.527 HG22 ' HG2' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' CG2' ' A' ' 27' ' ' VAL . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . 0.459 ' HA ' HG22 ' A' ' 27' ' ' VAL . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.658 ' O ' HD12 ' A' ' 33' ' ' ILE . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.57 HG22 ' H ' ' A' ' 37' ' ' HIS . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.822 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.57 ' H ' HG22 ' A' ' 35' ' ' THR . 8.6 t60 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.588 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.822 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.562 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.562 HD12 ' HA ' ' A' ' 51' ' ' LEU . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.822 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.462 HD12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CZ ' HD12 ' A' ' 56' ' ' ILE . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.822 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.527 ' HG2' HG22 ' A' ' 30' ' ' THR . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.754 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.638 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.762 HD13 ' HA ' ' A' ' 141' ' ' THR . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.579 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.482 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.514 ' CD1' HD11 ' A' ' 94' ' ' ILE . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.553 HG11 HG22 ' A' ' 174' ' ' VAL . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.554 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.811 0.338 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.53 ' HG2' HG23 ' A' ' 173' ' ' THR . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 139' ' ' LEU . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.668 HD23 ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.762 ' HA ' HD13 ' A' ' 94' ' ' ILE . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.495 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.601 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.754 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 93' ' ' LEU . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.593 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.466 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 147' ' ' GLY . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.668 ' CB ' HD23 ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . 0.497 ' O ' HD21 ' A' ' 139' ' ' LEU . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 173' ' ' THR . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.53 HG23 ' HG2' ' A' ' 127' ' ' MET . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.553 HG22 HG11 ' A' ' 106' ' ' VAL . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 166' ' ' ALA . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.804 ' HD2' HD13 ' A' ' 12' ' ' LEU . 53.0 Cg_exo . . . . . 0 C--O 1.231 0.165 0 CA-C-O 120.777 0.24 . . . . 0.0 112.331 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 74' ' ' ASP . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.804 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.611 ' O ' HG12 ' A' ' 16' ' ' VAL . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.629 HG22 ' HE3' ' A' ' 23' ' ' TRP . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.401 ' HA3' ' HD3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.629 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' HD12 ' A' ' 93' ' ' LEU . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.586 ' HB3' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 31' ' ' VAL . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.537 HG12 HG21 ' A' ' 27' ' ' VAL . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.726 HG21 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.486 ' H ' HG22 ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.726 ' CE1' HG21 ' A' ' 35' ' ' THR . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.43 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.461 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.466 ' O ' HD11 ' A' ' 54' ' ' ILE . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.601 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.601 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.941 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 63' ' ' THR . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.535 ' CG2' HG23 ' A' ' 56' ' ' ILE . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.941 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HG21 ' A' ' 11' ' ' THR . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.586 HD13 ' HB3' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.917 HD12 HG13 ' A' ' 160' ' ' VAL . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.806 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.667 ' CB ' HD12 ' A' ' 104' ' ' LEU . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.649 HD11 HD23 ' A' ' 12' ' ' LEU . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.769 HD12 ' HB3' ' A' ' 102' ' ' LEU . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.436 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.511 ' NH2' HD13 ' A' ' 142' ' ' ILE . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.769 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.813 HD13 ' HB3' ' A' ' 139' ' ' LEU . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 127' ' ' MET . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.863 HD12 ' NE2' ' A' ' 124' ' ' GLN . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.817 0.341 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . 0.863 ' NE2' HD12 ' A' ' 111' ' ' ILE . 6.7 mp0 -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.43 ' OG ' HG21 ' A' ' 173' ' ' THR . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.817 ' O ' HG22 ' A' ' 174' ' ' VAL . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . 0.463 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.686 ' CD2' ' HB2' ' A' ' 134' ' ' ALA . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . 0.686 ' HB2' ' CD2' ' A' ' 128' ' ' LEU . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.813 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.638 HG21 ' O ' ' A' ' 145' ' ' ASP . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.511 HD13 ' NH2' ' A' ' 96' ' ' ARG . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.638 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.645 ' O ' HG23 ' A' ' 160' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.806 HG22 ' O ' ' A' ' 91' ' ' SER . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.425 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.433 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.499 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.465 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 79' ' ' VAL . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.917 HG13 HD12 ' A' ' 80' ' ' LEU . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 147' ' ' GLY . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.475 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 19.6 t-80 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.903 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.447 ' O ' HD12 ' A' ' 128' ' ' LEU . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.43 HG21 ' OG ' ' A' ' 125' ' ' SER . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.903 HG12 ' HB2' ' A' ' 167' ' ' ALA . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . 0.442 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 CA--C 1.53 0.275 0 CA-C-O 120.682 0.201 . . . . 0.0 112.269 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 12' ' ' LEU . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' TRP . . . . . 0.738 ' O ' HG12 ' A' ' 16' ' ' VAL . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.736 ' NH2' HD22 ' A' ' 75' ' ' LEU . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.722 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PHE . . . . . 0.491 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TRP . . . . . 0.434 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 33' ' ' ILE . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 70' ' ' LYS . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.52 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.742 HG12 HG13 ' A' ' 27' ' ' VAL . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 37' ' ' HIS . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.788 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.648 ' H ' HG22 ' A' ' 35' ' ' THR . 8.5 t60 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.4 HG22 ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 36' ' ' THR . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.529 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.901 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . 0.404 ' HG2' HG23 ' A' ' 35' ' ' THR . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ARG . . . . . 0.901 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.628 ' CE2' ' HE3' ' A' ' 71' ' ' MET . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HA ' HG22 ' A' ' 30' ' ' THR . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' MET . . . . . 0.628 ' HE3' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.411 ' HG2' HD12 ' A' ' 75' ' ' LEU . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.736 HD22 ' NH2' ' A' ' 15' ' ' ARG . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.683 HD13 ' N ' ' A' ' 81' ' ' GLU . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.683 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.698 HG22 ' CE1' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.431 HD22 ' CD1' ' A' ' 13' ' ' TRP . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.738 HD13 HG22 ' A' ' 141' ' ' THR . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.523 HD12 HD11 ' A' ' 94' ' ' ILE . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.768 0.318 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.765 HD22 ' O ' ' A' ' 133' ' ' ASN . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.471 HG21 HD22 ' A' ' 133' ' ' ASN . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.765 ' O ' HD22 ' A' ' 128' ' ' LEU . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.532 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . 0.738 HG22 HD13 ' A' ' 94' ' ' ILE . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ASP . . . . . 0.647 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ALA . . . . . 0.605 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' PRO . . . . . 0.572 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.408 HG11 HD21 ' A' ' 12' ' ' LEU . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' HIS . . . . . 0.443 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' LYS . . . . . 0.429 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ARG . . . . . 0.469 ' HB2' HG23 ' A' ' 159' ' ' VAL . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' CYS . . . . . 0.68 ' O ' HG22 ' A' ' 178' ' ' VAL . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ALA . . . . . 0.419 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.482 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ASN . . . . . 0.515 HD22 HD21 ' A' ' 128' ' ' LEU . 18.7 m120 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.532 HG21 HD23 ' A' ' 139' ' ' LEU . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 176' ' ' CYS . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' CYS . . . . . 0.451 ' N ' HG12 ' A' ' 175' ' ' VAL . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.68 HG22 ' O ' ' A' ' 161' ' ' CYS . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 mtm . . . . . 0 N--CA 1.486 1.349 0 CA-C-O 120.849 0.357 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 34.4 m80 60.45 80.22 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -132.78 -46.73 0.87 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -68.55 136.93 53.87 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.893 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 61.12 112.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 8.0 m170 -143.26 169.19 18.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.925 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 4.0 t60 -60.29 146.22 44.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -97.14 149.77 36.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.13 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.474 ' CG ' HD13 ' A' ' 12' ' ' LEU . 36.2 Cg_endo -65.43 124.23 12.59 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.561 2.174 . . . . 0.0 112.254 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 20.7 Cg_endo -62.34 -60.92 0.17 Allowed 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.463 2.109 . . . . 0.0 112.611 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.4 m -49.53 -27.93 4.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.284 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.026 HD21 HG11 ' A' ' 151' ' ' VAL . 4.9 tt -69.74 -30.91 68.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.02 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.803 ' O ' HG12 ' A' ' 16' ' ' VAL . 71.6 m95 -79.39 -30.98 42.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.4 m -74.23 -21.29 59.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.194 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 16.0 mtt-85 -60.33 -41.13 92.89 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.89 0.376 . . . . 0.0 110.832 -179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.803 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.6 p -60.4 141.07 17.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.803 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -144.11 109.28 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.839 0.352 . . . . 0.0 111.811 -179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.3 OUTLIER -66.3 111.36 3.45 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.011 0.434 . . . . 0.0 110.645 179.376 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.484 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -122.18 139.23 54.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.63 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.16 -112.62 2.37 Favored Glycine 0 C--N 1.331 0.28 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.606 -179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -117.38 37.64 3.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.002 0.43 . . . . 0.0 110.354 179.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.426 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -166.52 -169.93 30.76 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.436 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.582 ' HE3' HG22 ' A' ' 16' ' ' VAL . 36.7 m95 -131.15 141.21 50.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.792 0.33 . . . . 0.0 110.767 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.75 -160.23 11.6 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.726 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.2 t80 -151.65 153.18 33.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.736 0.303 . . . . 0.0 111.145 -179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.451 ' CD2' HD11 ' A' ' 75' ' ' LEU . 47.5 m95 -91.2 90.51 7.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.723 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.866 HG21 HG23 ' A' ' 33' ' ' ILE . 23.3 t -58.99 -32.41 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.089 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB2' ' HB ' ' A' ' 31' ' ' VAL . 0.4 OUTLIER -172.54 175.72 1.04 Allowed Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.861 -179.992 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.408 ' HB2' ' HB3' ' A' ' 70' ' ' LYS . 83.1 Cg_exo -46.6 -47.54 15.52 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.796 2.331 . . . . 0.0 112.892 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.3 t -114.85 15.1 17.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.494 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.514 HG12 ' HB ' ' A' ' 27' ' ' VAL . 31.6 t -123.76 142.55 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.853 0.359 . . . . 0.0 111.296 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.403 ' CD1' ' HA ' ' A' ' 26' ' ' TRP . 15.9 t80 -147.31 165.55 29.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.996 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.866 HG23 HG21 ' A' ' 27' ' ' VAL . 12.3 pt -130.38 159.94 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.087 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 154.02 2.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.02 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.596 HG22 ' H ' ' A' ' 36' ' ' THR . 0.8 OUTLIER -84.22 -177.7 6.72 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.53 179.921 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.596 ' H ' HG22 ' A' ' 35' ' ' THR . 17.9 p -96.33 -41.38 8.66 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.621 ' CD2' HG13 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -73.24 -17.32 61.35 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.664 0.269 . . . . 0.0 111.412 -179.456 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.621 HG13 ' CD2' ' A' ' 37' ' ' HIS . 35.2 m -82.06 -35.45 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.355 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 35' ' ' THR . 21.4 t -55.99 119.8 29.18 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.261 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.46 -164.63 0.27 Allowed 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.546 2.164 . . . . 0.0 112.206 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.31 91.59 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 174.11 -34.67 0.11 Allowed Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.484 HG21 ' HE1' ' A' ' 19' ' ' PHE . 23.9 m -86.68 152.75 3.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.873 0.368 . . . . 0.0 111.113 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.54 32.43 3.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -174.69 150.27 1.31 Allowed 'General case' 0 CA--C 1.515 -0.37 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.724 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -126.53 133.84 51.02 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.4 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 39.48 35.08 0.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.171 0.51 . . . . 0.0 111.394 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.91 38.59 15.43 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.579 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HD11 ' A' ' 54' ' ' ILE . 1.9 mp0 -133.21 90.03 31.49 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 120.696 0.284 . . . . 0.0 110.787 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -50.56 140.37 36.27 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.61 2.207 . . . . 0.0 112.471 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.4 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -56.93 -26.77 60.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.072 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 m -53.34 -23.53 9.66 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.464 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.3 m -122.88 40.58 3.67 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.16 0.505 . . . . 0.0 110.734 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.525 HD11 ' O ' ' A' ' 49' ' ' GLU . 58.3 mt -133.93 158.36 42.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.913 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.92 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -122.97 138.11 54.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.126 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.655 HG23 ' CG2' ' A' ' 63' ' ' THR . 3.8 mp -123.82 138.99 51.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -145.25 99.34 3.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.925 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -73.18 157.92 36.25 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.34 77.3 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.161 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.446 ' HA3' HG21 ' A' ' 121' ' ' VAL . . . 59.53 70.23 1.06 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.406 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 24.8 mt-10 59.56 30.2 19.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 179' ' ' GLN . 3.8 t80 -140.58 101.54 4.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.655 ' CG2' HG23 ' A' ' 56' ' ' ILE . 76.7 m -99.77 133.96 43.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.947 -179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -96.2 113.74 25.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.771 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -94.26 113.26 25.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.005 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.92 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.3 ttt-85 -117.83 103.85 10.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.461 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.403 ' CE2' ' OE1' ' A' ' 49' ' ' GLU . 39.7 m-85 -78.74 150.35 32.49 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.068 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 46.6 t -72.11 -25.58 61.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.711 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.4 tttp -127.36 153.99 45.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -95.0 99.65 11.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.552 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.0 mmt -59.73 -43.74 94.07 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.783 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 46.9 ptt85 43.5 55.23 11.59 Favored Pre-proline 0 N--CA 1.463 0.199 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.54 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.45 -35.28 18.25 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.453 2.102 . . . . 0.0 112.298 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -171.89 35.17 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.87 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.451 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.1 mt -118.62 -170.72 1.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.019 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.1 m -161.93 -44.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.855 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 155.74 106.73 0.26 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.478 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -96.03 170.14 9.49 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.749 0.309 . . . . 0.0 110.903 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.457 ' O ' HG12 ' A' ' 160' ' ' VAL . 21.9 t -107.28 141.55 22.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.104 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.598 HD22 HG13 ' A' ' 160' ' ' VAL . 2.0 tm? -109.07 121.84 46.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.833 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.528 ' N ' HD13 ' A' ' 80' ' ' LEU . 0.4 OUTLIER -103.48 107.56 18.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.821 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.429 ' HA ' HG13 ' A' ' 178' ' ' VAL . 3.7 pm0 -67.6 75.11 0.17 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.79 -161.77 21.15 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.449 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.792 ' SG ' HG21 ' A' ' 88' ' ' THR . 1.4 m -164.75 153.76 11.33 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.649 0.262 . . . . 0.0 110.974 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.09 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.575 2.183 . . . . 0.0 112.294 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -88.59 108.84 19.64 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 113.02 28.14 3.47 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.792 HG21 ' SG ' ' A' ' 84' ' ' CYS . 5.1 m -99.58 115.35 29.18 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.685 0.278 . . . . 0.0 110.865 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.15 108.14 18.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.844 0.354 . . . . 0.0 111.163 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.8 m -98.49 160.11 14.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.957 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.502 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.9 OUTLIER -137.25 133.6 35.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.936 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.473 HG21 ' CE1' ' A' ' 164' ' ' HIS . 18.7 t -93.94 157.92 2.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.151 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.606 HD11 ' CD2' ' A' ' 12' ' ' LEU . 34.5 mt -112.82 97.34 6.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.958 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.542 HG23 ' CG ' ' A' ' 145' ' ' ASP . 30.3 mt -103.09 101.15 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.426 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -92.28 143.88 25.96 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.858 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.9 mtp180 -111.78 -175.45 2.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.91 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -82.18 -34.32 29.09 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.5 p -97.01 23.05 7.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.039 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 73.25 24.76 74.78 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.597 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -84.84 76.0 10.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.366 . . . . 0.0 110.917 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.646 HD23 ' CE3' ' A' ' 13' ' ' TRP . 6.4 mp -69.8 121.46 17.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.947 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.403 HD12 ' HA ' ' A' ' 102' ' ' LEU . 6.8 tp -108.13 88.11 4.47 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.46 98.25 1.16 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.557 2.172 . . . . 0.0 112.364 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.474 ' CD1' HD11 ' A' ' 94' ' ' ILE . 47.9 mt -88.92 163.47 15.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.868 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -135.52 145.4 47.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.661 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.7 t -145.79 142.47 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.113 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -93.68 121.53 35.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.854 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 7.7 mmt -65.4 150.62 48.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -111.45 -120.76 4.0 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.423 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.17 156.62 22.9 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.769 0.319 . . . . 0.0 111.118 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.465 HG23 ' O ' ' A' ' 111' ' ' ILE . 18.9 tt -94.48 122.54 46.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.074 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.48 168.63 21.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.122 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 88.8 p -100.93 105.12 16.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.5 mtp -80.28 168.13 19.43 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.962 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 16.2 ttm105 -124.82 109.71 13.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.864 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.614 HG22 ' OE1' ' A' ' 117' ' ' GLN . 4.6 mt -122.07 121.61 64.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.081 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.614 ' OE1' HG22 ' A' ' 116' ' ' ILE . 9.0 mp0 60.64 31.97 20.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.884 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.31 30.99 59.77 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.477 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -134.9 123.73 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.786 0.327 . . . . 0.0 110.907 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.5 mt -77.62 120.4 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.59 HG11 HD12 ' A' ' 116' ' ' ILE . 11.1 p -128.43 147.73 32.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.038 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -95.79 122.51 38.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.899 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -151.25 152.82 24.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.465 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.02 122.05 46.06 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.796 0.331 . . . . 0.0 110.845 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.3 -175.81 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -174.31 109.66 0.3 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.499 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.488 ' O ' HG13 ' A' ' 106' ' ' VAL . 26.0 mtm -80.3 134.68 36.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.865 0.364 . . . . 0.0 110.937 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.569 HD12 ' HB2' ' A' ' 134' ' ' ALA . 0.6 OUTLIER -59.95 144.91 47.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.855 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.419 ' N ' HD23 ' A' ' 128' ' ' LEU . 20.9 tp -141.77 47.76 1.64 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.895 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.6 -68.03 0.59 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.98 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -161.2 -76.23 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.51 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.45 36.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.805 0.336 . . . . 0.0 111.117 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -64.64 -28.01 69.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.943 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.569 ' HB2' HD12 ' A' ' 128' ' ' LEU . . . -57.77 136.89 56.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.145 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -111.93 -29.89 7.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.965 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.51 ' C ' ' HB3' ' A' ' 167' ' ' ALA . . . 147.51 -28.54 1.48 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.392 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.6 mtt -122.8 26.3 8.26 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.748 0.308 . . . . 0.0 111.094 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.559 ' HB3' HG22 ' A' ' 141' ' ' THR . 5.8 t70 173.52 165.85 0.17 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.396 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.854 HD23 ' CG2' ' A' ' 174' ' ' VAL . 0.9 OUTLIER -72.8 -41.87 64.5 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.987 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.17 89.12 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.308 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.559 HG22 ' HB3' ' A' ' 138' ' ' ASP . 6.9 t -136.98 150.15 47.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.952 0.406 . . . . 0.0 111.303 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.531 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -143.09 -55.11 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.138 179.533 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.531 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.2 Cg_endo -86.95 14.03 2.55 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 123.089 2.526 . . . . 0.0 112.554 -179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 104.54 33.3 3.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.138 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.542 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.6 OUTLIER -90.83 60.59 4.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.95 0.405 . . . . 0.0 110.878 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -108.21 148.08 30.45 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.462 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 87.59 -2.45 86.18 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.451 -0.88 . . . . 0.0 112.761 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -42.28 144.35 0.93 Allowed Pre-proline 0 N--CA 1.464 0.249 0 CA-C-N 116.756 0.278 . . . . 0.0 111.265 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.409 ' HB3' ' HB2' ' A' ' 25' ' ' PHE . 89.4 Cg_endo -82.02 146.79 14.61 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.551 2.168 . . . . 0.0 113.117 -179.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.711 ' O ' HG23 ' A' ' 160' ' ' VAL . 3.0 m-85 -101.96 143.02 32.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.262 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.026 HG11 HD21 ' A' ' 12' ' ' LEU . 33.5 m -134.72 162.76 38.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.786 0.327 . . . . 0.0 111.209 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.0 p-80 -167.33 152.17 7.1 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.705 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -78.82 125.33 29.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.236 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.46 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.95 97.58 4.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.282 179.601 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.9 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -117.01 37.37 3.85 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 120.841 0.353 . . . . 0.0 110.178 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -166.52 -177.27 3.91 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.977 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.416 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 11.4 m95 -121.96 118.87 29.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.498 179.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.46 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.6 t -98.52 148.39 6.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.861 0.362 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.1 p -96.39 136.71 26.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.2 m -87.08 -82.26 0.22 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.262 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -148.18 -137.41 2.88 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.782 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.452 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 3.6 m -136.5 158.68 37.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.948 0.404 . . . . 0.0 111.157 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.473 ' CE1' HG21 ' A' ' 92' ' ' VAL . 2.0 m170 -67.05 102.14 0.96 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.715 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -85.16 -66.35 0.91 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.229 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.64 174.37 4.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.315 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.51 ' HB3' ' C ' ' A' ' 136' ' ' GLY . . . -109.0 160.24 16.18 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.201 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.21 179.89 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.903 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.484 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -65.1 -24.33 67.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.105 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.06 -16.97 63.22 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.378 -0.373 . . . . 0.0 111.28 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 84.37 -55.64 5.0 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.59 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -90.71 50.49 1.82 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.881 0.372 . . . . 0.0 110.975 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.8 m -160.22 116.39 2.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.856 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.854 ' CG2' HD23 ' A' ' 139' ' ' LEU . 3.7 m -120.11 166.91 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.18 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.2 t -110.96 123.62 67.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.05 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 77.6 m -84.71 108.5 17.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.944 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.452 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -60.35 104.86 0.36 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.055 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.47 HG12 ' N ' ' A' ' 179' ' ' GLN . 21.3 t -92.42 158.87 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.47 ' N ' HG12 ' A' ' 178' ' ' VAL . 44.6 tt0 -92.08 158.85 15.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.924 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -99.24 129.1 45.45 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.093 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 180.0 -140.82 4.37 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -60.22 166.25 3.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.819 0.342 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 96.46 -27.5 17.1 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.473 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -86.85 -30.31 21.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.824 0.345 . . . . 0.0 110.919 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.63 -31.57 13.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.56 153.71 34.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.074 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 13.4 mt -91.6 -32.79 15.37 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.985 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.235 -0.888 . . . . 0.0 110.865 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 120.849 0.357 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.5 m-70 -131.95 -177.73 4.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.913 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.8 p80 -91.31 127.91 36.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 76.0 m-70 -132.72 141.63 48.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.94 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -97.99 -37.4 9.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.88 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.2 p80 -176.49 150.99 0.92 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -105.28 -68.06 0.88 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.864 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -144.65 165.64 21.97 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 37.3 Cg_endo -66.11 124.42 12.58 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.551 2.168 . . . . 0.0 112.355 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 21.4 Cg_endo -62.38 -61.71 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.534 2.156 . . . . 0.0 112.609 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.0 m -48.32 -30.54 4.98 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.227 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.484 HD13 ' CG ' ' A' ' 9' ' ' PRO . 5.0 tt -65.79 -30.44 71.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.768 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.881 ' CD1' HD22 ' A' ' 93' ' ' LEU . 34.0 m0 -73.68 -36.3 65.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.64 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.8 m -59.65 -20.79 58.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.167 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.822 ' NH1' HD13 ' A' ' 75' ' ' LEU . 5.3 mmt180 -56.07 -30.31 61.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.991 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.739 HG22 ' HE3' ' A' ' 23' ' ' TRP . 10.5 p -59.62 123.76 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.728 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 51.6 m -130.49 109.26 10.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.794 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.483 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.2 111.36 3.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.021 0.439 . . . . 0.0 110.898 179.613 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.428 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.8 t80 -124.11 130.93 53.38 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.443 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.28 -129.71 49.55 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.443 -179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.512 ' O ' HG12 ' A' ' 38' ' ' VAL . 0.4 OUTLIER -98.16 30.97 2.9 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.944 0.402 . . . . 0.0 110.789 179.845 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -166.17 -170.2 30.77 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 121.032 -0.604 . . . . 0.0 111.985 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.739 ' HE3' HG22 ' A' ' 16' ' ' VAL . 51.0 m95 -120.52 161.33 21.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.749 0.309 . . . . 0.0 110.704 179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.59 -166.93 11.77 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.604 -0.807 . . . . 0.0 112.386 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CZ ' HG11 ' A' ' 160' ' ' VAL . 41.2 t80 -151.73 127.46 10.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.166 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.492 ' CD1' ' CD1' ' A' ' 32' ' ' PHE . 3.6 m0 -76.44 98.48 4.59 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.379 179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.522 ' CG1' HG12 ' A' ' 31' ' ' VAL . 13.5 p -76.43 -26.22 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.194 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.1 156.75 24.16 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.643 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -49.32 -35.99 36.64 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.463 2.109 . . . . 0.0 112.47 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.768 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -116.36 13.96 15.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.505 -179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.522 HG12 ' CG1' ' A' ' 27' ' ' VAL . 38.6 t -129.26 129.32 67.39 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.834 0.35 . . . . 0.0 111.452 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.492 ' CD1' ' CD1' ' A' ' 26' ' ' TRP . 2.8 t80 -126.75 137.71 53.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.091 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.71 HD13 HD11 ' A' ' 80' ' ' LEU . 3.1 pt -122.5 148.12 26.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.061 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.35 167.34 4.75 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.003 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.674 HG22 ' H ' ' A' ' 37' ' ' HIS . 27.2 m -84.17 135.66 34.29 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.836 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.429 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 0.8 OUTLIER -68.54 -18.08 64.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.521 -179.608 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.674 ' H ' HG22 ' A' ' 35' ' ' THR . 9.3 t60 -73.21 -26.12 61.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.631 0.253 . . . . 0.0 111.418 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -109.48 36.48 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.675 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.429 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 55.6 t -104.82 122.62 42.74 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.858 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.428 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 89.7 Cg_endo -84.64 -165.47 0.3 Allowed 'Trans proline' 0 N--CA 1.46 -0.489 0 C-N-CA 122.61 2.207 . . . . 0.0 112.31 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -157.68 29.6 0.27 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.87 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.6 -39.45 2.56 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.497 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -80.66 147.62 6.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.929 0.395 . . . . 0.0 111.094 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 11.9 mptt -117.25 31.06 6.95 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.873 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.72 150.27 0.26 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.664 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.484 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.35 133.78 54.08 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.418 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.25 35.54 0.15 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.41 -179.298 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.24 39.39 19.33 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.663 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -134.13 92.57 21.35 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.714 0.292 . . . . 0.0 110.772 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -50.03 141.49 29.66 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.53 2.153 . . . . 0.0 112.496 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.561 HD22 HD11 ' A' ' 56' ' ' ILE . 9.2 mt -57.15 -27.25 61.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.144 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 9.4 t -53.12 -23.33 7.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.539 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.3 t -119.91 39.34 3.69 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.163 0.506 . . . . 0.0 110.746 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.488 HG22 ' N ' ' A' ' 55' ' ' ALA . 60.4 mt -134.8 158.63 41.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.835 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.851 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -122.86 113.58 19.32 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.118 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.561 HD11 HD22 ' A' ' 51' ' ' LEU . 3.6 mp -102.36 142.11 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.164 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -153.42 135.47 14.74 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.928 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.401 ' HG2' HG21 ' A' ' 36' ' ' THR . 11.0 mt-30 -103.51 164.1 11.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.92 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.03 48.52 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.068 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.03 88.26 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.511 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.424 ' O ' ' HB1' ' A' ' 177' ' ' ALA . 72.7 mm-40 59.16 30.05 19.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.929 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.496 ' CG ' ' HB3' ' A' ' 180' ' ' ALA . 30.9 t80 -144.16 101.55 3.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.803 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.1 m -105.23 118.04 35.54 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.935 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -96.16 113.85 25.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.697 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -102.83 113.27 26.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.872 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.851 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 7.6 mtm-85 -109.92 103.7 12.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.468 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.47 145.58 25.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.074 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 10.0 m -72.5 -28.99 63.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.74 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.48 156.04 25.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.817 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.768 ' CG ' HG23 ' A' ' 30' ' ' THR . 70.3 mttt -94.97 114.64 26.49 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.429 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 17.9 tpp -85.26 -26.84 26.4 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.848 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.597 ' CG ' HD12 ' A' ' 75' ' ' LEU . 11.7 mmt180 -107.45 76.33 0.51 Allowed Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.26 -23.38 24.32 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.625 2.216 . . . . 0.0 112.503 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.98 41.02 1.09 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.008 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.822 HD13 ' NH1' ' A' ' 15' ' ' ARG . 76.5 mt -149.28 107.35 3.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.852 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 m -59.06 -30.78 68.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 125.72 152.36 8.16 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.502 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.1 mmt -113.29 170.16 8.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.791 0.329 . . . . 0.0 110.845 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 159' ' ' VAL . 35.8 t -105.31 141.48 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.002 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.71 HD11 HD13 ' A' ' 33' ' ' ILE . 0.4 OUTLIER -120.94 110.27 16.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.897 -179.911 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.558 ' HG2' HG11 ' A' ' 159' ' ' VAL . 19.1 mm-40 -89.46 136.21 33.16 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.838 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -85.33 76.41 10.13 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 88.44 -174.33 43.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.585 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.6 164.19 12.24 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 120.634 0.254 . . . . 0.0 110.905 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.66 158.6 55.3 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.593 2.195 . . . . 0.0 112.24 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -60.38 146.38 44.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.883 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.41 -28.05 14.76 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.55 115.5 3.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.84 0.352 . . . . 0.0 110.905 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.25 112.6 27.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.145 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.2 m -89.74 174.06 7.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.682 ' O ' HG22 ' A' ' 151' ' ' VAL . 1.8 t -137.21 126.26 24.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.775 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.793 HG22 ' CE1' ' A' ' 150' ' ' TYR . 11.4 t -90.36 159.76 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.143 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.881 HD22 ' CD1' ' A' ' 13' ' ' TRP . 12.6 mt -119.92 86.51 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.671 HG23 ' CG ' ' A' ' 145' ' ' ASP . 33.7 mt -91.86 100.88 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.196 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 7.2 ttmm -95.04 152.82 18.0 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.852 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -115.56 -174.29 2.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.943 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -76.69 -34.11 58.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.965 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 m -96.93 22.83 7.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.006 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 71.98 24.87 75.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.55 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -84.03 79.97 9.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.755 0.312 . . . . 0.0 110.85 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 2.7 mt -69.85 150.52 46.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.7 tp -142.53 87.05 9.44 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 104.75 1.68 Allowed 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.561 2.174 . . . . 0.0 112.307 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.982 HD22 HG21 ' A' ' 130' ' ' THR . 48.3 mt -98.23 163.38 12.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.967 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -115.41 142.18 47.05 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.106 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.595 HG22 HD21 ' A' ' 139' ' ' LEU . 21.5 t -149.05 124.87 2.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.066 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.3 ttp85 -69.84 145.3 52.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . 0.443 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 0.9 OUTLIER -83.83 138.84 33.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.868 -179.985 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.77 -165.99 26.15 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.445 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.76 21.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.865 0.364 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -64.49 114.8 2.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.115 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -136.33 133.83 37.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.6 p -71.17 107.96 4.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.4 mmm -93.36 147.02 23.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.861 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -106.33 123.78 48.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.965 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.433 HD13 HG21 ' A' ' 121' ' ' VAL . 3.9 mp -139.21 124.4 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.162 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 60.29 31.45 20.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.874 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.13 28.51 64.17 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.521 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -131.8 140.32 49.15 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.6 mt -94.0 123.97 37.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.433 HG21 HD13 ' A' ' 116' ' ' ILE . 6.1 m -129.81 141.0 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.07 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 8.9 m80 -98.64 125.59 43.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.26 168.79 37.39 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.521 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -95.26 147.44 23.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.788 0.328 . . . . 0.0 110.963 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -109.28 -171.35 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.903 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.569 ' O ' HG23 ' A' ' 173' ' ' THR . . . -157.35 -169.78 21.51 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.48 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.442 ' O ' HG13 ' A' ' 106' ' ' VAL . 4.0 tpp -149.94 136.75 19.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.835 0.35 . . . . 0.0 110.855 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.599 ' CD2' HD13 ' A' ' 139' ' ' LEU . 6.9 mt -66.68 119.74 12.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.845 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.743 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 1.9 tt -133.93 47.23 2.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.982 HG21 HD22 ' A' ' 104' ' ' LEU . 26.9 m -121.88 -41.07 2.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.955 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 152.38 43.83 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.47 42.57 11.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.855 0.36 . . . . 0.0 111.054 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -103.94 82.37 1.97 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.934 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.403 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -146.99 149.8 33.86 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.079 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.04 -27.98 15.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.927 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 146.46 -30.14 1.58 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.308 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . 0.406 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 4.5 mtm -139.99 30.14 2.04 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 121.179 0.514 . . . . 0.0 109.693 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.672 ' HB2' HG23 ' A' ' 141' ' ' THR . 4.1 p30 -160.3 -176.44 5.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.206 -178.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.599 HD13 ' CD2' ' A' ' 128' ' ' LEU . 0.1 OUTLIER -98.89 34.22 2.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.467 179.809 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 86.49 39.68 7.65 Favored Glycine 0 N--CA 1.447 -0.569 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.033 -179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.672 HG23 ' HB2' ' A' ' 138' ' ' ASP . 28.0 p -74.06 133.09 42.88 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.827 0.346 . . . . 0.0 111.271 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.479 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -117.57 -52.84 0.04 OUTLIER Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 -179.827 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.479 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.0 OUTLIER -84.55 25.82 0.68 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.02 2.48 . . . . 0.0 112.889 -179.428 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.74 41.77 8.08 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.32 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.671 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.5 OUTLIER -81.42 57.75 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.047 0.451 . . . . 0.0 110.561 179.856 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.414 ' HB3' HG11 ' A' ' 38' ' ' VAL . 37.1 m -97.54 91.03 5.24 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.339 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.412 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.47 14.68 5.26 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.173 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.93 143.75 3.19 Favored Pre-proline 0 CA--C 1.53 0.174 0 CA-C-O 120.625 0.25 . . . . 0.0 111.198 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.564 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.7 Cg_endo -77.75 126.32 8.02 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.652 2.235 . . . . 0.0 112.881 -179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.793 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.5 m-85 -89.49 146.66 24.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.428 179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 160' ' ' VAL . 27.5 m -138.31 160.58 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.841 0.353 . . . . 0.0 110.971 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.42 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 22.0 p-80 -172.93 152.85 2.47 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.754 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.43 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 24.8 tptt -82.23 127.18 32.93 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.185 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.565 ' HD3' HG21 ' A' ' 159' ' ' VAL . 1.8 ttp85 -128.41 97.35 4.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.403 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.82 2.12 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.955 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -116.14 36.44 4.07 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.949 0.404 . . . . 0.0 110.285 179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.97 -175.8 3.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.984 -179.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CD1' ' HD2' ' A' ' 153' ' ' LYS . 9.7 m95 -123.85 121.83 36.42 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.568 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.565 HG21 ' HD3' ' A' ' 154' ' ' ARG . 39.7 t -109.46 138.88 34.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.121 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.905 HG12 HG12 ' A' ' 151' ' ' VAL . 15.0 m -93.86 131.2 41.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.075 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 1.6 m -68.75 -77.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.977 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -160.74 -126.45 0.83 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.517 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.419 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 12.8 m -141.64 160.49 21.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.446 0.165 . . . . 0.0 110.984 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER -80.95 122.88 27.81 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.959 0.409 . . . . 0.0 111.311 -179.878 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -108.46 -65.37 1.13 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.27 174.34 12.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.111 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.406 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -153.22 178.8 9.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.161 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.08 155.07 18.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.963 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -77.91 -55.87 4.95 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.8 p -121.62 16.71 11.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -97.64 -18.29 28.33 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.628 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 61.35 47.51 6.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.027 0.442 . . . . 0.0 110.895 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.569 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.3 m -140.69 140.62 34.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.868 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.518 HG11 HD23 ' A' ' 139' ' ' LEU . 30.5 m -109.89 174.12 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.058 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -119.06 105.48 17.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 4.5 t -83.3 110.08 17.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.896 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.424 ' HB1' ' O ' ' A' ' 61' ' ' GLU . . . -82.9 118.39 23.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.097 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.644 HG23 ' CD2' ' A' ' 80' ' ' LEU . 11.0 p -172.54 -41.69 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.087 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.432 ' N ' HG13 ' A' ' 178' ' ' VAL . 1.6 tp-100 -60.05 91.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.929 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.496 ' HB3' ' CG ' ' A' ' 62' ' ' PHE . . . -175.58 116.57 0.15 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.102 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -149.79 179.53 26.48 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.443 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -75.16 126.59 31.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.91 0.386 . . . . 0.0 110.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.67 43.97 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 -83.35 -49.27 9.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.733 0.302 . . . . 0.0 110.889 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.32 31.52 2.13 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.975 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.95 77.85 0.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.6 mp 60.3 79.97 0.22 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.859 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.949 -179.981 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.413 0 CA-C-O 120.856 0.36 . . . . 0.0 111.221 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.8 p-80 -134.16 -47.2 0.78 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.5 m80 60.43 -176.84 0.11 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -170.44 129.86 0.87 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.4 m-70 -130.29 131.48 45.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.831 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -109.62 131.09 55.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 3.3 p80 -132.08 28.56 4.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -144.76 90.02 6.49 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.022 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.459 ' HD2' HD13 ' A' ' 12' ' ' LEU . 57.4 Cg_exo -51.94 149.13 21.24 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.459 2.106 . . . . 0.0 112.409 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.54 -60.39 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.639 2.226 . . . . 0.0 112.498 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.703 HG23 ' O ' ' A' ' 74' ' ' ASP . 90.0 m -50.33 -27.48 6.3 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.199 -179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.091 HD21 HG11 ' A' ' 151' ' ' VAL . 4.4 tt -66.75 -26.92 67.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.095 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.878 ' O ' HG12 ' A' ' 16' ' ' VAL . 46.4 m0 -83.64 -44.97 13.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.908 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.3 -21.64 49.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.274 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' HG2' HD22 ' A' ' 75' ' ' LEU . 58.0 mtt-85 -57.63 -32.14 66.96 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.996 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.878 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.0 p -73.69 141.33 16.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.049 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 m -144.57 109.2 4.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.526 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.9 OUTLIER -66.48 111.35 3.53 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 179.555 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 43' ' ' VAL . 13.3 t80 -125.72 136.49 53.25 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.689 -179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.92 -124.78 36.74 Favored Glycine 0 C--N 1.33 0.242 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.277 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.538 ' O ' HG11 ' A' ' 38' ' ' VAL . 17.7 m -103.87 24.2 11.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.72 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -155.83 -170.37 21.12 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.359 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.489 ' HE3' HG22 ' A' ' 16' ' ' VAL . 21.3 m95 -129.34 147.39 51.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.706 0.289 . . . . 0.0 110.906 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -162.52 12.44 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.374 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.441 ' CE1' ' HB2' ' A' ' 15' ' ' ARG . 6.5 t80 -151.61 146.94 26.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.908 0.385 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.481 ' HB3' HD13 ' A' ' 75' ' ' LEU . 60.3 m95 -87.54 103.25 15.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.831 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.732 HG13 HG12 ' A' ' 33' ' ' ILE . 4.2 m -81.41 -24.15 10.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.031 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 2.2 p -168.51 159.28 8.6 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.373 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.3 -16.21 33.31 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.497 2.131 . . . . 0.0 112.503 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.4 OUTLIER -124.39 -0.26 8.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.524 -0.307 . . . . 0.0 111.639 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.48 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.8 t -131.08 142.45 43.51 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 120.887 0.375 . . . . 0.0 111.512 -179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -137.24 158.61 44.04 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.977 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.732 HG12 HG13 ' A' ' 27' ' ' VAL . 9.4 pt -136.82 135.93 48.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.075 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -147.13 166.31 27.33 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.585 HG22 ' H ' ' A' ' 37' ' ' HIS . 92.8 m -84.28 128.03 34.32 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.817 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -71.67 -18.86 62.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.422 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.585 ' H ' HG22 ' A' ' 35' ' ' THR . 10.3 t60 -71.24 -30.1 65.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.767 0.318 . . . . 0.0 110.913 -179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.538 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -114.84 27.07 3.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.25 -179.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.817 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -87.35 118.59 70.11 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.01 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.42 ' HD2' ' CE2' ' A' ' 19' ' ' PHE . 91.0 Cg_endo -83.28 -164.58 0.27 Allowed 'Trans proline' 0 N--CA 1.461 -0.388 0 C-N-CA 122.566 2.177 . . . . 0.0 112.219 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.502 HG22 ' O ' ' A' ' 41' ' ' THR . 17.0 m -157.57 30.09 0.28 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.772 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.38 -34.88 3.76 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.494 HG21 ' CE1' ' A' ' 19' ' ' PHE . 28.9 m -74.65 147.63 8.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.859 0.362 . . . . 0.0 111.122 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -119.6 28.14 8.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 178.16 150.21 0.22 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.73 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.498 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.86 133.83 53.69 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.358 178.269 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 39.03 35.58 0.13 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.161 0.505 . . . . 0.0 111.524 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.58 38.32 17.48 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.623 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -131.4 112.32 15.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 120.496 0.189 . . . . 0.0 110.767 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.38 136.02 41.81 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.391 2.061 . . . . 0.0 112.466 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.426 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.1 mt -54.55 -26.65 33.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.081 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 29.6 m -54.32 -22.87 13.17 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -121.58 40.03 3.71 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.177 0.513 . . . . 0.0 110.779 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.498 HD12 ' HE1' ' A' ' 46' ' ' PHE . 58.6 mt -134.1 158.51 42.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.857 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.925 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -121.27 126.06 48.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.946 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.7 mt -109.16 128.86 64.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.026 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -154.98 99.36 2.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.898 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.85 178.38 4.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.958 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 76.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.042 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 108.57 -89.39 0.56 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.453 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 -139.69 31.21 2.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.419 ' CE2' ' HA ' ' A' ' 179' ' ' GLN . 31.5 t80 -139.93 104.53 4.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.605 ' OG1' HG23 ' A' ' 36' ' ' THR . 67.5 m -101.12 116.62 33.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 12.5 tm0? -96.12 117.12 30.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.869 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.2 m-85 -101.2 113.36 26.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.933 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.925 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.5 tpp180 -104.62 103.73 13.44 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.748 179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -78.85 151.35 31.89 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.961 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.6 p -96.35 24.31 5.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.939 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.483 ' C ' HG23 ' A' ' 30' ' ' THR . 0.0 OUTLIER -160.89 135.35 7.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.83 -179.981 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.61 90.87 8.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 mtt -62.35 -48.3 80.42 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.727 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 28.8 ptt180 43.6 53.39 9.87 Favored Pre-proline 0 N--CA 1.463 0.216 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.483 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.49 -28.68 38.35 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.59 2.193 . . . . 0.0 112.214 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.703 ' O ' HG23 ' A' ' 11' ' ' THR . 0.5 OUTLIER -175.26 36.71 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.841 179.929 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.481 HD13 ' HB3' ' A' ' 26' ' ' TRP . 1.2 mt -134.25 148.05 50.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.907 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -111.65 -63.46 1.41 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.782 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 164.15 107.88 0.21 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.512 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 8.2 mmm -99.46 170.19 8.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.834 0.349 . . . . 0.0 110.927 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -105.44 141.5 20.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.091 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.505 HD12 HG13 ' A' ' 160' ' ' VAL . 9.8 tp -114.72 138.56 50.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.83 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -111.38 108.17 17.66 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.964 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -73.13 76.96 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.871 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.57 150.76 22.99 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.398 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 2.5 m -137.0 160.01 67.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.705 0.288 . . . . 0.0 110.882 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.08 148.46 56.58 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.535 2.157 . . . . 0.0 112.291 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -60.41 103.95 0.29 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 139.46 -25.3 2.74 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.598 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.8 m -56.71 145.92 27.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.704 0.288 . . . . 0.0 110.87 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.3 t -117.17 109.87 29.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.085 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -87.22 167.9 13.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.007 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 124.7 22.04 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.745 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.768 HG22 ' CE1' ' A' ' 150' ' ' TYR . 14.8 t -86.94 159.41 3.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.135 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.515 HD22 ' HE1' ' A' ' 13' ' ' TRP . 2.0 mt -129.21 77.91 1.82 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.954 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 1.044 HD11 HD11 ' A' ' 104' ' ' LEU . 32.0 mt -74.06 151.44 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.17 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.55 163.53 22.52 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -143.62 -176.54 5.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.91 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.69 -36.07 60.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 t -99.57 24.63 7.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.909 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 67.17 24.84 73.46 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.594 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -76.89 82.31 3.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.813 0.339 . . . . 0.0 110.869 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.76 HD23 ' O ' ' A' ' 94' ' ' ILE . 0.5 OUTLIER -69.92 134.29 48.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.796 -179.909 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.0 tp -120.41 86.68 39.4 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.89 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.13 108.77 2.55 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.517 2.145 . . . . 0.0 112.416 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.044 HD11 HD11 ' A' ' 94' ' ' ILE . 14.1 mt -97.61 163.42 12.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.899 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.49 134.1 46.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.146 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.737 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.5 t -138.69 151.56 24.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.12 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.59 ' HG3' HD12 ' A' ' 129' ' ' LEU . 11.8 mtt180 -106.07 125.27 50.79 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.924 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -82.79 146.91 28.7 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.872 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.15 -122.27 5.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.514 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.04 157.73 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.837 0.351 . . . . 0.0 111.133 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 23.4 mt -93.33 135.18 28.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.07 152.94 49.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.127 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.6 t -102.29 103.22 13.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -85.02 157.57 20.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.84 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 24.8 ttm180 -109.54 109.55 20.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.902 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 25.2 mm -116.23 106.24 19.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.127 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 6.0 tt0 60.29 35.63 20.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.37 28.31 55.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.522 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.4 ttt-85 -130.09 119.05 22.44 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.809 0.338 . . . . 0.0 110.96 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.3 mt -71.32 104.8 3.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.796 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 19.5 m -106.35 145.56 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 18.1 m170 -98.94 119.25 37.4 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.42 130.6 5.33 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.516 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -102.02 138.59 38.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.795 0.331 . . . . 0.0 110.89 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 18.8 m -124.77 158.99 31.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.771 ' O ' HG23 ' A' ' 173' ' ' THR . . . -167.38 -142.36 3.44 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.1 mtt -150.23 139.48 21.27 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.676 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -80.38 163.95 23.48 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.59 HD12 ' HG3' ' A' ' 107' ' ' ARG . 95.1 mt -146.34 66.72 1.18 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.933 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 31.28 2.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.982 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 82.81 27.0 43.39 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.607 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.533 ' HA ' HD11 ' A' ' 128' ' ' LEU . . . 61.56 31.35 18.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.892 0.377 . . . . 0.0 111.088 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.2 m-20 -75.6 80.26 2.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.889 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -147.04 164.61 32.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.069 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 5.7 tptm -97.81 -29.79 13.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.88 -27.37 1.45 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.4 mtt -139.31 30.87 2.15 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 121.204 0.526 . . . . 0.0 109.718 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.732 ' HB2' HG23 ' A' ' 141' ' ' THR . 5.2 p30 -161.9 -179.32 7.09 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.142 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.692 HD23 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.98 32.64 2.59 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.518 179.785 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.97 36.36 6.4 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.235 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.732 HG23 ' HB2' ' A' ' 138' ' ' ASP . 24.5 p -74.12 133.12 42.8 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.891 0.377 . . . . 0.0 111.012 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.464 ' H ' ' CD ' ' A' ' 143' ' ' PRO . 1.8 mm -114.85 -52.56 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.825 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.464 ' CD ' ' H ' ' A' ' 142' ' ' ILE . 1.8 Cg_endo -83.39 24.93 0.71 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.868 2.379 . . . . 0.0 112.904 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 83.51 40.69 8.83 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.333 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.61 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -80.78 57.78 3.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.199 0.523 . . . . 0.0 110.701 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 m -93.33 90.13 6.65 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.936 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.66 19.98 5.54 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.914 -0.66 . . . . 0.0 111.588 -178.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.614 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -44.37 165.69 0.14 Allowed Pre-proline 0 C--N 1.332 -0.168 0 CA-C-O 120.64 0.257 . . . . 0.0 111.244 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.614 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 92.2 Cg_endo -83.45 130.58 5.35 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.602 2.202 . . . . 0.0 112.962 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.768 ' CE1' HG22 ' A' ' 92' ' ' VAL . 2.8 m-85 -109.99 128.89 55.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.405 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.091 HG11 HD21 ' A' ' 12' ' ' LEU . 4.3 m -133.13 179.82 4.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 111.383 -179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.4 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 55.1 p-80 -177.37 153.0 0.89 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.655 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.418 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -82.51 126.98 32.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.31 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.736 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.1 OUTLIER -127.54 97.55 4.91 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.286 179.642 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.33 -106.84 2.12 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.844 -179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -116.25 37.2 3.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.224 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -166.74 -174.67 2.84 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.068 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.418 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.4 m0 -124.45 126.77 46.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.702 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.736 HG23 ' HB2' ' A' ' 154' ' ' ARG . 31.1 t -108.91 141.88 22.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 120.897 0.38 . . . . 0.0 111.084 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -89.33 134.18 29.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.003 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.474 ' O ' HD11 ' A' ' 80' ' ' LEU . 53.2 t -87.81 -71.69 0.56 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.853 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -167.2 -143.5 3.79 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.6 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 5.2 m -131.32 159.8 42.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.593 0.235 . . . . 0.0 111.02 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.444 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 1.6 t-80 -76.31 106.83 8.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.908 0.385 . . . . 0.0 111.179 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -83.52 -65.23 1.03 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.178 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -158.39 174.46 15.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.187 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.826 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -147.74 174.43 11.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.125 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -92.27 153.75 19.05 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.813 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 29.9 tttt -74.99 -55.89 5.3 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.919 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 19.5 m -119.69 16.69 12.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.258 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -104.53 -23.91 7.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.598 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 33.3 m120 61.16 47.65 6.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.942 0.401 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 126' ' ' GLY . 1.7 m -131.76 126.21 33.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.897 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.826 HG12 ' HB2' ' A' ' 167' ' ' ALA . 9.1 m -109.78 152.09 11.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.6 t -110.9 111.27 35.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.061 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -84.9 123.65 30.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.3 127.28 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 31.1 m -130.24 -179.64 3.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.107 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.419 ' HA ' ' CE2' ' A' ' 62' ' ' PHE . 0.0 OUTLIER -61.81 130.78 47.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.962 179.89 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -95.59 123.67 39.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.027 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -142.34 130.92 4.46 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.525 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -97.49 122.61 40.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.739 0.304 . . . . 0.0 110.875 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 156.41 46.24 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.553 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -105.3 -40.02 5.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.793 0.33 . . . . 0.0 110.885 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 4.4 m -98.08 -32.15 11.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.865 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -99.97 175.63 5.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.102 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 1.2 tp 60.5 35.43 20.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.965 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.289 -0.863 . . . . 0.0 110.882 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 8.8 mmm . . . . . 0 N--CA 1.487 1.399 0 CA-C-O 120.764 0.316 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -67.61 91.03 0.28 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 23.1 m-70 -107.46 164.76 11.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.9 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m-70 -143.21 134.63 26.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.863 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.3 p80 -103.11 134.73 46.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -176.7 118.97 0.12 Allowed 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.87 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 68.39 -68.87 0.16 Allowed 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.005 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.76 ' HB1' ' CZ2' ' A' ' 13' ' ' TRP . . . -123.7 77.07 56.4 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.013 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_exo -56.87 161.16 10.83 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.615 2.21 . . . . 0.0 112.476 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -59.24 -59.77 0.4 Allowed 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.8 2.333 . . . . 0.0 112.42 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.1 m -46.53 -28.18 1.34 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.521 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.404 ' O ' HD23 ' A' ' 12' ' ' LEU . 3.8 tt -61.75 -28.23 69.29 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.979 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.76 ' CZ2' ' HB1' ' A' ' 8' ' ' ALA . 12.5 m95 -80.55 -31.12 37.02 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.701 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.6 m -58.78 -20.56 50.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.314 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.681 ' NH1' HD22 ' A' ' 75' ' ' LEU . 3.7 mmt-85 -55.49 -26.39 42.34 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.836 0.35 . . . . 0.0 111.016 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.757 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -81.41 140.18 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.947 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.1 m -142.43 109.0 5.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.357 -179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.445 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 8.8 tmtt? -66.71 111.25 3.59 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.992 0.425 . . . . 0.0 110.709 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.536 ' HE1' HG21 ' A' ' 43' ' ' VAL . 18.0 t80 -126.64 138.34 53.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.636 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.72 -129.61 47.24 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 15.7 m -99.17 27.57 5.03 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.853 0.358 . . . . 0.0 110.811 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.618 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -163.01 -170.33 27.72 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.218 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.514 ' HE3' HG22 ' A' ' 16' ' ' VAL . 16.9 m95 -125.38 151.85 45.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.723 0.297 . . . . 0.0 110.888 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -120.1 -159.71 10.97 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.397 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.801 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.0 t80 -151.69 150.9 30.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.823 0.344 . . . . 0.0 111.094 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 55.3 m95 -92.44 98.61 11.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.781 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.797 HG21 HG23 ' A' ' 33' ' ' ILE . 17.7 t -75.76 -25.27 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.961 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.402 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -173.03 165.87 3.15 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.626 179.874 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.402 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 18.9 Cg_endo -59.11 -23.41 68.91 Favored 'Trans proline' 0 C--O 1.233 0.254 0 C-N-CA 122.475 2.117 . . . . 0.0 112.304 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.453 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -121.15 -0.99 9.84 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.57 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.448 HG22 ' HD2' ' A' ' 66' ' ' ARG . 41.3 t -126.02 142.52 42.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 121.031 0.443 . . . . 0.0 111.385 -179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.402 ' CE1' ' O ' ' A' ' 25' ' ' PHE . 11.9 t80 -140.26 163.82 31.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.817 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.801 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -139.62 153.42 23.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.116 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.86 167.29 4.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.783 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 38' ' ' VAL . 11.4 m -84.13 151.77 24.71 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.719 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.401 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 2.5 m -81.67 -20.79 38.81 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.406 -179.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.618 ' H ' HG22 ' A' ' 35' ' ' THR . 11.0 t60 -73.25 -32.56 64.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.927 0.394 . . . . 0.0 110.82 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.683 HG22 ' HB ' ' A' ' 35' ' ' THR . 30.8 m -93.24 36.27 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.501 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.746 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 26.2 t -102.93 111.2 64.82 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.561 -0.29 . . . . 0.0 111.2 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.14 -164.8 0.28 Allowed 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.518 2.145 . . . . 0.0 112.146 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -148.37 29.47 0.86 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.964 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.96 -22.67 8.19 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.496 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' HE1' ' A' ' 19' ' ' PHE . 27.7 m -101.07 147.64 7.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.787 0.327 . . . . 0.0 111.135 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.7 tptt -129.01 30.47 5.05 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.824 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER 178.15 150.18 0.22 Allowed 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.524 179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.442 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -123.71 133.81 53.81 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.243 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 41.33 35.25 0.4 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.45 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.78 35.62 45.01 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.706 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' ' CD2' ' A' ' 67' ' ' PHE . 0.4 OUTLIER -123.54 118.27 27.5 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.572 0.225 . . . . 0.0 110.658 179.809 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.86 132.76 29.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.317 2.011 . . . . 0.0 112.472 -179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.586 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.9 mt -51.43 -26.33 7.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.19 179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.9 p -58.91 -18.72 35.95 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.507 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -118.73 39.14 3.57 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.236 0.541 . . . . 0.0 110.675 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.586 HD12 ' HA ' ' A' ' 51' ' ' LEU . 58.8 mt -131.79 158.36 43.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 115.423 -0.808 . . . . 0.0 110.955 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -123.63 113.44 18.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.079 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 12.1 tt -103.58 130.3 54.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.109 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.7 m170 -113.29 99.41 7.78 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.897 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -71.45 126.19 28.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.93 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -165.86 77.32 0.25 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.006 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.63 -118.58 14.9 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.459 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.456 ' HB3' HG23 ' A' ' 35' ' ' THR . 38.6 mt-10 -98.93 29.96 3.59 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.816 0.341 . . . . 0.0 110.853 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.444 ' CZ ' ' HG2' ' A' ' 179' ' ' GLN . 35.4 t80 -136.23 121.06 18.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.846 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.7 m -129.27 121.45 27.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.969 -179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.17 114.75 26.48 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.8 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -100.91 113.34 26.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.99 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.898 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 14.4 mmm-85 -111.48 103.73 12.1 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.712 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.401 ' CD2' ' OE1' ' A' ' 49' ' ' GLU . 5.3 m-85 -81.39 156.2 25.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.056 -179.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.7 t -95.78 23.92 5.83 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.953 179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 30' ' ' THR . 1.5 ttmp? -162.88 151.13 14.05 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.752 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.05 101.22 13.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.414 ' HE1' ' HD2' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -85.54 -26.83 25.95 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.05 59.8 1.76 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.59 -23.44 49.69 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.475 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -64.38 -30.88 71.92 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.941 0.401 . . . . 0.0 110.939 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.681 HD22 ' NH1' ' A' ' 15' ' ' ARG . 11.0 mt -64.17 -176.41 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.879 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 66.4 m -117.15 -69.7 0.84 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.859 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 156.32 124.99 0.87 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.534 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . 0.459 ' HE3' ' N ' ' A' ' 160' ' ' VAL . 1.9 tpt -107.7 141.41 39.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.765 0.317 . . . . 0.0 110.89 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.636 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -93.65 141.46 14.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.119 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 81' ' ' GLU . 7.9 tt -107.95 145.4 33.88 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.467 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.5 mm-40 -128.14 119.13 24.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.852 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -67.79 74.75 0.19 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.636 ' N ' HG11 ' A' ' 178' ' ' VAL . . . 97.1 -162.9 21.98 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.448 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.3 m -165.72 164.13 12.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.736 0.303 . . . . 0.0 110.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.65 -176.2 1.65 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.616 2.211 . . . . 0.0 112.373 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -78.44 140.12 38.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.831 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.54 28.19 48.59 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.541 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 m -98.2 115.56 28.6 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.8 0.333 . . . . 0.0 110.862 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -100.35 108.16 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.143 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 84.5 m -102.11 174.1 6.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.874 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.775 ' O ' HG22 ' A' ' 151' ' ' VAL . 2.8 t -137.32 128.98 28.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.86 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.595 HG21 ' NE2' ' A' ' 164' ' ' HIS . 20.7 t -87.34 159.79 3.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.015 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.486 ' N ' HG12 ' A' ' 92' ' ' VAL . 31.1 mt -113.29 115.71 28.59 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.935 0.397 . . . . 0.0 111.054 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.883 HG21 HG13 ' A' ' 142' ' ' ILE . 23.4 mt -122.92 96.21 3.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.081 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.8 tttt -82.3 177.78 8.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.936 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 54.1 mtt180 -148.52 -177.12 5.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -79.22 -37.99 36.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.831 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 m -68.99 -27.41 65.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.975 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.48 24.77 6.93 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.514 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -107.87 95.29 5.58 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.891 0.377 . . . . 0.0 110.874 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.6 mt -69.75 138.84 53.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.899 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.752 ' CD2' HD11 ' A' ' 142' ' ' ILE . 10.0 tp -114.32 87.54 13.8 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.935 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.33 93.99 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.652 2.235 . . . . 0.0 112.314 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.4 HD12 HD11 ' A' ' 94' ' ' ILE . 57.8 mt -82.05 163.41 22.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -116.45 137.73 51.93 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.206 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.565 HG22 HD23 ' A' ' 128' ' ' LEU . 21.9 t -142.17 139.46 29.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.078 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 13.2 ttp85 -89.28 145.25 25.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.942 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 15.4 mmt -101.21 148.35 25.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.32 -126.58 4.49 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.06 153.88 27.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.805 0.335 . . . . 0.0 111.092 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 6.0 tt -83.06 150.09 4.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.069 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.61 148.98 31.68 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.7 108.48 20.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.956 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.66 137.92 34.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.956 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 -114.2 118.59 34.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.874 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.5 112.39 27.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER 60.28 35.67 20.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.56 28.61 57.1 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 52.2 mtt-85 -127.44 120.48 28.48 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.871 0.367 . . . . 0.0 110.871 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.7 mt -82.29 125.26 30.77 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 121' ' ' VAL . 5.7 m -134.76 97.55 2.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.121 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -66.53 125.65 26.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.878 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -137.74 130.06 4.91 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 18.1 tt0 -90.49 144.52 25.71 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 110.888 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -88.48 -176.18 5.22 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.429 ' C ' HG22 ' A' ' 174' ' ' VAL . . . 176.11 160.51 23.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.544 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 10.1 ttm -126.0 121.67 33.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.815 0.34 . . . . 0.0 110.956 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.621 HD21 HG11 ' A' ' 174' ' ' VAL . 2.8 mt -73.27 163.88 27.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.921 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.584 HD12 ' C ' ' A' ' 128' ' ' LEU . 6.2 mp -141.02 46.93 1.74 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.78 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.51 -40.34 0.64 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.037 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 132' ' ' ALA . . . -169.89 -34.52 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.706 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.552 ' HB2' ' OD1' ' A' ' 172' ' ' ASN . . . 70.66 41.35 0.93 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.074 0.464 . . . . 0.0 110.634 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 6.5 m-80 -78.71 177.99 8.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.046 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.96 135.89 0.17 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.058 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.03 -20.06 16.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 125.37 -28.48 5.03 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.201 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . 0.427 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 3.7 mtm -139.22 31.77 2.14 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 16.4 p30 -162.43 166.37 25.12 Favored 'General case' 0 N--CA 1.449 -0.508 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.955 -178.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.432 ' HG ' ' CG ' ' A' ' 164' ' ' HIS . 0.2 OUTLIER -59.16 -27.73 65.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.877 179.785 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.75 -27.57 19.65 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.535 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.404 ' O ' ' HB ' ' A' ' 142' ' ' ILE . 2.4 t -86.58 133.07 33.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 110.887 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.883 HG13 HG21 ' A' ' 94' ' ' ILE . 35.4 mm 66.61 141.14 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.859 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.625 ' HD2' HG23 ' A' ' 142' ' ' ILE . 15.8 Cg_exo -36.59 75.84 0.0 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 123.359 2.706 . . . . 0.0 113.595 -179.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.657 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 57.99 49.89 70.96 Favored Glycine 0 N--CA 1.45 -0.398 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.612 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.586 ' OD1' HG23 ' A' ' 94' ' ' ILE . 24.5 t70 -80.49 57.85 3.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.044 0.449 . . . . 0.0 110.86 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 p -88.44 152.44 21.89 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.309 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.26 -19.22 44.5 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.266 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.87 137.15 13.38 Favored Pre-proline 0 CA--C 1.528 0.128 0 CA-C-O 120.573 0.225 . . . . 0.0 111.065 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.438 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 94.2 Cg_endo -87.26 155.94 8.15 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.673 2.249 . . . . 0.0 112.753 -179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.881 ' O ' HG23 ' A' ' 160' ' ' VAL . 54.7 m-85 -98.15 161.08 13.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.676 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 91' ' ' SER . 28.6 m -145.06 151.64 15.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.017 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.456 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 16.2 p-80 -167.43 167.27 13.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.805 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -97.64 133.4 42.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.493 ' HD3' HG21 ' A' ' 159' ' ' VAL . 18.5 ttp85 -131.24 97.38 4.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.438 179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.26 -107.45 2.27 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.178 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.7 t30 -114.11 36.27 3.78 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.029 0.442 . . . . 0.0 110.405 179.399 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.0 -170.73 1.39 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.812 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.481 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 5.9 m95 -129.0 137.53 51.4 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.517 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.636 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.2 t -123.44 142.82 38.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.359 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.881 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.9 p -85.95 135.4 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.966 179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -82.31 -80.99 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.014 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -147.28 -140.71 3.44 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.496 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.769 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 5.9 m -134.2 173.74 14.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.87 0.367 . . . . 0.0 111.121 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.595 ' NE2' HG21 ' A' ' 92' ' ' VAL . 1.8 m170 -79.09 101.72 8.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.923 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -86.88 -67.44 0.82 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.149 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.72 174.44 3.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.088 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.821 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -160.4 159.59 31.24 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.154 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -91.4 175.17 7.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.752 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -87.08 -47.04 9.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 4.5 m -115.28 -16.9 11.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.354 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -71.18 -33.45 64.92 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.561 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.552 ' OD1' ' HB2' ' A' ' 132' ' ' ALA . 2.8 m-80 59.27 46.95 12.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.887 0.375 . . . . 0.0 110.925 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 70.5 m -124.18 118.15 26.22 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.799 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.821 HG12 ' HB2' ' A' ' 167' ' ' ALA . 30.8 m -109.78 169.12 3.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.216 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.421 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.5 t -132.05 111.81 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.062 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 45.6 m -85.86 99.09 11.15 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.95 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.769 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -59.46 123.55 17.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.636 HG11 ' N ' ' A' ' 83' ' ' GLY . 5.7 m -118.49 179.35 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.096 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.444 ' HG2' ' CZ ' ' A' ' 62' ' ' PHE . 39.7 mt-30 -63.4 146.11 54.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.41 133.54 11.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.124 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 103.74 28.7 5.86 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.53 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -90.82 129.54 36.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.916 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.72 34.81 5.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.49 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 -132.17 -67.15 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 9.7 m -132.51 -64.86 0.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.907 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.44 -178.38 0.1 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.152 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.618 ' O ' HD13 ' A' ' 187' ' ' LEU . 0.5 OUTLIER -99.0 -31.36 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.928 -179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.937 179.974 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.6 mtt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.806 0.336 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 23.8 m170 -87.53 138.87 31.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.916 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -105.67 127.15 52.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.797 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.1 100.79 4.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.893 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -137.73 -179.1 5.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.897 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -71.64 -177.43 1.89 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.936 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -176.58 111.24 0.09 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.609 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -74.37 152.85 87.96 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.102 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.784 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo -54.09 154.75 17.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.609 2.206 . . . . 0.0 112.253 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.63 -59.13 0.32 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.54 2.16 . . . . 0.0 112.411 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -55.03 -27.86 47.72 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.221 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.942 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -65.63 -29.42 70.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.791 ' O ' HG12 ' A' ' 16' ' ' VAL . 30.0 m0 -79.03 -31.88 44.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.957 0.408 . . . . 0.0 110.861 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 41.1 m -67.09 -20.85 65.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.202 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 9.2 mtm-85 -57.79 -36.59 72.4 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.873 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.791 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -60.67 138.04 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.652 179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 22.6 m -144.14 109.17 5.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.84 0.352 . . . . 0.0 111.84 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HB2' ' CH2' ' A' ' 23' ' ' TRP . 12.0 tttt -66.27 111.52 3.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.014 0.435 . . . . 0.0 110.495 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -124.67 138.51 54.29 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.819 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 58.69 -110.98 2.89 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.327 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.4 ' CB ' HG12 ' A' ' 38' ' ' VAL . 3.2 m -109.36 -19.57 13.23 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.987 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.42 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -117.48 -170.39 15.2 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.483 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.66 ' HE3' HG22 ' A' ' 16' ' ' VAL . 31.9 m95 -117.66 154.0 32.36 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.742 0.306 . . . . 0.0 110.779 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -121.95 -160.84 11.11 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.477 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.664 ' CE2' HG11 ' A' ' 160' ' ' VAL . 2.3 t80 -151.75 155.59 38.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.865 0.364 . . . . 0.0 111.07 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.552 ' CB ' HD13 ' A' ' 75' ' ' LEU . 37.6 m95 -100.77 97.61 8.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.696 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.782 HG21 HG23 ' A' ' 33' ' ' ILE . 21.9 t -67.16 -29.47 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.275 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -175.02 173.87 0.96 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.01 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -57.17 -23.9 55.94 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.672 2.248 . . . . 0.0 112.488 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.533 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -124.91 2.2 8.06 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.601 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 21.7 t -118.83 142.47 33.65 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.759 0.314 . . . . 0.0 111.116 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -142.9 147.71 35.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.034 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.782 HG23 HG21 ' A' ' 27' ' ' VAL . 13.3 pt -132.17 155.05 41.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.148 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.76 167.38 4.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.91 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.738 HG21 ' CE1' ' A' ' 37' ' ' HIS . 19.4 m -84.16 161.22 20.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.625 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.845 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -100.79 -27.21 13.47 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.829 -179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.738 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.0 p-80 -67.55 -20.87 65.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.65 0.262 . . . . 0.0 111.108 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.642 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.35 26.97 3.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.292 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.845 HG12 ' O ' ' A' ' 36' ' ' THR . 12.5 p -91.55 120.51 68.19 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.044 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.13 -164.54 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.573 2.182 . . . . 0.0 112.197 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.05 30.0 0.25 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.893 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.39 -38.18 2.89 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.407 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.7 m -76.85 147.57 7.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.792 0.329 . . . . 0.0 111.081 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 5.2 mmmm -118.05 29.56 7.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 177.96 150.32 0.21 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.632 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.2 OUTLIER -123.59 133.83 53.9 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.305 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 38.93 35.81 0.13 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.514 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.78 38.09 17.47 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.663 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -131.24 110.67 15.3 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-O 120.449 0.166 . . . . 0.0 110.657 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.39 136.35 43.01 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.389 2.059 . . . . 0.0 112.394 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -54.99 -27.63 45.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.022 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.9 p -55.84 -21.59 20.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.553 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 66.8 m -121.99 40.32 3.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.14 0.495 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.8 mt -131.84 158.15 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.899 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.937 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.58 93.77 3.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.943 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.857 HD11 HG23 ' A' ' 63' ' ' THR . 0.0 OUTLIER -96.44 119.71 44.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.188 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.52 ' N ' HD13 ' A' ' 56' ' ' ILE . 1.9 m-70 -107.82 99.87 9.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.807 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -63.75 146.22 54.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.927 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -173.68 80.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.133 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.92 -119.84 20.1 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -98.7 29.76 3.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.9 0.381 . . . . 0.0 110.92 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 73.3 t80 -138.42 125.15 20.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.825 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.857 HG23 HD11 ' A' ' 56' ' ' ILE . 62.6 m -128.24 120.84 27.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.945 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.5 tt0 -96.23 126.53 41.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.752 179.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -108.53 113.34 26.27 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.937 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 8.4 ttm180 -110.32 103.7 12.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.601 179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -86.96 146.19 26.24 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.059 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.2 p -74.83 -30.77 61.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.543 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 28.3 tttp -124.63 153.28 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.627 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.533 ' HB3' HG23 ' A' ' 30' ' ' THR . 1.5 pttp -102.99 115.55 30.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.935 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.6 ppp? -105.6 17.32 24.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.198 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.45 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.0 mmp_? -136.73 64.35 50.05 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 120.839 0.352 . . . . 0.0 111.014 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . 0.415 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 32.7 Cg_exo -61.41 -25.73 80.36 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.577 2.185 . . . . 0.0 112.384 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.07 -31.68 61.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.967 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.552 HD13 ' CB ' ' A' ' 26' ' ' TRP . 63.9 mt -72.31 96.52 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -59.13 -30.66 68.3 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.873 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 100.89 177.78 29.34 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . 0.519 ' CE ' HG13 ' A' ' 160' ' ' VAL . 56.5 mmm -145.67 152.97 40.48 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.853 0.359 . . . . 0.0 110.807 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.438 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -80.42 133.82 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.173 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -106.22 134.62 49.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.824 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 17.1 mt-10 -126.25 118.94 26.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.923 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.655 ' HA ' HG21 ' A' ' 178' ' ' VAL . 9.3 pt-20 -65.48 79.32 0.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.45 -176.56 48.29 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.505 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -159.91 162.8 23.95 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 120.716 0.293 . . . . 0.0 110.906 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.14 175.07 9.73 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.562 2.175 . . . . 0.0 112.237 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -69.47 136.49 51.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.938 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 105.15 -27.29 19.17 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.494 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -58.68 115.52 3.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.775 0.322 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.38 111.3 26.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.345 -0.388 . . . . 0.0 111.105 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.7 m -84.43 165.97 17.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.626 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.32 106.95 6.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.938 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.836 HG22 ' CE1' ' A' ' 150' ' ' TYR . 39.5 t -71.99 156.32 6.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.977 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.838 HD21 HG21 ' A' ' 151' ' ' VAL . 32.9 mt -110.58 95.81 5.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.964 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.765 HD11 ' CG ' ' A' ' 104' ' ' LEU . 29.6 mt -94.2 138.05 21.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.066 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.7 ttpp -137.4 146.57 44.6 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.943 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -117.69 -176.16 2.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -77.11 -35.96 55.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.867 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 92.0 p -68.97 -24.83 64.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.99 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 107.7 23.95 6.61 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.567 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -83.88 175.45 9.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.774 0.321 . . . . 0.0 110.822 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.589 HD11 ' CD2' ' A' ' 13' ' ' TRP . 0.2 OUTLIER -141.03 149.95 42.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.874 -179.914 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.741 ' HB3' HD12 ' A' ' 94' ' ' ILE . 2.6 tp -148.27 88.71 5.34 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.872 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -74.44 96.47 0.98 Allowed 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.587 2.192 . . . . 0.0 112.374 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.765 ' CG ' HD11 ' A' ' 94' ' ' ILE . 29.6 mt -63.4 163.6 10.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.937 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -133.22 103.03 5.8 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.117 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.779 HG22 HD23 ' A' ' 128' ' ' LEU . 18.7 t -120.77 141.29 41.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.127 -179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.2 ttt180 -91.87 138.69 31.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.837 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.0 mmt -88.84 146.1 25.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -113.27 -132.19 5.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 157.87 21.15 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.872 0.368 . . . . 0.0 111.046 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.775 HG23 ' OE1' ' A' ' 124' ' ' GLN . 25.7 mt -77.29 118.14 23.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.078 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.57 163.86 35.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -98.09 110.68 23.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.888 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.52 145.67 25.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.928 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 12.3 ttt180 -108.11 136.61 47.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.869 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.1 mt -140.05 110.7 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.091 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.4 mm-40 60.34 35.45 20.64 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.919 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.13 31.05 39.87 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.469 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.7 mmt180 -131.09 109.02 10.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.837 0.351 . . . . 0.0 110.918 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.1 mt -79.78 113.29 17.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.844 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.06 127.36 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.176 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.2 t-160 -90.15 115.8 27.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.847 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -162.22 -165.78 19.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.518 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . 0.775 ' OE1' HG23 ' A' ' 111' ' ' ILE . 3.0 mp0 -106.71 140.62 39.28 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.825 0.345 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 55.6 m -109.33 118.59 37.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.882 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 173' ' ' THR . . . -127.18 158.02 20.91 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.417 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.2 mtt -115.1 153.77 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.757 0.313 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.779 HD23 HG22 ' A' ' 106' ' ' VAL . 0.7 OUTLIER -98.31 162.85 12.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.932 -179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.454 HD12 ' C ' ' A' ' 128' ' ' LEU . 9.5 mp -113.31 47.7 1.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.805 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.421 HG21 HD22 ' A' ' 133' ' ' ASN . 89.4 m -127.14 -71.68 0.67 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 121.58 98.72 1.56 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.524 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 59.65 84.47 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.869 0.366 . . . . 0.0 111.167 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.488 ' O ' HD13 ' A' ' 139' ' ' LEU . 17.7 t-20 -144.02 81.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.517 ' HB2' HD22 ' A' ' 139' ' ' LEU . . . -147.24 150.43 34.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.3 tttt -109.1 -27.61 9.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.885 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 149.83 -25.57 1.17 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.323 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.6 mtp -139.73 26.53 2.29 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 121.127 0.489 . . . . 0.0 109.741 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.7 p30 -162.66 171.37 17.0 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.925 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.855 HD23 ' HB2' ' A' ' 167' ' ' ALA . 0.1 OUTLIER -133.91 50.36 2.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.987 0.422 . . . . 0.0 110.767 179.969 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 159.08 -39.74 0.49 Allowed Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.138 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.702 ' HA ' HD13 ' A' ' 94' ' ' ILE . 6.0 p -74.3 -174.93 2.13 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.742 0.306 . . . . 0.0 110.882 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.554 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.4 OUTLIER -142.8 -53.9 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.978 -179.974 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.554 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.1 Cg_exo -67.2 60.31 0.66 Allowed 'Trans proline' 0 C--N 1.352 0.75 0 C-N-CA 122.784 2.323 . . . . 0.0 112.561 -179.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.408 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.47 52.71 7.27 Favored Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.867 179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.769 ' CG ' ' HB2' ' A' ' 148' ' ' ALA . 3.4 t0 -81.9 58.02 3.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.095 0.474 . . . . 0.0 110.918 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -80.34 84.77 5.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.364 179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.42 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 120.82 12.62 5.89 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.908 -0.663 . . . . 0.0 112.506 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.769 ' HB2' ' CG ' ' A' ' 145' ' ' ASP . . . -44.16 141.81 2.39 Favored Pre-proline 0 N--CA 1.462 0.141 0 CA-C-O 120.551 0.215 . . . . 0.0 111.273 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.459 ' HG2' HD12 ' A' ' 93' ' ' LEU . 95.9 Cg_endo -79.41 129.95 8.78 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.679 2.252 . . . . 0.0 113.028 -179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.836 ' CE1' HG22 ' A' ' 92' ' ' VAL . 3.3 m-85 -88.95 145.38 25.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.436 179.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.942 HG11 HD21 ' A' ' 12' ' ' LEU . 16.0 m -141.62 154.84 20.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.885 0.374 . . . . 0.0 110.994 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.408 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 56.3 p-80 -168.77 152.42 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.787 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.422 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.3 tttp -79.53 126.57 31.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.235 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.474 ' CB ' HG23 ' A' ' 159' ' ' VAL . 1.0 OUTLIER -129.44 97.98 4.72 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.265 179.656 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.24 -106.78 2.11 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.536 -0.84 . . . . 0.0 111.96 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -116.5 37.31 3.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.877 0.37 . . . . 0.0 110.207 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.89 -174.47 2.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.046 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.576 ' CZ3' ' HB2' ' A' ' 8' ' ' ALA . 3.5 m0 -124.25 118.53 27.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.65 179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.474 HG23 ' CB ' ' A' ' 154' ' ' ARG . 21.5 t -98.82 147.86 6.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.169 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.862 HG12 HG12 ' A' ' 151' ' ' VAL . 8.5 m -109.27 123.1 64.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.036 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.502 ' O ' HG11 ' A' ' 178' ' ' VAL . 10.2 m -63.42 -79.23 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.885 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -161.21 -125.32 0.76 Allowed Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.505 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 148' ' ' ALA . 11.0 m -138.91 157.85 29.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.593 0.235 . . . . 0.0 111.055 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.457 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 10.6 t-80 -73.61 125.55 28.26 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.846 0.355 . . . . 0.0 111.047 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.476 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -101.8 -69.85 0.77 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.421 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -170.3 174.4 5.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.855 ' HB2' HD23 ' A' ' 139' ' ' LEU . . . -87.49 154.1 20.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.487 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 176.37 6.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.907 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.487 ' H ' HG22 ' A' ' 168' ' ' THR . 0.3 OUTLIER -59.44 -25.71 64.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.065 179.993 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.4 m -70.07 -17.07 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.349 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.37 -56.47 4.75 Favored Glycine 0 C--N 1.331 0.283 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.401 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 35.6 m-20 -93.65 47.62 1.24 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.857 0.36 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.546 HG23 ' O ' ' A' ' 126' ' ' GLY . 6.8 m -141.61 140.92 33.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.8 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.568 ' CG2' HG11 ' A' ' 106' ' ' VAL . 16.8 m -109.84 165.33 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.197 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 165' ' ' ALA . 29.4 t -118.88 110.01 28.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.01 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.43 118.82 21.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.919 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -108.43 115.4 30.03 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.655 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.2 m -146.6 -47.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.438 ' N ' HG23 ' A' ' 178' ' ' VAL . 7.3 mm-40 -134.02 142.12 47.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.803 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -111.25 84.26 1.91 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.028 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 105.86 -177.39 22.59 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.492 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -131.76 166.96 20.37 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.791 0.329 . . . . 0.0 110.874 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -149.04 28.5 1.26 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.446 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -109.89 -67.49 0.98 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.838 0.352 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.12 -56.99 2.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -81.14 117.4 21.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.095 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 8.4 tt -177.53 -39.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.061 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.955 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.5 mtt . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.818 0.342 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -106.82 116.66 32.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.877 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -163.86 31.69 0.08 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.968 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -113.83 137.95 50.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.879 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -140.16 -68.2 0.42 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.984 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.1 t-160 -160.58 145.13 14.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.904 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 5.2 m170 -169.98 -176.43 2.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.896 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.544 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -57.0 108.99 1.41 Allowed Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.052 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.644 ' HD2' HD13 ' A' ' 12' ' ' LEU . 46.7 Cg_exo -56.3 148.69 59.67 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.438 2.092 . . . . 0.0 112.419 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.47 -60.6 0.21 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.624 2.216 . . . . 0.0 112.334 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.56 HG23 ' O ' ' A' ' 74' ' ' ASP . 86.4 m -49.91 -27.54 5.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.242 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.644 HD13 ' HD2' ' A' ' 9' ' ' PRO . 3.9 tt -63.04 -32.61 74.01 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.985 -179.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.79 ' O ' HG12 ' A' ' 16' ' ' VAL . 51.3 m0 -83.74 -32.35 25.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.958 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.2 m -76.49 -20.9 56.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.299 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 11.8 mtt-85 -56.94 -29.87 63.52 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.801 0.334 . . . . 0.0 110.964 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.79 HG12 ' O ' ' A' ' 13' ' ' TRP . 12.3 p -71.43 141.17 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.938 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.9 m -147.14 108.99 4.38 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.617 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CE3' ' A' ' 23' ' ' TRP . 13.3 tttt -66.31 111.44 3.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.638 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.467 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.1 t80 -128.05 137.01 52.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.743 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.07 -130.42 49.13 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.433 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -98.55 31.02 3.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 0.0 110.704 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -165.33 -170.29 30.08 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.323 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.5 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.2 m95 -126.08 154.57 42.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.824 0.345 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -123.83 -163.83 11.84 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.424 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.826 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.1 t80 -151.76 149.81 29.47 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 110.938 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.518 ' CD2' HD11 ' A' ' 75' ' ' LEU . 64.5 m95 -91.95 101.64 14.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.698 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.844 HG13 HD11 ' A' ' 80' ' ' LEU . 21.9 t -78.76 -25.25 13.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.037 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.404 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 1.1 p -166.57 163.14 11.36 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.519 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 28' ' ' SER . 28.6 Cg_endo -62.46 -14.86 41.78 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.404 2.069 . . . . 0.0 112.299 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.628 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.49 2.13 6.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.393 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 58.6 t -131.67 142.48 43.01 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-O 120.849 0.357 . . . . 0.0 111.494 -179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.05 155.65 49.39 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.928 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.826 HD11 ' HB3' ' A' ' 25' ' ' PHE . 2.8 pp -131.6 152.91 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.153 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.2 t -172.22 167.26 5.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.852 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.771 ' HB ' HG22 ' A' ' 38' ' ' VAL . 73.0 m -84.21 148.41 26.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.743 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 1.3 m -77.43 -22.44 51.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.489 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.767 ' H ' HG22 ' A' ' 35' ' ' THR . 10.1 t60 -73.29 -34.6 65.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.115 0.483 . . . . 0.0 110.718 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.771 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.1 m -93.28 36.15 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.705 -179.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.9 t -108.33 113.96 59.84 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.074 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -83.68 -164.87 0.28 Allowed 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.614 2.209 . . . . 0.0 112.246 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -149.97 29.7 0.73 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.008 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -104.13 -23.35 8.16 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.515 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.467 HG21 ' HE1' ' A' ' 19' ' ' PHE . 29.2 m -98.35 159.1 3.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.782 0.325 . . . . 0.0 111.163 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 3.1 mptt -132.76 30.59 4.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER 178.62 150.22 0.25 Allowed 'General case' 0 CA--C 1.517 -0.321 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.594 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.4 OUTLIER -124.55 133.69 53.22 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 178.297 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 40.83 35.39 0.33 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.449 -179.276 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 79.19 34.74 32.15 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.714 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -125.21 111.58 26.45 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.534 0.207 . . . . 0.0 110.757 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.53 134.74 36.62 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.43 2.087 . . . . 0.0 112.334 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.654 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.5 mt -52.75 -27.26 17.0 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.123 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 17.9 t -59.56 -18.8 43.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.513 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 5.6 m -123.16 40.75 3.64 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.138 0.494 . . . . 0.0 110.836 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.674 HG21 ' CD2' ' A' ' 65' ' ' PHE . 57.8 mt -129.99 145.3 35.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.869 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.794 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -106.9 107.35 18.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.136 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.563 HG23 ' HE1' ' A' ' 65' ' ' PHE . 29.7 mt -89.89 142.17 13.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.163 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.44 110.92 4.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.831 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -89.05 159.56 17.5 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.46 49.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 64.97 89.27 0.04 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 66.1 mm-40 58.91 27.96 16.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.861 0.362 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 74.2 t80 -141.94 101.61 3.98 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.713 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 12.0 m -111.29 111.57 22.72 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.059 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -96.55 118.83 33.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.674 ' CD2' HG21 ' A' ' 54' ' ' ILE . 2.1 m-85 -107.48 113.29 26.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.011 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.794 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 75.7 mtt180 -102.98 103.62 13.75 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.697 179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.52 149.82 36.66 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.055 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.97 29.45 3.45 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.904 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.628 ' C ' HG23 ' A' ' 30' ' ' THR . 26.1 tttp -157.39 114.81 3.06 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.866 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.57 ' N ' HG23 ' A' ' 30' ' ' THR . 6.8 ttpt -87.19 91.53 8.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.652 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 50.3 mtp -80.49 -26.54 38.15 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.977 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.479 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 7.7 ptm180 43.42 57.33 12.42 Favored Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.314 -179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . 0.479 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.3 Cg_exo -53.01 -39.7 78.69 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.459 2.106 . . . . 0.0 112.213 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.56 ' O ' HG23 ' A' ' 11' ' ' THR . 14.0 p30 -171.79 33.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.771 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.518 HD11 ' CD2' ' A' ' 26' ' ' TRP . 1.6 mt -121.15 173.41 7.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.985 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.0 m -144.38 -47.36 0.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 162.39 152.07 6.6 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.543 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.9 mmt -145.71 170.18 17.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.854 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.662 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.8 t -112.89 141.43 28.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 27' ' ' VAL . 7.1 mp -118.61 117.64 29.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.952 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -92.78 164.24 13.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.871 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -134.52 80.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.892 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.539 ' HA2' HD11 ' A' ' 111' ' ' ILE . . . 110.74 145.4 10.35 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.468 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -158.11 162.79 26.3 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.753 0.311 . . . . 0.0 110.851 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.07 -173.63 0.95 Allowed 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.621 2.214 . . . . 0.0 112.303 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -102.66 103.91 14.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 151.25 -27.38 0.99 Allowed Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 19.7 m -60.0 115.36 3.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.758 0.314 . . . . 0.0 110.94 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.662 HG22 HD22 ' A' ' 129' ' ' LEU . 21.1 t -84.99 117.57 30.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.062 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 68.3 m -84.5 170.4 13.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.486 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.2 103.46 5.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.777 179.921 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.712 HG22 ' CE1' ' A' ' 150' ' ' TYR . 13.3 t -71.09 158.0 6.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.091 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.45 ' N ' HG12 ' A' ' 92' ' ' VAL . 3.5 mt -124.48 88.7 2.94 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.636 HD11 ' CD1' ' A' ' 104' ' ' LEU . 29.7 mt -99.37 104.96 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.14 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.55 143.95 25.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -108.86 -171.58 1.88 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.912 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 18.4 m-20 -78.49 -34.95 47.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.954 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 15.1 m -98.1 23.69 7.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.96 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 72.08 24.89 75.82 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -81.16 80.33 7.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.74 126.77 30.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.991 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.4 HD12 ' HA ' ' A' ' 102' ' ' LEU . 12.0 tp -116.29 87.94 21.55 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.867 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.27 107.25 2.22 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.616 2.211 . . . . 0.0 112.354 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.636 ' CD1' HD11 ' A' ' 94' ' ' ILE . 48.9 mt -92.31 163.36 13.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.912 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -126.28 141.18 52.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.123 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.4 t -152.25 120.33 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.031 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 140.23 58.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.822 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.12 143.51 57.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.37 -148.24 20.47 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.484 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.03 157.74 21.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.837 0.351 . . . . 0.0 111.205 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.539 HD11 ' HA2' ' A' ' 83' ' ' GLY . 30.0 mm -91.91 113.83 27.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.159 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.44 151.77 49.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.162 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -97.06 111.02 23.44 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.896 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -91.43 157.91 16.8 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.899 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 15.7 ttp180 -127.52 121.86 31.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.924 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.35 113.51 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? 60.4 31.68 20.42 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 80.67 28.8 45.7 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.5 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.2 mmp_? -128.97 108.11 10.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.933 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 12.0 mt -72.82 130.62 40.86 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.63 129.23 6.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.109 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 36.2 m80 -69.61 136.37 51.13 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.832 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.9 128.96 4.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.431 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -90.77 146.31 24.07 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.778 0.323 . . . . 0.0 110.919 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -114.68 171.76 7.45 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -162.39 138.18 5.24 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.471 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 3.6 ttm -102.91 149.73 24.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.843 0.354 . . . . 0.0 110.901 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.618 HD23 HD11 ' A' ' 139' ' ' LEU . 6.4 mt -72.37 114.57 10.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.662 HD22 HG22 ' A' ' 89' ' ' VAL . 18.0 tp -105.8 47.77 0.86 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 49.6 m -146.16 -46.45 0.2 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.936 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -178.2 -74.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.49 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HA ' HD13 ' A' ' 128' ' ' LEU . . . -177.07 37.3 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.735 0.302 . . . . 0.0 111.013 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.8 m-80 -72.04 98.81 2.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.953 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.88 129.16 0.77 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -96.78 -29.25 13.87 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.965 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.18 -27.51 1.4 Allowed Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.449 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.3 mtt -139.09 29.57 2.25 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-O 121.174 0.511 . . . . 0.0 109.654 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 4.0 p30 -162.2 -177.26 5.61 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.036 -178.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.826 HD22 HG11 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.11 35.75 2.0 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.135 0.493 . . . . 0.0 110.112 179.346 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.11 12.76 57.21 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.454 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.641 HG21 ' HB3' ' A' ' 145' ' ' ASP . 3.8 p -74.77 -174.83 2.28 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.857 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.579 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -144.88 -53.72 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.936 179.991 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.579 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.0 Cg_exo -67.0 60.55 0.6 Allowed 'Trans proline' 0 C--N 1.351 0.703 0 C-N-CA 122.725 2.283 . . . . 0.0 112.678 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.413 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 45.01 53.16 7.64 Favored Glycine 0 CA--C 1.518 0.234 0 CA-C-N 115.605 -0.725 . . . . 0.0 112.958 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.641 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.7 OUTLIER -84.09 58.2 4.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.015 0.436 . . . . 0.0 110.785 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.639 ' O ' HG11 ' A' ' 38' ' ' VAL . 19.3 m -97.81 96.69 8.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.362 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 117.94 9.79 9.59 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.418 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.613 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.83 141.5 5.49 Favored Pre-proline 0 CA--C 1.528 0.129 0 CA-C-O 120.599 0.238 . . . . 0.0 111.181 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.455 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 72.6 Cg_endo -76.03 131.11 12.82 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.66 2.24 . . . . 0.0 112.826 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.74 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.0 m-85 -106.49 129.67 54.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.235 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 91' ' ' SER . 3.6 m -121.8 169.57 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.995 0.426 . . . . 0.0 111.036 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.407 ' O ' ' HA ' ' A' ' 158' ' ' TRP . 27.1 p-80 -165.18 152.21 10.66 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.556 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.415 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 7.7 tttp -76.78 124.7 28.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.159 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.455 ' CB ' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -128.06 97.84 4.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.148 179.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.85 -179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -116.73 37.18 3.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.912 0.387 . . . . 0.0 110.213 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -167.17 -172.6 2.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.025 -179.584 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.415 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.5 m0 -123.56 122.07 37.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.631 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.4 t -108.17 141.35 23.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.376 -179.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.5 p -89.53 138.89 18.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.024 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 28.0 p -93.06 -41.19 10.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.188 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 169.81 -143.77 8.11 Favored Glycine 0 CA--C 1.517 0.204 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.76 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -127.89 167.08 23.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.682 0.277 . . . . 0.0 110.965 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.7 t-80 -79.01 139.06 38.27 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.846 0.355 . . . . 0.0 110.992 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -117.46 -77.41 0.57 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.288 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.11 174.35 10.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.195 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.644 ' CB ' HG12 ' A' ' 174' ' ' VAL . . . -147.68 155.06 41.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.19 145.43 26.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.92 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.0 ttpp -65.74 -55.88 14.95 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.821 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -115.18 -16.96 11.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.352 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -58.34 -23.5 53.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.664 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.1 m120 61.23 47.47 7.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.92 0.39 . . . . 0.0 110.836 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 1.3 m -145.91 163.53 34.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.826 HG11 HD22 ' A' ' 139' ' ' LEU . 27.5 m -144.45 151.15 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -110.97 136.22 47.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 6.3 p -123.36 135.77 54.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -72.71 108.27 5.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.123 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.486 HG22 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -79.66 158.37 4.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.023 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.486 ' N ' HG22 ' A' ' 178' ' ' VAL . 4.2 tt0 -66.49 143.93 56.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.927 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -109.99 -171.24 1.8 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.019 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -175.22 66.44 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.526 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -97.25 167.76 10.83 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.908 0.385 . . . . 0.0 110.852 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 174.76 -95.57 0.1 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.534 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -89.97 -43.18 10.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.857 0.361 . . . . 0.0 110.974 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.1 m -68.11 74.32 0.21 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.84 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -103.08 -177.88 3.5 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.108 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.3 tp 60.43 80.1 0.22 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.861 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.872 179.917 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.802 0.334 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 50.6 p-80 -81.35 98.71 8.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.0 m80 60.34 81.33 0.18 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.959 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 48.7 p-80 -98.81 31.53 2.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.89 31.67 6.04 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.829 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 1.5 t-160 -141.46 129.68 22.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.932 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.403 ' CG ' ' O ' ' A' ' 6' ' ' HIS . 2.5 m170 -171.71 140.91 1.37 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.424 ' HB3' ' NE1' ' A' ' 13' ' ' TRP . . . -66.37 147.17 99.02 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.056 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.763 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.2 Cg_exo -53.95 154.43 17.41 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.499 2.133 . . . . 0.0 112.345 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.446 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.8 Cg_endo -61.44 -59.3 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.677 2.251 . . . . 0.0 112.369 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.0 m -54.39 -28.92 46.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.104 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.771 HD21 HG11 ' A' ' 151' ' ' VAL . 4.6 tt -64.01 -30.13 71.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.95 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.768 ' O ' HG12 ' A' ' 16' ' ' VAL . 19.7 m0 -77.05 -32.16 56.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.768 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 5.1 t -76.16 -20.67 57.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.262 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.464 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 8.1 mmt180 -56.09 -27.91 55.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.879 0.371 . . . . 0.0 110.984 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.768 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.3 p -74.89 141.13 16.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.885 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.3 m -135.64 109.03 7.84 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.882 0.372 . . . . 0.0 111.571 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 13.5 tmtt? -66.63 111.64 3.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.001 0.429 . . . . 0.0 110.96 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -119.75 130.26 54.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.34 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 58.37 -120.87 24.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.1 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.555 ' O ' HG12 ' A' ' 38' ' ' VAL . 8.9 m -106.63 25.83 10.71 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.538 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' CA ' ' O ' ' A' ' 146' ' ' CYS . . . -153.25 -170.22 19.21 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 121.03 -0.605 . . . . 0.0 112.531 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.485 ' HE3' HG22 ' A' ' 16' ' ' VAL . 20.1 m95 -133.53 142.88 48.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 0.0 110.995 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.89 -163.8 12.92 Favored Glycine 0 C--N 1.331 0.263 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.374 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.621 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.3 t80 -151.72 152.03 32.21 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.852 0.358 . . . . 0.0 111.191 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.45 ' CE2' ' NE ' ' A' ' 72' ' ' ARG . 11.0 m0 -87.45 103.65 15.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.54 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.557 ' CG2' HG12 ' A' ' 31' ' ' VAL . 3.0 m -84.44 -24.64 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.226 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -166.65 153.56 8.49 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.41 ' HB2' ' CG ' ' A' ' 70' ' ' LYS . 77.9 Cg_exo -50.6 -24.73 13.25 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.648 2.232 . . . . 0.0 112.522 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.98 12.77 8.4 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.279 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.557 HG12 ' CG2' ' A' ' 27' ' ' VAL . 44.4 t -135.22 142.55 39.55 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 CA-C-O 120.951 0.405 . . . . 0.0 111.014 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 3.1 t80 -132.77 168.84 17.62 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.043 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.621 HD11 ' HB3' ' A' ' 25' ' ' PHE . 35.7 pt -143.71 150.27 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.1 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.6 t -173.83 160.83 3.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.943 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.515 ' HB ' HG22 ' A' ' 38' ' ' VAL . 2.3 m -84.21 171.43 12.78 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.541 179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.785 ' O ' HG12 ' A' ' 39' ' ' VAL . 5.7 m -102.61 -23.85 13.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.559 ' HD2' HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -72.22 -12.4 61.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.64 0.257 . . . . 0.0 111.453 -179.575 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' HD2' ' A' ' 37' ' ' HIS . 0.9 OUTLIER -113.13 -21.63 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.329 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 -179.637 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.785 HG12 ' O ' ' A' ' 36' ' ' THR . 14.4 p -53.17 120.96 22.12 Favored Pre-proline 0 CA--C 1.532 0.25 0 CA-C-N 116.641 -0.254 . . . . 0.0 111.288 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.4 ' HG3' ' CA ' ' A' ' 20' ' ' GLY . 87.8 Cg_endo -82.71 -164.27 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.551 2.167 . . . . 0.0 112.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.54 30.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.943 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.78 -31.04 4.97 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.422 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.3 m -88.75 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.767 0.317 . . . . 0.0 111.157 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.8 31.02 6.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.827 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.35 150.16 0.23 Allowed 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.642 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.462 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -122.77 133.73 54.45 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 41.16 35.37 0.38 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.452 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.48 36.12 45.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.891 -0.671 . . . . 0.0 112.713 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -122.7 127.17 25.87 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 120.53 0.205 . . . . 0.0 110.653 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -72.74 131.38 17.09 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.374 2.05 . . . . 0.0 112.553 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.611 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.0 mt -50.82 -26.37 5.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.144 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 69.6 p -61.71 -16.68 51.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.503 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.66 39.49 3.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.149 0.499 . . . . 0.0 110.667 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.611 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.4 mt -131.5 158.59 43.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.968 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 126.81 39.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.053 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.466 HG13 HG23 ' A' ' 63' ' ' THR . 2.7 tt -110.14 142.15 23.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.117 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -141.7 99.45 3.55 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.823 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -75.73 152.6 37.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.916 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.73 60.89 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.07 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.09 82.05 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.556 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 58.87 28.16 17.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.728 0.299 . . . . 0.0 110.918 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.446 ' CE1' ' CG ' ' A' ' 179' ' ' GLN . 25.5 t80 -136.21 101.58 4.74 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.746 179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.466 HG23 HG13 ' A' ' 56' ' ' ILE . 12.4 m -116.39 121.18 41.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.016 -179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.414 ' NE2' HG13 ' A' ' 31' ' ' VAL . 0.4 OUTLIER -96.19 117.5 30.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.617 179.739 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -95.16 113.18 24.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.962 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.3 ttt85 -111.37 103.57 11.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.6 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -83.86 160.95 21.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.98 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 22.8 t -96.42 24.86 5.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.877 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 30.4 tttt -162.1 161.95 28.42 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.82 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.41 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 9.9 ttmt -98.06 113.12 24.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.679 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.9 mmt -85.59 -28.36 24.89 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.905 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.535 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -132.57 68.46 79.31 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.968 179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -57.11 -26.66 70.29 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.603 2.202 . . . . 0.0 112.344 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -68.02 -33.49 74.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.535 HD12 ' CB ' ' A' ' 72' ' ' ARG . 13.9 mt -59.7 135.69 57.76 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.925 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 m -81.81 -31.2 31.87 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.921 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 110.47 160.65 17.69 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.528 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.6 mtt -130.3 153.2 48.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.774 0.321 . . . . 0.0 110.951 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.584 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -97.85 141.37 16.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.062 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.795 HD21 HG23 ' A' ' 178' ' ' VAL . 4.3 tt -107.49 140.67 40.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.853 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.462 ' N ' HD23 ' A' ' 80' ' ' LEU . 1.4 mm-40 -110.53 118.59 36.65 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.797 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.473 ' HA ' HG21 ' A' ' 178' ' ' VAL . 35.4 mp0 -74.41 75.01 1.91 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.841 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.48 174.19 49.32 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.537 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -162.73 157.72 18.66 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.23 -168.22 0.33 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.576 2.184 . . . . 0.0 112.288 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -85.29 111.65 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 140.7 -30.64 2.28 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.469 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.86 115.55 3.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.5 t -94.74 112.85 28.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.086 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.8 m -96.43 159.73 14.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.787 ' O ' HG22 ' A' ' 151' ' ' VAL . 22.7 t -137.22 111.59 8.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.884 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 93' ' ' LEU . 22.3 t -75.19 158.97 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.058 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.537 HD22 ' HD1' ' A' ' 13' ' ' TRP . 9.2 mt -114.97 102.05 9.59 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.775 HG23 ' CG ' ' A' ' 145' ' ' ASP . 29.4 mt -106.63 128.72 61.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.093 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 15.3 tttp -137.39 161.77 35.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mpp_? -132.94 -176.95 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.95 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -71.18 -38.34 72.14 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.859 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -69.2 -27.86 65.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.38 24.81 6.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.542 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -91.35 91.49 8.17 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.897 0.38 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.613 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.83 157.41 37.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 6.9 tp -150.46 87.64 4.82 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.004 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.99 100.57 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.728 2.286 . . . . 0.0 112.328 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.894 HD22 HG21 ' A' ' 130' ' ' THR . 25.0 mt -81.24 163.48 22.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.937 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -130.04 115.52 17.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.999 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.558 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.3 t -128.36 129.51 69.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.244 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 22.8 mtt85 -82.58 145.28 29.8 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.927 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.1 mmt -79.31 128.31 33.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.904 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -89.51 -135.24 5.61 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.57 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.15 157.81 21.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.844 0.354 . . . . 0.0 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.765 HG23 ' NE2' ' A' ' 124' ' ' GLN . 4.7 mt -85.2 117.22 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.118 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.5 151.04 47.02 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.1 p -87.37 114.21 23.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.88 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -97.06 145.12 26.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.855 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -111.94 132.86 54.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.8 mp -137.87 115.72 12.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 60.58 31.32 20.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.93 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 79.83 30.92 41.59 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.456 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -132.45 109.91 10.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.896 0.379 . . . . 0.0 110.935 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 52.0 mt -73.1 135.9 44.84 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.92 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.418 HG22 ' N ' ' A' ' 122' ' ' HIS . 9.9 p -147.68 154.46 11.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.108 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.418 ' N ' HG22 ' A' ' 121' ' ' VAL . 37.8 m80 -102.27 130.41 48.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.871 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -154.28 155.97 26.54 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . 0.765 ' NE2' HG23 ' A' ' 111' ' ' ILE . 2.2 mp0 -107.1 132.32 53.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.906 0.384 . . . . 0.0 110.846 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.7 t -88.63 -178.8 5.9 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' O ' HG23 ' A' ' 173' ' ' THR . . . 179.86 138.88 3.52 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.523 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.477 ' O ' HG13 ' A' ' 106' ' ' VAL . 14.4 ttm -87.88 131.44 34.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.758 0.313 . . . . 0.0 110.96 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.556 HD11 HG13 ' A' ' 174' ' ' VAL . 6.1 mt -74.57 138.89 43.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.806 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.34 47.19 2.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.894 HG21 HD22 ' A' ' 104' ' ' LEU . 0.2 OUTLIER -133.88 -45.03 0.8 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.915 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 132' ' ' ALA . . . -156.44 -107.87 0.27 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.857 -0.687 . . . . 0.0 112.412 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.432 ' HB1' ' OD1' ' A' ' 172' ' ' ASN . . . 176.91 39.96 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.021 0.439 . . . . 0.0 110.941 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.416 ' HB3' ' HA3' ' A' ' 140' ' ' GLY . 31.4 m-80 -69.09 174.87 4.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.875 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -178.65 121.55 0.09 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.213 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 2.1 ttmm -123.3 -3.97 8.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.44 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 95.61 -38.66 3.05 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.465 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.7 mtm -123.56 26.23 7.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.819 0.342 . . . . 0.0 111.09 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.795 ' OD1' HD23 ' A' ' 139' ' ' LEU . 1.2 t70 178.86 166.83 0.91 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.184 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.96 HD22 ' CE1' ' A' ' 164' ' ' HIS . 1.1 pt? -48.99 -29.45 4.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.137 0.494 . . . . 0.0 110.604 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.416 ' HA3' ' HB3' ' A' ' 133' ' ' ASN . . . 118.53 34.34 1.1 Allowed Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.55 -0.75 . . . . 0.0 112.663 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.657 HG21 ' HB3' ' A' ' 145' ' ' ASP . 1.0 OUTLIER -77.63 144.57 37.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.75 0.31 . . . . 0.0 110.793 179.859 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.463 ' N ' ' CD ' ' A' ' 143' ' ' PRO . 8.9 mm -86.55 -47.22 0.53 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.6 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.463 ' CD ' ' N ' ' A' ' 142' ' ' ILE . 17.2 Cg_exo -70.86 47.72 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.472 0 C-N-CA 123.043 2.496 . . . . 0.0 112.785 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.31 40.67 6.14 Favored Glycine 0 CA--C 1.517 0.208 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.89 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.775 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.2 OUTLIER -86.71 56.73 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.167 0.508 . . . . 0.0 110.843 -179.846 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.407 ' O ' ' CA ' ' A' ' 22' ' ' GLY . 74.6 m -103.41 128.75 50.48 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.889 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 96.2 -0.03 61.82 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.056 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -47.21 140.04 7.12 Favored Pre-proline 0 CA--C 1.529 0.166 0 CA-C-N 116.839 0.32 . . . . 0.0 111.182 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.466 ' HG3' ' CD1' ' A' ' 25' ' ' PHE . 84.2 Cg_endo -84.87 152.94 11.35 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.62 2.213 . . . . 0.0 112.783 -179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.861 ' O ' HG23 ' A' ' 160' ' ' VAL . 6.1 m-85 -99.94 157.78 16.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.687 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 91' ' ' SER . 26.9 m -144.91 152.65 14.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.091 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.422 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 52.8 p-80 -167.32 152.78 7.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.935 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 21.8 tttt -82.46 129.64 34.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.198 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.494 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -129.64 98.34 4.8 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.372 179.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.36 -106.81 2.12 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.058 -179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -115.37 36.57 3.88 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.915 0.388 . . . . 0.0 110.305 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -167.98 -170.94 1.44 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.96 -0.563 . . . . 0.0 110.878 -179.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.422 ' CZ3' ' HA ' ' A' ' 152' ' ' HIS . 8.5 m95 -126.74 127.94 45.87 Favored 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.517 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.584 HG13 ' O ' ' A' ' 79' ' ' VAL . 16.3 t -109.99 145.01 17.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.428 -179.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.861 HG23 ' O ' ' A' ' 150' ' ' TYR . 9.8 p -94.9 132.43 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.903 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.9 t -80.51 -74.67 0.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.113 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -157.39 -144.6 3.98 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.601 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.0 m -133.45 164.19 35.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.788 0.328 . . . . 0.0 111.013 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.96 ' CE1' HD22 ' A' ' 139' ' ' LEU . 0.3 OUTLIER -72.94 101.79 3.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.739 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 177' ' ' ALA . . . -88.55 -68.55 0.76 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.122 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 172.09 16.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.26 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.11 159.65 14.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.127 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -92.17 167.95 11.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.007 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.0 mttt -87.05 -9.13 56.23 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.345 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -69.92 -16.97 63.3 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.292 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 99.18 111.17 3.16 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.563 -0.827 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.432 ' OD1' ' HB1' ' A' ' 132' ' ' ALA . 95.8 m-20 61.43 70.89 0.57 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.953 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.42 HG23 ' O ' ' A' ' 126' ' ' GLY . 7.3 m -160.29 129.79 5.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.558 ' CG2' HG11 ' A' ' 106' ' ' VAL . 5.2 m -109.86 149.0 13.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.139 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.4 t -110.93 112.68 41.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.153 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -75.32 111.63 10.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.869 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 165' ' ' ALA . . . -80.37 115.29 19.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.795 HG23 HD21 ' A' ' 80' ' ' LEU . 10.9 p -138.57 158.5 30.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.479 ' N ' HG22 ' A' ' 178' ' ' VAL . 1.2 mm100 -59.7 134.38 56.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.841 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -107.55 157.07 18.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.145 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 88.86 -134.37 12.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.5 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.7 mp0 -89.76 172.52 8.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.841 0.353 . . . . 0.0 110.902 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 165.19 -73.31 0.17 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 -104.68 -31.71 9.24 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.883 0.373 . . . . 0.0 110.948 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -72.53 -31.62 65.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.977 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -59.95 104.37 0.29 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.11 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 4.1 mt -136.44 102.9 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.926 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.864 -179.98 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.3 mtp . . . . . 0 N--CA 1.485 1.297 0 CA-C-O 120.763 0.315 . . . . 0.0 111.233 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -143.62 125.52 15.23 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.883 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -106.65 128.03 53.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.898 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -97.48 -31.64 12.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.862 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -84.15 -177.62 6.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.857 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.4 m80 -127.23 -174.82 3.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -106.98 -39.52 5.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.892 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.7 87.82 15.24 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.06 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.687 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.8 Cg_exo -53.23 152.23 19.96 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.696 2.264 . . . . 0.0 112.351 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -61.32 -60.64 0.21 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.726 2.284 . . . . 0.0 112.39 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.9 m -51.04 -27.04 7.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.215 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.687 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.2 tt -64.62 -28.76 69.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.024 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.879 ' O ' HG12 ' A' ' 16' ' ' VAL . 40.5 m0 -83.7 -29.95 27.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.921 179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.32 -21.4 49.3 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.296 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.7 mtt180 -58.04 -29.72 65.58 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.844 0.354 . . . . 0.0 111.052 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.879 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.2 p -73.4 141.22 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.5 m -145.34 109.13 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.64 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.4 OUTLIER -66.42 111.32 3.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.969 0.414 . . . . 0.0 110.506 179.323 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.7 t80 -126.14 139.26 53.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.745 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.51 -123.36 27.97 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.365 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.0 m -105.86 30.82 5.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.827 0.346 . . . . 0.0 110.588 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.51 -170.26 27.06 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.6 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 21.3 m95 -129.64 146.24 51.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.684 0.278 . . . . 0.0 110.778 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.78 -162.83 12.58 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.51 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.77 ' CE2' HG11 ' A' ' 160' ' ' VAL . 1.7 t80 -151.67 147.34 26.6 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.875 0.369 . . . . 0.0 111.018 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.435 ' HB3' HD13 ' A' ' 75' ' ' LEU . 64.5 m95 -87.14 101.25 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.693 179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.544 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.8 m -79.17 -24.97 12.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.155 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.413 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -164.86 165.79 11.8 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.603 179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.413 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 30.7 Cg_endo -63.8 -14.67 44.38 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.564 2.176 . . . . 0.0 112.486 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -130.07 3.99 4.84 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.609 -179.803 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.49 HG12 ' CG2' ' A' ' 27' ' ' VAL . 48.7 t -132.69 142.53 42.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.886 0.374 . . . . 0.0 111.213 -179.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -135.37 156.52 48.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.544 HD13 ' CG1' ' A' ' 27' ' ' VAL . 28.2 pt -127.71 154.38 38.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.087 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.4 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.3 t -173.73 167.37 4.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.955 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.754 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.0 m -84.12 148.13 26.97 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.73 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.8 m -77.85 -23.72 48.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.528 -179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.754 ' H ' HG22 ' A' ' 35' ' ' THR . 7.1 t60 -73.36 -32.36 64.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.058 0.456 . . . . 0.0 110.761 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.718 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.1 m -93.17 36.03 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.697 -179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 t -106.82 113.76 62.4 Favored Pre-proline 0 C--N 1.327 -0.388 0 CA-C-N 116.552 -0.294 . . . . 0.0 111.154 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.36 -164.78 0.28 Allowed 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.608 2.205 . . . . 0.0 112.132 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 1.3 m -155.19 31.08 0.39 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.846 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.33 -30.98 4.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.0 m -89.94 147.57 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.812 0.339 . . . . 0.0 111.096 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.4 mttt -122.84 30.48 6.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 179.12 150.29 0.29 Allowed 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.688 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -125.17 133.8 52.64 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.476 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.36 35.31 0.16 Allowed 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.151 0.501 . . . . 0.0 111.432 -179.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.3 40.2 20.45 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.612 179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.23 91.98 22.11 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 120.67 0.271 . . . . 0.0 110.81 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -49.43 140.56 27.21 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.581 2.188 . . . . 0.0 112.486 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.508 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.3 mt -55.1 -26.4 37.87 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.076 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.1 t -53.37 -23.26 9.11 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.423 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.39 39.65 3.67 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.137 0.494 . . . . 0.0 110.751 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.508 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.5 mt -132.65 156.66 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.917 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.88 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.73 98.67 4.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.014 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 56' ' ' ILE . 12.2 tt -96.2 114.09 32.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.049 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -90.57 101.02 13.76 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -59.87 139.08 57.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.921 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.505 ' HB3' ' HB3' ' A' ' 62' ' ' PHE . . . -167.97 146.91 4.66 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.842 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -56.11 108.54 1.16 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.589 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 60.8 30.44 19.67 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.505 ' HB3' ' HB3' ' A' ' 59' ' ' ALA . 5.0 t80 -153.0 123.85 7.38 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.827 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.4 ' HB ' HG23 ' A' ' 34' ' ' THR . 88.3 m -131.14 112.57 12.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.935 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 31.3 mm-40 -96.23 114.11 25.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.734 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -98.72 113.31 25.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.034 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.88 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 11.5 tpp180 -110.27 103.68 12.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.632 179.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 4.3 m-85 -89.01 147.38 24.31 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.003 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.2 m -69.55 -30.32 68.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 14.5 tttp -114.06 162.18 16.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.692 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.575 ' HB3' HG23 ' A' ' 30' ' ' THR . 4.6 pttt -112.33 120.9 43.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.951 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -63.16 -30.08 71.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.809 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 8.8 ptt85 43.86 59.06 12.78 Favored Pre-proline 0 N--CA 1.464 0.228 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.457 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -84.65 40.39 0.85 Allowed 'Trans proline' 0 N--CA 1.461 -0.427 0 C-N-CA 122.713 2.275 . . . . 0.0 112.718 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.7 t0 73.87 48.55 0.14 Allowed 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.01 0.433 . . . . 0.0 110.918 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.435 HD13 ' HB3' ' A' ' 26' ' ' TRP . 28.4 mt -106.72 123.07 47.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.896 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.0 m -76.55 -30.68 57.2 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.867 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 115.8 100.35 2.24 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.86 170.15 9.5 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.867 0.365 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.467 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -128.79 141.5 46.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.047 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.713 HD21 HG12 ' A' ' 178' ' ' VAL . 10.5 tt -107.13 124.26 49.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.815 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -86.64 117.42 25.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.961 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.415 ' HA ' HG21 ' A' ' 178' ' ' VAL . 7.4 mp0 -70.46 67.63 0.35 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.821 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.33 159.72 35.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.522 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -148.87 163.12 27.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.61 0.243 . . . . 0.0 110.977 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.84 -168.25 0.31 Allowed 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.578 2.185 . . . . 0.0 112.343 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -86.92 146.49 26.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.885 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.31 -26.94 19.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.557 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.3 m -58.67 115.47 3.08 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.752 0.31 . . . . 0.0 110.904 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.7 p -85.05 146.43 6.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.859 0.361 . . . . 0.0 111.14 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 33.3 m -131.55 163.81 27.21 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.747 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.27 110.26 7.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.954 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG22 ' CE2' ' A' ' 150' ' ' TYR . 21.6 t -75.73 155.58 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.177 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.55 HD21 HG21 ' A' ' 151' ' ' VAL . 11.2 mt -112.35 101.88 10.05 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.888 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.577 HD12 ' HG ' ' A' ' 104' ' ' LEU . 10.8 mt -109.58 103.63 15.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.097 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -113.06 146.92 38.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.952 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.5 ttp180 -111.78 -177.25 3.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.916 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -73.95 -36.56 64.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 m -69.13 -25.71 64.53 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.941 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.86 24.72 6.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.548 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -99.41 91.1 4.77 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.555 HD22 ' CE3' ' A' ' 13' ' ' TRP . 2.1 mp -69.78 157.47 37.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.887 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.427 ' O ' HD12 ' A' ' 94' ' ' ILE . 9.9 tp -145.34 88.8 6.55 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.883 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -77.16 105.37 2.05 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.612 2.208 . . . . 0.0 112.314 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.577 ' HG ' HD12 ' A' ' 94' ' ' ILE . 63.4 mt -95.07 163.54 13.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.99 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -108.33 145.59 34.22 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.009 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.615 HG22 HD23 ' A' ' 128' ' ' LEU . 17.0 t -151.41 127.59 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.154 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.01 135.14 34.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 47.6 mmm -85.94 150.48 24.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.842 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -119.51 -128.7 3.77 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.497 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.1 157.78 21.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.784 0.326 . . . . 0.0 111.141 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.564 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.7 mp -73.04 144.99 12.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.105 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.56 127.42 13.52 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.065 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.4 m -87.69 96.67 10.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mtt -93.45 163.62 13.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.88 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 57.7 ttp180 -106.73 121.11 43.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.857 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.416 HD13 ' CG2' ' A' ' 121' ' ' VAL . 3.9 mp -118.1 106.37 19.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.118 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.9 mm100 60.31 31.24 20.36 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.853 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 97.1 -25.61 26.22 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.551 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.3 ttt85 -91.28 125.03 35.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 20.7 mt -80.4 142.24 34.56 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.933 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.439 HG13 ' HB2' ' A' ' 180' ' ' ALA . 21.5 t -147.75 153.96 11.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.1 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -82.38 114.21 20.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -121.2 101.51 0.79 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.455 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -66.57 122.57 17.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.898 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 59.0 m -84.07 118.59 24.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -132.55 152.68 20.33 Favored Glycine 0 N--CA 1.453 -0.214 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.479 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.9 mtt -111.52 147.04 36.21 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.843 0.354 . . . . 0.0 110.889 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 1.049 HD13 HD12 ' A' ' 139' ' ' LEU . 0.6 OUTLIER -110.46 159.75 17.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.997 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.406 HD12 ' N ' ' A' ' 129' ' ' LEU . 5.0 mp -121.2 47.93 1.75 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.796 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 6.7 m -106.73 -32.27 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.928 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 135.56 -100.15 0.34 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.513 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -150.99 70.96 1.0 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.932 0.396 . . . . 0.0 111.108 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 8.8 m-80 -109.71 99.31 8.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -136.8 122.94 20.4 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 6.2 tttp -106.97 -29.35 9.49 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.882 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.94 -27.24 1.44 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.399 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 10.7 mtt -139.13 29.52 2.24 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-O 121.243 0.544 . . . . 0.0 109.718 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 19.0 p30 -161.46 163.38 30.45 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.96 -178.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 1.049 HD12 HD13 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -139.99 55.48 1.64 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.918 0.389 . . . . 0.0 110.982 -179.936 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 156.48 -41.46 0.56 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.486 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.691 HG21 ' HB3' ' A' ' 145' ' ' ASP . 2.6 p -74.34 -175.11 2.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.751 0.31 . . . . 0.0 110.819 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.537 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -142.2 -54.41 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.892 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.537 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.92 60.33 0.58 Allowed 'Trans proline' 0 C--N 1.35 0.641 0 C-N-CA 122.871 2.381 . . . . 0.0 112.676 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.42 52.18 7.43 Favored Glycine 0 CA--C 1.518 0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 113.028 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.691 ' HB3' HG21 ' A' ' 141' ' ' THR . 1.0 OUTLIER -83.47 58.02 4.33 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.166 0.508 . . . . 0.0 110.89 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.566 ' O ' HG11 ' A' ' 38' ' ' VAL . 3.5 m -82.11 87.43 6.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.207 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.432 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 121.53 10.92 6.29 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.403 -179.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.58 ' HB2' ' OD1' ' A' ' 145' ' ' ASP . . . -44.3 132.54 4.55 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-O 120.542 0.21 . . . . 0.0 111.199 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.446 ' HG2' HD12 ' A' ' 93' ' ' LEU . 96.7 Cg_endo -80.4 129.74 7.69 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.62 2.214 . . . . 0.0 113.058 -179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.461 ' CE2' HG22 ' A' ' 92' ' ' VAL . 5.1 m-85 -86.41 154.21 21.34 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.494 179.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 160' ' ' VAL . 28.6 m -142.08 157.32 20.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.091 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.408 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 30.1 p-80 -170.64 167.28 7.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.413 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 25.6 tttt -91.34 129.84 37.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.157 -179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.515 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -130.39 92.43 3.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.451 179.602 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.42 -117.15 5.43 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.547 -0.835 . . . . 0.0 112.056 -179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 6.1 m-20 -101.35 33.22 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.903 0.382 . . . . 0.0 110.356 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.12 -170.37 1.7 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.821 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.539 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 3.8 m95 -128.56 133.05 48.27 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.493 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 154' ' ' ARG . 21.2 t -118.17 147.18 21.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.261 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.858 HG12 HG12 ' A' ' 151' ' ' VAL . 29.1 m -98.98 134.04 39.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.039 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 53.8 t -70.62 -72.52 0.2 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.899 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -166.49 -140.96 3.01 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.517 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.432 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.6 m -130.14 159.31 42.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.691 0.281 . . . . 0.0 110.962 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.2 t-80 -77.42 133.73 38.58 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 120.848 0.356 . . . . 0.0 111.094 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.13 -75.76 0.58 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.086 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -147.77 174.43 11.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.129 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.916 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -152.82 165.74 34.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.126 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.25 145.05 24.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.893 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -87.17 -15.01 39.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.295 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 5.7 t -69.98 -16.96 63.26 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.335 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -156.78 -108.59 0.28 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.558 -0.83 . . . . 0.0 112.484 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.431 ' O ' HD12 ' A' ' 128' ' ' LEU . 11.1 m120 -161.78 47.48 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.931 0.396 . . . . 0.0 110.908 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.425 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -99.45 132.2 44.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.93 -179.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.883 HG13 HD11 ' A' ' 128' ' ' LEU . 3.1 m -109.83 170.13 3.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.13 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.02 108.65 19.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -90.35 131.8 35.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.905 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.79 136.12 48.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.061 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.713 HG12 HD21 ' A' ' 80' ' ' LEU . 6.1 m -144.94 -48.33 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.121 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.434 ' N ' HG23 ' A' ' 178' ' ' VAL . 3.0 mm-40 -154.86 137.7 15.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.844 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.439 ' HB2' HG13 ' A' ' 121' ' ' VAL . . . -109.0 -171.19 1.8 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.058 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -138.51 133.31 6.2 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.554 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 4.6 tp10 -139.82 121.23 15.04 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.868 0.366 . . . . 0.0 110.921 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 75.58 28.23 61.76 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -104.23 -62.71 1.28 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.859 0.361 . . . . 0.0 110.884 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.67 -42.14 8.54 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.949 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.03 129.27 40.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.091 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -132.47 -67.09 0.66 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.966 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.189 -0.91 . . . . 0.0 110.76 -179.953 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.862 0.363 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 46.5 m170 60.42 35.48 20.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.3 m80 -168.91 119.99 0.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.91 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 7.5 t-160 -74.16 132.15 41.95 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.935 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.5 t60 -152.56 79.81 1.22 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.874 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.47 ' CE1' ' HB2' ' A' ' 8' ' ' ALA . 1.2 t-160 -74.24 -179.6 3.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.889 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.6 p-80 -172.48 35.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.905 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.575 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -60.39 149.65 76.14 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.082 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.7 Cg_exo -53.95 148.59 37.77 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.508 2.139 . . . . 0.0 112.315 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.44 -60.37 0.2 Allowed 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.578 2.185 . . . . 0.0 112.475 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.9 m -50.49 -28.03 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.309 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.578 ' CD2' HD11 ' A' ' 93' ' ' LEU . 4.5 tt -67.0 -29.1 68.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.006 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.778 ' O ' HG12 ' A' ' 16' ' ' VAL . 33.4 m0 -83.78 -32.28 25.47 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.866 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 m -73.32 -20.89 60.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.174 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.451 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 29.9 mtt180 -57.62 -34.81 69.69 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.846 0.355 . . . . 0.0 110.965 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.7 p -63.87 141.12 18.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.824 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.2 m -143.18 109.11 5.19 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.739 0.305 . . . . 0.0 111.668 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.446 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 24.5 tttt -66.25 116.64 7.52 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.416 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.6 t80 -128.05 120.65 27.92 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.711 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 64.22 -129.47 37.54 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.305 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.463 ' HB3' HG12 ' A' ' 38' ' ' VAL . 2.7 m -85.56 -19.31 31.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.752 0.31 . . . . 0.0 110.999 179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' HG21 ' A' ' 38' ' ' VAL . . . -118.87 -169.97 14.58 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.544 -179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.604 ' HE3' HG22 ' A' ' 16' ' ' VAL . 17.7 m95 -124.55 165.49 17.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.866 0.365 . . . . 0.0 110.793 -179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -130.48 -165.12 11.49 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.37 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.55 ' HB3' HD11 ' A' ' 33' ' ' ILE . 16.9 t80 -151.66 155.82 39.14 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.822 0.344 . . . . 0.0 111.122 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.436 ' CD2' ' HG3' ' A' ' 72' ' ' ARG . 46.8 m95 -99.01 97.97 9.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.726 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.707 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.84 -28.38 36.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.07 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.407 ' CB ' ' HD2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -172.57 165.92 3.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.522 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' CB ' ' A' ' 28' ' ' SER . 10.2 Cg_endo -53.65 -30.13 54.16 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.546 2.164 . . . . 0.0 112.316 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.594 HG23 ' HD3' ' A' ' 70' ' ' LYS . 1.0 OUTLIER -117.11 7.83 13.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.522 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 48.2 t -130.11 142.6 43.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.802 0.334 . . . . 0.0 111.271 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 25' ' ' PHE . 15.0 t80 -139.49 168.38 19.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.987 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.707 HG23 HG21 ' A' ' 27' ' ' VAL . 11.8 pt -147.87 154.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.074 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 12.1 t -173.44 165.48 4.68 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.827 HG21 ' CE1' ' A' ' 37' ' ' HIS . 6.2 m -84.26 167.18 16.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.634 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.778 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.4 OUTLIER -109.41 -26.4 10.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.59 -179.461 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.827 ' CE1' HG21 ' A' ' 35' ' ' THR . 3.3 p-80 -68.9 -17.13 63.92 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.611 0.243 . . . . 0.0 111.574 -179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -114.83 -19.19 6.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.698 -179.669 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.778 HG12 ' O ' ' A' ' 36' ' ' THR . 11.3 p -49.8 122.89 14.33 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-O 120.636 0.255 . . . . 0.0 111.429 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 87.1 Cg_endo -83.5 -164.71 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.485 0 C-N-CA 122.605 2.203 . . . . 0.0 112.217 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -152.35 35.7 0.52 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.818 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -107.56 -35.17 2.69 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.509 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -78.66 161.52 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 111.188 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.9 mttm -134.87 29.16 3.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.81 150.25 0.2 Allowed 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.012 0.434 . . . . 0.0 110.586 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.467 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.27 133.78 53.4 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 178.461 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.49 35.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.572 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 76.44 41.22 25.9 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.753 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 -133.42 92.81 23.22 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.732 0.301 . . . . 0.0 110.679 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_exo -48.16 139.1 21.71 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.487 2.125 . . . . 0.0 112.643 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.636 ' HA ' HD12 ' A' ' 54' ' ' ILE . 8.4 mt -54.67 -26.96 36.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.08 179.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 47.8 t -57.13 -20.26 24.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.484 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 75.0 m -121.16 40.11 3.65 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.232 0.539 . . . . 0.0 110.79 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.636 HD12 ' HA ' ' A' ' 51' ' ' LEU . 51.3 mt -129.93 158.37 42.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.931 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.926 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -126.62 93.85 3.9 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.982 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 2.6 tt -82.44 142.16 14.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.107 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.66 99.39 2.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.827 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.704 ' HG3' HG21 ' A' ' 36' ' ' THR . 1.8 tm0? -76.17 163.05 27.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.931 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.41 75.47 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.23 73.47 0.47 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 58.56 28.13 16.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.747 0.308 . . . . 0.0 111.047 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.883 ' CD2' ' HB2' ' A' ' 180' ' ' ALA . 0.5 OUTLIER -141.63 101.61 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.821 179.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 6.8 m -107.4 123.1 47.89 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.022 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -96.21 115.3 27.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.635 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -95.85 113.14 24.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.984 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.926 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 1.7 ttt-85 -107.61 103.75 13.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.57 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -82.31 153.88 25.59 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.038 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -96.37 23.41 6.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.891 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.522 ' C ' HG22 ' A' ' 30' ' ' THR . 22.2 tptp -163.78 156.46 17.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.796 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.594 ' HD3' HG23 ' A' ' 30' ' ' THR . 10.1 mmtt -90.8 95.98 10.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.646 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 3.2 tpt -86.37 -25.75 25.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.0 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.571 ' HG3' HD12 ' A' ' 75' ' ' LEU . 3.2 mmp_? -105.57 77.68 0.4 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.949 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.16 -22.67 46.65 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.603 2.202 . . . . 0.0 112.432 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -78.12 -30.59 49.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.839 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.571 HD12 ' HG3' ' A' ' 72' ' ' ARG . 41.4 mt -84.14 117.58 23.56 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 68.7 m -78.44 -69.79 0.53 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 174.31 146.37 5.62 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.52 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.34 170.21 9.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.796 0.331 . . . . 0.0 110.898 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.683 ' O ' HG22 ' A' ' 160' ' ' VAL . 27.8 t -99.24 137.88 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.997 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.854 HD12 HG23 ' A' ' 160' ' ' VAL . 3.9 tp -112.42 133.88 54.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.836 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -119.18 125.16 48.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.996 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -102.55 77.6 1.63 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.899 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.404 ' HA3' HD13 ' A' ' 111' ' ' ILE . . . 105.23 136.18 8.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.457 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.25 162.89 40.46 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 120.695 0.283 . . . . 0.0 110.878 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.0 166.56 28.75 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.523 2.149 . . . . 0.0 112.382 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -73.38 138.9 45.57 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.951 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.69 -22.76 27.61 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.579 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.0 m -53.25 145.92 12.94 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.729 0.3 . . . . 0.0 110.984 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -107.81 130.42 60.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.356 -0.383 . . . . 0.0 111.156 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -120.49 155.78 32.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.816 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.13 131.45 32.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.972 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.51 HG22 ' CE1' ' A' ' 150' ' ' TYR . 18.9 t -96.98 159.21 3.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.578 HD11 ' CD2' ' A' ' 12' ' ' LEU . 11.3 mt -121.22 106.39 11.46 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.998 HD11 HD11 ' A' ' 104' ' ' LEU . 28.7 mt -97.79 138.43 22.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.087 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -131.23 156.94 44.5 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.88 -175.38 4.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.985 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -70.87 -33.3 70.47 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -94.36 20.57 8.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.225 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 58.74 24.71 57.75 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.608 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -69.57 79.45 0.41 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.887 0.375 . . . . 0.0 110.889 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -69.79 124.5 24.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.923 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.783 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.9 tp -124.85 88.89 53.3 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.35 104.18 1.52 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.531 2.154 . . . . 0.0 112.353 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.998 HD11 HD11 ' A' ' 94' ' ' ILE . 5.3 mt -85.8 163.47 18.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.762 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -136.87 124.46 22.27 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.154 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.478 HG12 ' N ' ' A' ' 107' ' ' ARG . 15.4 t -122.94 159.97 26.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.035 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.478 ' N ' HG12 ' A' ' 106' ' ' VAL . 13.8 ttt180 -111.17 123.38 50.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.869 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 9.0 mmm -68.96 131.27 44.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -103.79 -117.91 4.4 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.518 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.08 147.08 38.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.84 0.352 . . . . 0.0 111.136 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.404 HD13 ' HA3' ' A' ' 83' ' ' GLY . 2.8 tt -96.22 141.79 14.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.043 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -144.68 129.14 17.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.108 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.06 108.1 12.31 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.881 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 2.4 mtp -91.85 163.46 14.03 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -127.46 120.54 28.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.963 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.78 115.78 32.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.17 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 13.9 mt-30 60.15 35.65 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 74.01 30.92 60.48 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.457 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.1 tpt180 -130.76 107.94 9.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.848 0.356 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.7 mt -74.69 120.65 20.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.882 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 29.2 m -130.11 169.8 20.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.071 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -106.87 127.99 53.9 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.933 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -138.17 94.87 0.22 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.454 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.02 141.86 35.52 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.827 0.346 . . . . 0.0 110.89 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.5 m -114.39 119.26 36.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -118.53 171.29 14.05 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.476 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -107.81 144.91 34.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.768 0.318 . . . . 0.0 110.916 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.901 HD23 HD13 ' A' ' 139' ' ' LEU . 0.7 OUTLIER -67.75 127.32 32.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.802 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.9 tp -114.06 47.26 1.22 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.843 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.73 -42.0 2.22 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.063 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 147.95 47.45 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.507 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.19 40.76 11.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.838 0.352 . . . . 0.0 111.034 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.8 m-80 -96.31 99.26 10.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.895 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.42 140.45 20.21 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.047 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 24.5 tttt -100.8 -30.19 11.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.97 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.67 -30.75 1.81 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.464 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 6.1 mtt -138.69 31.39 2.28 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.304 0.573 . . . . 0.0 109.678 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 16.4 p30 -159.1 -173.35 4.18 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.112 -178.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.901 HD13 HD23 ' A' ' 128' ' ' LEU . 0.2 OUTLIER -98.96 29.61 3.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.98 0.419 . . . . 0.0 110.334 179.545 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.89 10.88 33.82 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.619 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.42 HG21 ' O ' ' A' ' 145' ' ' ASP . 1.7 p -76.5 133.19 39.84 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.81 0.338 . . . . 0.0 110.63 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.535 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.51 -49.02 0.33 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.835 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 15.5 Cg_exo -72.33 46.78 1.0 Allowed 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 123.04 2.494 . . . . 0.0 112.698 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 46.04 43.92 13.51 Favored Glycine 0 N--CA 1.454 -0.158 0 C-N-CA 121.121 -0.561 . . . . 0.0 112.69 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.706 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.4 OUTLIER -86.31 59.91 5.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.175 0.512 . . . . 0.0 110.861 -179.742 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 85.1 m -92.45 174.84 7.07 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.908 179.298 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 57.91 6.5 2.81 Favored Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.588 -0.815 . . . . 0.0 113.045 -179.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -51.95 148.33 10.9 Favored Pre-proline 0 C--N 1.333 -0.112 0 CA-C-N 116.973 0.386 . . . . 0.0 111.087 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.465 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 72.0 Cg_endo -74.59 135.3 19.72 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.646 2.23 . . . . 0.0 112.785 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.51 ' CE1' HG22 ' A' ' 92' ' ' VAL . 7.2 m-85 -104.09 124.46 49.11 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.426 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 160' ' ' VAL . 31.3 m -122.94 150.43 26.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.294 -179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -146.29 167.29 23.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.731 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.447 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 30.6 tptt -108.86 128.06 54.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.221 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.35 92.23 3.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.066 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.29 -106.73 2.1 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.423 -0.894 . . . . 0.0 111.568 -179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 34.0 t-20 -117.7 37.01 4.06 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.926 0.393 . . . . 0.0 109.97 179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.54 137.83 5.97 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.198 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.447 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 5.4 m95 -85.64 163.01 18.56 Favored 'General case' 0 N--CA 1.452 -0.357 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.638 179.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.422 HG12 ' N ' ' A' ' 160' ' ' VAL . 23.2 t -149.44 155.58 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.107 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.926 HG12 HG12 ' A' ' 151' ' ' VAL . 16.5 m -114.28 138.97 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.111 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.691 ' O ' HG12 ' A' ' 178' ' ' VAL . 1.7 t -90.9 -46.19 8.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.941 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 163.6 -123.7 1.21 Allowed Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.601 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 147' ' ' GLY . 7.8 m -133.62 159.81 42.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.729 0.299 . . . . 0.0 111.019 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 21.9 t-80 -68.74 139.2 55.33 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.873 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -103.61 -74.71 0.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.181 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -172.71 155.62 3.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.129 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.621 ' HB2' ' CG1' ' A' ' 174' ' ' VAL . . . -108.72 177.83 4.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.158 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.466 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.16 174.47 7.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.466 ' H ' HG22 ' A' ' 168' ' ' THR . 76.1 tttt -87.1 -55.74 3.68 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.985 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 8.5 p -123.98 16.64 9.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.236 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -106.3 -25.17 6.48 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.631 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.8 m120 60.85 61.66 1.61 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.923 0.392 . . . . 0.0 110.828 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 29.9 m -148.57 129.08 13.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.661 HG21 ' CD2' ' A' ' 139' ' ' LEU . 4.5 m -109.83 161.11 8.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.083 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.7 t -110.99 131.78 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.071 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -92.84 114.82 27.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.88 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.505 ' HB1' ' CD1' ' A' ' 62' ' ' PHE . . . -73.99 116.3 14.46 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.035 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 161' ' ' CYS . 18.9 m -139.72 179.6 2.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.103 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER 59.97 102.8 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.822 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.883 ' HB2' ' CD2' ' A' ' 62' ' ' PHE . . . -142.19 152.51 43.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.156 179.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 59.77 168.86 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.47 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tt0 -107.62 48.07 0.86 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.938 0.399 . . . . 0.0 110.848 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -99.33 -27.52 8.09 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.623 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -86.47 -30.63 21.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.775 0.322 . . . . 0.0 110.873 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -93.31 47.58 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -136.97 102.87 4.98 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 5.4 mt -60.24 -33.01 71.69 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.939 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.895 -179.998 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 9.0 ptt? . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.831 0.348 . . . . 0.0 111.126 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -137.49 150.86 47.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.9 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 24.7 m-70 -72.82 154.0 40.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.951 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -133.53 97.09 3.85 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 63.7 m80 -106.92 85.63 2.18 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.951 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t60 -96.46 137.1 36.04 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 m170 -171.25 146.75 2.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.885 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.753 ' HB1' HD13 ' A' ' 12' ' ' LEU . . . -79.75 149.77 71.49 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.013 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.417 ' HD2' HD13 ' A' ' 12' ' ' LEU . 37.5 Cg_endo -66.52 171.78 10.15 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.548 2.166 . . . . 0.0 112.295 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -58.11 -60.31 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.724 2.283 . . . . 0.0 112.643 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.7 m -46.14 -30.4 1.91 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.37 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.753 HD13 ' HB1' ' A' ' 8' ' ' ALA . 4.6 tt -70.23 -35.65 73.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.998 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.818 ' O ' HG12 ' A' ' 16' ' ' VAL . 88.3 m95 -83.4 -30.23 27.51 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.908 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 t -75.1 -20.82 59.29 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.237 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.465 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 19.4 mtt85 -58.11 -32.06 67.74 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.774 0.321 . . . . 0.0 110.889 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 13' ' ' TRP . 11.8 p -68.59 141.15 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.898 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 m -142.11 109.23 5.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.806 0.336 . . . . 0.0 111.7 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.464 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.42 111.52 3.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.671 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -122.73 134.85 54.44 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.782 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 54.29 -117.8 8.3 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.389 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.3 m -109.97 34.0 4.11 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.863 0.363 . . . . 0.0 110.466 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.401 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -162.34 -170.1 26.66 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' HE3' HG22 ' A' ' 16' ' ' VAL . 26.4 m95 -134.74 141.93 46.62 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.726 0.298 . . . . 0.0 110.497 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -163.17 12.7 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.404 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.465 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.3 t80 -150.48 146.09 26.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.343 . . . . 0.0 110.948 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.432 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 64.8 m95 -79.76 94.78 5.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.1 m -73.85 -25.43 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.058 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.513 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.2 p -163.28 163.67 16.57 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -55.63 -26.94 58.08 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.563 2.175 . . . . 0.0 112.427 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.432 HG22 ' O ' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -124.0 6.06 8.62 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.71 -179.609 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' A' ' 27' ' ' VAL . 35.4 t -127.46 142.5 43.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-O 120.864 0.364 . . . . 0.0 111.248 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -138.14 159.4 42.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.973 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.554 ' CG2' HG11 ' A' ' 27' ' ' VAL . 31.7 pt -124.54 160.0 29.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.194 -179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.81 167.45 4.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.814 HG21 ' CE1' ' A' ' 37' ' ' HIS . 10.7 m -83.99 167.35 16.99 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.504 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.889 ' O ' HG12 ' A' ' 39' ' ' VAL . 8.7 m -89.23 -37.85 14.67 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.76 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.814 ' CE1' HG21 ' A' ' 35' ' ' THR . 6.5 p-80 -73.36 -21.05 60.62 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.712 0.291 . . . . 0.0 111.404 -179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.545 HG22 ' HB ' ' A' ' 35' ' ' THR . 24.2 m -82.19 -32.18 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.435 0 CA-C-N 116.309 -0.405 . . . . 0.0 112.081 -179.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.889 HG12 ' O ' ' A' ' 36' ' ' THR . 11.7 p -51.67 118.47 11.5 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.624 -0.262 . . . . 0.0 111.507 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -83.8 -165.1 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.59 2.193 . . . . 0.0 112.25 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 t -152.66 30.41 0.52 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -109.35 -20.57 7.76 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.612 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 27.6 m -104.28 164.53 3.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.337 . . . . 0.0 111.127 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 2.5 pttt -136.69 34.38 2.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.72 150.15 0.64 Allowed 'General case' 0 CA--C 1.516 -0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.711 179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.454 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -124.42 133.81 53.28 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.274 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER 39.89 35.69 0.24 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.412 -179.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 75.3 37.83 40.88 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.675 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.86 125.2 25.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.628 0.252 . . . . 0.0 110.62 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.34 130.19 17.05 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.37 2.047 . . . . 0.0 112.453 -179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.418 ' HA ' HD12 ' A' ' 54' ' ' ILE . 5.8 mt -50.8 -26.58 5.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.17 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.2 p -62.87 -15.72 55.83 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.504 -179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.29 39.68 3.65 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.212 0.529 . . . . 0.0 110.802 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 52.3 mt -132.36 158.29 43.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.95 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.65 128.68 54.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.081 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.6 mt -112.74 142.16 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.154 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -161.25 109.64 1.54 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.518 ' NE2' HG21 ' A' ' 36' ' ' THR . 21.8 mt-30 -77.42 169.74 17.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.936 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.19 48.57 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.528 ' HA3' HG11 ' A' ' 121' ' ' VAL . . . 65.83 86.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.491 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER 59.24 29.07 18.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.42 ' CD2' ' HG3' ' A' ' 179' ' ' GLN . 1.1 t80 -142.55 101.62 3.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.78 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.418 HG22 ' HD1' ' A' ' 65' ' ' PHE . 41.0 m -95.94 116.2 28.58 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -96.21 117.3 30.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.633 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.418 ' HD1' HG22 ' A' ' 63' ' ' THR . 2.5 m-85 -111.87 113.37 25.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.934 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.783 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 32.7 mtm180 -107.39 103.79 13.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.674 179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.432 ' O ' HG22 ' A' ' 30' ' ' THR . 6.6 m-85 -81.22 147.57 29.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.021 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 51.8 m -76.74 -28.12 55.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.783 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.93 151.89 22.62 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.793 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 32.3 mttp -96.18 115.04 26.81 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.504 179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.432 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 0.0 OUTLIER -86.22 -26.47 25.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.003 -179.798 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.8 mtt-85 -122.52 78.3 46.36 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.63 -18.19 46.3 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.655 2.236 . . . . 0.0 112.472 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -94.5 39.13 1.09 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.102 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 21.5 mt -134.02 152.12 51.71 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.928 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.05 -40.58 2.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.94 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.58 138.01 3.68 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.534 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 11.3 mmm -95.76 162.42 13.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.789 0.328 . . . . 0.0 110.936 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 159' ' ' VAL . 20.2 t -93.69 139.79 17.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.028 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.36 122.95 47.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.91 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.439 ' HG2' HG11 ' A' ' 159' ' ' VAL . 1.2 mm-40 -92.4 106.79 18.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.909 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.519 ' HA ' HG21 ' A' ' 178' ' ' VAL . 0.9 OUTLIER -78.96 70.25 5.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.841 179.98 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.7 148.66 15.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.495 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 3.6 m -156.15 158.53 31.62 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 120.688 0.28 . . . . 0.0 110.839 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -71.24 177.95 6.02 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.519 2.146 . . . . 0.0 112.361 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -82.47 120.26 25.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.885 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.96 -27.97 3.11 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.516 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.5 m -59.28 115.5 3.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.77 0.319 . . . . 0.0 110.877 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -94.52 108.27 20.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.939 0.399 . . . . 0.0 111.076 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 11.9 m -84.71 171.73 12.11 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.926 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.416 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.22 116.5 12.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.944 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.846 HG11 ' CE1' ' A' ' 164' ' ' HIS . 16.5 t -80.44 143.14 12.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.057 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.799 HD11 HG13 ' A' ' 151' ' ' VAL . 1.0 OUTLIER -105.35 86.47 2.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.958 -179.966 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.507 HD12 HD11 ' A' ' 104' ' ' LEU . 27.7 mt -110.17 94.67 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -83.65 -178.49 7.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.956 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -143.21 173.0 11.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.871 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.67 -36.33 65.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.02 -25.13 64.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.001 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.05 24.74 6.76 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.528 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -104.66 95.1 5.67 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.783 0.325 . . . . 0.0 110.815 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.41 HD22 ' CE3' ' A' ' 13' ' ' TRP . 3.8 mt -69.86 127.31 32.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.837 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.522 HD23 HD21 ' A' ' 104' ' ' LEU . 3.3 tp -108.4 86.0 3.18 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.973 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -75.1 84.89 1.6 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.549 2.166 . . . . 0.0 112.293 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.522 HD21 HD23 ' A' ' 102' ' ' LEU . 49.6 mt -66.76 163.42 19.27 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.585 ' HB3' ' OG1' ' A' ' 130' ' ' THR . . . -132.48 133.15 43.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.114 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.72 HG21 ' OH ' ' A' ' 150' ' ' TYR . 21.8 t -140.14 142.1 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.071 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 11.5 ttt180 -91.79 129.9 37.67 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.6 mmt -69.1 148.8 49.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -112.78 -132.51 5.73 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.13 157.77 21.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.837 0.351 . . . . 0.0 111.125 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.568 ' H ' HD12 ' A' ' 111' ' ' ILE . 3.9 mp -81.92 128.86 38.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.102 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -131.38 141.38 49.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.068 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.665 ' HB3' HD11 ' A' ' 120' ' ' LEU . 1.3 m -91.0 115.71 28.22 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.882 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.659 ' O ' HD13 ' A' ' 120' ' ' LEU . 2.3 mtt -104.9 162.78 13.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.865 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.6 ttp180 -127.43 121.46 30.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -140.13 128.56 25.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.191 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 71.7 mm-40 60.25 35.86 20.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.942 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 65.38 28.43 73.57 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.455 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -134.46 107.85 7.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.346 . . . . 0.0 110.934 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.665 HD11 ' HB3' ' A' ' 113' ' ' SER . 0.1 OUTLIER -64.51 119.1 9.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.846 -179.969 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.528 HG11 ' HA3' ' A' ' 60' ' ' GLY . 31.3 m -115.42 175.56 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.093 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -127.38 119.43 26.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.886 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -136.47 143.85 15.38 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.463 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -102.68 154.51 19.08 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.864 0.364 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.31 -177.34 6.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.89 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -176.55 101.43 0.16 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.56 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.55 ' O ' HG13 ' A' ' 106' ' ' VAL . 2.0 mtt -88.31 141.75 28.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.786 0.327 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 132' ' ' ALA . 3.1 mp -59.54 150.51 26.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.975 -179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 11.3 tp -152.8 47.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.864 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.585 ' OG1' ' HB3' ' A' ' 105' ' ' ALA . 90.4 m -142.2 -70.67 0.34 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.9 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -152.75 25.93 0.83 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.611 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.519 ' HA ' HD22 ' A' ' 128' ' ' LEU . . . 61.62 30.83 18.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.777 0.322 . . . . 0.0 111.102 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.442 ' O ' HD21 ' A' ' 128' ' ' LEU . 3.3 m-80 -70.19 95.68 1.02 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.848 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -152.63 148.37 27.24 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.053 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 10.4 tptm -99.33 -29.3 12.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 144.9 -27.77 1.89 Allowed Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.385 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 17.6 mtp -138.74 32.22 2.24 Favored 'General case' 0 N--CA 1.451 -0.412 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.466 ' CG ' HG22 ' A' ' 141' ' ' THR . 2.5 p30 -162.54 -175.11 4.31 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.067 -178.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.866 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -100.3 28.23 5.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.867 179.847 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.41 87.59 1.93 Allowed Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.756 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.466 HG22 ' CG ' ' A' ' 138' ' ' ASP . 0.6 OUTLIER -145.3 166.9 24.21 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.823 0.344 . . . . 0.0 110.962 179.978 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.516 ' N ' HD12 ' A' ' 142' ' ' ILE . 0.5 OUTLIER -145.82 -53.17 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.738 179.887 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.506 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 1.3 Cg_endo -85.61 23.41 0.84 Allowed 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 122.938 2.425 . . . . 0.0 112.924 -179.44 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 91.43 37.29 6.24 Favored Glycine 0 N--CA 1.453 -0.222 0 C-N-CA 120.589 -0.815 . . . . 0.0 112.504 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.505 ' OD1' HG23 ' A' ' 94' ' ' ILE . 4.0 m-20 -89.7 56.29 3.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.985 0.421 . . . . 0.0 110.835 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 m -107.67 156.74 18.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.405 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 77.05 1.39 73.55 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.539 -0.838 . . . . 0.0 112.802 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.44 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -45.87 134.54 6.62 Favored Pre-proline 0 CA--C 1.531 0.225 0 CA-C-N 116.788 0.294 . . . . 0.0 111.135 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.638 ' O ' HD12 ' A' ' 93' ' ' LEU . 12.0 Cg_exo -70.71 149.19 60.42 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.606 2.204 . . . . 0.0 112.562 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.6 m-85 -104.27 133.65 48.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.429 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.799 HG13 HD11 ' A' ' 93' ' ' LEU . 30.6 m -133.38 151.33 33.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.884 0.373 . . . . 0.0 111.134 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.426 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 52.9 p-80 -159.75 167.28 28.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.711 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.42 ' HB2' ' CE2' ' A' ' 158' ' ' TRP . 19.3 tttp -106.44 137.4 44.48 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.889 0.376 . . . . 0.0 111.361 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 12.8 mtp85 -134.89 96.05 3.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.875 179.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.72 2.1 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.505 -178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -120.09 38.59 3.91 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 178.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -168.25 146.73 4.38 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.129 -179.228 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.472 ' CH2' ' HB2' ' A' ' 8' ' ' ALA . 9.7 m95 -99.21 148.53 24.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.626 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.548 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.1 t -131.53 141.04 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.407 -0.36 . . . . 0.0 111.245 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.6 p -96.01 128.06 47.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.044 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 42.5 t -80.03 -80.2 0.13 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.068 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -151.83 -140.36 3.12 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.719 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 2.5 m -136.41 159.0 38.27 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-O 120.825 0.345 . . . . 0.0 111.116 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.846 ' CE1' HG11 ' A' ' 92' ' ' VAL . 11.6 m170 -67.22 101.77 0.96 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.671 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -85.85 -67.06 0.83 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.196 -179.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -171.57 174.41 4.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.279 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.59 155.8 19.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.132 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.24 179.87 5.43 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.887 179.987 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 2.9 tppp? -60.99 -23.84 65.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 21.1 t -70.07 -17.16 63.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.482 -0.327 . . . . 0.0 111.267 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 83.32 -55.64 5.04 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.625 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.511 ' HA ' HD13 ' A' ' 128' ' ' LEU . 22.1 m-20 -92.93 50.54 1.57 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.993 0.425 . . . . 0.0 111.014 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 3.4 m -160.25 116.36 2.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.801 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.866 HG21 HD23 ' A' ' 139' ' ' LEU . 3.6 m -116.46 167.21 9.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.194 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.493 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.2 t -111.02 110.73 33.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.034 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 3.2 t -80.35 117.43 21.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -71.38 109.35 5.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.991 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.519 HG21 ' HA ' ' A' ' 82' ' ' GLU . 11.6 p -119.31 158.53 20.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.066 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.49 ' N ' HG22 ' A' ' 178' ' ' VAL . 30.3 mt-30 -96.62 178.01 5.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.868 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 82' ' ' GLU . . . 59.9 -171.12 0.13 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.128 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.09 28.16 3.45 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.496 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . 0.4 ' HB2' ' HB2' ' A' ' 186' ' ' ALA . 4.0 pt-20 -61.46 -178.08 0.12 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 166.77 -87.48 0.1 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -87.32 -31.43 20.19 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -98.7 31.48 2.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.4 ' HB2' ' HB2' ' A' ' 182' ' ' GLU . . . -85.02 133.85 34.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.9 mp -90.29 -32.83 16.36 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.208 -0.901 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 mtt . . . . . 0 N--CA 1.485 1.3 0 CA-C-O 120.784 0.326 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.4 m-70 60.85 156.7 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 60.46 100.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -108.28 136.22 48.29 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.925 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.7 m170 -164.51 -177.81 5.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . 0.401 ' CD2' ' O ' ' A' ' 103' ' ' PRO . 18.7 m170 60.47 64.46 1.2 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.828 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 27.9 t-80 -177.29 106.48 0.06 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.902 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.713 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -93.08 149.1 36.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.146 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.643 ' HD2' HD13 ' A' ' 12' ' ' LEU . 54.2 Cg_exo -52.0 159.93 3.5 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.614 2.21 . . . . 0.0 112.406 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.7 -60.04 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.64 2.226 . . . . 0.0 112.531 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 71.6 m -50.86 -26.92 6.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.286 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.643 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.1 tt -65.47 -51.39 60.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.938 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.713 ' HE1' ' HB3' ' A' ' 8' ' ' ALA . 34.3 m0 -60.36 -28.4 68.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.722 179.761 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.48 -20.27 44.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.474 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HB3' ' CD1' ' A' ' 25' ' ' PHE . 0.4 OUTLIER -82.99 -29.65 28.78 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 121.064 0.459 . . . . 0.0 110.437 179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.761 HG12 ' HE3' ' A' ' 23' ' ' TRP . 5.5 t -69.87 106.77 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.616 179.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.4 m -122.14 112.8 18.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.91 0.386 . . . . 0.0 111.766 -179.298 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.442 ' HG3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.49 111.51 3.62 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.501 179.406 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -122.37 144.88 48.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.877 -179.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 47.29 -100.57 0.03 OUTLIER Glycine 0 C--N 1.331 0.278 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.744 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m -120.43 -8.26 9.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.567 0.223 . . . . 0.0 111.46 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.431 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -135.66 156.85 22.99 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.814 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.761 ' HE3' HG12 ' A' ' 16' ' ' VAL . 42.4 m95 -85.47 147.25 26.56 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.884 0.373 . . . . 0.0 110.985 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -118.01 -162.02 12.19 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.128 179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.507 ' HB3' HD11 ' A' ' 33' ' ' ILE . 3.5 t80 -151.68 145.19 24.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.882 0.373 . . . . 0.0 111.052 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.616 ' HB3' HD13 ' A' ' 75' ' ' LEU . 89.4 m95 -93.53 106.85 18.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.715 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.505 HG13 HG12 ' A' ' 33' ' ' ILE . 3.5 m -84.2 -26.59 7.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.201 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 1.6 m -160.0 153.29 18.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.763 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -50.74 -24.03 12.44 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.552 2.168 . . . . 0.0 112.68 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.473 HG23 ' CA ' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -121.15 9.18 10.43 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.546 -179.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.501 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.5 t -131.45 139.41 50.82 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.948 0.404 . . . . 0.0 111.348 -179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.42 ' CD1' ' CD2' ' A' ' 26' ' ' TRP . 5.7 t80 -133.79 146.18 50.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.0 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.84 HD13 ' CD1' ' A' ' 80' ' ' LEU . 4.8 pt -126.61 152.33 34.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.078 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.0 t -173.17 167.25 4.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.008 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.786 HG22 ' H ' ' A' ' 37' ' ' HIS . 85.2 m -84.33 142.79 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.697 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.44 ' HA ' ' CG2' ' A' ' 39' ' ' VAL . 11.7 m -74.94 -19.82 59.95 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.665 -179.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.786 ' H ' HG22 ' A' ' 35' ' ' THR . 10.3 t60 -73.29 -25.07 60.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 111.436 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -109.84 36.52 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.805 0.336 . . . . 0.0 111.769 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.44 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 49.0 t -103.03 120.36 52.54 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.999 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -83.37 -164.76 0.28 Allowed 'Trans proline' 0 N--CA 1.46 -0.477 0 C-N-CA 122.681 2.254 . . . . 0.0 112.212 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.424 HG22 ' O ' ' A' ' 41' ' ' THR . 7.5 m -159.95 30.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.958 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.81 -30.83 3.58 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.2 m -90.65 150.45 3.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.84 0.353 . . . . 0.0 111.13 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 22.1 mttt -118.36 33.76 5.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -179.92 150.24 0.38 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.772 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -124.12 133.75 53.52 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.357 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 39.1 35.56 0.14 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.144 0.497 . . . . 0.0 111.45 -179.271 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 80.85 38.28 16.65 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.639 179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.501 ' O ' HD11 ' A' ' 54' ' ' ILE . 17.2 mm-40 -132.48 91.2 31.4 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 120.622 0.249 . . . . 0.0 110.808 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -50.38 140.34 34.94 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.615 2.21 . . . . 0.0 112.513 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.6 mt -58.18 -26.31 62.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.025 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.89 -23.87 7.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.469 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 1.5 m -122.62 40.41 3.69 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.201 0.524 . . . . 0.0 110.81 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.501 HD11 ' O ' ' A' ' 49' ' ' GLU . 59.4 mt -134.86 158.41 41.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.943 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.891 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -124.7 120.74 32.69 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.971 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.5 mt -99.83 121.83 50.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.082 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 1.8 m170 -113.45 99.46 7.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 9.0 pt20 -73.53 126.24 29.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -155.59 77.25 0.97 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.059 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.57 -119.34 17.78 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.473 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.8 mp0 -98.69 30.3 3.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.811 0.338 . . . . 0.0 110.899 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.426 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 15.3 t80 -135.24 113.28 11.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.813 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 27.2 m -108.93 111.81 23.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.947 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.8 tt0 -96.3 113.84 25.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.779 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -98.82 113.27 25.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.891 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 3.1 tpm_? -101.82 103.76 14.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.678 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -85.82 149.7 25.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.046 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 11.5 p -96.78 24.5 6.04 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.419 ' C ' HG23 ' A' ' 30' ' ' THR . 9.1 tttp -158.47 139.78 13.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.804 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.473 ' CA ' HG23 ' A' ' 30' ' ' THR . 36.9 mttt -87.98 90.87 8.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.743 179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 9.6 tpt -69.27 -54.73 13.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.578 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.432 ' N ' ' HD3' ' A' ' 73' ' ' PRO . 1.3 ttt-85 47.14 60.13 15.52 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.381 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . 0.432 ' HD3' ' N ' ' A' ' 72' ' ' ARG . 50.2 Cg_exo -53.23 -35.77 75.1 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.439 2.093 . . . . 0.0 111.963 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -173.29 35.59 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.583 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.616 HD13 ' HB3' ' A' ' 26' ' ' TRP . 2.0 mt -102.89 -170.02 1.74 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.037 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.1 m -153.35 -45.44 0.09 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.769 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 149.01 90.53 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.41 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . 0.439 ' HE3' ' HE2' ' A' ' 25' ' ' PHE . 1.5 mmm -95.83 170.25 9.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.883 0.373 . . . . 0.0 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 16.6 t -117.23 141.48 35.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.042 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.84 ' CD1' HD13 ' A' ' 33' ' ' ILE . 9.5 tt -128.6 113.6 15.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.989 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -108.11 147.79 30.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.951 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -94.63 124.21 38.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 71.99 166.72 8.63 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.488 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.5 m -164.42 163.63 14.64 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.13 -172.72 0.76 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.535 2.157 . . . . 0.0 112.284 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.07 151.02 20.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 96.5 -28.46 13.2 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.469 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.6 m -59.8 115.57 3.47 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.791 0.329 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -92.82 108.51 20.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.078 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 56.7 m -84.5 174.18 10.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.033 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.13 103.47 5.13 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.767 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.765 HG22 ' CE2' ' A' ' 150' ' ' TYR . 10.3 t -60.44 142.51 15.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.14 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.577 HD11 ' CG1' ' A' ' 151' ' ' VAL . 3.5 mt -111.38 76.31 0.97 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.901 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.493 HD11 HD12 ' A' ' 104' ' ' LEU . 26.8 mt -86.83 97.25 6.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.284 -0.417 . . . . 0.0 111.133 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.469 ' HG3' HD11 ' A' ' 101' ' ' LEU . 12.6 tttt -93.63 162.22 14.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.904 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 32.6 mtp85 -138.75 172.52 12.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.947 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -75.32 -37.63 60.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.877 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.1 m -69.1 -26.96 65.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.909 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 106.12 24.62 6.79 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.608 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -104.02 83.69 2.14 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.471 HD22 ' CE2' ' A' ' 13' ' ' TRP . 8.0 mp -69.9 138.72 52.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.862 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 4.8 tp -116.07 86.35 16.78 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.902 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.401 ' O ' ' CD2' ' A' ' 6' ' ' HIS . 73.4 Cg_endo -75.92 96.39 1.06 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.666 2.244 . . . . 0.0 112.392 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 139' ' ' LEU . 36.1 mt -94.0 163.37 13.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.844 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -120.46 143.96 48.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.178 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.563 HG13 ' O ' ' A' ' 127' ' ' MET . 24.1 t -151.56 140.29 14.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.038 -179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.446 ' CZ ' HD13 ' A' ' 129' ' ' LEU . 8.5 mtm-85 -87.41 130.59 34.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.796 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.2 mmt -70.59 150.59 45.9 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -115.19 -137.43 6.3 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.445 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.23 140.31 48.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 111.033 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.564 HG23 ' O ' ' A' ' 111' ' ' ILE . 7.2 tt -85.72 113.47 23.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.12 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.97 173.16 11.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.133 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.8 p -97.42 96.22 8.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.8 mmm -80.47 150.09 29.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.889 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -99.34 117.27 33.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.969 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -127.42 119.5 52.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.133 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 60.3 31.3 20.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.969 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.73 27.76 56.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.512 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -136.47 134.64 37.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.916 0.389 . . . . 0.0 110.887 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 82.5 mt -88.12 118.42 27.68 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.945 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.45 136.32 60.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.6 t-160 -91.23 121.34 32.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -159.78 164.01 33.94 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.483 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 29.3 tt0 -98.14 139.37 34.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.867 0.365 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 72.2 m -109.75 118.7 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.881 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.37 143.37 17.98 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.493 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.563 ' O ' HG13 ' A' ' 106' ' ' VAL . 3.1 ttp -106.46 144.04 33.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.744 0.307 . . . . 0.0 110.829 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.983 HD21 HD11 ' A' ' 139' ' ' LEU . 3.2 mt -59.1 159.06 7.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.935 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.446 HD13 ' CZ ' ' A' ' 107' ' ' ARG . 17.7 tp -148.0 47.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.0 m -147.7 -69.37 0.24 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.883 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -135.05 -86.25 0.23 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.532 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -178.28 37.92 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.775 0.321 . . . . 0.0 110.996 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.528 ' O ' HD11 ' A' ' 128' ' ' LEU . 26.8 m-80 -69.63 129.14 38.82 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -179.26 116.65 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.123 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.27 -25.72 17.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.93 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.61 -34.36 1.71 Allowed Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.24 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . 0.402 ' HA ' ' HA ' ' A' ' 166' ' ' ALA . 3.4 mtt -140.12 32.17 1.95 Allowed 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.6 p30 -160.07 169.36 23.52 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.88 -178.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.983 HD11 HD21 ' A' ' 128' ' ' LEU . 1.0 OUTLIER -87.48 -53.7 4.67 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.892 0.377 . . . . 0.0 111.125 179.908 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.449 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -146.73 17.51 1.62 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.88 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.568 HG21 ' H ' ' A' ' 146' ' ' CYS . 16.4 p -76.73 133.07 39.6 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-O 120.786 0.327 . . . . 0.0 110.772 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.475 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.6 OUTLIER -110.8 -52.23 0.05 OUTLIER Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.982 -179.601 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.475 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 6.9 Cg_exo -76.44 38.36 0.61 Allowed 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.89 2.393 . . . . 0.0 112.377 -179.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 57.72 50.59 64.18 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.193 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.427 ' HB2' ' HB ' ' A' ' 141' ' ' THR . 0.5 OUTLIER -75.7 -74.14 0.23 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.792 0.33 . . . . 0.0 110.878 -179.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.568 ' H ' HG21 ' A' ' 141' ' ' THR . 1.7 m 56.2 166.0 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.606 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.432 ' N ' ' HB2' ' A' ' 164' ' ' HIS . . . 83.67 -23.03 6.91 Favored Glycine 0 CA--C 1.519 0.296 0 C-N-CA 120.53 -0.843 . . . . 0.0 113.313 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.807 ' HB3' ' ND1' ' A' ' 164' ' ' HIS . . . -40.65 114.96 1.15 Allowed Pre-proline 0 N--CA 1.463 0.223 0 CA-C-N 116.924 0.362 . . . . 0.0 111.644 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.563 ' HG2' HD12 ' A' ' 93' ' ' LEU . 87.9 Cg_endo -81.71 129.0 6.21 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.603 2.202 . . . . 0.0 113.043 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.765 ' CE2' HG22 ' A' ' 92' ' ' VAL . 63.5 m-85 -78.17 118.45 20.42 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.225 179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.577 ' CG1' HD11 ' A' ' 93' ' ' LEU . 20.8 m -117.45 148.58 20.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 120.987 0.422 . . . . 0.0 111.462 -179.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.425 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 41.8 p-80 -132.41 152.47 51.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.673 179.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.407 ' HE3' ' N ' ' A' ' 157' ' ' ASP . 7.4 tptt -105.67 124.75 50.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.053 -179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 25.7 ttp85 -122.38 99.38 6.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.484 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.27 -106.77 2.11 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.075 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -118.32 37.05 4.14 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.901 0.381 . . . . 0.0 110.428 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . 0.407 ' N ' ' HE3' ' A' ' 153' ' ' LYS . 1.2 t0 -161.26 154.01 20.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.206 -179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CD2' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -117.72 148.11 42.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.642 179.698 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.425 ' HB ' ' CE1' ' A' ' 152' ' ' HIS . 16.2 t -140.0 151.79 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.367 -179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 9.2 p -100.5 151.89 5.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.968 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.6 -47.72 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.297 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -152.31 -161.71 10.39 Favored Glycine 0 N--CA 1.453 -0.168 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.638 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.632 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 6.0 m -144.62 165.12 13.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.732 0.301 . . . . 0.0 111.389 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.807 ' ND1' ' HB3' ' A' ' 148' ' ' ALA . 10.5 m170 -64.36 101.72 0.46 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.513 179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -109.86 -76.02 0.62 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.353 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.402 ' HA ' ' HA ' ' A' ' 137' ' ' MET . . . -120.06 174.46 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.294 -179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.497 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -159.81 155.26 25.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.014 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.21 162.87 14.13 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.919 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 9.9 tttp -87.02 -55.85 3.64 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.966 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -123.24 16.67 9.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.166 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -100.31 -21.4 13.28 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.631 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 61.55 65.73 0.92 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.7 m -160.17 159.06 31.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.824 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.616 HG21 HD23 ' A' ' 139' ' ' LEU . 2.9 m -141.54 171.2 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.206 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.8 t -112.05 121.95 65.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.059 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.7 m -87.12 98.22 11.18 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.885 179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.632 ' HB3' ' CG2' ' A' ' 163' ' ' VAL . . . -66.85 127.41 32.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.084 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.711 HG23 HD21 ' A' ' 80' ' ' LEU . 11.0 p -171.06 156.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.049 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.444 ' N ' HG22 ' A' ' 178' ' ' VAL . 0.0 OUTLIER -176.91 -170.1 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.975 179.944 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -149.96 121.49 7.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.092 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -83.76 109.37 3.17 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.561 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -110.16 -174.44 2.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.746 0.308 . . . . 0.0 110.919 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 106.71 -30.94 8.74 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.534 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -104.15 -33.52 8.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.911 0.386 . . . . 0.0 110.978 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . 0.571 ' O ' HG22 ' A' ' 185' ' ' THR . 29.6 m -106.33 35.6 2.89 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.89 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -146.72 97.94 2.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.105 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.676 ' O ' HD12 ' A' ' 187' ' ' LEU . 4.1 pp -134.18 125.99 29.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.889 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.892 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.7 mtt . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 120.898 0.38 . . . . 0.0 111.209 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . 0.4 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 11.8 m-70 -82.77 -179.25 7.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.4 ' CG ' ' O ' ' A' ' 2' ' ' HIS . 50.8 m-70 -163.79 -177.92 5.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.77 157.19 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.004 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -133.54 -176.5 4.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -98.72 31.21 2.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.949 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 7.2 m80 60.15 103.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.907 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.527 ' HB1' ' HE1' ' A' ' 13' ' ' TRP . . . -144.76 69.81 14.97 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.004 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.78 ' HD2' HD13 ' A' ' 12' ' ' LEU . 51.7 Cg_exo -52.85 155.4 10.97 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.568 2.179 . . . . 0.0 112.445 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -61.2 -59.34 0.32 Allowed 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.776 2.317 . . . . 0.0 112.378 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 65.5 m -54.38 -27.46 36.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.133 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.78 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.69 -29.09 69.59 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.088 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.867 ' CZ3' HD22 ' A' ' 93' ' ' LEU . 99.1 m95 -83.81 -30.92 26.16 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.05 -20.89 65.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.294 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.745 ' NE ' HD21 ' A' ' 75' ' ' LEU . 1.7 mtt180 -58.67 -39.51 80.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.859 0.362 . . . . 0.0 110.822 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.755 HG12 ' O ' ' A' ' 13' ' ' TRP . 9.8 p -60.32 124.05 13.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.645 179.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.696 HG21 ' CE2' ' A' ' 47' ' ' PHE . 4.2 m -135.86 109.32 7.91 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.872 0.368 . . . . 0.0 111.928 -179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.17 111.48 3.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.631 179.452 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.439 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 11.1 t80 -123.98 132.81 53.76 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.494 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.3 -129.4 46.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.403 -179.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.2 m -98.03 35.88 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.982 0.42 . . . . 0.0 110.479 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -168.13 -169.81 32.07 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.299 -179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.731 ' HE3' HG22 ' A' ' 16' ' ' VAL . 39.6 m95 -127.48 158.12 38.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.792 0.329 . . . . 0.0 110.598 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -131.35 -176.24 14.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.39 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.669 ' HB3' HD11 ' A' ' 33' ' ' ILE . 32.9 t80 -144.34 146.02 32.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.783 0.325 . . . . 0.0 110.94 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . . . . . . . . . 69.0 m95 -86.46 97.25 10.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.544 HG11 ' CG2' ' A' ' 33' ' ' ILE . 5.4 m -77.03 -24.41 15.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.282 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.407 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.8 OUTLIER -161.54 160.74 23.21 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.674 -179.989 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 15.5 Cg_endo -57.31 -19.68 36.02 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.561 2.174 . . . . 0.0 112.554 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.483 HG23 ' HB3' ' A' ' 70' ' ' LYS . 0.2 OUTLIER -129.28 7.09 5.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.499 -179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 27' ' ' VAL . 46.4 t -129.3 140.71 48.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.854 0.359 . . . . 0.0 111.116 -179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -135.74 148.49 48.84 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.002 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.669 HD11 ' HB3' ' A' ' 25' ' ' PHE . 38.1 pt -115.62 151.92 17.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.999 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.546 HG23 ' HB ' ' A' ' 63' ' ' THR . 11.1 t -173.41 167.35 4.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.595 ' HB ' HG22 ' A' ' 38' ' ' VAL . 7.0 m -84.12 167.35 16.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.642 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.404 ' N ' HG22 ' A' ' 35' ' ' THR . 41.4 m -90.37 -34.35 15.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.453 -0.34 . . . . 0.0 111.326 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.413 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.3 t60 -73.31 -24.09 60.35 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.057 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.595 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.9 m -80.98 -28.42 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.802 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 35' ' ' THR . 22.5 t -56.49 116.07 11.83 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.251 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 91.8 Cg_endo -83.32 -164.44 0.26 Allowed 'Trans proline' 0 N--CA 1.461 -0.415 0 C-N-CA 122.623 2.216 . . . . 0.0 112.205 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.67 39.12 0.23 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -116.98 -34.67 1.21 Allowed Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.487 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.58 161.53 3.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.1 -179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.88 30.33 6.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.891 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.94 150.23 0.76 Allowed 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.696 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.545 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -123.73 133.83 53.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.51 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.696 ' CE2' HG21 ' A' ' 17' ' ' THR . 0.1 OUTLIER 37.73 35.99 0.08 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.064 0.459 . . . . 0.0 111.396 -179.265 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.78 44.21 95.1 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.421 ' HA ' ' HD3' ' A' ' 50' ' ' PRO . 0.9 OUTLIER -126.05 142.96 44.01 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 120.625 0.25 . . . . 0.0 110.886 179.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 49' ' ' GLU . 37.9 Cg_exo -57.06 112.05 0.99 Allowed 'Trans proline' 0 C--N 1.346 0.446 0 C-N-CA 122.502 2.135 . . . . 0.0 112.509 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.578 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.9 OUTLIER -58.35 -40.96 83.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.572 179.574 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 p -67.45 -7.8 28.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.833 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.94 38.02 3.29 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-O 121.267 0.556 . . . . 0.0 110.505 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.545 HD12 ' CE1' ' A' ' 46' ' ' PHE . 44.4 mt -123.45 158.35 28.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.027 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.872 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -118.66 93.76 4.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.013 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 27.1 mt -86.76 141.76 13.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.193 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -163.18 99.38 0.95 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.782 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -108.67 153.95 22.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 48.58 0.73 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.987 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 122.96 -81.48 0.35 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.433 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 9.6 mp0 -139.84 29.76 2.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.853 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -135.22 114.36 12.22 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.752 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 ' HB ' HG23 ' A' ' 34' ' ' THR . 15.1 m -117.22 111.49 19.5 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.032 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -96.55 113.86 25.46 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.785 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -98.55 113.3 25.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.872 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.6 tpt180 -112.05 103.76 11.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.73 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -85.99 151.69 23.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.017 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 4.6 m -71.64 -29.38 64.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.737 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.9 tppp? -119.48 155.54 31.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.483 ' HB3' HG23 ' A' ' 30' ' ' THR . 2.8 pttm -104.48 116.92 32.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.897 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 4.2 tmm? -106.94 25.85 10.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.018 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.709 ' HG2' HD12 ' A' ' 75' ' ' LEU . 2.6 tpt85 -150.02 54.28 1.5 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 120.899 0.381 . . . . 0.0 110.951 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.7 -25.0 29.32 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -58.59 -29.95 66.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.894 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.745 HD21 ' NE ' ' A' ' 15' ' ' ARG . 0.8 OUTLIER -59.54 168.07 1.74 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.82 -179.966 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 56.8 m -109.08 -35.53 6.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.883 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 120.29 110.92 2.28 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.388 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 1.4 mmm -95.98 170.19 9.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.898 0.38 . . . . 0.0 110.844 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 159' ' ' VAL . 26.7 t -118.2 138.9 47.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.982 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.7 tt -120.5 105.8 11.19 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -83.62 158.14 22.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.801 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -107.73 80.84 1.43 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.958 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.5 147.61 15.91 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.472 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -143.51 162.85 39.96 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.674 0.273 . . . . 0.0 110.947 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.12 142.85 42.94 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.331 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -61.34 138.46 58.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.936 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.09 -27.98 14.32 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.509 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 31.2 m -61.06 115.33 3.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.798 0.333 . . . . 0.0 110.827 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 89' ' ' VAL . 12.3 p -78.21 126.28 38.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.948 0.404 . . . . 0.0 111.052 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 15.0 m -93.64 169.37 10.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.845 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.793 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.27 103.5 5.12 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.844 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.514 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 18.2 t -78.93 154.98 4.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.049 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.867 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 12.5 mt -117.06 98.7 6.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.922 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.804 HG23 ' CG ' ' A' ' 145' ' ' ASP . 35.4 mt -106.52 96.26 4.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.023 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -104.39 155.65 18.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.6 ttt180 -128.42 176.54 7.64 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.842 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.69 -38.18 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.57 -27.73 64.35 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.896 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.39 24.75 6.96 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.595 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.8 tt0 -92.62 84.72 5.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.709 0.29 . . . . 0.0 110.976 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.582 HD23 ' CZ3' ' A' ' 13' ' ' TRP . 6.2 mp -69.83 142.34 53.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 10.1 tp -133.45 88.68 33.96 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.979 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -76.17 106.68 2.31 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.574 2.183 . . . . 0.0 112.353 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.667 HD13 HD12 ' A' ' 139' ' ' LEU . 42.9 mt -95.75 163.39 13.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.013 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -119.59 148.52 43.23 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.498 HG11 HG23 ' A' ' 174' ' ' VAL . 22.2 t -153.07 111.79 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.101 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 5.8 ttp180 -62.71 140.67 58.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . 0.409 ' HE2' ' HA ' ' A' ' 108' ' ' MET . 10.5 mmt -75.78 150.57 37.72 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.874 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -126.99 -156.44 9.17 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.528 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -103.03 155.13 18.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.798 0.332 . . . . 0.0 111.117 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.573 HG22 ' NE2' ' A' ' 122' ' ' HIS . 3.8 mp -82.89 121.44 35.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.093 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -142.53 160.77 39.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.9 t -88.22 105.8 17.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.865 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.3 mtp -93.17 140.65 29.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.947 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.2 ttt85 -94.73 116.78 29.16 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -140.16 138.84 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.098 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 8.2 mm100 59.98 29.32 18.89 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.945 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 78.04 8.69 87.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.939 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.45 146.97 46.96 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.809 0.338 . . . . 0.0 110.953 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 24.6 mt -81.93 147.16 29.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.909 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 15.3 m -142.06 142.75 27.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.573 ' NE2' HG22 ' A' ' 111' ' ' ILE . 2.0 t-160 -84.02 111.42 19.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.902 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -141.72 153.49 24.19 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.455 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . 0.663 ' C ' HG13 ' A' ' 175' ' ' VAL . 7.8 tt0 -100.01 115.36 29.53 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.833 0.349 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.645 ' HA ' HG22 ' A' ' 175' ' ' VAL . 1.3 m -60.43 152.58 25.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -147.07 136.81 6.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.441 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 11.2 ttp -94.02 163.66 13.39 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.89 0.376 . . . . 0.0 110.834 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.586 HD21 HG22 ' A' ' 174' ' ' VAL . 4.4 mm? -108.46 140.16 42.17 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.975 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 3.6 mp -137.16 47.24 2.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.75 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 3.2 m -128.87 -43.93 1.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 176.67 -77.71 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.558 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -177.68 37.67 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.8 0.333 . . . . 0.0 111.091 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.1 m-80 -79.85 115.05 19.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.927 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -173.84 124.82 0.36 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 -28.97 13.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.936 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 145.03 -32.17 1.69 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 8.7 mtt -139.82 30.0 2.08 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-O 121.219 0.533 . . . . 0.0 109.581 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.474 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 6.7 p30 -158.65 -171.33 3.39 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.001 -178.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.873 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -97.42 36.21 1.51 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.056 0.455 . . . . 0.0 110.179 179.503 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 82.86 11.32 81.7 Favored Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.453 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.537 HG21 ' HB3' ' A' ' 145' ' ' ASP . 11.8 p -76.64 133.75 39.51 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-O 120.713 0.292 . . . . 0.0 110.972 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.549 ' H ' HD12 ' A' ' 142' ' ' ILE . 1.2 mp -91.37 -48.41 0.34 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.75 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.455 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 22.7 Cg_exo -68.94 52.8 0.76 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 123.111 2.541 . . . . 0.0 112.86 -179.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 41.96 41.51 3.63 Favored Glycine 0 CA--C 1.518 0.259 0 CA-C-N 115.961 -0.563 . . . . 0.0 113.114 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.804 ' CG ' HG23 ' A' ' 94' ' ' ILE . 0.3 OUTLIER -84.55 58.72 5.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.122 0.487 . . . . 0.0 110.953 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -94.72 167.95 11.13 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.102 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 51.28 15.77 1.87 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.8 -0.714 . . . . 0.0 113.221 -179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.434 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -53.36 146.96 20.8 Favored Pre-proline 0 C--N 1.332 -0.159 0 CA-C-N 116.994 0.397 . . . . 0.0 111.059 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.606 ' CD ' HG23 ' A' ' 16' ' ' VAL . 23.0 Cg_exo -64.55 140.6 69.65 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.566 2.177 . . . . 0.0 112.464 -179.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.514 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 9.7 m-85 -116.33 136.54 52.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.614 179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 160' ' ' VAL . 32.2 m -129.13 162.36 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.019 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 18.0 p-80 -165.11 152.04 10.65 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.779 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -76.93 123.36 26.18 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.206 -179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 5.1 ttt-85 -128.34 96.61 4.48 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.253 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.41 -106.8 2.12 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.471 -0.871 . . . . 0.0 111.897 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 62.7 t-20 -117.44 37.05 4.02 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.943 0.402 . . . . 0.0 110.173 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -165.43 -178.94 5.21 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.019 -179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . . . . . . . . . 14.9 m95 -118.72 116.1 25.87 Favored 'General case' 0 N--CA 1.453 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.614 179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -106.27 143.28 17.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.241 -179.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.845 HG12 HG12 ' A' ' 151' ' ' VAL . 18.0 m -96.25 136.63 26.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.063 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 29.6 p -83.7 -36.66 23.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.054 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 160.6 -126.71 1.65 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.805 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 7.3 m -133.53 171.02 18.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.618 0.247 . . . . 0.0 110.912 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.474 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 23.8 t-80 -73.67 138.55 44.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.84 0.352 . . . . 0.0 110.825 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -105.74 -70.76 0.77 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.136 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -167.81 174.36 7.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.107 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.514 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -117.74 163.02 17.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.056 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.494 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.1 179.87 5.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.952 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.494 ' H ' HG22 ' A' ' 168' ' ' THR . 0.0 OUTLIER -72.91 -21.83 60.84 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.194 -179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 11.2 t -70.1 -16.94 63.19 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.285 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.41 -54.46 4.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.586 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.534 ' O ' HG23 ' A' ' 173' ' ' THR . 8.4 m-80 -87.96 53.69 2.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.908 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.585 ' N ' HD23 ' A' ' 128' ' ' LEU . 2.8 p -160.28 117.82 2.53 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.862 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.873 HG21 ' CD2' ' A' ' 139' ' ' LEU . 17.3 m -133.97 144.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.08 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.76 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 21.7 t -111.08 128.29 67.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.052 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.78 132.25 36.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -74.94 128.94 36.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.099 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 9.4 p -178.43 145.98 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.038 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 36.2 tt0 59.89 79.76 0.22 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.967 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -100.99 172.76 6.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.105 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -169.76 140.48 6.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.509 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . 0.483 ' HB2' HD12 ' A' ' 187' ' ' LEU . 1.1 mt-10 -76.12 178.49 6.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.791 0.329 . . . . 0.0 110.957 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -161.95 34.21 0.35 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.511 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -89.42 -46.72 8.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 0.0 110.821 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 2.0 m -130.91 35.92 3.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.92 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 62.01 151.1 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.107 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.483 HD12 ' HB2' ' A' ' 182' ' ' GLU . 14.7 mt -153.75 131.04 11.21 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.965 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.946 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.83 0.348 . . . . 0.0 111.207 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -80.6 115.38 20.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.881 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 -101.14 -174.53 2.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.906 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.8 m-70 -98.49 -74.55 0.58 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.911 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -78.31 153.17 31.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.877 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -176.64 -40.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.887 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -84.09 -178.63 7.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.865 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.689 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -61.19 164.63 7.98 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.133 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.689 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 24.8 Cg_endo -61.97 129.17 26.43 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.614 2.209 . . . . 0.0 112.265 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.76 -61.17 0.19 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.542 2.161 . . . . 0.0 112.696 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.683 HG23 HD23 ' A' ' 75' ' ' LEU . 90.0 m -46.75 -28.9 1.67 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.551 -179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.506 HD13 ' HG2' ' A' ' 9' ' ' PRO . 4.6 tt -66.0 -39.18 90.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.015 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.69 ' O ' HG12 ' A' ' 16' ' ' VAL . 87.0 m95 -72.25 -30.98 65.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.826 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.5 -20.8 56.58 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.291 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -57.34 -34.88 69.24 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.897 0.379 . . . . 0.0 110.972 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.3 p -75.3 141.26 16.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.027 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 8.7 m -146.2 109.15 4.59 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.4 -0.363 . . . . 0.0 111.618 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.466 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 11.3 tmtt? -66.16 111.39 3.4 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.972 0.415 . . . . 0.0 110.616 179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.489 ' HE1' HG21 ' A' ' 43' ' ' VAL . 15.3 t80 -124.79 138.18 54.28 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.644 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 53.77 -125.72 33.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.401 -179.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 63.7 m -103.0 31.25 4.31 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.806 0.336 . . . . 0.0 110.481 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' HA3' HG11 ' A' ' 38' ' ' VAL . . . -162.12 -170.16 26.49 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.508 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.491 ' HE3' HG22 ' A' ' 16' ' ' VAL . 23.4 m95 -130.58 146.41 52.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.781 0.324 . . . . 0.0 110.815 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.96 -165.12 13.39 Favored Glycine 0 C--N 1.332 0.311 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.256 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 33' ' ' ILE . 2.7 t80 -151.66 147.03 26.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.455 ' CB ' HD13 ' A' ' 75' ' ' LEU . 76.0 m95 -89.73 103.84 16.45 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.806 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.539 ' CG2' HG12 ' A' ' 31' ' ' VAL . 2.8 m -84.69 -23.24 7.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.096 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.505 ' OG ' HG23 ' A' ' 31' ' ' VAL . 1.4 p -171.37 158.46 4.91 Favored Pre-proline 0 C--N 1.331 -0.223 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.645 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.78 -28.83 49.49 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.482 2.121 . . . . 0.0 112.413 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.662 HG23 ' C ' ' A' ' 69' ' ' LYS . 0.1 OUTLIER -115.19 1.25 13.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.796 -179.615 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.539 HG12 ' CG2' ' A' ' 27' ' ' VAL . 26.9 t -127.38 139.92 50.56 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-O 120.861 0.362 . . . . 0.0 111.335 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -136.65 156.45 48.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.999 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.637 HD11 ' HB3' ' A' ' 25' ' ' PHE . 44.9 pt -132.27 148.53 31.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.011 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.421 HG23 ' HB ' ' A' ' 63' ' ' THR . 10.3 t -172.36 167.39 5.72 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.742 HG22 ' H ' ' A' ' 37' ' ' HIS . 87.8 m -84.18 145.54 28.32 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.72 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.723 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -82.32 -21.15 36.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.491 -179.589 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.742 ' H ' HG22 ' A' ' 35' ' ' THR . 10.0 t60 -73.47 -31.56 63.84 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.015 0.436 . . . . 0.0 110.797 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.715 HG22 ' HB ' ' A' ' 35' ' ' THR . 33.8 m -93.65 24.58 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.535 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.939 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 36' ' ' THR . 14.2 p -88.88 115.41 63.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.559 0.219 . . . . 0.0 111.209 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -82.65 -164.19 0.26 Allowed 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.463 2.108 . . . . 0.0 112.19 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -157.35 35.85 0.28 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.871 -179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -112.97 -28.56 3.34 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.392 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.489 HG21 ' HE1' ' A' ' 19' ' ' PHE . 30.6 m -94.97 167.79 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.763 0.316 . . . . 0.0 111.158 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 18.7 mmtp -141.08 34.59 1.73 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.934 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.4 150.22 0.31 Allowed 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.657 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 65' ' ' PHE . 0.2 OUTLIER -124.28 133.76 53.4 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.361 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 39.08 35.72 0.14 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.112 0.482 . . . . 0.0 111.433 -179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.81 40.33 22.07 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.594 179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' O ' HD11 ' A' ' 54' ' ' ILE . 34.0 mm-40 -134.79 92.03 19.79 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.704 0.288 . . . . 0.0 110.82 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -49.22 141.75 23.06 Favored 'Trans proline' 0 C--N 1.346 0.407 0 C-N-CA 122.569 2.179 . . . . 0.0 112.502 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.7 mt -56.8 -27.96 60.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.001 179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 31.0 t -53.02 -23.49 7.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.488 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 3.2 t -120.12 39.58 3.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.235 0.54 . . . . 0.0 110.716 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 51' ' ' LEU . 55.7 mt -132.63 158.46 43.28 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.839 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.806 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -128.97 93.77 3.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.053 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 18.4 tt -91.01 142.1 13.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.143 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.83 117.03 5.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.92 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -82.72 164.01 20.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.985 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.25 76.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.2 72.65 0.58 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 59.45 29.84 19.45 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -132.15 101.57 5.44 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.842 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.421 ' HB ' HG23 ' A' ' 34' ' ' THR . 78.6 m -97.32 111.52 23.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.93 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.59 113.81 26.46 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.808 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.474 ' CZ ' ' CZ ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -97.55 113.33 25.02 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.856 -179.82 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.806 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.8 ttt85 -108.41 103.71 12.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.473 ' O ' HG22 ' A' ' 30' ' ' THR . 4.6 m-85 -75.69 151.11 37.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -77.65 -27.13 50.88 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.856 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.662 ' C ' HG23 ' A' ' 30' ' ' THR . 52.3 tttp -129.24 166.82 18.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.999 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.47 98.45 11.78 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.688 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 6.2 tpt -85.02 -29.98 24.53 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.726 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.405 ' CB ' HD12 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -116.17 70.02 3.95 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.808 179.892 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.01 -23.59 34.07 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.623 2.215 . . . . 0.0 112.44 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 23.0 p-10 -75.67 -29.12 58.97 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.909 0.385 . . . . 0.0 110.882 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.683 HD23 HG23 ' A' ' 11' ' ' THR . 62.5 mt -71.98 99.12 2.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.126 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -72.11 114.39 10.17 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.677 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -50.5 132.79 30.57 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.778 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 3.2 ttm -95.82 170.26 9.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.833 0.349 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.637 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.7 t -78.1 123.58 35.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.1 179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 3.5 tt -105.39 105.52 15.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.871 179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -93.38 110.01 21.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.841 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.44 79.58 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.799 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.97 143.63 11.24 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.493 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.7 m -139.4 161.8 55.11 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.627 0.251 . . . . 0.0 110.968 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.44 -168.17 0.33 Allowed 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.621 2.214 . . . . 0.0 112.347 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -96.23 124.43 40.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.978 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 120.47 -26.17 7.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.594 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.0 m -57.59 115.55 2.84 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.738 0.304 . . . . 0.0 110.837 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.646 HG22 ' HG3' ' A' ' 107' ' ' ARG . 26.6 t -90.9 116.74 32.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.046 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 8.9 m -84.36 168.61 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.963 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.21 111.94 8.8 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.94 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 93' ' ' LEU . 21.6 t -83.5 158.9 3.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.081 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.601 HD11 HG22 ' A' ' 151' ' ' VAL . 1.1 mp -127.95 87.43 2.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 1.117 HD11 HD11 ' A' ' 104' ' ' LEU . 27.9 mt -82.33 96.61 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.123 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.28 145.77 26.22 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.898 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.8 ttt180 -135.06 160.44 38.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.93 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -70.19 -38.45 75.35 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 2.4 m -69.0 -27.87 66.08 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.952 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.37 24.72 6.99 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.567 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -100.26 87.04 3.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.767 0.317 . . . . 0.0 110.926 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 17.6 mt -69.83 157.38 37.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.734 ' HB3' HD12 ' A' ' 94' ' ' ILE . 12.3 tp -149.13 86.46 5.62 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.96 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.49 109.54 2.64 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.549 2.166 . . . . 0.0 112.296 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.117 HD11 HD11 ' A' ' 94' ' ' ILE . 6.3 mt -91.92 163.38 14.04 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.528 ' HB3' ' O ' ' A' ' 129' ' ' LEU . . . -139.79 140.11 36.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.106 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.595 HG11 ' CG2' ' A' ' 174' ' ' VAL . 21.7 t -152.12 128.53 1.92 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.064 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.71 ' HB2' HD12 ' A' ' 129' ' ' LEU . 5.6 mtt180 -84.23 116.99 23.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.788 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.5 mmt -62.65 142.67 57.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.93 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -101.99 -116.61 4.14 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.854 -0.689 . . . . 0.0 112.531 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.0 54.79 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.815 0.341 . . . . 0.0 111.09 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.579 HG23 ' O ' ' A' ' 111' ' ' ILE . 8.5 tp -84.12 111.93 20.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.051 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -130.95 174.42 10.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.122 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.487 ' HB2' HD11 ' A' ' 120' ' ' LEU . 0.9 OUTLIER -102.64 112.28 24.97 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.888 -179.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.477 ' O ' HD13 ' A' ' 120' ' ' LEU . 1.2 mtt -101.31 179.41 4.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.501 ' O ' HD13 ' A' ' 116' ' ' ILE . 17.9 ttp180 -127.46 127.79 44.65 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.92 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.501 HD13 ' O ' ' A' ' 115' ' ' ARG . 26.6 mm -128.96 114.12 31.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.139 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.2 35.66 20.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.936 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.5 28.3 57.79 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.507 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.9 mtt85 -132.77 125.4 30.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.487 HD11 ' HB2' ' A' ' 113' ' ' SER . 0.1 OUTLIER -76.08 117.54 17.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.948 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.39 145.41 29.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.032 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -88.31 137.85 31.96 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.953 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -143.63 135.01 6.1 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.55 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -94.17 120.91 35.09 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.784 0.326 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.81 162.99 10.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.93 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -161.38 128.98 2.01 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.33 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.459 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.5 mtp -105.29 145.95 30.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.955 0.407 . . . . 0.0 111.065 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -58.54 134.73 56.96 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.945 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.71 HD12 ' HB2' ' A' ' 107' ' ' ARG . 9.4 mt -157.56 48.1 0.4 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 179.832 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.858 HG21 ' HA ' ' A' ' 104' ' ' LEU . 0.2 OUTLIER -129.08 -46.01 1.24 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.963 179.926 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 162.41 41.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.606 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 62.05 69.42 0.63 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.89 0.376 . . . . 0.0 111.174 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -131.15 117.28 18.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.857 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -177.2 150.15 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.39 -27.81 8.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.902 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.23 -32.3 2.19 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.287 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 9.7 mtt -126.11 26.23 6.55 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.76 0.314 . . . . 0.0 111.131 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB3' HG22 ' A' ' 141' ' ' THR . 4.0 t70 176.26 167.12 0.45 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.489 -179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.769 HD12 HD22 ' A' ' 104' ' ' LEU . 0.8 OUTLIER -72.53 -42.05 65.16 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.904 -179.77 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -164.92 94.89 0.11 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.385 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.549 HG22 ' HB3' ' A' ' 138' ' ' ASP . 7.9 t -146.49 159.3 43.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.029 0.442 . . . . 0.0 111.352 -179.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.496 ' CB ' ' HD3' ' A' ' 143' ' ' PRO . 0.3 OUTLIER -155.97 -56.74 0.02 OUTLIER Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.699 179.43 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.496 ' HD3' ' CB ' ' A' ' 142' ' ' ILE . 3.0 Cg_endo -87.6 16.81 1.84 Allowed 'Trans proline' 0 N--CA 1.459 -0.557 0 C-N-CA 123.104 2.536 . . . . 0.0 112.557 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 105.55 34.99 3.18 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.118 -179.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -88.42 59.75 5.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.097 0.475 . . . . 0.0 110.833 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 35.3 m -105.8 167.87 9.49 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.769 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 54.76 18.7 11.66 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.358 -179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 149' ' ' PRO . . . -47.63 170.16 0.1 Allowed Pre-proline 0 C--N 1.332 -0.19 0 CA-C-O 120.728 0.299 . . . . 0.0 111.056 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 148' ' ' ALA . 95.1 Cg_endo -83.29 134.77 6.93 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.628 2.218 . . . . 0.0 112.764 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 7.4 m-85 -119.92 125.42 48.41 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.513 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.601 HG22 HD11 ' A' ' 93' ' ' LEU . 28.6 m -146.71 150.01 15.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 120.968 0.413 . . . . 0.0 111.441 -179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.415 ' CE1' ' HB ' ' A' ' 159' ' ' VAL . 7.5 p-80 -134.05 153.01 52.07 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.684 179.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -105.55 122.11 45.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.056 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.87 91.94 3.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.354 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.39 -106.77 2.11 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.584 -0.817 . . . . 0.0 111.933 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -115.84 38.76 3.22 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.825 0.345 . . . . 0.0 110.526 179.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -161.22 140.21 10.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.188 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.478 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -96.72 161.53 13.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.641 179.717 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.637 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.5 t -149.55 141.53 17.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.208 -179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.7 p -113.6 139.25 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.946 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 20.5 p -96.08 -39.84 9.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.072 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 159.74 -118.59 0.84 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.496 -0.859 . . . . 0.0 112.76 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.2 m -137.61 173.48 12.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.607 0.241 . . . . 0.0 111.236 -179.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.498 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 14.9 t-80 -78.56 139.28 38.63 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.819 0.343 . . . . 0.0 111.033 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -102.19 -74.42 0.63 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.282 -179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -175.26 174.47 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.168 -179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.703 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -145.58 -177.22 5.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.221 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -92.18 178.04 5.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.785 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 17.2 pttp -85.78 -47.39 9.77 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 89.3 p -123.95 16.73 9.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.255 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -91.13 -26.85 20.42 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.624 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 15.7 m-20 60.28 47.13 9.44 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.989 0.424 . . . . 0.0 110.858 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.403 ' O ' ' HB1' ' A' ' 167' ' ' ALA . 28.4 m -141.56 127.33 19.2 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.876 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.703 HG12 ' HB2' ' A' ' 167' ' ' ALA . 6.8 m -110.05 151.68 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.044 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 27.4 t -110.93 139.59 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 10.3 m -101.92 134.15 45.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.53 108.84 14.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.035 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 178' ' ' VAL . 31.2 m -134.53 120.46 32.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.108 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -177.06 -174.97 0.55 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -155.13 -175.85 5.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -132.71 27.92 3.45 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.452 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -113.23 78.99 1.18 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.895 0.379 . . . . 0.0 110.825 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 142.78 51.64 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.4 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.1 tp10 -89.07 -32.38 17.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.751 0.31 . . . . 0.0 110.869 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 62.9 m -107.42 -31.54 8.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -79.99 -169.89 2.21 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.063 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.54 -32.83 9.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.958 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 21.5 tp10 . . . . . 0 C--O 1.248 1.009 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.884 179.989 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.5 ttp . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 120.828 0.347 . . . . 0.0 111.129 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -103.06 149.5 24.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.6 m170 -100.38 126.33 46.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.83 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 t60 -92.54 124.1 36.32 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.88 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.8 t-160 -89.92 -53.41 4.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.909 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.8 t-80 -176.57 152.41 1.03 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.853 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -129.91 131.75 46.14 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.933 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 9' ' ' PRO . . . -97.73 171.39 5.98 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.083 -179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 81.4 Cg_exo -48.42 104.17 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.673 2.248 . . . . 0.0 112.513 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 9' ' ' PRO . 18.7 Cg_endo -61.15 -60.55 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.56 2.173 . . . . 0.0 112.44 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.1 m -49.67 -27.72 5.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.142 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.866 HD11 ' HE3' ' A' ' 78' ' ' MET . 4.2 tt -66.6 -30.9 71.29 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.717 ' O ' HG12 ' A' ' 16' ' ' VAL . 13.0 m0 -75.08 -34.72 61.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.637 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 m -60.99 -20.91 63.01 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.101 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 6.0 mtt180 -56.49 -28.66 60.38 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.921 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.851 HG22 ' CE3' ' A' ' 23' ' ' TRP . 10.6 p -65.47 119.06 9.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.662 179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.3 m -124.69 113.61 18.22 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -179.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.1 OUTLIER -66.14 111.29 3.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.012 0.434 . . . . 0.0 110.859 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 19.5 t80 -119.03 119.6 34.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.432 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.402 ' CA ' ' HG3' ' A' ' 40' ' ' PRO . . . 68.05 -110.18 3.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.304 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.7 m -117.21 36.15 4.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.837 0.351 . . . . 0.0 110.68 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.416 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.17 -169.72 31.99 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.945 -0.645 . . . . 0.0 112.353 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.851 ' CE3' HG22 ' A' ' 16' ' ' VAL . 73.2 m95 -126.5 145.3 50.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.742 0.306 . . . . 0.0 110.723 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.91 -157.97 10.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.244 179.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.516 ' HB3' HD11 ' A' ' 33' ' ' ILE . 20.3 t80 -151.68 142.93 23.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.866 0.365 . . . . 0.0 111.07 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.426 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 78.2 m95 -87.96 98.18 11.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.827 179.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.705 HG21 HG23 ' A' ' 33' ' ' ILE . 21.5 t -69.69 -31.54 49.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.001 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -164.75 164.53 13.27 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.652 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_exo -52.13 -31.19 44.14 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.533 2.155 . . . . 0.0 112.364 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 69' ' ' LYS . 0.0 OUTLIER -119.06 12.32 12.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.306 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 61.6 t -132.12 142.61 42.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 120.848 0.356 . . . . 0.0 111.174 -179.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -140.06 166.1 25.56 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.056 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.705 HG23 HG21 ' A' ' 27' ' ' VAL . 11.2 pt -143.38 154.93 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.93 179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.75 167.32 4.46 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.054 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.752 ' O ' HG23 ' A' ' 39' ' ' VAL . 6.5 m -84.2 168.72 15.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.414 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.415 ' H ' HG22 ' A' ' 35' ' ' THR . 1.1 m -86.13 -32.38 21.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.513 -179.298 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.653 ' CE1' HG21 ' A' ' 35' ' ' THR . 4.6 p-80 -73.17 -25.38 60.77 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.212 -179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.608 HG13 ' CD2' ' A' ' 37' ' ' HIS . 34.0 m -81.13 -30.72 11.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.559 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 35' ' ' THR . 36.2 t -59.41 115.45 12.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.144 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.446 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 92.7 Cg_endo -81.98 -163.41 0.22 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.616 2.21 . . . . 0.0 112.061 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.2 t -157.81 31.86 0.26 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.921 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -110.8 -20.1 7.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.665 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.3 m -94.82 165.05 2.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 120.813 0.339 . . . . 0.0 111.175 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 1.7 tppt? -132.5 29.6 4.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.898 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 179.56 150.21 0.33 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.66 179.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.457 ' CE1' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -121.74 133.82 54.93 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 40.21 35.77 0.28 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.473 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 72.91 38.2 56.26 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.684 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 142.42 38.13 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.546 0.212 . . . . 0.0 110.699 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -69.43 130.7 20.21 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.406 2.071 . . . . 0.0 112.438 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.406 HD21 ' HZ ' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -56.3 -22.24 29.1 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.332 179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -85.71 13.8 6.68 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.862 -179.543 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 54.8 m -130.48 43.58 3.09 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.032 0.444 . . . . 0.0 110.839 179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CE2' ' A' ' 67' ' ' PHE . 78.1 mt -138.57 158.97 31.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.94 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.93 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -117.4 93.78 4.3 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.972 179.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 1.2 tp -82.51 137.42 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.128 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -156.01 99.46 1.96 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.822 179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 63' ' ' THR . 44.6 mt-30 -100.74 152.32 20.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.956 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.844 ' HB3' ' HB1' ' A' ' 180' ' ' ALA . . . -175.63 77.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.6 53.87 1.28 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.594 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.428 ' OE1' ' HB1' ' A' ' 165' ' ' ALA . 6.0 mt-10 58.16 28.36 16.36 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.745 0.307 . . . . 0.0 110.976 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.431 ' CD1' ' HA ' ' A' ' 178' ' ' VAL . 49.4 t80 -130.06 101.54 5.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.739 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 HG23 ' HG2' ' A' ' 58' ' ' GLN . 4.3 m -96.57 118.87 33.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.99 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -96.22 113.92 25.56 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.704 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -97.57 113.36 25.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.98 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.93 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 32.4 ttt180 -116.27 103.69 10.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.432 179.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.533 ' CE2' HD11 ' A' ' 54' ' ' ILE . 38.0 m-85 -89.64 143.06 27.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.053 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.0 m -66.9 -26.91 67.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.452 ' O ' HG22 ' A' ' 30' ' ' THR . 12.8 tptp -104.85 163.01 12.83 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.872 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.437 ' HG2' HG23 ' A' ' 30' ' ' THR . 0.5 OUTLIER -100.7 117.37 34.68 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.513 179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.426 ' HB2' ' CH2' ' A' ' 26' ' ' TRP . 5.4 mmt -85.35 -29.43 24.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.946 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.471 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.4 tpp180 -132.16 67.64 79.24 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.988 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.34 -26.9 55.03 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.645 2.23 . . . . 0.0 112.275 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.8 m-20 -68.09 -34.11 75.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.951 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.471 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.8 mt -59.92 135.22 57.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.923 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 23.9 m -90.72 -52.25 4.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.876 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 136.43 134.76 3.34 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.614 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . 0.866 ' HE3' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -105.99 170.16 8.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.819 0.342 . . . . 0.0 110.827 -179.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.592 ' HB ' HG13 ' A' ' 159' ' ' VAL . 21.4 t -83.09 141.53 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.036 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 1.6 tt -119.8 105.46 11.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.888 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.76 ' HG2' HG11 ' A' ' 159' ' ' VAL . 7.6 mm-40 -86.75 112.69 21.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.999 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -97.89 77.09 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.97 99.43 2.61 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 1.6 m -109.52 150.75 41.61 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.691 0.281 . . . . 0.0 110.924 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.99 -170.95 0.6 Allowed 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.564 2.176 . . . . 0.0 112.404 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -81.43 151.82 27.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.871 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 97.89 -29.77 10.56 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.0 m -60.0 115.66 3.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.773 0.321 . . . . 0.0 110.81 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -95.98 108.21 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.063 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.6 m -85.97 165.3 16.83 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.598 ' O ' HG22 ' A' ' 151' ' ' VAL . 6.2 t -137.32 110.48 7.81 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.928 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.592 HG22 ' CE2' ' A' ' 150' ' ' TYR . 25.0 t -74.63 151.69 6.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.105 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.495 HD11 HG11 ' A' ' 151' ' ' VAL . 24.0 mt -110.27 96.0 5.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.886 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.849 HD13 ' HA ' ' A' ' 141' ' ' THR . 34.2 mt -109.71 99.77 9.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.178 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HD2' ' CH2' ' A' ' 23' ' ' TRP . 0.2 OUTLIER -81.74 -178.29 6.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.926 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 -148.15 165.89 29.53 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -69.11 -36.64 77.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.843 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.2 p -69.09 -25.64 64.53 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.942 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.59 24.89 6.84 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.51 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.56 99.75 8.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.797 0.332 . . . . 0.0 110.813 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.4 mp -69.72 146.7 51.34 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.425 HD23 HD21 ' A' ' 104' ' ' LEU . 2.8 tp -123.45 87.77 51.84 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.999 -179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -77.03 98.08 1.2 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.652 2.235 . . . . 0.0 112.273 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.433 HD11 ' O ' ' A' ' 140' ' ' GLY . 48.5 mt -85.19 163.4 18.73 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.873 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -115.64 135.42 54.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.119 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.69 HG11 HG21 ' A' ' 174' ' ' VAL . 21.4 t -143.05 124.54 11.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.185 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 18.4 ttt85 -69.21 145.29 53.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.863 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . 0.455 ' HE3' ' HB3' ' A' ' 124' ' ' GLN . 0.0 OUTLIER -99.03 132.56 44.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.035 179.899 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -106.52 -148.83 16.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.427 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.19 157.74 21.32 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.782 0.325 . . . . 0.0 111.13 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.766 HD11 ' HB3' ' A' ' 122' ' ' HIS . 12.0 tt -68.52 145.86 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.138 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.49 137.96 23.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.78 85.28 7.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -75.95 163.35 27.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.584 ' O ' HD13 ' A' ' 116' ' ' ILE . 6.1 ttm180 -95.75 120.13 35.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.871 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 115' ' ' ARG . 30.2 mm -127.21 110.88 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 9.5 tt0 60.63 30.68 19.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.037 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.72 -25.67 23.86 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.584 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 8.7 mtp180 -89.33 172.7 8.85 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.795 0.331 . . . . 0.0 110.898 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.428 HD23 ' HA ' ' A' ' 120' ' ' LEU . 21.8 mt -109.65 126.05 53.25 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.825 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -116.17 133.55 62.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.13 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.766 ' HB3' HD11 ' A' ' 111' ' ' ILE . 3.9 m170 -89.21 111.47 22.27 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.903 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -135.07 155.24 21.94 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.504 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . 0.594 ' NE2' HD12 ' A' ' 111' ' ' ILE . 1.2 mp0 -98.6 115.35 28.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 110.917 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 10.5 m -92.28 170.6 9.67 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.856 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.781 ' O ' HG23 ' A' ' 173' ' ' THR . . . -175.81 -157.25 16.62 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 1.5 ttt -158.34 138.2 12.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.817 0.341 . . . . 0.0 110.944 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.844 HD11 HD12 ' A' ' 139' ' ' LEU . 0.2 OUTLIER -109.73 163.93 13.04 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.988 -179.956 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 1.2 mp -114.88 47.86 1.22 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.91 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.6 m -103.74 -32.74 9.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 139.82 -110.97 0.72 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -144.98 36.93 1.14 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.816 0.341 . . . . 0.0 111.085 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.3 m-80 -72.91 130.63 40.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.971 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.89 129.05 1.43 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.072 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 25.2 tttt -107.19 -29.0 9.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.987 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.02 -27.55 1.42 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.378 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.8 mtt -139.08 29.73 2.25 Favored 'General case' 0 N--CA 1.45 -0.439 0 CA-C-O 121.229 0.538 . . . . 0.0 109.709 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.6 p30 -161.4 162.18 30.56 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.051 -178.757 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.935 HD23 ' HB3' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -136.22 52.55 1.97 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.134 0.492 . . . . 0.0 110.675 179.764 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.433 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 155.4 -27.51 0.61 Allowed Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.21 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.849 ' HA ' HD13 ' A' ' 94' ' ' ILE . 14.1 p -74.28 133.08 42.61 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.791 0.329 . . . . 0.0 110.794 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.443 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 4.0 mt -97.84 -49.44 0.22 Allowed Pre-proline 0 C--N 1.33 -0.249 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 -179.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.443 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 4.3 Cg_exo -78.4 29.0 0.46 Allowed 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.762 2.308 . . . . 0.0 112.419 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 67.81 41.58 88.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 111.953 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.842 ' O ' HG21 ' A' ' 141' ' ' THR . 0.1 OUTLIER -84.91 58.08 4.79 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.082 0.468 . . . . 0.0 111.022 -179.723 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.9 m -71.15 162.87 28.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.037 179.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.497 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 56.07 10.64 3.91 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.461 -0.876 . . . . 0.0 112.719 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.69 141.03 5.58 Favored Pre-proline 0 CA--C 1.529 0.171 0 CA-C-N 116.884 0.342 . . . . 0.0 111.175 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.469 ' HD3' HG23 ' A' ' 16' ' ' VAL . 93.7 Cg_endo -79.24 120.19 4.45 Favored 'Trans proline' 0 N--CA 1.462 -0.352 0 C-N-CA 122.67 2.247 . . . . 0.0 112.881 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.592 ' CE2' HG22 ' A' ' 92' ' ' VAL . 36.1 m-85 -77.23 143.72 38.76 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.404 179.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 160' ' ' VAL . 19.7 m -140.22 152.88 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.03 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.43 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 44.1 p-80 -167.55 167.27 13.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.904 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.411 ' HG3' ' CD1' ' A' ' 158' ' ' TRP . 20.1 tttt -94.66 132.49 39.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.181 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -132.13 95.84 3.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.39 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.31 -112.64 3.82 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.598 -0.81 . . . . 0.0 111.984 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -108.24 35.71 3.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.954 0.407 . . . . 0.0 110.224 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.03 -170.65 1.37 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.924 -179.507 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.43 ' CE3' ' N ' ' A' ' 152' ' ' HIS . 5.0 m95 -128.53 139.08 52.49 Favored 'General case' 0 N--CA 1.452 -0.336 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.606 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.76 HG11 ' HG2' ' A' ' 81' ' ' GLU . 22.0 t -120.74 139.56 47.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.438 -0.347 . . . . 0.0 111.236 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.945 HG12 HG12 ' A' ' 151' ' ' VAL . 4.8 m -100.13 124.71 53.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.045 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.766 ' O ' HG11 ' A' ' 178' ' ' VAL . 52.8 t -65.48 -75.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.052 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.458 ' HA3' HG13 ' A' ' 178' ' ' VAL . . . -168.45 -134.84 1.78 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.727 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 147' ' ' GLY . 12.3 m -128.68 149.13 33.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.529 0.204 . . . . 0.0 110.979 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 12.9 t-80 -63.53 124.81 22.32 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.804 0.335 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.428 ' HB1' ' OE1' ' A' ' 61' ' ' GLU . . . -109.51 -76.32 0.61 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.2 -179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -139.19 174.36 10.6 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.14 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.935 ' HB3' HD23 ' A' ' 139' ' ' LEU . . . -164.93 -178.04 5.0 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.202 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -69.2 164.12 23.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 5.8 ttmm -87.14 -55.79 3.66 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -124.02 16.61 9.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.337 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -103.67 -112.24 3.67 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.64 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 175.21 74.27 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.77 0.319 . . . . 0.0 110.788 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 126' ' ' GLY . 67.7 m -154.6 128.9 9.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.852 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.69 HG21 HG11 ' A' ' 106' ' ' VAL . 16.9 m -109.84 164.86 5.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.246 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.65 109.6 22.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.127 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 75.0 m -75.96 130.46 38.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.692 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -108.25 125.15 51.33 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.188 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.766 HG11 ' O ' ' A' ' 161' ' ' CYS . 0.3 OUTLIER -166.0 -42.16 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.265 -179.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -60.2 147.49 39.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.953 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.844 ' HB1' ' HB3' ' A' ' 59' ' ' ALA . . . -171.36 106.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.129 -179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 69.52 129.69 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.448 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -59.06 175.28 0.3 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.807 0.337 . . . . 0.0 111.037 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.56 -44.95 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.467 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . 0.464 ' O ' HG22 ' A' ' 185' ' ' THR . 9.3 mt-10 -91.51 -31.95 15.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.84 0.352 . . . . 0.0 110.918 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 184' ' ' GLU . 15.3 t 44.83 36.56 1.91 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.361 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -91.36 130.11 37.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.007 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 51.2 mt -90.44 119.21 30.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.864 179.935 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 46.7 ttm . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.891 0.376 . . . . 0.0 111.255 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 12.4 m80 -131.73 -52.27 0.99 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -142.8 86.88 1.96 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 8.0 m80 61.64 153.46 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.912 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -58.94 -28.74 66.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.014 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.5 m-70 -128.07 163.37 24.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.928 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -134.53 149.87 50.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.873 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.733 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -137.0 165.25 36.34 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.043 179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 34.7 Cg_endo -64.78 124.71 13.57 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.582 2.188 . . . . 0.0 112.324 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.28 -61.56 0.15 Allowed 'Trans proline' 0 C--N 1.347 0.493 0 C-N-CA 122.469 2.113 . . . . 0.0 112.616 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 91.7 m -48.21 -28.74 3.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.312 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.667 HD21 HG11 ' A' ' 151' ' ' VAL . 4.7 tt -66.63 -28.54 68.56 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.996 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.859 ' O ' HG12 ' A' ' 16' ' ' VAL . 44.5 m0 -79.0 -30.94 44.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.901 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.4 t -57.83 -21.92 44.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.212 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.463 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 7.5 mtm-85 -57.89 -31.73 67.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.038 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.859 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.1 p -65.32 140.71 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.964 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.1 m -145.34 109.14 4.74 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.897 0.38 . . . . 0.0 111.784 -179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' CD2' ' A' ' 23' ' ' TRP . 4.0 tptp -65.87 111.44 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.624 179.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.553 ' HE1' HG21 ' A' ' 43' ' ' VAL . 21.5 t80 -130.84 139.59 50.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.546 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.17 -131.03 48.23 Favored Glycine 0 C--N 1.332 0.325 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.507 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.05 32.02 2.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.878 0.37 . . . . 0.0 110.634 179.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.407 ' HA3' ' CG1' ' A' ' 38' ' ' VAL . . . -168.18 -170.05 32.42 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.388 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.577 ' HE3' HG22 ' A' ' 16' ' ' VAL . 29.0 m95 -123.77 154.57 39.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.871 0.367 . . . . 0.0 110.759 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -122.2 -161.04 11.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.228 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.655 ' HB3' HD11 ' A' ' 33' ' ' ILE . 1.5 t80 -151.82 146.39 25.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.82 0.343 . . . . 0.0 111.134 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.644 ' HB3' HD11 ' A' ' 75' ' ' LEU . 54.2 m95 -94.25 102.6 14.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.713 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.503 HG21 HG12 ' A' ' 31' ' ' VAL . 4.1 m -82.65 -22.04 9.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.283 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.47 ' C ' HD13 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -171.68 166.18 4.08 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.642 179.988 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.39 -13.92 41.14 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.465 2.11 . . . . 0.0 112.619 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.743 HG23 ' O ' ' A' ' 69' ' ' LYS . 0.3 OUTLIER -127.72 -0.66 6.08 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.772 -179.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.503 HG12 HG21 ' A' ' 27' ' ' VAL . 39.2 t -128.63 141.93 45.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-O 120.931 0.396 . . . . 0.0 111.22 -179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -137.69 163.86 30.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.063 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.655 HD11 ' HB3' ' A' ' 25' ' ' PHE . 17.6 pt -137.28 155.47 32.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.985 179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.3 t -173.58 167.33 4.58 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.995 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.592 ' HB ' HG22 ' A' ' 38' ' ' VAL . 6.8 m -84.12 166.81 17.33 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.625 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 m -89.86 -34.61 16.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.288 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.411 ' CD2' ' O ' ' A' ' 37' ' ' HIS . 9.1 t60 -73.26 -24.73 60.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.08 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HB ' ' A' ' 35' ' ' THR . 23.4 m -80.91 -25.12 10.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.857 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 35' ' ' THR . 21.3 t -56.15 119.11 24.79 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.242 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -83.51 -164.66 0.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.445 0 C-N-CA 122.618 2.212 . . . . 0.0 112.241 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.96 35.51 0.54 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -117.93 -35.25 1.06 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.553 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -83.29 161.42 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.89 0.376 . . . . 0.0 111.163 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -136.4 31.26 2.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.821 -179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -179.25 150.2 0.44 Allowed 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.692 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' HE1' HD12 ' A' ' 54' ' ' ILE . 0.4 OUTLIER -123.76 133.72 53.79 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 178.215 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.44 ' CE1' ' CE ' ' A' ' 71' ' ' MET . 0.3 OUTLIER 41.56 35.38 0.46 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.432 -179.233 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 74.24 33.89 55.91 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.795 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -119.76 132.39 24.06 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.563 0.22 . . . . 0.0 110.651 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -73.58 131.49 16.17 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.403 2.069 . . . . 0.0 112.495 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 4.0 mt -53.13 -25.19 12.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.126 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.3 m -65.69 -13.31 58.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.619 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.92 39.14 3.6 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.254 0.549 . . . . 0.0 110.737 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.489 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.4 mt -133.18 158.24 43.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.876 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.912 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -127.41 93.77 3.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.058 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.417 HG12 ' CZ ' ' A' ' 65' ' ' PHE . 4.5 mt -89.28 142.22 13.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.126 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -137.3 99.45 3.98 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.85 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -77.57 150.75 34.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.946 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.536 ' HB1' HE22 ' A' ' 179' ' ' GLN . . . -174.89 77.0 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.085 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 78.28 -103.09 1.89 Allowed Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.495 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.65 ' OE2' ' HB1' ' A' ' 165' ' ' ALA . 1.6 tt0 -121.84 30.21 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.936 0.398 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.422 ' CE2' ' HG2' ' A' ' 64' ' ' GLN . 16.5 t80 -134.47 127.99 32.55 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.883 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 70.5 m -129.02 112.25 13.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.935 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.422 ' HG2' ' CE2' ' A' ' 62' ' ' PHE . 8.0 mt-30 -96.24 118.5 32.93 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.843 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.434 ' CE2' HG21 ' A' ' 54' ' ' ILE . 1.2 m-85 -98.45 113.22 25.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.912 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.6 tpp180 -107.79 103.69 13.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.775 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -79.71 157.15 27.25 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.914 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.4 m -96.06 23.27 6.62 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.952 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . 0.743 ' O ' HG23 ' A' ' 30' ' ' THR . 23.7 tptt -163.17 151.28 13.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.744 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -92.85 93.68 8.54 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.609 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.44 ' CE ' ' CE1' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -54.67 -30.28 54.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.993 -179.866 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 58.54 59.62 5.81 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.06 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 97.6 Cg_endo -85.33 40.55 0.81 Allowed 'Trans proline' 0 N--CA 1.461 -0.4 0 C-N-CA 122.666 2.244 . . . . 0.0 112.523 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 4.9 t70 71.35 43.69 0.6 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.959 0.409 . . . . 0.0 110.694 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.644 HD11 ' HB3' ' A' ' 26' ' ' TRP . 58.5 mt -106.92 -178.47 3.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.934 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.4 m -145.81 -46.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 137.26 100.54 0.55 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.509 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 33.5 ttm -95.87 163.16 13.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.721 0.296 . . . . 0.0 110.936 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.638 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.5 t -108.84 141.46 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.037 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 160' ' ' VAL . 6.1 mt -107.64 145.43 33.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.974 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -118.27 137.35 53.11 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.507 ' HA ' HG11 ' A' ' 178' ' ' VAL . 2.0 tt0 -115.62 89.3 3.07 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.837 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.41 129.07 6.15 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.5 m -148.01 154.17 42.8 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 120.665 0.269 . . . . 0.0 110.916 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.81 168.34 23.21 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.615 2.21 . . . . 0.0 112.286 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -68.4 151.6 46.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 107.48 -28.97 11.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.528 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.4 m -61.32 115.48 3.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.775 0.322 . . . . 0.0 110.905 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.651 HG22 ' HG2' ' A' ' 107' ' ' ARG . 28.0 t -99.37 108.87 23.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.033 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 12.3 m -84.41 166.79 17.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.943 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.23 103.55 5.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.778 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.529 HG22 ' CE1' ' A' ' 150' ' ' TYR . 21.5 t -66.94 158.86 5.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.105 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.853 HD22 ' CD1' ' A' ' 13' ' ' TRP . 4.1 mt -124.15 103.3 8.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 1.065 HD11 HD11 ' A' ' 104' ' ' LEU . 31.0 mt -98.36 121.92 49.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.133 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -112.72 147.64 36.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.97 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.73 169.69 16.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.862 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.3 -38.45 65.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 70.4 p -69.16 -28.03 66.06 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.921 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.31 24.78 6.98 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.494 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -99.68 90.44 4.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.789 0.328 . . . . 0.0 110.801 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 94' ' ' ILE . 1.8 mt -69.81 149.0 48.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.937 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.749 ' HB3' HD12 ' A' ' 94' ' ' ILE . 10.0 tp -134.33 86.85 34.64 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -72.65 105.03 1.83 Allowed 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.586 2.19 . . . . 0.0 112.265 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.065 HD11 HD11 ' A' ' 94' ' ' ILE . 10.6 mt -87.66 163.32 16.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.954 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -131.95 127.25 35.95 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.117 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.445 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.2 t -132.94 156.7 42.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.651 ' HG2' HG22 ' A' ' 89' ' ' VAL . 7.0 mtt180 -116.57 135.54 53.72 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.802 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 3.2 mtp -77.69 143.22 38.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -107.13 -113.91 3.82 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.496 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.2 157.68 21.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.826 0.346 . . . . 0.0 111.052 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.568 HD12 ' O ' ' A' ' 123' ' ' GLY . 8.9 tp -122.16 115.12 45.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -141.42 167.15 22.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.05 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' HIS . 72.6 p -102.44 90.59 3.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 4.9 mmm -68.47 147.14 52.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.971 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.1 ttm-85 -95.53 134.37 38.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.917 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.0 mt -138.12 103.19 2.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.142 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.9 mm-40 60.69 31.29 20.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.951 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 88.33 27.84 24.17 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.573 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 80.2 mtt85 -136.4 127.01 27.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 0.0 110.919 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.3 mt -88.17 118.86 28.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.869 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.417 ' O ' HG13 ' A' ' 121' ' ' VAL . 11.0 p -115.15 125.55 72.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.054 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . 0.435 ' CE1' ' HB3' ' A' ' 113' ' ' SER . 29.2 m80 -87.17 112.38 21.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.568 ' O ' HD12 ' A' ' 111' ' ' ILE . . . -135.46 146.96 18.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.538 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 2.9 tm0? -108.37 115.25 29.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.748 0.309 . . . . 0.0 110.897 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.429 ' OG ' HG22 ' A' ' 175' ' ' VAL . 2.9 m -96.92 140.94 30.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -144.96 162.51 28.1 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.536 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 50.6 mtt -103.11 154.01 19.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.783 0.325 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.474 HD11 ' HB2' ' A' ' 134' ' ' ALA . 4.8 mt -74.29 133.38 42.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.954 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.615 HD22 ' HG3' ' A' ' 107' ' ' ARG . 15.5 tp -119.33 47.9 1.61 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.0 0.428 . . . . 0.0 110.886 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -139.08 -67.94 0.45 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . -159.15 28.28 0.39 Allowed Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.884 -0.674 . . . . 0.0 112.476 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.637 ' HB1' ' ND2' ' A' ' 172' ' ' ASN . . . 61.67 36.04 16.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.897 0.379 . . . . 0.0 111.15 -179.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -76.38 106.29 7.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.857 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.474 ' HB2' HD11 ' A' ' 128' ' ' LEU . . . -168.37 128.22 1.23 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.242 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 1.5 mtpm? -95.34 -28.75 14.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.939 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.5 ' O ' ' HB3' ' A' ' 167' ' ' ALA . . . 146.15 -28.55 1.68 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.213 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 3.2 mtt -139.5 30.04 2.14 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 121.261 0.553 . . . . 0.0 109.737 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.467 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.3 p30 -161.92 -175.92 4.93 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.09 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.675 HD12 HD13 ' A' ' 104' ' ' LEU . 0.3 OUTLIER -97.18 34.02 1.84 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.374 179.586 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 84.82 8.51 82.52 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.632 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.65 HG21 ' HB3' ' A' ' 145' ' ' ASP . 5.6 p -74.25 145.47 44.03 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.874 0.369 . . . . 0.0 110.797 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.9 OUTLIER -97.5 -50.3 0.22 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.886 -179.734 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.478 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.9 Cg_exo -71.34 48.57 0.97 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.031 2.487 . . . . 0.0 112.738 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 44.44 45.48 8.38 Favored Glycine 0 CA--C 1.517 0.188 0 C-N-CA 121.155 -0.545 . . . . 0.0 112.8 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.65 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -82.97 58.48 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.118 0.485 . . . . 0.0 110.922 -179.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 m -91.12 174.63 7.3 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.977 179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.435 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 59.1 5.21 2.95 Favored Glycine 0 CA--C 1.521 0.442 0 C-N-CA 120.555 -0.831 . . . . 0.0 113.044 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -49.04 141.11 11.05 Favored Pre-proline 0 CA--C 1.529 0.163 0 CA-C-N 116.953 0.376 . . . . 0.0 111.167 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.457 ' CB ' ' CD1' ' A' ' 25' ' ' PHE . 87.2 Cg_endo -78.2 135.66 13.83 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.692 2.261 . . . . 0.0 112.746 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.675 ' O ' HG23 ' A' ' 160' ' ' VAL . 5.6 m-85 -103.31 126.8 50.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.456 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.667 HG11 HD21 ' A' ' 12' ' ' LEU . 13.4 m -123.48 152.72 28.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.307 -179.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.401 ' NE2' ' HB ' ' A' ' 159' ' ' VAL . 15.2 p-80 -148.48 167.32 25.63 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.75 179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.444 ' HD2' ' CD2' ' A' ' 158' ' ' TRP . 32.4 tptt -108.95 128.16 54.69 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.194 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -121.79 91.12 3.44 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.086 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.43 -106.65 2.09 Favored Glycine 0 N--CA 1.448 -0.51 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.605 -179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 15.4 m-80 -117.25 36.42 4.25 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.913 0.387 . . . . 0.0 109.984 179.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -162.94 136.5 5.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.813 -0.631 . . . . 0.0 111.239 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.444 ' CD2' ' HD2' ' A' ' 153' ' ' LYS . 4.8 m95 -86.96 160.14 18.77 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.605 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.638 HG13 ' O ' ' A' ' 79' ' ' VAL . 21.8 t -149.55 141.2 17.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.111 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.675 HG23 ' O ' ' A' ' 150' ' ' TYR . 13.1 p -105.63 130.66 56.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.157 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.7 t -75.22 -70.6 0.41 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.893 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.32 -124.98 0.76 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.647 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.435 HG12 ' O ' ' A' ' 147' ' ' GLY . 8.7 m -135.36 162.19 38.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.649 0.261 . . . . 0.0 110.91 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.467 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 27.9 t-80 -67.89 136.68 54.42 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.84 0.352 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.65 ' HB1' ' OE2' ' A' ' 61' ' ' GLU . . . -109.33 -76.24 0.61 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.173 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -161.87 174.54 12.99 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.171 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.5 ' HB3' ' O ' ' A' ' 136' ' ' GLY . . . -109.11 169.86 8.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.076 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.497 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.13 179.82 5.47 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.497 ' H ' HG22 ' A' ' 168' ' ' THR . 17.0 pttt -66.01 -24.79 66.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.053 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 30.8 t -70.02 -17.0 63.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.272 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 85.43 -55.34 4.9 Favored Glycine 0 C--N 1.331 0.276 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.549 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.637 ' ND2' ' HB1' ' A' ' 132' ' ' ALA . 2.8 m-20 -86.66 55.22 3.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 9.2 m -160.26 116.39 2.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.6 HG21 ' CD2' ' A' ' 139' ' ' LEU . 5.0 m -115.4 149.16 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.108 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.429 HG22 ' OG ' ' A' ' 125' ' ' SER . 21.4 t -110.97 133.71 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.23 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 20.3 m -104.6 131.55 51.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.949 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -114.59 153.32 30.32 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.159 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.507 HG11 ' HA ' ' A' ' 82' ' ' GLU . 10.9 p -154.77 -45.34 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.135 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.536 HE22 ' HB1' ' A' ' 59' ' ' ALA . 1.1 tt0 59.09 -168.63 0.14 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.896 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . 60.84 106.76 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.11 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 135.15 44.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -163.7 135.17 4.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.781 0.324 . . . . 0.0 110.993 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -177.08 49.59 0.1 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.619 -0.8 . . . . 0.0 112.435 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -159.4 -45.61 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.838 0.352 . . . . 0.0 110.922 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -68.36 -40.77 81.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -83.7 125.78 32.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.101 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.418 HD13 ' HA ' ' A' ' 187' ' ' LEU . 4.4 mm? -106.46 31.6 5.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.92 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.304 -0.855 . . . . 0.0 110.895 179.946 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.6 mmt . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.852 0.358 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -147.58 -48.1 0.17 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.862 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 2.9 p-80 -137.1 35.36 2.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -127.8 34.66 4.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.924 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 24.4 t60 -96.76 -31.17 12.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.966 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 67.6 m80 -94.77 137.2 34.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -105.71 -29.69 9.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.912 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.604 ' HB3' ' HZ2' ' A' ' 13' ' ' TRP . . . -107.47 99.43 28.41 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.067 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HD2' HD13 ' A' ' 12' ' ' LEU . 78.5 Cg_exo -50.59 151.26 10.7 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.47 2.113 . . . . 0.0 112.512 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.435 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 19.0 Cg_endo -61.52 -60.74 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.581 2.187 . . . . 0.0 112.528 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.3 m -49.5 -27.96 4.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.263 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.492 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.4 tt -65.35 -27.33 68.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.023 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.887 ' O ' HG12 ' A' ' 16' ' ' VAL . 17.5 m0 -83.78 -40.16 19.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.83 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -58.81 -20.9 54.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.33 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 13.5 mtt180 -57.75 -29.9 65.16 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.849 0.357 . . . . 0.0 111.028 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.887 HG12 ' O ' ' A' ' 13' ' ' TRP . 13.9 p -68.59 141.38 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.036 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.537 HG21 ' CD2' ' A' ' 47' ' ' PHE . 5.9 m -139.78 109.15 6.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.538 -179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.45 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.34 111.3 3.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.627 179.3 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' HE1' HG21 ' A' ' 43' ' ' VAL . 14.8 t80 -125.37 136.96 53.98 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.641 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.58 -122.17 27.28 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.335 -179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.48 ' O ' HG11 ' A' ' 38' ' ' VAL . 52.2 m -106.59 26.51 9.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.873 0.368 . . . . 0.0 110.786 179.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -157.07 -170.42 22.0 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.508 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.45 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.1 m95 -130.64 143.09 50.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.637 0.256 . . . . 0.0 110.677 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.74 -166.95 14.08 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 120.65 -0.786 . . . . 0.0 112.576 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.453 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 3.6 t80 -151.0 145.8 25.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.741 0.305 . . . . 0.0 111.083 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.42 ' CE3' ' HA ' ' A' ' 15' ' ' ARG . 8.8 m0 -77.6 100.13 6.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.82 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 80' ' ' LEU . 5.5 m -78.55 -24.75 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.095 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 29' ' ' PRO . 0.7 OUTLIER -162.99 158.67 18.56 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.533 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 28' ' ' SER . 11.2 Cg_endo -54.66 -21.59 25.53 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.557 2.171 . . . . 0.0 112.413 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.469 HG23 ' CG ' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -131.64 14.68 4.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.37 -179.888 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.54 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.6 t -132.35 142.47 42.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.894 0.378 . . . . 0.0 111.116 -179.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -135.35 162.78 31.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.217 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.515 ' C ' HD12 ' A' ' 33' ' ' ILE . 2.7 pp -140.85 154.68 21.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.994 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.85 166.86 4.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.942 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.698 HG22 ' H ' ' A' ' 37' ' ' HIS . 95.5 m -84.32 135.24 34.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.799 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.847 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -77.17 -17.09 58.83 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.558 -179.62 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.698 ' H ' HG22 ' A' ' 35' ' ' THR . 9.9 t60 -72.01 -24.82 61.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 111.147 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.48 HG11 ' O ' ' A' ' 21' ' ' SER . 0.1 OUTLIER -108.82 -11.78 11.03 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.833 -179.702 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.847 HG12 ' O ' ' A' ' 36' ' ' THR . 14.9 p -53.17 121.12 22.85 Favored Pre-proline 0 C--N 1.332 -0.191 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.202 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -83.93 -164.8 0.27 Allowed 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.573 2.182 . . . . 0.0 112.161 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.5 m -164.23 31.25 0.07 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -113.62 -27.08 3.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.601 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.473 HG21 ' HE1' ' A' ' 19' ' ' PHE . 13.0 m -74.52 152.07 6.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 111.116 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . 0.54 ' O ' HD23 ' A' ' 51' ' ' LEU . 16.5 mttt -115.69 30.58 7.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.872 179.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 177.76 150.1 0.2 Allowed 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.437 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.6 OUTLIER -124.56 133.63 53.23 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.537 ' CD2' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER 38.91 35.96 0.14 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.38 -179.188 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 64.0 40.3 98.09 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.606 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.422 ' N ' ' O ' ' A' ' 46' ' ' PHE . 3.7 mm-40 -125.86 160.03 58.59 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.751 0.31 . . . . 0.0 110.916 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.416 ' HB2' ' CB ' ' A' ' 53' ' ' SER . 50.4 Cg_exo -53.57 114.77 1.92 Allowed 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.579 2.186 . . . . 0.0 112.64 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 51' ' ' LEU . 0.7 OUTLIER -69.77 -40.55 76.0 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.646 179.835 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 m -83.39 12.57 5.3 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.908 -179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.416 ' CB ' ' HB2' ' A' ' 50' ' ' PRO . 0.2 OUTLIER -129.31 43.36 3.15 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.103 0.478 . . . . 0.0 110.826 179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 54.7 mt -125.53 158.62 34.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.919 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.846 ' HB3' ' HB2' ' A' ' 66' ' ' ARG . . . -119.16 93.71 4.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.054 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.586 HG23 ' CG2' ' A' ' 63' ' ' THR . 28.3 mt -93.68 138.52 20.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.166 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -125.38 99.4 6.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.77 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.464 ' NE2' HG22 ' A' ' 56' ' ' ILE . 0.0 OUTLIER -66.03 129.97 41.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.926 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -166.3 85.17 0.31 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.1 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.76 -124.7 37.05 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.444 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.62 ' CG ' HG23 ' A' ' 35' ' ' THR . 1.1 tt0 -98.67 30.08 3.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.423 ' CE1' ' HA ' ' A' ' 178' ' ' VAL . 6.6 t80 -139.76 126.67 20.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.586 ' CG2' HG23 ' A' ' 56' ' ' ILE . 69.5 m -128.62 129.23 45.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tt0 -96.2 113.82 25.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.755 179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -102.24 113.27 26.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.094 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.846 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 30.2 mtm180 -117.1 103.71 10.5 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.592 179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.464 ' CZ ' HD13 ' A' ' 54' ' ' ILE . 20.8 m-85 -86.24 144.47 27.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.055 -179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 21.2 m -66.43 -28.38 68.56 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.675 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 36.1 tttp -109.54 165.47 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.813 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.469 ' CG ' HG23 ' A' ' 30' ' ' THR . 19.2 mttp -102.72 125.77 49.58 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.514 ' HE2' ' HB3' ' A' ' 47' ' ' PHE . 1.0 OUTLIER -85.66 -30.4 23.24 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.875 -179.866 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.447 ' HB3' HD12 ' A' ' 75' ' ' LEU . 1.9 tpt180 -131.97 67.88 79.77 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.919 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.72 -27.26 51.07 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.501 2.134 . . . . 0.0 112.302 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -68.13 -34.58 76.63 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.447 HD12 ' HB3' ' A' ' 72' ' ' ARG . 13.7 mt -60.51 148.38 38.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -100.34 -52.55 3.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 138.8 136.29 3.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.523 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 14.3 mtp -101.94 170.23 8.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.826 0.346 . . . . 0.0 110.843 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.646 ' O ' HG13 ' A' ' 159' ' ' VAL . 30.9 t -99.2 139.13 21.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.927 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.572 HD21 HG12 ' A' ' 27' ' ' VAL . 3.5 mp -118.34 126.51 52.27 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.943 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -94.21 113.66 25.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.857 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.2 mp0 -79.62 75.47 6.27 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.67 146.82 21.48 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 14.6 m -139.94 154.41 70.55 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.744 0.307 . . . . 0.0 110.952 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.4 -168.07 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.522 2.148 . . . . 0.0 112.313 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -91.79 107.81 19.47 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 141.5 -31.36 2.14 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.577 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.8 m -59.66 115.44 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 0.0 110.967 179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 27.4 t -95.89 108.2 20.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.096 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 50.2 m -85.21 169.04 14.21 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.931 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.572 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.5 OUTLIER -137.21 109.99 7.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.96 179.977 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.614 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 21.6 t -74.25 153.28 6.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.728 HD22 ' CD1' ' A' ' 13' ' ' TRP . 19.0 mt -107.59 96.6 6.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.421 HD11 HD12 ' A' ' 104' ' ' LEU . 28.0 mt -102.47 96.48 4.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.137 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -85.4 172.55 10.96 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.863 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.655 HH22 HD22 ' A' ' 102' ' ' LEU . 18.5 mmt85 -140.08 -174.29 3.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -73.33 -33.85 65.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.0 t -96.3 22.33 7.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.962 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 65.62 24.74 71.27 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.576 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -87.02 84.25 7.35 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.89 0.376 . . . . 0.0 110.82 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.505 HD13 ' CD2' ' A' ' 13' ' ' TRP . 1.5 mt -69.82 143.66 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.898 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.655 HD22 HH22 ' A' ' 96' ' ' ARG . 4.7 tp -129.36 90.11 45.55 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.935 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -73.88 102.56 1.53 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.602 2.202 . . . . 0.0 112.325 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.573 HD21 HD23 ' A' ' 102' ' ' LEU . 38.3 mt -90.52 163.39 14.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.97 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -103.74 134.28 47.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.19 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.513 HG22 ' HG ' ' A' ' 139' ' ' LEU . 20.4 t -142.76 107.23 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.223 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.423 ' HB2' HD13 ' A' ' 129' ' ' LEU . 16.4 ttt180 -68.27 145.35 54.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.1 mmt -88.87 149.77 23.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.947 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -121.82 -145.66 7.16 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.484 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.11 157.78 21.2 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 111.144 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.477 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -88.03 121.77 38.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.062 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -138.95 135.19 34.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.116 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.7 t -80.13 103.96 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . 0.408 ' O ' HG22 ' A' ' 121' ' ' VAL . 0.9 OUTLIER -87.66 146.53 25.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.915 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 19.2 ttm180 -99.45 122.13 42.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.912 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 31.8 mt -137.87 121.57 21.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.137 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 60.44 31.34 20.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 75.9 29.71 58.69 Favored Glycine 0 N--CA 1.453 -0.218 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.483 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 10.5 mtt180 -136.42 136.05 39.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.798 0.332 . . . . 0.0 110.837 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 23.8 mt -88.85 111.63 22.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.935 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.408 HG22 ' O ' ' A' ' 114' ' ' MET . 6.3 m -108.54 126.85 65.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 41.7 m80 -93.31 119.75 32.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.923 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -152.5 139.78 7.24 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.529 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -80.9 115.24 20.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.86 0.362 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.484 ' OG ' HG22 ' A' ' 173' ' ' THR . 0.3 OUTLIER -77.33 163.35 26.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.859 179.911 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.512 ' O ' HG23 ' A' ' 173' ' ' THR . . . -153.36 -164.06 12.29 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.553 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.1 mtp -161.2 122.09 2.81 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.591 ' HB3' HD21 ' A' ' 139' ' ' LEU . 4.2 pp -72.7 161.63 30.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.996 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.433 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.0 mp -146.92 47.78 1.16 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.779 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.9 m -104.57 -32.7 8.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.965 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 142.27 -55.34 0.59 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.505 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.3 67.18 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.911 0.386 . . . . 0.0 111.063 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 -124.8 79.86 1.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.843 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -161.16 121.42 2.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.075 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -93.69 -27.73 16.37 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.921 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.36 -27.85 1.37 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.289 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . 0.478 ' HA ' ' HB1' ' A' ' 166' ' ' ALA . 9.9 mtt -140.49 29.42 1.96 Allowed 'General case' 0 N--CA 1.45 -0.446 0 CA-C-O 121.165 0.507 . . . . 0.0 109.735 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.523 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 1.8 p30 -161.98 164.88 28.11 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.514 -0.767 . . . . 0.0 111.192 -178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.703 ' CD2' HG21 ' A' ' 174' ' ' VAL . 0.1 OUTLIER -99.72 32.01 3.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.072 179.2 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 103.24 26.22 7.06 Favored Glycine 0 N--CA 1.447 -0.604 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.709 -179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.509 HG23 ' HB2' ' A' ' 138' ' ' ASP . 20.5 p -75.61 133.25 40.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.863 0.363 . . . . 0.0 111.212 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.499 ' H ' HD12 ' A' ' 142' ' ' ILE . 0.7 OUTLIER -105.93 -50.64 0.11 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.86 -179.919 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 3.2 Cg_exo -78.33 31.46 0.45 Allowed 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 123.021 2.481 . . . . 0.0 112.614 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 66.68 47.11 70.21 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.183 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.459 ' O ' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -81.25 58.34 3.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.2 0.524 . . . . 0.0 110.731 -179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 11.2 m -90.03 95.71 10.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.163 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.493 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 118.24 10.42 8.87 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.003 -0.618 . . . . 0.0 111.997 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 163' ' ' VAL . . . -45.71 143.21 3.2 Favored Pre-proline 0 CA--C 1.529 0.138 0 CA-C-O 120.647 0.26 . . . . 0.0 111.264 179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.728 ' HG2' HD12 ' A' ' 93' ' ' LEU . 89.6 Cg_endo -78.98 123.0 5.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.618 2.212 . . . . 0.0 112.822 -179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.614 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 5.9 m-85 -81.55 151.47 27.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.547 179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 160' ' ' VAL . 5.6 m -142.49 156.42 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.032 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . . . . . . . . . 39.9 p-80 -170.93 152.67 3.63 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.841 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.427 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 10.0 tttp -79.4 126.54 30.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.166 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 1.2 ttt-85 -128.34 97.38 4.72 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.34 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.22 -106.74 2.1 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.528 -0.844 . . . . 0.0 111.948 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -115.83 36.29 4.08 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.952 0.406 . . . . 0.0 110.343 179.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -166.28 -172.63 2.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.048 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.427 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 3.3 m0 -124.59 120.43 31.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.61 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 79' ' ' VAL . 34.0 t -105.08 140.18 23.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.089 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.917 HG12 HG12 ' A' ' 151' ' ' VAL . 27.6 m -99.79 128.69 51.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.121 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.4 t -65.82 -70.77 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -172.29 -130.05 1.2 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.574 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 147' ' ' GLY . 14.4 m -127.92 148.65 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.593 0.235 . . . . 0.0 110.909 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.523 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 36.4 t-80 -67.12 130.16 42.21 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 120.861 0.363 . . . . 0.0 111.132 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.603 ' HB3' ' O ' ' A' ' 175' ' ' VAL . . . -101.37 -66.09 0.94 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.253 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.478 ' HB1' ' HA ' ' A' ' 137' ' ' MET . . . -176.71 141.29 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.743 ' HB2' HG22 ' A' ' 174' ' ' VAL . . . -107.41 122.82 47.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.234 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.4 145.01 39.66 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.918 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -87.14 -9.2 55.87 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.455 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 22.3 t -70.0 -17.02 63.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.651 -0.249 . . . . 0.0 111.422 -179.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -175.8 31.07 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.897 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 46.68 47.43 14.82 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.91 0.386 . . . . 0.0 111.286 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.512 HG23 ' O ' ' A' ' 126' ' ' GLY . 0.2 OUTLIER -106.17 122.97 47.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.841 -179.969 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.743 HG22 ' HB2' ' A' ' 167' ' ' ALA . 2.4 t -109.84 152.9 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.122 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.603 ' O ' ' HB3' ' A' ' 165' ' ' ALA . 22.3 t -110.92 130.67 63.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.038 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -111.57 135.6 51.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.898 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -110.09 138.5 46.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.056 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 179' ' ' GLN . 11.1 p -163.57 -44.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.182 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.481 ' N ' HG13 ' A' ' 178' ' ' VAL . 0.4 OUTLIER -60.85 147.93 41.16 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.942 179.935 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -145.69 -172.11 3.83 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.35 -137.62 9.68 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.486 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -78.97 153.34 30.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.786 0.327 . . . . 0.0 110.941 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -157.8 -99.13 0.15 Allowed Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.506 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -103.21 -57.01 2.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.794 0.33 . . . . 0.0 110.913 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . 0.405 HG23 ' N ' ' A' ' 186' ' ' ALA . 4.9 t -141.53 -48.33 0.39 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.889 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . 0.405 ' N ' HG23 ' A' ' 185' ' ' THR . . . -84.17 105.27 14.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.084 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . 0.603 HD12 ' HG3' ' A' ' 188' ' ' GLU . 4.2 pp -106.38 -32.97 7.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.017 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.603 ' HG3' HD12 ' A' ' 187' ' ' LEU . 5.4 mt-10 . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.289 -0.862 . . . . 0.0 110.894 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.9 ptt? . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.774 0.321 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 t-160 60.55 89.44 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.008 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -134.09 106.89 7.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.95 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 37.8 m80 -83.99 -59.01 2.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -166.87 162.99 16.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.902 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -96.72 41.93 1.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.836 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 10.2 t60 61.09 90.75 0.06 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -67.16 157.5 84.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.07 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HB2' ' HB2' ' A' ' 12' ' ' LEU . 58.2 Cg_exo -51.97 125.05 16.09 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.586 2.191 . . . . 0.0 112.281 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -62.76 -59.65 0.23 Allowed 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.546 2.164 . . . . 0.0 112.625 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.2 m -50.93 -37.86 46.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.307 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 12' ' ' LEU . 6.0 tt -63.49 -30.83 71.89 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.017 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.849 ' O ' HG12 ' A' ' 16' ' ' VAL . 10.9 m95 -83.83 -31.45 25.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.85 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -70.5 -20.87 62.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.207 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.453 ' NE ' HD21 ' A' ' 75' ' ' LEU . 12.8 mtt85 -56.99 -26.87 60.84 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.478 -0.328 . . . . 0.0 111.023 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.849 HG12 ' O ' ' A' ' 13' ' ' TRP . 14.5 p -70.16 141.42 17.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.991 179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.0 m -136.06 108.9 7.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.844 -179.447 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 0.7 OUTLIER -66.52 111.44 3.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.425 179.016 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' HE1' HG21 ' A' ' 43' ' ' VAL . 16.8 t80 -122.46 135.05 54.58 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.771 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 55.31 -117.74 9.02 Favored Glycine 0 C--N 1.331 0.275 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.419 -179.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.0 m -109.94 32.14 5.32 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.865 0.364 . . . . 0.0 110.628 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -160.95 -170.43 25.55 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.715 -179.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.468 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 22.8 m95 -133.39 138.3 46.22 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.599 0.238 . . . . 0.0 110.679 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.83 -164.87 13.35 Favored Glycine 0 C--N 1.331 0.296 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.552 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.452 ' CE2' ' HB2' ' A' ' 15' ' ' ARG . 17.0 t80 -151.56 152.18 32.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.905 0.383 . . . . 0.0 111.056 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.449 ' CH2' ' CB ' ' A' ' 71' ' ' MET . 87.4 m95 -83.82 98.71 9.87 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.814 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.707 ' CG1' HD13 ' A' ' 33' ' ' ILE . 4.5 m -73.28 -29.84 29.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.106 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -154.07 158.06 32.45 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.732 179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.93 -23.05 19.95 Favored 'Trans proline' 0 C--N 1.342 0.234 0 C-N-CA 122.768 2.312 . . . . 0.0 112.382 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.738 HG22 ' HA ' ' A' ' 70' ' ' LYS . 74.6 p -129.87 13.95 5.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.352 -179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.626 HG22 ' HD2' ' A' ' 66' ' ' ARG . 56.1 t -135.04 142.69 39.39 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.796 0.332 . . . . 0.0 110.999 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -132.99 168.76 17.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.707 HD13 ' CG1' ' A' ' 27' ' ' VAL . 29.1 pt -141.26 157.6 22.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.113 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -173.84 167.2 4.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.777 HG22 ' H ' ' A' ' 37' ' ' HIS . 89.7 m -84.13 147.78 27.15 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.731 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -75.26 -24.23 57.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.497 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.777 ' H ' HG22 ' A' ' 35' ' ' THR . 8.1 t60 -73.62 -33.87 64.75 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.99 0.424 . . . . 0.0 110.643 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.767 HG22 ' HB ' ' A' ' 35' ' ' THR . 32.7 m -93.52 35.9 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.812 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 32.0 t -106.12 114.31 62.61 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.111 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -84.16 -164.98 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.629 2.219 . . . . 0.0 112.227 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.3 t -158.27 28.36 0.25 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.985 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.21 -21.43 7.7 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.459 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.465 HG21 ' HE1' ' A' ' 19' ' ' PHE . 31.2 m -92.93 149.56 4.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.768 0.318 . . . . 0.0 111.186 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 21.8 mmtp -115.07 29.28 8.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 179.99 150.26 0.37 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.665 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.443 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.1 OUTLIER -120.58 133.8 55.34 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 178.518 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 39.49 35.99 0.21 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.4 -179.297 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 65.12 43.26 95.85 Favored Glycine 0 N--CA 1.452 -0.251 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.512 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -122.97 150.91 60.29 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.861 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 110.65 2.58 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.587 2.191 . . . . 0.0 112.391 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.613 ' HA ' HD12 ' A' ' 54' ' ' ILE . 2.5 pt? -53.69 -44.75 70.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.79 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.555 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 2.8 m -59.76 -14.98 16.88 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.636 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -112.88 37.04 3.23 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.398 0.618 . . . . 0.0 110.689 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.621 HG21 ' CD2' ' A' ' 65' ' ' PHE . 94.3 mt -129.86 105.34 11.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.806 179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.791 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -66.83 97.35 0.47 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.068 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.686 HG23 ' CE1' ' A' ' 65' ' ' PHE . 4.3 mt -80.42 142.09 14.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.195 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -142.77 99.53 3.49 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.754 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -79.65 123.9 28.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.967 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.428 ' HB3' ' O ' ' A' ' 62' ' ' PHE . . . -131.95 48.55 2.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.038 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.18 -90.33 1.6 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.544 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -109.38 -29.18 8.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.738 0.304 . . . . 0.0 110.997 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.428 ' O ' ' HB3' ' A' ' 59' ' ' ALA . 3.2 t80 -93.74 108.61 20.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.4 m -103.43 133.2 48.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.889 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -110.23 129.28 55.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.686 ' CE1' HG23 ' A' ' 56' ' ' ILE . 1.9 m-85 -119.5 113.29 20.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.823 -179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.791 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 4.0 tpt180 -100.18 103.59 15.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.567 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 18.2 m-85 -80.31 124.78 29.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 2.8 m -62.81 -23.78 67.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.905 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -104.83 163.87 12.2 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.002 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.738 ' HA ' HG22 ' A' ' 30' ' ' THR . 11.1 ttmt -97.52 109.23 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.717 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.449 ' CB ' ' CH2' ' A' ' 26' ' ' TRP . 4.0 mmt -89.21 -39.16 13.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.898 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.722 ' HG2' HD12 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -106.17 87.64 2.65 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 -179.921 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.84 -27.99 20.63 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.611 2.207 . . . . 0.0 112.371 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -74.56 -29.83 61.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.027 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.722 HD12 ' HG2' ' A' ' 72' ' ' ARG . 1.6 mt -65.9 175.05 2.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.36 -47.17 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 153.22 115.47 0.59 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.559 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.84 170.17 9.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 159' ' ' VAL . 38.5 t -101.56 141.49 17.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.984 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.649 HD23 HG13 ' A' ' 160' ' ' VAL . 6.7 mt -117.4 127.99 54.58 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.901 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -104.71 113.77 27.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.945 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -91.98 75.67 5.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 105.63 156.0 22.1 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.479 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.412 ' HB2' ' HE3' ' A' ' 108' ' ' MET . 1.5 m -164.31 163.55 14.92 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.727 0.299 . . . . 0.0 110.945 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.02 -168.14 0.31 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.602 2.201 . . . . 0.0 112.395 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -92.91 106.35 18.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.911 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 150.28 -29.88 1.08 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.48 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.7 m -59.67 115.41 3.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.696 0.284 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -93.33 116.25 34.06 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 120.883 0.373 . . . . 0.0 111.116 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 13.1 m -95.41 161.91 13.88 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.748 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.4 OUTLIER -137.24 107.92 6.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.913 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.716 ' HB ' HD12 ' A' ' 104' ' ' LEU . 21.5 t -69.13 159.39 5.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.083 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.573 HD22 ' CD2' ' A' ' 13' ' ' TRP . 63.6 mt -113.99 99.11 7.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.14 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.756 HD11 HD11 ' A' ' 104' ' ' LEU . 35.2 mt -100.09 95.56 4.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.987 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.17 162.64 12.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.973 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 7.2 tpt180 -152.22 156.48 39.82 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -60.0 -38.57 83.0 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.91 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.5 t -70.16 -27.31 64.43 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.932 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 104.25 24.83 7.34 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.526 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 23.7 tt0 -88.99 82.28 6.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.819 0.342 . . . . 0.0 110.989 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.684 HD23 ' CE3' ' A' ' 13' ' ' TRP . 7.1 mp -69.83 151.52 45.63 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.9 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.675 ' HB3' HD12 ' A' ' 94' ' ' ILE . 5.9 tp -153.73 88.88 3.55 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.019 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.85 96.39 1.0 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.594 2.196 . . . . 0.0 112.242 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.837 HD13 ' HB3' ' A' ' 139' ' ' LEU . 19.2 mt -63.58 163.41 11.24 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -129.78 101.87 6.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.025 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.475 HG12 ' N ' ' A' ' 107' ' ' ARG . 21.0 t -111.06 158.93 11.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.192 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.475 ' N ' HG12 ' A' ' 106' ' ' VAL . 2.3 ttm-85 -120.01 135.15 55.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . 0.412 ' HE3' ' HB2' ' A' ' 84' ' ' CYS . 4.6 mmt -74.71 129.9 38.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.965 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -109.81 -122.66 4.52 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.496 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.18 149.31 33.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.758 0.313 . . . . 0.0 111.128 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.497 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -96.48 120.41 45.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.005 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 148.14 30.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -87.03 103.38 15.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.91 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -87.41 159.33 18.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.434 ' HA ' HD23 ' A' ' 120' ' ' LEU . 0.1 OUTLIER -90.78 126.86 36.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.932 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 30.9 mt -128.88 108.47 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.129 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 60.68 31.19 20.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.911 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 96.15 -25.66 24.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.51 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.4 ttp180 -99.31 130.33 45.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.858 0.361 . . . . 0.0 110.851 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.462 HD12 ' HB2' ' A' ' 184' ' ' GLU . 12.3 mt -79.33 139.92 37.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.908 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.33 145.39 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.075 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -86.58 127.18 34.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.951 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -160.87 127.21 1.72 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.492 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 3.9 tt0 -77.41 120.31 22.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.854 0.359 . . . . 0.0 110.904 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 49.2 m -85.49 118.85 25.27 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.808 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -127.59 146.97 16.91 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.537 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 4.2 ttp -89.92 163.41 14.99 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.858 0.361 . . . . 0.0 110.825 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.506 HD21 ' HA ' ' A' ' 172' ' ' ASN . 0.1 OUTLIER -105.66 121.71 44.55 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.927 179.888 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.406 HD11 ' CZ ' ' A' ' 107' ' ' ARG . 15.6 mt -102.51 83.82 2.35 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.978 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.746 HG21 HD22 ' A' ' 133' ' ' ASN . 61.8 m -155.42 -45.16 0.08 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.007 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.83 22.18 62.08 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.589 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.27 36.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.723 0.297 . . . . 0.0 111.104 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.746 HD22 HG21 ' A' ' 130' ' ' THR . 1.7 m-20 -141.62 75.57 1.5 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.723 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.89 130.2 0.24 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.241 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.11 -35.46 13.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.654 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.46 -27.12 0.68 Allowed Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.115 -179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . 0.799 ' HA ' ' HB3' ' A' ' 167' ' ' ALA . 8.6 mtm -140.87 29.39 1.89 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.127 0.489 . . . . 0.0 109.707 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.55 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 11.1 p30 -160.81 -174.69 4.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.237 -178.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.837 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -97.82 30.67 2.91 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.026 0.441 . . . . 0.0 110.468 179.56 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.21 30.64 7.28 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.917 -0.659 . . . . 0.0 112.246 -179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.485 HG21 ' O ' ' A' ' 145' ' ' ASP . 18.6 p -81.67 162.99 22.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.831 0.348 . . . . 0.0 111.019 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.421 ' O ' ' N ' ' A' ' 144' ' ' GLY . 0.8 OUTLIER -109.53 165.9 11.79 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.272 -179.938 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -44.5 89.18 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.962 2.442 . . . . 0.0 112.807 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 142' ' ' ILE . . . 118.85 20.35 4.17 Favored Glycine 0 N--CA 1.45 -0.385 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.935 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.485 ' O ' HG21 ' A' ' 141' ' ' THR . 0.3 OUTLIER -123.23 77.06 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.124 0.488 . . . . 0.0 110.702 179.69 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.647 ' O ' HG11 ' A' ' 38' ' ' VAL . 1.6 m -128.23 110.03 12.03 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.173 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 117.8 11.64 8.37 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.196 -179.306 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -48.02 136.58 11.13 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-O 120.626 0.25 . . . . 0.0 111.09 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.531 ' HG2' HD12 ' A' ' 93' ' ' LEU . 90.5 Cg_endo -78.86 127.51 7.87 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.626 2.217 . . . . 0.0 112.884 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.85 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.9 m-85 -83.82 153.18 24.21 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.43 179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 91' ' ' SER . 28.5 m -143.03 154.25 17.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.061 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.452 ' N ' ' CE3' ' A' ' 158' ' ' TRP . 49.1 p-80 -168.76 167.25 11.27 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.799 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 6.9 tttp -94.65 133.06 38.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.222 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.555 ' HB3' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -132.04 96.13 3.84 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.369 179.6 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.38 -110.31 3.05 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.032 -179.428 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -110.89 35.92 3.33 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.9 0.381 . . . . 0.0 110.257 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -168.04 -170.43 1.33 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.871 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.505 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 6.1 m95 -127.32 134.65 49.97 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.577 179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.555 HG23 ' HB3' ' A' ' 154' ' ' ARG . 25.7 t -115.7 143.93 24.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.9 0.381 . . . . 0.0 111.287 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.85 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.4 p -96.96 126.32 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.989 179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.407 ' HB3' ' HB2' ' A' ' 150' ' ' TYR . 53.0 t -71.84 -72.6 0.22 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.984 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -170.39 -139.94 2.87 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.713 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.422 HG12 ' O ' ' A' ' 147' ' ' GLY . 15.4 m -127.87 158.2 39.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.496 0.189 . . . . 0.0 110.89 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.55 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 18.5 t-80 -77.84 137.4 38.38 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.919 0.39 . . . . 0.0 111.26 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -111.99 -70.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.101 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -163.92 174.36 11.56 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.082 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.799 ' HB3' ' HA ' ' A' ' 137' ' ' MET . . . -112.67 170.28 8.3 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.209 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.19 179.83 5.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.912 -179.947 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 63.0 pttt -71.45 -22.69 61.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -70.06 -16.95 63.22 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.186 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 86.04 -55.12 4.78 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.596 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.506 ' HA ' HD21 ' A' ' 128' ' ' LEU . 24.9 m-20 -88.73 53.44 2.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.402 . . . . 0.0 110.908 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 5.1 m -160.23 116.34 2.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.827 HG21 HD23 ' A' ' 139' ' ' LEU . 6.3 m -118.59 169.9 8.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.212 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.5 t -127.87 121.42 56.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.097 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 86.2 m -87.58 129.81 34.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 178' ' ' VAL . . . -76.08 107.85 8.58 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.418 HG13 ' O ' ' A' ' 177' ' ' ALA . 23.1 m -156.87 141.83 8.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 60.32 108.47 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.878 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -142.52 131.18 22.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 161.14 -28.47 0.3 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.593 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -131.42 129.41 41.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 111.001 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -140.45 -66.53 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . 0.462 ' HB2' HD12 ' A' ' 120' ' ' LEU . 31.1 tt0 -106.34 -70.05 0.8 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.897 0.38 . . . . 0.0 110.927 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 3.0 t -111.37 -38.7 4.9 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 60.54 88.67 0.08 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.078 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 11.1 mt -69.05 -31.86 70.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.835 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.191 -0.909 . . . . 0.0 110.813 -179.867 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.851 0.357 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 4.4 m80 -106.39 -176.61 3.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.898 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -109.46 37.65 2.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.953 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -60.09 -57.22 13.75 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.913 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER 60.73 -170.05 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 19.6 m-70 -80.8 -176.62 5.94 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -66.83 -68.09 0.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.94 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -98.37 149.29 35.58 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.008 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.774 ' HD2' HD13 ' A' ' 12' ' ' LEU . 50.9 Cg_exo -53.84 151.94 24.57 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.62 2.213 . . . . 0.0 112.338 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.99 -60.26 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.559 2.173 . . . . 0.0 112.405 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 56.4 m -52.1 -26.66 11.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.296 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.774 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.0 tt -63.54 -30.5 71.61 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.011 -179.741 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.684 ' O ' HG12 ' A' ' 16' ' ' VAL . 96.9 m95 -83.74 -32.94 25.2 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.817 179.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -77.43 -20.79 54.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.448 ' CB ' ' CE1' ' A' ' 25' ' ' PHE . 28.3 mtm-85 -55.48 -27.54 49.01 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.996 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 13' ' ' TRP . 10.3 p -71.07 141.16 17.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.971 179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.4 m -141.14 109.2 5.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.771 0.32 . . . . 0.0 111.719 -179.459 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' CG ' ' CE2' ' A' ' 23' ' ' TRP . 4.5 tmtt? -66.42 111.31 3.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.926 0.393 . . . . 0.0 110.513 179.248 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -125.75 137.39 53.81 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.667 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 56.28 -121.43 23.99 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.436 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.588 ' O ' HG11 ' A' ' 38' ' ' VAL . 57.8 m -107.16 27.41 9.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.747 0.308 . . . . 0.0 110.748 179.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 145' ' ' ASP . . . -158.8 -170.39 23.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.587 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.467 ' CE2' ' CG ' ' A' ' 18' ' ' LYS . 20.4 m95 -129.83 143.03 50.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.722 0.296 . . . . 0.0 110.617 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.9 -160.6 11.69 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.617 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.448 ' CE1' ' CB ' ' A' ' 15' ' ' ARG . 2.7 t80 -151.57 147.76 27.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.753 0.311 . . . . 0.0 110.949 -179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.42 ' HA ' ' CD1' ' A' ' 32' ' ' PHE . 62.6 m95 -79.69 98.47 6.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.929 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.545 HG11 ' CG2' ' A' ' 33' ' ' ILE . 4.9 m -78.31 -23.96 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -163.22 157.6 17.44 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.716 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -53.54 -23.56 25.65 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.677 2.251 . . . . 0.0 112.378 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.527 HG22 ' HG2' ' A' ' 70' ' ' LYS . 0.1 OUTLIER -126.96 3.95 6.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.324 179.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' CG2' ' A' ' 27' ' ' VAL . 41.1 t -125.99 142.46 42.61 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.879 0.371 . . . . 0.0 111.187 -179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . 0.459 ' HA ' HG22 ' A' ' 27' ' ' VAL . 13.3 t80 -139.05 155.31 48.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.943 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.658 ' O ' HD12 ' A' ' 33' ' ' ILE . 2.8 pp -127.06 145.83 33.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.125 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 9.9 t -156.21 167.23 31.07 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.81 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.57 HG22 ' H ' ' A' ' 37' ' ' HIS . 96.0 m -84.39 126.35 33.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.718 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.822 ' O ' HG12 ' A' ' 39' ' ' VAL . 1.5 m -73.02 -16.69 61.49 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.372 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.57 ' H ' HG22 ' A' ' 35' ' ' THR . 8.6 t60 -71.17 -26.66 63.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.714 0.292 . . . . 0.0 110.932 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.588 HG11 ' O ' ' A' ' 21' ' ' SER . 0.0 OUTLIER -111.3 -9.08 11.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.575 -179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.822 HG12 ' O ' ' A' ' 36' ' ' THR . 13.2 p -50.65 124.0 18.82 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-O 120.634 0.254 . . . . 0.0 111.188 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -84.92 -165.41 0.29 Allowed 'Trans proline' 0 N--CA 1.46 -0.495 0 C-N-CA 122.649 2.233 . . . . 0.0 112.358 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.0 t -156.71 27.27 0.33 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.869 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -105.1 -23.03 7.91 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.424 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 31.4 m -83.16 147.61 5.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 111.006 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 6.3 mttm -124.16 27.06 7.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.019 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 177.55 150.17 0.19 Allowed 'General case' 0 CA--C 1.514 -0.405 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.576 179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.453 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.5 OUTLIER -125.03 133.65 52.87 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.205 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 5.9 m-85 40.75 35.55 0.33 Allowed 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.467 -179.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 77.0 35.24 39.52 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.744 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.8 mm-40 -123.29 114.32 29.11 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.511 0.196 . . . . 0.0 110.615 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.33 132.64 30.06 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.396 2.064 . . . . 0.0 112.477 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.562 ' HA ' HD12 ' A' ' 54' ' ' ILE . 6.7 mt -51.47 -26.08 7.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 11.6 p -57.3 -19.83 24.61 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.438 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 42.0 m -121.18 40.06 3.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.184 0.516 . . . . 0.0 110.858 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.562 HD12 ' HA ' ' A' ' 51' ' ' LEU . 47.9 mt -129.39 157.97 42.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.943 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.822 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.01 93.78 3.67 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.018 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.462 HD12 ' CZ ' ' A' ' 65' ' ' PHE . 4.3 tt -80.8 142.27 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.178 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -160.64 99.46 1.27 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.857 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -101.48 176.43 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.961 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 48.44 0.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.052 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 114.41 -79.67 0.28 Allowed Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.414 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 11.0 mm-40 -134.81 31.23 3.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.868 0.366 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.404 ' CG ' ' O ' ' A' ' 178' ' ' VAL . 79.3 t80 -147.12 101.54 3.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.906 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 59.7 m -96.95 115.67 27.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.959 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tt0 -96.19 113.75 25.38 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.875 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . 0.462 ' CZ ' HD12 ' A' ' 56' ' ' ILE . 9.1 m-85 -95.3 113.32 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.822 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 5.7 tpt180 -104.39 105.9 16.19 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.67 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.45 ' CE2' ' CD1' ' A' ' 54' ' ' ILE . 54.0 m-85 -87.51 151.98 22.58 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.997 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 9.1 t -75.21 -21.95 58.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.879 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.0 tmtt? -128.47 161.18 30.11 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.89 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.527 ' HG2' HG22 ' A' ' 30' ' ' THR . 44.6 mttt -97.91 113.67 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.568 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -84.14 -28.83 27.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.731 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.4 73.29 0.37 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.814 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.68 -26.98 45.48 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.642 2.228 . . . . 0.0 112.332 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.28 -28.91 68.41 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -66.42 147.29 53.52 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.897 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 m -107.56 -31.26 8.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 132.85 158.63 8.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.537 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 23.6 mmm -128.81 139.34 52.22 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.922 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.18 106.21 17.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.059 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 10.9 mp -83.74 144.47 29.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.87 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -107.39 106.51 16.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -74.18 81.29 1.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.867 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.59 166.84 42.09 Favored Glycine 0 N--CA 1.453 -0.225 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.401 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 4.8 p -167.71 157.2 9.09 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 120.704 0.288 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.59 -173.31 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.614 2.209 . . . . 0.0 112.238 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -91.07 142.76 27.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.994 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 110.83 -26.03 13.47 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.531 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.7 m -55.75 145.82 23.06 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.73 0.3 . . . . 0.0 110.966 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.5 t -117.9 108.2 23.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.08 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 9.5 m -88.34 166.91 13.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.892 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -137.26 109.89 7.52 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.796 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.754 HG22 ' CZ ' ' A' ' 150' ' ' TYR . 16.6 t -68.5 157.98 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.638 HD22 ' CZ3' ' A' ' 13' ' ' TRP . 7.2 mt -128.24 82.36 2.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.893 179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.762 HD13 ' HA ' ' A' ' 141' ' ' THR . 26.4 mt -81.81 124.15 38.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.131 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.87 155.81 30.59 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.932 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -139.12 166.44 24.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.88 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.8 -38.37 83.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.882 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m -69.18 -28.19 66.18 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.886 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.19 24.74 7.04 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.659 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -96.63 87.71 4.44 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.579 HD23 ' O ' ' A' ' 94' ' ' ILE . 2.4 mt -69.71 154.34 42.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.926 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.482 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.2 tp -142.93 86.1 9.54 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.955 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.81 103.36 1.56 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.572 2.182 . . . . 0.0 112.331 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.514 ' CD1' HD11 ' A' ' 94' ' ' ILE . 50.8 mt -97.53 163.45 12.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.947 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -123.22 146.13 48.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.128 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.553 HG11 HG22 ' A' ' 174' ' ' VAL . 29.8 t -147.61 137.74 16.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.064 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 42.3 mtt85 -93.19 128.2 39.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.887 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 12.0 mmt -71.1 132.19 44.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.942 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -102.38 -120.18 4.69 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.498 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 145.4 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.787 0.327 . . . . 0.0 111.102 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.554 HG23 ' O ' ' A' ' 111' ' ' ILE . 1.1 tp -89.22 114.65 27.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -128.93 177.49 7.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.066 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -102.8 107.0 17.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.917 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 1.2 mtt -84.69 148.71 26.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.96 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 29.6 ttt180 -96.91 127.94 43.37 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.825 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 3.9 mp -135.45 108.76 9.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.19 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 60.38 33.62 20.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.59 28.43 43.29 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 5.7 mmm180 -135.3 131.62 36.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.814 0.34 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.1 mt -87.21 121.88 30.25 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.884 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -127.6 135.8 62.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -76.7 126.85 31.7 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.902 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -155.06 138.65 6.21 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.5 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -94.67 126.7 40.14 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.803 0.335 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.3 m -84.59 -179.69 7.19 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.899 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 173.53 134.11 1.78 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.53 ' HG2' HG23 ' A' ' 173' ' ' THR . 5.2 mtp -90.66 151.3 21.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.847 0.355 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 139' ' ' LEU . 4.2 pp -106.38 148.15 28.42 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.42 75.82 0.94 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.844 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 2.0 m -142.19 -46.51 0.34 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 173.66 -89.71 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.54 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -175.59 40.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.069 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -59.46 127.33 31.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.897 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -162.82 126.64 2.94 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.151 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.4 -38.22 6.9 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.783 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 154.03 -24.99 0.71 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.238 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 18.4 mtm -139.01 29.8 2.26 Favored 'General case' 0 N--CA 1.451 -0.413 0 CA-C-O 121.242 0.544 . . . . 0.0 109.693 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 2.8 p30 -160.02 167.5 27.76 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.989 -178.785 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.668 HD23 ' CB ' ' A' ' 167' ' ' ALA . 0.2 OUTLIER -140.97 59.84 1.53 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.057 0.455 . . . . 0.0 110.849 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.43 ' O ' HD11 ' A' ' 104' ' ' LEU . . . 171.38 -47.27 0.19 Allowed Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.148 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.762 ' HA ' HD13 ' A' ' 94' ' ' ILE . 3.6 p -74.11 -174.8 2.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.783 0.325 . . . . 0.0 110.595 179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.495 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.9 OUTLIER -136.05 -55.57 0.02 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.96 -179.839 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.495 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 16.3 Cg_exo -72.08 49.55 1.34 Allowed 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.867 2.378 . . . . 0.0 112.475 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 45.77 51.63 10.24 Favored Glycine 0 CA--C 1.516 0.153 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.547 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.601 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.2 OUTLIER -73.38 -75.82 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.833 0.349 . . . . 0.0 110.882 -179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.1 m 63.59 148.07 0.03 OUTLIER 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.244 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.431 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 77.88 0.65 75.96 Favored Glycine 0 CA--C 1.52 0.393 0 C-N-CA 120.531 -0.843 . . . . 0.0 112.774 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . . . . . . . . . . . -46.65 141.5 5.25 Favored Pre-proline 0 CA--C 1.529 0.141 0 CA-C-N 116.736 0.268 . . . . 0.0 111.292 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -81.66 138.14 10.51 Favored 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.575 2.183 . . . . 0.0 112.832 -179.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.754 ' CZ ' HG22 ' A' ' 92' ' ' VAL . 4.8 m-85 -105.51 139.33 40.28 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.544 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 93' ' ' LEU . 29.4 m -151.79 150.24 13.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.958 0.409 . . . . 0.0 111.298 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.593 ' CD2' HG23 ' A' ' 159' ' ' VAL . 3.2 p-80 -133.41 153.51 51.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.798 179.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . . . . . . . . . 7.3 tptt -120.17 120.23 35.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.092 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . . . . . . . . . 24.9 mtp180 -121.46 106.47 11.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.19 179.516 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.44 -106.97 2.15 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.618 -179.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.0 14.78 10.73 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.722 0.296 . . . . 0.0 110.614 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.63 138.8 54.18 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.006 -179.394 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.466 ' CE3' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -119.78 127.19 52.57 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.589 179.714 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 152' ' ' HIS . 0.0 OUTLIER -116.97 169.73 7.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.939 0.399 . . . . 0.0 111.159 -179.844 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 150' ' ' TYR . 11.2 p -131.26 143.13 41.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.976 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 51.2 t -93.75 -75.18 0.51 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.937 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -169.1 -136.86 2.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.543 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.431 HG12 ' O ' ' A' ' 147' ' ' GLY . 3.4 m -127.9 155.48 39.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 59.0 t-80 -70.86 120.66 16.77 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.887 0.375 . . . . 0.0 110.941 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -98.29 -50.0 4.49 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.225 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 175' ' ' VAL . . . -176.62 174.48 1.85 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.102 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.668 ' CB ' HD23 ' A' ' 139' ' ' LEU . . . -101.34 169.18 9.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.154 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . 0.489 HG22 ' H ' ' A' ' 169' ' ' LYS . 0.2 OUTLIER -92.14 179.87 5.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.964 179.931 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . 0.489 ' H ' HG22 ' A' ' 168' ' ' THR . 16.1 pttp -64.88 -28.26 69.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.038 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 50.6 m -70.12 -17.04 63.19 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.221 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . 0.497 ' O ' HD21 ' A' ' 139' ' ' LEU . . . 84.93 -56.03 5.0 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.536 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 173' ' ' THR . 2.2 m120 -83.09 59.06 4.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.941 0.4 . . . . 0.0 110.833 -179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.53 HG23 ' HG2' ' A' ' 127' ' ' MET . 1.2 p -160.2 144.27 14.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.969 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.553 HG22 HG11 ' A' ' 106' ' ' VAL . 27.1 m -109.97 171.31 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.986 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.671 HG23 ' O ' ' A' ' 166' ' ' ALA . 35.5 t -128.02 105.51 13.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.965 179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 23.2 m -77.74 118.91 20.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -120.49 131.14 54.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.08 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.404 ' O ' ' CG ' ' A' ' 62' ' ' PHE . 21.6 t -145.72 -66.9 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.137 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 27.0 mm100 58.91 31.29 21.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.924 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -60.44 87.35 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.063 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.66 173.6 43.84 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.58 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.4 pt-20 -59.17 122.16 13.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.888 0.375 . . . . 0.0 111.005 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -136.52 -69.52 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.526 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -94.39 -36.33 11.97 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.865 0.364 . . . . 0.0 110.881 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.59 31.06 3.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -60.34 -53.21 60.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.037 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.17 -31.81 71.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.906 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 7.5 tm-20 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.264 -0.874 . . . . 0.0 110.992 179.946 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 120.774 0.321 . . . . 0.0 111.22 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 27.8 m80 68.6 -68.12 0.19 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.895 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 55.7 m-70 -124.85 -175.47 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.923 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -99.58 -67.95 0.83 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.855 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.1 m170 -73.74 -176.55 2.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.929 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -122.21 -176.47 3.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.901 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -175.38 140.9 0.51 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.456 ' HB3' ' HE1' ' A' ' 13' ' ' TRP . . . -85.61 144.55 40.19 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.033 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.804 ' HD2' HD13 ' A' ' 12' ' ' LEU . 53.0 Cg_exo -54.82 154.77 19.95 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.553 2.169 . . . . 0.0 112.331 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -61.72 -59.57 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.715 2.277 . . . . 0.0 112.368 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 74' ' ' ASP . 61.5 m -54.46 -29.6 50.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.11 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.804 HD13 ' HD2' ' A' ' 9' ' ' PRO . 4.6 tt -63.04 -28.65 70.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.611 ' O ' HG12 ' A' ' 16' ' ' VAL . 29.3 m0 -78.41 -33.51 48.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.742 179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 50.1 m -74.03 -20.96 60.14 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.169 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.46 ' HB2' ' CE1' ' A' ' 25' ' ' PHE . 12.2 mtm-85 -56.42 -30.57 62.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.956 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.629 HG22 ' HE3' ' A' ' 23' ' ' TRP . 8.9 p -63.8 137.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.3 m -142.47 108.79 5.27 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.816 -179.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB3' ' CE2' ' A' ' 23' ' ' TRP . 0.0 OUTLIER -66.14 132.93 49.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.023 0.44 . . . . 0.0 110.735 179.346 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 6.0 t80 -139.04 106.64 5.59 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.119 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.401 ' HA3' ' HD3' ' A' ' 40' ' ' PRO . . . 75.2 -110.52 3.08 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.943 -179.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.7 m -114.11 16.08 18.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.944 0.402 . . . . 0.0 110.807 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -138.28 -169.62 11.64 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.18 -179.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.629 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.1 m95 -142.31 142.81 32.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.592 0.234 . . . . 0.0 110.476 -179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -117.79 -167.06 14.09 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.51 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.519 ' CE1' HD12 ' A' ' 93' ' ' LEU . 1.2 t80 -147.15 150.85 35.77 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.8 0.333 . . . . 0.0 111.01 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.586 ' HB3' HD13 ' A' ' 75' ' ' LEU . 56.9 m95 -89.86 101.67 14.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.631 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 31' ' ' VAL . 6.6 m -79.79 -23.95 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.182 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -169.47 166.06 6.05 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -64.19 -13.5 38.29 Favored 'Trans proline' 0 C--N 1.343 0.245 0 C-N-CA 122.526 2.15 . . . . 0.0 112.562 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.21 -0.45 5.77 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.537 HG12 HG21 ' A' ' 27' ' ' VAL . 40.8 t -130.27 142.62 43.29 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 CA-C-O 120.943 0.401 . . . . 0.0 111.429 -179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -137.57 163.26 31.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.974 179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 10.2 pt -134.34 152.81 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.052 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -173.84 162.6 4.0 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.957 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.726 HG21 ' CE1' ' A' ' 37' ' ' HIS . 2.8 m -84.27 171.69 12.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.55 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.486 ' H ' HG22 ' A' ' 35' ' ' THR . 0.2 OUTLIER -107.38 -28.8 9.64 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.255 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.726 ' CE1' HG21 ' A' ' 35' ' ' THR . 9.5 p-80 -70.83 -17.63 62.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.497 HG13 ' CD2' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -116.41 36.46 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.926 0.393 . . . . 0.0 111.43 -179.767 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.43 ' CG2' ' HA ' ' A' ' 36' ' ' THR . 41.3 t -105.66 122.06 43.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.949 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.461 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 88.8 Cg_endo -82.74 -164.22 0.26 Allowed 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.703 2.269 . . . . 0.0 112.236 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.4 m -152.99 31.17 0.49 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.837 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -103.32 -30.71 5.24 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.43 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 28.5 m -86.19 166.54 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.808 0.337 . . . . 0.0 111.03 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.22 29.38 1.63 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.02 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 178.51 150.23 0.24 Allowed 'General case' 0 CA--C 1.515 -0.368 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.692 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' CD1' ' N ' ' A' ' 46' ' ' PHE . 0.3 OUTLIER -124.67 133.8 53.09 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.292 -0.632 . . . . 0.0 109.292 178.449 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER 38.92 35.47 0.12 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.161 0.505 . . . . 0.0 111.459 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 78.25 40.13 20.85 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.629 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.466 ' O ' HD11 ' A' ' 54' ' ' ILE . 5.6 mp0 -134.03 91.27 24.44 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 120.634 0.254 . . . . 0.0 110.781 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -48.97 140.81 23.29 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.533 2.156 . . . . 0.0 112.51 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.601 ' HA ' HD12 ' A' ' 54' ' ' ILE . 9.1 mt -55.61 -27.52 50.01 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.064 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 60.6 p -55.94 -21.5 21.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.378 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -120.77 39.94 3.65 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.191 0.52 . . . . 0.0 110.657 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.601 HD12 ' HA ' ' A' ' 51' ' ' LEU . 53.9 mt -131.43 158.45 43.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.877 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.941 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -129.65 106.9 9.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.058 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 63' ' ' THR . 23.5 mt -94.76 140.39 16.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.184 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -142.13 99.41 3.51 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.882 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -78.85 155.21 29.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.978 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -175.61 75.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.052 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.4 73.06 0.52 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.464 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 59.19 28.28 17.54 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.719 0.295 . . . . 0.0 110.898 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . 0.442 ' CD2' ' HB3' ' A' ' 179' ' ' GLN . 25.9 t80 -134.92 101.51 4.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.826 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.535 ' CG2' HG23 ' A' ' 56' ' ' ILE . 7.7 m -110.38 118.69 36.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.006 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.9 mm-40 -96.24 113.82 25.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -91.89 113.32 25.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.96 -179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.941 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 0.2 OUTLIER -109.09 103.78 12.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.619 179.823 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . . . . . . . . . 81.0 m-85 -82.65 153.58 25.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.023 -179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.7 p -96.83 28.17 3.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.819 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -161.26 128.88 4.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.86 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 1.4 mptt -86.65 90.91 8.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.597 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.13 -54.16 38.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.703 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 27.6 ttm180 52.01 60.93 13.0 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.062 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.26 -32.74 15.95 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.518 2.145 . . . . 0.0 112.255 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HG21 ' A' ' 11' ' ' THR . 0.7 OUTLIER -173.07 35.85 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.586 HD13 ' HB3' ' A' ' 26' ' ' TRP . 8.9 mt -115.5 172.16 7.28 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.915 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.1 m -140.79 -47.27 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.92 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 146.51 112.53 0.74 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.595 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 6.2 mmt -105.8 170.14 8.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.807 0.337 . . . . 0.0 110.866 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.6 t -107.63 141.43 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.917 HD12 HG13 ' A' ' 160' ' ' VAL . 8.0 tp -110.19 130.22 55.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.928 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -106.18 106.49 17.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.939 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 180' ' ' ALA . 1.2 pm0 -73.37 78.65 1.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.764 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 102.72 150.97 23.04 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.388 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -141.95 151.65 59.89 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 120.706 0.289 . . . . 0.0 110.935 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -71.22 -168.14 0.32 Allowed 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.555 2.17 . . . . 0.0 112.3 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -96.38 112.37 24.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 133.15 -28.15 3.35 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 4.4 m -59.29 115.47 3.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.734 0.302 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.86 108.14 19.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.88 0.371 . . . . 0.0 111.149 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.3 m -87.14 167.16 14.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.032 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.806 ' O ' HG22 ' A' ' 151' ' ' VAL . 0.6 OUTLIER -137.24 103.44 5.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.79 179.993 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.667 ' CB ' HD12 ' A' ' 104' ' ' LEU . 21.7 t -66.55 159.14 4.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.058 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.649 HD11 HD23 ' A' ' 12' ' ' LEU . 37.0 mt -115.99 94.5 4.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.915 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.769 HD12 ' HB3' ' A' ' 102' ' ' LEU . 28.5 mt -92.66 138.36 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.049 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.436 ' HB3' ' CH2' ' A' ' 23' ' ' TRP . 2.0 ttpp -115.67 165.28 13.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.511 ' NH2' HD13 ' A' ' 142' ' ' ILE . 40.9 mtt-85 -152.25 -176.05 5.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -77.73 -33.92 52.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.95 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 64.8 p -96.17 22.34 7.77 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.088 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 60.51 24.79 62.21 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.605 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 70.1 tt0 -77.77 87.5 4.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.853 0.359 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.76 120.4 15.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.832 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.769 ' HB3' HD12 ' A' ' 94' ' ' ILE . 8.4 tp -110.13 89.97 9.05 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.7 99.19 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.554 2.169 . . . . 0.0 112.267 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.813 HD13 ' HB3' ' A' ' 139' ' ' LEU . 14.6 mt -66.64 163.41 19.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.946 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -132.21 113.19 12.97 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.111 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 127' ' ' MET . 21.5 t -131.52 146.57 33.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 14.6 ttt180 -104.72 117.94 35.33 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.844 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.0 150.62 28.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.966 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -123.99 -125.26 2.97 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.12 154.78 26.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.802 0.334 . . . . 0.0 111.162 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.863 HD12 ' NE2' ' A' ' 124' ' ' GLN . 17.9 tt -91.66 115.38 30.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.031 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -147.6 169.91 18.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.109 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 84.1 p -86.72 102.24 14.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 5.6 mtp -86.17 150.01 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.4 ttt85 -106.46 109.54 21.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 4.7 mt -110.18 110.73 33.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.056 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 60.4 31.35 20.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 81.62 28.51 42.89 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.463 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.429 ' O ' HG23 ' A' ' 121' ' ' VAL . 2.7 mmp_? -130.57 107.9 9.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.86 0.362 . . . . 0.0 110.837 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.8 mt -65.45 122.49 17.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.928 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.429 HG23 ' O ' ' A' ' 119' ' ' ARG . 21.5 t -135.44 144.76 33.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.103 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -93.51 117.28 29.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -161.17 146.46 12.34 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.497 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . 0.863 ' NE2' HD12 ' A' ' 111' ' ' ILE . 6.7 mp0 -74.42 146.78 42.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.878 179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.43 ' OG ' HG21 ' A' ' 173' ' ' THR . 0.3 OUTLIER -70.46 179.59 2.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.817 ' O ' HG22 ' A' ' 174' ' ' VAL . . . -178.15 95.85 0.1 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.451 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . 0.463 ' O ' HG13 ' A' ' 106' ' ' VAL . 6.0 ttt -76.36 141.88 41.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.828 0.347 . . . . 0.0 110.856 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.686 ' CD2' ' HB2' ' A' ' 134' ' ' ALA . 2.6 mp -78.28 148.4 33.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.873 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.415 HD12 ' C ' ' A' ' 128' ' ' LEU . 3.8 mp -143.13 47.7 1.51 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.43 31.25 1.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.51 27.04 18.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.574 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . 61.59 31.17 18.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.793 0.33 . . . . 0.0 111.108 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -72.74 94.86 1.82 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.835 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.686 ' HB2' ' CD2' ' A' ' 128' ' ' LEU . . . -163.23 156.96 19.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.061 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 7.8 tptm -109.09 -30.0 8.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.976 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 148.01 -26.26 1.44 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.502 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 2.4 mtt -138.72 30.56 2.3 Favored 'General case' 0 N--CA 1.451 -0.414 0 CA-C-O 121.226 0.536 . . . . 0.0 109.653 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.614 ' HB2' HG23 ' A' ' 141' ' ' THR . 1.6 p30 -162.01 165.54 27.21 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.158 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.813 ' HB3' HD13 ' A' ' 104' ' ' LEU . 0.1 OUTLIER -101.58 31.3 3.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.044 0.45 . . . . 0.0 110.235 179.421 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 108.28 26.78 5.3 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.09 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.638 HG21 ' O ' ' A' ' 145' ' ' ASP . 6.2 p -82.77 133.24 35.15 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 120.714 0.292 . . . . 0.0 110.847 -179.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.511 HD13 ' NH2' ' A' ' 96' ' ' ARG . 0.5 OUTLIER -108.64 -51.96 0.07 OUTLIER Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.054 -179.526 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.464 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 2.5 Cg_endo -82.4 25.62 0.66 Allowed 'Trans proline' 0 C--N 1.349 0.582 0 C-N-CA 122.857 2.371 . . . . 0.0 112.828 -179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 79.83 41.31 12.81 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.135 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.638 ' O ' HG21 ' A' ' 141' ' ' THR . 0.4 OUTLIER -83.29 57.48 4.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.069 0.462 . . . . 0.0 111.036 -179.859 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.3 m -90.86 165.1 13.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.999 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.414 ' O ' HG12 ' A' ' 163' ' ' VAL . . . 63.05 7.42 17.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.35 -0.928 . . . . 0.0 112.687 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.476 ' HA ' ' HD3' ' A' ' 149' ' ' PRO . . . -49.07 132.72 15.61 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 122.695 -0.297 . . . . 0.0 111.111 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 148' ' ' ALA . 25.4 Cg_exo -62.92 141.83 85.84 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.566 2.177 . . . . 0.0 112.516 -179.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.645 ' O ' HG23 ' A' ' 160' ' ' VAL . 8.4 m-85 -110.12 142.54 41.47 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.474 179.5 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.806 HG22 ' O ' ' A' ' 91' ' ' SER . 34.7 m -133.47 174.49 13.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.911 0.386 . . . . 0.0 111.09 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.425 ' HA ' ' CZ3' ' A' ' 158' ' ' TRP . 53.8 p-80 -176.7 153.01 1.05 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.666 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.433 ' HD2' ' CD1' ' A' ' 158' ' ' TRP . 12.2 tptt -80.96 125.25 29.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.165 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.499 ' HB2' HG23 ' A' ' 159' ' ' VAL . 0.0 OUTLIER -126.44 96.71 4.78 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.354 179.703 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.35 -106.9 2.13 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.912 -179.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 4.4 m120 -115.79 36.59 3.94 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.914 0.387 . . . . 0.0 110.288 179.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.91 -176.31 3.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.898 -179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.465 ' HZ3' HG23 ' A' ' 151' ' ' VAL . 9.8 m95 -123.7 122.51 38.28 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.555 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 79' ' ' VAL . 15.8 t -103.41 146.27 11.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.858 0.361 . . . . 0.0 111.317 -179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.917 HG13 HD12 ' A' ' 80' ' ' LEU . 13.2 p -94.42 126.2 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.121 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . . . . . . . . . 52.3 t -74.4 -73.94 0.21 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.991 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -168.75 -130.42 1.19 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.659 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 147' ' ' GLY . 9.4 m -135.39 159.27 40.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.704 0.288 . . . . 0.0 111.057 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.475 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 19.6 t-80 -72.52 139.14 47.41 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.97 0.414 . . . . 0.0 110.959 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . . . . . . . . . . . -119.56 -77.78 0.58 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.307 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -153.05 174.47 14.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.179 -179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.903 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -142.5 -178.01 5.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.131 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -92.15 171.31 9.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.821 179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.06 -55.88 4.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.791 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 1.5 m -114.2 -16.96 11.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.358 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -65.05 -27.18 71.96 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.628 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.447 ' O ' HD12 ' A' ' 128' ' ' LEU . 33.4 m120 61.02 55.69 3.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.806 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.43 HG21 ' OG ' ' A' ' 125' ' ' SER . 76.3 m -145.75 141.28 27.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.903 HG12 ' HB2' ' A' ' 167' ' ' ALA . 16.2 m -109.68 175.48 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.176 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . . . . . . . . . 21.6 t -131.3 120.59 46.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.034 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . . . . . . . . . 1.6 m -86.61 122.66 30.84 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.967 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -83.68 118.95 24.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.159 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.42 ' HA ' ' CE1' ' A' ' 62' ' ' PHE . 17.4 m -144.1 165.15 13.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.109 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . 0.442 ' HB3' ' CD2' ' A' ' 62' ' ' PHE . 11.4 tp60 -176.96 93.92 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.912 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . 0.406 ' HB3' ' HB3' ' A' ' 82' ' ' GLU . . . -154.17 116.79 4.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.102 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -158.05 -172.82 25.68 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -151.54 -172.58 4.26 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.812 0.339 . . . . 0.0 110.906 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . -164.72 -65.93 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.514 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -64.73 -54.53 30.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.837 0.351 . . . . 0.0 110.957 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . 0.564 ' O ' HG22 ' A' ' 185' ' ' THR . 89.1 m 55.83 54.93 7.56 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.964 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . 59.11 31.15 21.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.176 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.9 106.64 11.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.902 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.178 -0.915 . . . . 0.0 110.937 179.917 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.4 ttt . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.871 0.367 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -98.84 31.65 2.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.867 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -149.1 -47.16 0.14 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.963 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.5 t60 -91.17 129.65 37.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.86 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.2 t-80 -100.36 -31.51 11.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.941 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.9 m170 -59.99 127.86 33.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.876 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . . . . . . . . . 2.0 t-160 -126.98 157.52 39.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.512 ' HB3' ' NE1' ' A' ' 13' ' ' TRP . . . -63.41 158.34 58.43 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.12 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HD2' ' HB1' ' A' ' 8' ' ' ALA . 18.6 Cg_endo -58.66 144.74 97.45 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.684 2.256 . . . . 0.0 112.269 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.429 ' HA ' ' CE3' ' A' ' 13' ' ' TRP . 24.1 Cg_endo -63.82 -60.61 0.15 Allowed 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.636 2.224 . . . . 0.0 112.745 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 97.0 m -46.85 -33.31 4.38 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.419 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 12' ' ' LEU . 5.5 tt -70.28 -31.35 68.66 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.944 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' TRP . . . . . 0.738 ' O ' HG12 ' A' ' 16' ' ' VAL . 23.2 m0 -70.63 -32.56 69.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.86 179.815 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.8 t -66.75 -20.81 66.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.251 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.736 ' NH2' HD22 ' A' ' 75' ' ' LEU . 74.4 mtt-85 -56.66 -34.2 67.11 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.889 0.376 . . . . 0.0 110.992 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 13' ' ' TRP . 8.5 p -61.48 124.88 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.786 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.8 m -132.77 109.28 9.55 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.792 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.478 ' HB2' ' CZ3' ' A' ' 23' ' ' TRP . 0.8 OUTLIER -66.31 111.4 3.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.078 0.466 . . . . 0.0 110.693 179.479 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.423 ' CZ ' ' HD2' ' A' ' 40' ' ' PRO . 9.7 t80 -124.03 130.34 52.41 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.488 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 59.67 -129.79 49.03 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.309 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 58.3 m -97.7 26.19 5.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.861 0.362 . . . . 0.0 110.817 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.56 -170.3 23.96 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.114 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.722 ' HE3' HG22 ' A' ' 16' ' ' VAL . 38.2 m95 -123.82 160.33 27.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.735 0.302 . . . . 0.0 110.817 179.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -128.18 -163.88 11.44 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.563 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PHE . . . . . 0.491 ' CD1' ' HB3' ' A' ' 149' ' ' PRO . 26.7 t80 -151.73 147.05 26.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.756 0.312 . . . . 0.0 110.975 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TRP . . . . . 0.434 ' CH2' ' HB2' ' A' ' 71' ' ' MET . 67.3 m95 -89.61 102.35 15.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.842 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.742 HG13 HG12 ' A' ' 33' ' ' ILE . 4.4 m -78.96 -25.85 13.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.053 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -163.3 165.8 13.87 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.604 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -61.13 -21.44 71.63 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.557 2.171 . . . . 0.0 112.529 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.484 HG22 ' HA ' ' A' ' 70' ' ' LYS . 75.6 p -126.18 6.42 7.13 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.537 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.52 HG12 ' CG2' ' A' ' 27' ' ' VAL . 43.7 t -131.28 142.55 43.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.894 0.378 . . . . 0.0 111.319 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -135.91 164.75 27.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.901 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.742 HG12 HG13 ' A' ' 27' ' ' VAL . 16.2 pt -143.15 153.23 16.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.151 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.1 t -171.8 166.08 6.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.798 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.648 HG22 ' H ' ' A' ' 37' ' ' HIS . 23.4 m -84.34 129.84 34.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.799 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.788 ' O ' HG12 ' A' ' 39' ' ' VAL . 0.2 OUTLIER -67.1 -13.85 62.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.632 -179.675 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.648 ' H ' HG22 ' A' ' 35' ' ' THR . 8.5 t60 -73.08 -27.42 61.71 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.734 0.302 . . . . 0.0 111.025 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.4 HG22 ' HB ' ' A' ' 35' ' ' THR . 0.1 OUTLIER -107.99 27.15 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.437 -179.628 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.788 HG12 ' O ' ' A' ' 36' ' ' THR . 14.5 p -90.04 118.13 68.64 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.061 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.423 ' HD2' ' CZ ' ' A' ' 19' ' ' PHE . 97.8 Cg_endo -84.13 -164.85 0.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.57 0 C-N-CA 122.595 2.196 . . . . 0.0 112.295 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 4.8 t -159.75 28.7 0.19 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -108.54 -21.58 7.51 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.405 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 24.8 m -88.24 160.72 2.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.696 0.284 . . . . 0.0 111.167 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LYS . . . . . . . . . . . . . 4.9 pttt -132.37 31.08 4.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.929 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -175.15 150.18 1.15 Allowed 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.635 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 46' ' ' PHE . 0.2 OUTLIER -125.79 133.76 51.92 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.481 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 38.6 35.55 0.11 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.164 0.507 . . . . 0.0 111.334 -179.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 63.77 44.88 95.61 Favored Glycine 0 N--CA 1.452 -0.279 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.443 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -128.2 146.89 61.26 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 120.661 0.267 . . . . 0.0 110.917 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_exo -56.47 112.93 1.23 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.622 2.215 . . . . 0.0 112.478 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.529 ' HG ' ' N ' ' A' ' 52' ' ' SER . 2.5 pt? -56.78 -43.61 81.01 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.768 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.529 ' N ' ' HG ' ' A' ' 51' ' ' LEU . 3.8 m -67.65 -7.89 30.32 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.836 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.1 t -109.46 35.98 3.11 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-O 121.481 0.657 . . . . 0.0 110.469 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 55' ' ' ALA . 56.2 mt -125.81 158.81 34.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 114.987 -1.006 . . . . 0.0 110.903 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.901 ' HB3' ' HB3' ' A' ' 66' ' ' ARG . . . -116.12 93.69 4.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.051 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 4.3 mt -80.43 142.24 14.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.208 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -138.79 99.43 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.847 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -72.52 140.58 48.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.974 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -169.45 76.62 0.1 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.988 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 59.41 -118.47 14.46 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.466 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.404 ' HG2' HG23 ' A' ' 35' ' ' THR . 0.5 OUTLIER -98.69 30.09 3.44 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.81 0.338 . . . . 0.0 110.918 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -137.84 127.24 24.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.769 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.2 m -128.27 117.75 22.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -96.24 113.75 25.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.747 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -100.5 113.21 25.81 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.059 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ARG . . . . . 0.901 ' HB3' ' HB3' ' A' ' 55' ' ' ALA . 6.1 ttm-85 -110.46 103.71 12.36 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.604 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.628 ' CE2' ' HE3' ' A' ' 71' ' ' MET . 43.8 m-85 -86.95 132.41 33.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.008 -179.788 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -64.28 -25.41 68.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.841 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 5.3 tttt -107.42 164.6 12.06 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.968 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.484 ' HA ' HG22 ' A' ' 30' ' ' THR . 0.0 OUTLIER -99.27 117.09 32.96 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.44 179.914 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' MET . . . . . 0.628 ' HE3' ' CE2' ' A' ' 67' ' ' PHE . 0.0 OUTLIER -85.58 -29.71 23.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.89 -179.851 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.411 ' HG2' HD12 ' A' ' 75' ' ' LEU . 5.8 tpt180 -130.97 66.8 79.92 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.974 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_exo -51.66 -27.13 25.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.535 2.157 . . . . 0.0 112.403 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -67.5 -31.13 71.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.859 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.736 HD22 ' NH2' ' A' ' 15' ' ' ARG . 12.0 mt -78.69 126.13 30.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.88 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.8 m -74.68 -55.66 5.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 147.73 142.04 3.61 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.497 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' MET . . . . . . . . . . . . . 30.5 mmm -95.85 170.16 9.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.88 0.371 . . . . 0.0 110.829 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 159' ' ' VAL . 21.9 t -103.71 141.45 19.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.055 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.683 HD13 ' N ' ' A' ' 81' ' ' GLU . 0.7 OUTLIER -111.37 128.14 55.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.912 179.96 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.683 ' N ' HD13 ' A' ' 80' ' ' LEU . 1.6 mm-40 -97.3 151.86 19.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -129.36 84.31 2.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 106.6 114.89 3.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.54 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -121.11 152.02 56.26 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 120.696 0.284 . . . . 0.0 110.884 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.1 -172.49 0.73 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.594 2.196 . . . . 0.0 112.336 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -102.69 110.37 22.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 136.35 -24.88 3.19 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.566 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.3 m -55.15 145.89 19.97 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.842 0.353 . . . . 0.0 110.96 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -115.58 121.25 66.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.104 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 10.6 m -87.39 168.56 13.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.939 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.29 103.47 5.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.782 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.698 HG22 ' CE1' ' A' ' 150' ' ' TYR . 16.3 t -74.42 155.71 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.175 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.431 HD22 ' CD1' ' A' ' 13' ' ' TRP . 9.2 mt -120.59 79.58 1.51 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.869 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.738 HD13 HG22 ' A' ' 141' ' ' THR . 28.0 mt -86.74 105.81 15.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.163 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 19.3 tttt -98.11 161.73 13.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.975 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 27.0 mtt180 -135.56 174.52 10.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -71.67 -37.88 70.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.94 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.3 p -69.19 -27.59 65.64 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.916 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 105.32 24.87 6.93 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -103.12 91.6 4.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.773 0.32 . . . . 0.0 110.9 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.79 139.7 53.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.821 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . . . . . . . . . 9.7 tp -119.11 87.45 34.59 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.901 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.94 102.95 1.4 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.558 2.172 . . . . 0.0 112.273 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.523 HD12 HD11 ' A' ' 94' ' ' ILE . 49.1 mt -96.45 163.46 13.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.998 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -125.13 149.23 48.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.118 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.8 t -151.95 120.17 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . . . . . . . . . 6.5 ttt180 -77.14 124.67 28.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.871 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' MET . . . . . . . . . . . . . 5.7 mmt -76.22 143.1 41.22 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.888 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -105.46 -123.99 5.29 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.527 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -113.16 153.72 27.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.858 0.361 . . . . 0.0 111.059 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 1.1 tp -92.64 128.06 44.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.018 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -146.21 159.1 43.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.118 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.3 m -84.93 109.79 18.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -95.63 154.43 17.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.907 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 4.4 ttt180 -98.01 128.84 44.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.915 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 32.8 mt -140.19 119.35 11.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.129 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.71 31.39 20.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.825 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 76.4 28.0 60.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.568 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.7 mtp85 -136.44 141.18 43.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 62.4 mt -88.38 118.9 28.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.916 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.4 t -129.46 138.58 53.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.197 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' HIS . . . . . . . . . . . . . 1.9 t-160 -76.0 141.63 42.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . -165.91 -178.3 38.7 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.437 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -130.56 160.94 32.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.79 0.329 . . . . 0.0 110.9 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.4 m -129.99 133.56 46.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.959 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -142.02 168.31 25.72 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.558 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' MET . . . . . . . . . . . . . 5.5 ttm -122.93 144.71 49.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.883 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.765 HD22 ' O ' ' A' ' 133' ' ' ASN . 2.9 pp -82.46 138.81 34.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.874 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 5.1 mt -97.25 79.71 2.84 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.959 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.471 HG21 HD22 ' A' ' 133' ' ' ASN . 63.1 m -161.08 -45.1 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.878 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 81.74 25.79 52.13 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.573 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -176.42 37.69 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.84 0.352 . . . . 0.0 111.143 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.765 ' O ' HD22 ' A' ' 128' ' ' LEU . 1.9 m-20 -137.9 78.3 1.68 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.834 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -175.66 122.33 0.2 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.077 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.61 -29.49 13.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 147.31 -28.29 1.52 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.34 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' MET . . . . . . . . . . . . . 5.3 mtt -139.0 30.72 2.22 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.274 0.559 . . . . 0.0 109.707 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.503 ' HA ' ' CE1' ' A' ' 164' ' ' HIS . 10.9 p30 -161.73 -174.87 4.4 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.083 -178.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.532 HD23 HG21 ' A' ' 174' ' ' VAL . 0.2 OUTLIER -98.8 32.39 2.63 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 121.008 0.432 . . . . 0.0 110.179 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.64 11.73 46.47 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.919 -0.657 . . . . 0.0 112.411 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . 0.738 HG22 HD13 ' A' ' 94' ' ' ILE . 5.5 p -74.18 -174.8 2.04 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-O 120.899 0.381 . . . . 0.0 110.891 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' ILE . . . . . 0.573 ' HB ' ' HD3' ' A' ' 143' ' ' PRO . 0.5 OUTLIER -144.02 -53.77 0.02 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.925 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.573 ' HD3' ' HB ' ' A' ' 142' ' ' ILE . 27.5 Cg_exo -66.9 60.57 0.58 Allowed 'Trans proline' 0 C--N 1.351 0.666 0 C-N-CA 122.76 2.307 . . . . 0.0 112.594 -179.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.409 ' O ' ' CD1' ' A' ' 23' ' ' TRP . . . 44.84 53.17 7.45 Favored Glycine 0 CA--C 1.517 0.216 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.002 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ASP . . . . . 0.647 ' HB3' HG21 ' A' ' 141' ' ' THR . 0.6 OUTLIER -84.55 58.06 4.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.079 0.466 . . . . 0.0 110.717 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 16.2 m -98.81 96.35 7.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.386 179.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 115.59 12.75 9.3 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.275 -179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ALA . . . . . 0.605 ' HB2' ' OD2' ' A' ' 145' ' ' ASP . . . -46.22 149.84 1.22 Allowed Pre-proline 0 C--N 1.334 -0.099 0 CA-C-O 120.737 0.304 . . . . 0.0 111.193 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' PRO . . . . . 0.572 ' HD3' HG23 ' A' ' 16' ' ' VAL . 81.0 Cg_endo -77.79 121.48 5.5 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.624 2.216 . . . . 0.0 112.854 -179.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' TYR . . . . . 0.792 ' O ' HG23 ' A' ' 160' ' ' VAL . 4.3 m-85 -98.43 128.67 44.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.382 179.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.408 HG11 HD21 ' A' ' 12' ' ' LEU . 3.1 m -125.95 174.2 10.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 120.86 0.362 . . . . 0.0 111.182 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' HIS . . . . . 0.443 ' CD2' ' HG3' ' A' ' 154' ' ' ARG . 38.5 p-80 -170.67 167.29 7.87 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.587 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' LYS . . . . . 0.429 ' HA ' ' CD1' ' A' ' 158' ' ' TRP . 27.1 tttt -96.4 133.59 40.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.783 0.325 . . . . 0.0 111.383 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ARG . . . . . 0.469 ' HB2' HG23 ' A' ' 159' ' ' VAL . 8.2 mtp85 -132.16 98.52 4.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.294 179.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . 74.32 -106.78 2.11 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.003 -179.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -116.32 37.09 3.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 110.273 179.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -167.83 -171.88 1.71 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.962 -179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' TRP . . . . . 0.429 ' CD1' ' HA ' ' A' ' 153' ' ' LYS . 4.5 m0 -123.22 153.94 39.43 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.64 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 79' ' ' VAL . 20.2 t -142.52 144.31 24.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG23 ' O ' ' A' ' 150' ' ' TYR . 12.2 p -93.91 128.23 45.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.042 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' CYS . . . . . 0.68 ' O ' HG22 ' A' ' 178' ' ' VAL . 30.4 p -86.53 -40.2 15.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.125 -179.743 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 171.73 -145.2 8.59 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.687 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.8 m -129.02 171.11 17.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.613 0.244 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.503 ' CE1' ' HA ' ' A' ' 138' ' ' ASP . 17.9 t-80 -80.36 139.0 36.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.962 0.41 . . . . 0.0 111.056 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ALA . . . . . 0.419 ' HB3' ' HB ' ' A' ' 175' ' ' VAL . . . -111.46 -76.21 0.6 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.234 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -156.46 174.38 15.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.116 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.482 ' HB2' HG12 ' A' ' 174' ' ' VAL . . . -125.15 161.42 26.88 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.081 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -92.2 146.26 23.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.948 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' LYS . . . . . . . . . . . . . 3.5 tppt? -86.75 -19.6 28.88 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.082 179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' SER . . . . . . . . . . . . . 61.7 p -70.14 -16.91 63.16 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.527 -0.306 . . . . 0.0 111.309 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . -166.29 -105.46 0.19 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.583 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ASN . . . . . 0.515 HD22 HD21 ' A' ' 128' ' ' LEU . 18.7 m120 -159.38 47.83 0.3 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.907 0.384 . . . . 0.0 110.877 -179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.1 127.12 52.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.532 HG21 HD23 ' A' ' 139' ' ' LEU . 4.4 m -110.2 169.25 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 176' ' ' CYS . 21.5 t -110.95 156.84 12.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.153 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' CYS . . . . . 0.451 ' N ' HG12 ' A' ' 175' ' ' VAL . 52.1 t -128.56 136.0 50.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.27 103.96 13.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.036 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.68 HG22 ' O ' ' A' ' 161' ' ' CYS . 21.4 t -108.57 -66.57 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.183 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -110.61 165.84 11.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' ALA . . . . . . . . . . . . . . . -174.9 145.22 0.83 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 101.79 35.3 4.07 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.442 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -90.91 131.35 36.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.843 0.354 . . . . 0.0 110.92 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' GLY . . . . . . . . . . . . . . . 97.86 28.42 8.31 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.526 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -106.1 -64.26 1.18 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.847 0.356 . . . . 0.0 110.966 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' THR . . . . . . . . . . . . . 63.1 m -106.12 -47.07 3.92 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' ALA . . . . . . . . . . . . . . . -63.58 165.89 7.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.101 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' LEU . . . . . . . . . . . . . 10.3 tp -172.51 121.06 0.42 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.88 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.926 179.982 . . . . . . . . 0 0 . 1 stop_ save_